UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the fiscal year ended December 31, 2004

OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from _____________ to ________________

Commission file number 0-12938

INVACARE CORPORATION
(Exact name of Registrant as specified in its charter)

            Ohio                                              95-2680965
_______________________________                          ______________________
(State or other jurisdiction of                            (I.R.S. Employer
 incorporation or organization)                          Identification Number)

One Invacare Way, P.O. Box 4028, Elyria, Ohio 44036
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (440) 329-6000

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class                         Name of Exchange on which Registered
-------------------                         ------------------------------------
Common Shares, without par value                   New York Stock Exchange
Rights to Purchase Commons Shares,                 New York Stock Exchange
  without par value

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the Registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to the filing requirements for the past 90 days.
Yes X No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy of information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark if the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act).
Yes X No

As of June 30, 2004, the aggregate market value of the 27,329,710 Common Shares of the Registrant held by non-affiliates was $1,222,184,631 and the aggregate market value of the 31,803 Class B Common Shares of the Registrant held by non-affiliates was $1,422,230. While the Class B Common Shares are not listed for public trading on any exchange or market system, shares of that class are convertible into Common Shares at any time on a share-for-share basis. The market values indicated were calculated based upon the last sale price of the Common Shares as reported by The New York Stock Exchange on June 30, 2004, which was $44.72. For purposes of this information, the 2,724,495 Common Shares and 1,080,174 Class B Common Shares which were held by Executive Officers and Directors of the Registrant were deemed to be the Common Shares and Class B Common Shares held by affiliates.

As of February 24, 2005, 30,322,573 Common Shares and 1,111,965 Class B Common Shares were outstanding.

Documents Incorporated By Reference

Portions of the Registrant's definitive Proxy Statement to be filed in connection with its 2005 Annual Meeting of Shareholders are incorporated by reference into Part III (Items 10, 11, 12, 13 and 14) of this report.

Except as otherwise stated, the information contained in this Annual Report on Form 10-K is as of December 31, 2004.

I-1

INVACARE CORPORATION
2004 ANNUAL REPORT ON FORM 10-K CONTENTS

                                                                            Page
Item
PART I:

1. Business                                                                  I-3

2. Properties                                                               I-14

3. Legal Proceedings                                                        I-17

4. Submission of Matters to a Vote of Security Holders                      I-17

   Executive Officers of the Registrant                                     I-17

PART II:

5. Market for the Registrant's Common Equity, Related Stockholder           I-19
     Matters and Issuer Purchases of Equity Securities

6. Selected Financial Data                                                  I-20

7. Management's Discussion and Analysis of Financial Condition and          I-21
     Results of Operations

7A.Quantitative and Qualitative Disclosures About Market Risk               I-29

8. Financial Statements and Supplementary Data                              I-29

9. Changes in and Disagreements with Accountants on Accounting and          I-29
     Financial Disclosure

9A. Controls and Procedures                                                 I-29

PART III:

10. Directors and Executive Officers of the Registrant                      I-30

11. Executive Compensation                                                  I-30

12. Security Ownership of Certain Beneficial Owners and Management          I-31

13. Certain Relationships and Related Transactions                          I-31

14. Principal Accounting Fees and Services                                  I-31

PART IV:

15. Exhibits and Financial Statement Schedules                              I-31

    Signatures                                                              I-32

                                       I-2



PART I

Item 1. Business.

GENERAL
Invacare Corporation is the world's leading manufacturer and distributor of non-acute health care products based upon its distribution channels, the breadth of its product line and its net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets. Invacare continuously revises and expands its product lines to meet changing market demands and currently offers over two dozen product lines. The company's products are sold principally to over 25,000 home health care and medical equipment provider locations in the U.S., Australia, Canada, Europe and New Zealand, with the remainder of its sales being primarily to government agencies and distributors. Invacare's products are sold through its worldwide distribution network by its sales force, telesales associates and various organizations of independent manufacturers' representatives and distributors. The company also distributes medical equipment and related supplies manufactured by others.

Invacare is committed to design, manufacture and deliver the best value in medical products, which promote recovery and active lifestyles for people requiring home and other non-acute health care. Invacare pursues this vision by:

* designing and developing innovative and technologically superior products;
* ensuring continued focus on our primary market - the non-acute health care market;
* marketing our broad range of products;
* providing the industry's most professional and cost-effective sales, customer service and distribution organization;
* supplying superior and innovative provider support and aggressive product line extensions;
* building a strong referral base among health care professionals;
* building brand preference with consumers;
* continuous advancement and recruitment of top management candidates;
* empowering all employees;
* providing a performance-based reward environment; and
* continually striving for total quality throughout the organization.

When the company was acquired in December 1979 by a group of investors, including certain of our current officers and Directors, it had $19.5 million in net sales and a limited product line of standard wheelchairs and patient aids. In 2004, Invacare reached $1.403 billion in net sales, representing a 19% compound average sales growth rate since 1979, and currently is the leading company in the industry that manufactures, distributes and markets products in each of the following major, non-acute, medical equipment categories: power and manual wheelchairs, patient aids, home care beds, home respiratory products, low air loss therapy products, seating and positioning products, bathing equipment and distributed products.

The company operates in a single industry, the home medical equipment (HME) industry segment. For information relating to net sales, operating income, identifiable assets and other information for this industry segment, see the Consolidated Financial Statements of the company.

The company's executive offices are located at One Invacare Way, Elyria, Ohio and its telephone number is (440) 329-6000. In this report, Invacare and the company refer to Invacare Corporation and, unless the context otherwise indicates, its consolidated subsidiaries.

I-3

THE HOME MEDICAL EQUIPMENT INDUSTRY

North America
The home medical equipment market includes home health care products, physical rehabilitation products and other non-disposable products used for the recovery and long-term care of patients. The company believes that sales of domestic home medical equipment products will continue to grow during the next decade and beyond as a result of several factors, including:

Growth in population over age 65. The nation's overall life expectancy continues to increase. A recent report from the U.S. Department of Health and Human Services (DHHS) states that the average life expectancy for men and women who reach the age of 65 is now 81 and 84, respectively and life expectancy at birth is now 74 for men and almost 80 for women. The DHHS also reports that people age 65 or older represent the vast majority of home health care patients and will increase from 12% of the population in 2000 to 20% of the population by the year 2050. A significant percentage of people using home and community-based health care services are 65 years of age and older.

Treatment trends. Many medical professionals and patients prefer home health care over institutional care because they believe that home health care results in greater patient independence, increased patient responsibility and improved responsiveness to treatment because familiar surroundings are conducive to improved patient outcomes. Health care professionals, public payers and private payers agree that home care is a cost effective, clinically appropriate alternative to facility-based care. Recent surveys show that approximately 70% of adults would rather recover from an accident or illness in their home, while approximately 90% of the older population showed preference for home-based, long-term care.

Technological trends. Technological advances have made medical equipment increasingly adaptable for use in the home. Current hospital procedures often allow for earlier patient discharge, thereby lengthening recuperation periods outside of the traditional institutional setting. In addition, continuing medical advances prolong the lives of adults and children, thus increasing the demand for home medical care equipment.

Health care cost containment trends. In 2002, health care expenditures in the U.S. totaled $1.5 trillion dollars or approximately 14.9% of the Gross Domestic Product (GDP), the highest among industrialized countries. In 2013, the nation's health care spending is projected to increase to $3.4 trillion, growing at an average annual rate of 7.3%. Over this same period, spending on health care is expected to increase to approximately 18.4% as a share of GDP. The rising cost of health care has caused many payers of health care expenses to look for ways to contain costs. Home health care has gained widespread acceptance among health care providers and public policy makers as a cost effective, clinically appropriate and patient preferred alternative to facility-based care for a variety of acute and long-term illnesses and disabilities. Thus, the company believes that home health care and home medical equipment will play a significant role in reducing health care costs.

Society's mainstreaming of people with disabilities. People with disabilities are part of the fabric of society and this has increased, in large part, due to the 1991 Americans with Disabilities Act (ADA). This legislation provides mainstream opportunities to people with disabilities. The ADA imposes requirements on certain components of society to make reasonable accommodations to integrate people with disabilities into the community and the workplace.

Distribution channels. The changing home health care market continues to provide new ways of reaching the end user. The distribution network for products has expanded to include not only specialized home health care providers and extended care facilities but retail drug stores, surgical supply houses, rental, hospital and HMO-based stores, home health agencies, mass merchandisers, direct sales and the Internet.

Europe/Asia/Pacific
The company believes that, while many of the market factors influencing demand in the U.S. are also present in Europe and Asia/Pacific - aging of the population, technological trends and society's acceptance of people with disabilities - each of the major national markets within Europe and in Asia/Pacific have distinctive characteristics. The health care industry is more heavily socialized and, therefore, is more influenced by government regulation and fiscal policy. Variations in product specifications, regulatory approvals, distribution requirements and reimbursement policies require the company to tailor its approach to each national market. Management believes that as the European markets become more homogeneous and the company continues to refine its distribution channels, the company can more effectively penetrate these markets. Likewise, the company expects to increase its sales in the highly fragmented Australian, New Zealand and Asian markets.

I-4

GEOGRAPHICAL SEGMENTS AND PRODUCT CATEGORIES
North America
North American operations are aligned into five primary product groups, which manufacture and market products in all of the major home medical equipment categories. In Canada, the company primarily sells Invacare products manufactured in the U.S.

REHAB PRODUCTS

Power wheelchairs. Invacare manufactures a complete line of power wheelchairs for individuals who require independent powered mobility. The range includes products that can be significantly customized to meet an individual's specific needs, as well as products that are inherently versatile and meet a broad range of individual requirements. Power wheelchair lines are marketed under the Invacare(R) Storm Series(R) and Xterra(TM) brand names and include a full range of powered mobility products. The Storm Series(R) was expanded in 2004 with the introduction of the TDX(TM) line of power wheelchairs which offer an unprecedented combination of power, stability and maneuverability. The Pronto(TM) Series Power Wheelchairs with SureStep(TM), introduced in 2002, feature center-wheel drive performance for exceptional maneuverability and intuitive driving. The power tilt and recline systems are now offered also as a result of the company's acquisition of Motion Concepts, Inc.

Custom manual wheelchairs. Invacare manufactures and markets a range of custom manual wheelchairs for everyday, sports and recreational uses. These lightweight chairs are marketed under the Invacare(R) and Invacare Top End(R) brand names. The chairs provide mobility for people with moderate to severe disabilities in their everyday activities as well as for use in various sports such as basketball, racing, skiing and tennis.

Personal Mobility. In 2003, Invacare introduced the HMV(TM) (Highly Maneuverable Vehicle) product, which in 2004 replaced the three and four-wheeled motorized scooters, including rear-wheel drive models for both outdoor and indoor use, marketed under the Invacare(R) brand name that include scooters under the Lynx(TM) and Panther(TM) product names.

Seating and positioning products. Invacare markets seat cushions, back supports and accessories under three series. Invacare(R) Essential(TM) Series provides simple seating solutions for comfort, fit and function. Invacare Infinity(TM) Series includes versatile modular seating, providing optimal rehab solutions. Invacare PinDot(R) Series offers custom seating solutions personalized for the most challenged clients. The company has also expanded its product line of seating products and wheelchairs for the pediatric market with the acquisition of Freedom Designs, Inc.

STANDARD PRODUCTS

Manual wheelchairs. Invacare's manual wheelchairs are sold for use inside and outside the home, institutional settings, or public places (e.g., airports, malls, etc.). Our clients include people who are chronically or temporarily disabled and require basic mobility performance with little or no frame modification. Examples of Invacare manual wheelchair lines, which are marketed under the Invacare(R) brand name, include the 9000 and Tracer(R) product lines. These lines offer wheelchairs that are designed to accommodate the diverse capabilities and unique needs of the individual from petite to bariatric sizes.

Personal care. Invacare manufactures and/or distributes a full line of personal care products, including ambulatory aids such as crutches, canes, walkers and wheeled walkers. This line also features one of Invacare's latest product innovations, the Rollite(TM) Rollator, a truly unique solution in patient mobility. Also available are safety aids such as tub transfer benches, shower chairs and grab bars, and patient care products such as commodes and other toilet assist aids.

Home care beds. Invacare manufactures and distributes a wide variety of manual, semi-electric and fully electric beds for home use under the Invacare(R) brand name. Home care bed accessories include bedside rails, mattresses, overbed tables, trapeze bars and traction equipment. Also available are the new bariatric beds and accompanying accessories to serve the special needs of bariatric patients.

Low air loss therapy products. Invacare manufactures and markets a complete line of mattress overlays and replacement products, under the Invacare(R) brand name. These products, which use air flotation to redistribute weight and move moisture away from patients, assist in the total care of those who are immobile and spend a great deal of time in bed.

Patient Transport. Invacare manufactures and markets products needed to assist in transferring individuals from surface to surface (bed to chair) or transporting from room to room. Designed for use in the home and institutional settings, these products include patient lifts and slings, and a new series of mobile, multi-functional recliners.

I-5

RESPIRATORY PRODUCTS

Home respiratory products. Invacare manufactures and/or distributes home respiratory products, including oxygen concentrators, nebulizer compressors and respiratory disposables, sleep therapy products and portable compressed oxygen systems. Invacare home respiratory products are marketed predominantly under the Invacare(R) brand name. The Invacare Venture HomeFill(TM) II Oxygen Compressor enables people to safely and easily make compressed oxygen in their home and store it in cylinders for future use.

DISTRIBUTED PRODUCTS

Distributed products. Invacare distributes numerous lines of branded medical supplies including ostomy, incontinence, diabetic, wound care and miscellaneous home medical products, as well as HME aids for daily living. In 2004, Invacare introduced its own private label brand of certain medical supplies.

CONTINUING CARE

Health Care Furnishings. Invacare, operating as Invacare Continuing Care Group, is a manufacturer and distributor of beds and furnishings for the long-term care markets. In addition, certain home medical equipment also is sold through this channel.

OTHER PRODUCTS

Accessory Products. Invacare also manufactures, markets and distributes many accessory products, including spare parts, wheelchair cushions, arm rests, wheels and respiratory parts. In some cases, Invacare's accessory items are built to be interchangeable so that they can be used to replace parts on products manufactured by others.

Asia/Pacific
The company's Asia/Pacific operations consist of Invacare Australia, which imports and distributes the Invacare range of products and manufactures and distributes the Rollerchair range of custom power wheelchairs and Pro Med lifts; Dynamic Controls, a New Zealand manufacturer of electronic operating components used in power wheelchairs and scooters; Invacare New Zealand, a manufacturer of wheelchairs and beds and a distributor of a wide range of home medical equipment; and Invacare Asia Sales, which imports and distributes home medical equipment to the Asia markets.

Europe
The company's European operations operate as a "common market" company with sales throughout Europe. The European operations currently sell a line of products providing significant room for growth as Invacare continues to broaden its product line offerings to more closely resemble that of the North American operations.

Most wheelchair products sold in Europe are designed locally to meet specific market requirements. The company manufactures and/or assembles both manual and power wheelchair products at the following European facilities: Invacare (UK) Ltd. in the United Kingdom, Invacare Poirier S.A.S. in France, and Invacare Deutschland GmbH in Germany. Manual wheelchair products are also manufactured and/or assembled at Invacare Lda. in Portugal, Invacare AG in Switzerland (the Kuschall Range), and Invacare Rea AB in Sweden. Beds and patient lifts are manufactured at Invacare Hong A/S in Denmark. A range of patient lifts is also assembled at Invacare (UK) Ltd. in the United Kingdom. Oxygen products are imported from Invacare U.S. operations. In addition to distributing the Invacare range of products, Invacare Mecc San SrL in Italy manufactures beds, patient lifts and commodes specifically for the local market.

With the acquisition in September 2004 of WP Domus GmbH (Domus), the European product range has been enhanced and market share increased. Domus is a European-based holding company that manufactures several complementary product lines to Invacare's product lines, including power add-on products, bath lifts and walking aids. Domus has three divisions: Alber, Aquatec and Dolomite.

For information relating to net sales by product group, see Business Segments in Notes to the Consolidated Financial Statements.

WARRANTY
Generally, the company's products are covered by warranties against defects in material and workmanship for periods up to six years from the date of sale to the customer. Certain components carry a lifetime warranty.

I-6

North America and Asia/Pacific
The home medical equipment market is highly competitive and Invacare products face significant competition from other well-established manufacturers. The company believes that its success in increasing market share is dependent on providing value to the customer based on the quality, performance and price of the company products, the range of products offered, the technical expertise of the sales force, the effectiveness of the company distribution system, the strength of the dealer and distributor network and the availability of prompt and reliable service for its products. Various manufacturers, from time to time, have instituted price-cutting programs in an effort to gain market share. There can be no assurance that other HME manufacturers will not attempt to implement such aggressive pricing in the future.

Europe
As a result of the differences encountered in the European marketplace, competition generally varies from one country to another. The company typically encounters one or two strong competitors in each country, some of them becoming regional leaders in specific product lines.

MARKETING AND DISTRIBUTION
North America and Asia/Pacific
Invacare's products are marketed in the United States and Asia/Pacific primarily to providers who in turn sell or rent these products directly to consumers within the non-acute care setting. Invacare's primary customer is the home medical equipment (HME) provider. The company also employs a "pull-through" marketing strategy to medical professionals, including physical and occupational therapists, who refer their patients to HME providers to obtain specific types of home medical equipment, as well as to consumers, who express a product or brand preference.

Invacare's domestic sales and marketing organization consists primarily of a home care sales force, which markets and sells Invacare(R)-branded products to HME providers. Each member of Invacare's home care sales force functions as a Territory Business Manager (TBM) and handles all product and service needs for an account, thus saving customers valuable time. The TBM also provides training and servicing information to providers, as well as product literature, point-of-sale materials and other advertising and merchandising aids. In Canada, products are sold by a sales force and distributed through regional distribution centers in British Columbia, Ontario and Quebec to health care providers throughout Canada. Manufacturers' representatives market and sell Invacare products through the company's Invacare Continuing Care Group to the non-acute care market.

The Inside Sales Department provides increased sales coverage of smaller accounts and complements the efforts of the field sales force. Inside Sales offers cost-effective sales coverage through a targeted telesales effort, and has delivered excellent sales growth in each of its five years of existence.

The Invacare Service and Parts Division (ISP) focuses on improving operations and enhancing overall service to its customers. Recent initiatives included the pre-packaging of parts and adding a bar code to the label, the kitting of upholstery with associated hardware, and introducing 15 new power wheelchair and scooter accessories. ISP's Technical Education department recently consolidated its Power Wheelchair and Respiratory schools into a four-day format and continued its emphasis on improving providers repair technicians' productivity. The Service Referral Network includes over 600 providers who honor Invacare's product warranties regardless of where the product was purchased. This network of servicing providers helps ensure that all consumers using Invacare products receive quality service and support that is consistent with the Invacare brand promise.

The company sells distributed products, primarily soft goods and disposable medical supplies, through the Invacare Supply Group (ISG). ISG is an important component of Invacare's "Total One Stop Shopping" program, through which Invacare offers HME providers of all sizes a broader range of products and services at a lower total cost. ISG products include ostomy, incontinence, wound care and diabetic supplies, as well as other soft goods and disposables which complement other Invacare products that are purchased by many of the same customers who buy Invacare equipment. ISG markets its products through an inside telesales and customer service department, the Internet and Invacare's HME field sales force. ISG also markets a Home Delivery Program to HME providers through which ISG drop-ships supplies in the provider's name to the customer's address. Thus, providers have no products to stock, no minimum order requirements and delivery is made within 24 to 48 hours nationwide. In 2004, ISG completed the purchase and integration of ACS, a home infusion company, opening up a new market for ISG. ISG also added more than 150 SKUs to its Invacare-branded consumable line. The company opened a new state-of-the-art distribution facility in Jamesburg, New Jersey and closed its existing Edison, New Jersey facility. The move more than doubled available space, while also enhancing Invacare Supply Group's ability to effectively pick, pack and ship customer orders.

I-7

In 2004, Invacare, through its co-op advertising program, continued to offer direct response television commercials designed to generate demand for Invacare Power Chairs, Scooters and the HomeFill Oxygen System sold by the HME provider. These commercials feature Arnold Palmer, Invacare's worldwide spokesperson, who has become an integral part of Invacare's "Yes, you can(TM)" promotional and marketing efforts. This program encourages consumers to achieve personal independence and participate in the activities of life, facilitated by the home health care products, which Invacare manufactures, distributes and/or markets throughout the world. The company signed an extended agreement with Arnold Palmer through the end of 2006. Mr. Palmer, serving as Invacare's spokesperson, is helping accomplish three objectives: (i) creating attention and awareness for the category of home health care products, (ii) accelerating the acceptance of these products as lifestyle enhancing so that consumers want these products and don't just need them, and (iii) establishing the Invacare brand as the consumer category-brand for home health care products. Mr. Palmer is featured throughout Invacare's marketing communications, including Invacare direct-response television commercials, print advertising, point-of-purchase displays, and other merchandising and marketing materials.

Invacare continues to enhance www.invacare.com, maintaining its position as the leader in e-commerce in the HME industry. In 2004, Invacare's website utilization continued to increase. Thirty-two-percent of all standard domestic orders were placed over the web. Another 14% of orders were EDI, for a total of 46% of all orders being placed electronically, resulting in a significant cost savings. New online offerings in 2004 included online financing for Invacare providers, resulting in additional transactional cost savings for the company. A full transactional web site for Invacare Canada went live in March. Major enhancements to the administration tools for the online Product Catalog were developed. A web version of the tool makes updating the online catalog quicker and easier. Users can make faster updates to product PDF documents in the online product catalog, streamlining the content management process. The integration of Invacare's website with the new Oracle ERP system began in 2004 and will continue into 2005. Increasing web transactions are reducing the number of calls to the customer service call center, which also results in significant cost savings. This integration is expected to further improve the online customer experience by adding additional website features such as contract pricing, financing options, coupons and product security.

In 2004, Invacare continued its strategic advertising campaign in key trade publications that reach the providers of home medical equipment. The company also contributed extensively to editorial coverage in trade publications concerning the products it manufactures. Company representatives attended numerous trade shows and conferences on a national and regional basis in which Invacare products were displayed to providers, health care professionals and consumers.

Invacare continues to generate greater consumer awareness of the company and its products. This was evidenced by enhancements made to its consumer-marketing program in 2004 through sponsorships of a variety of wheelchair sporting events and support of various philanthropic causes benefiting the consumers of its products. For the eleventh consecutive year, Invacare continued as a National Corporate Partner with Easter Seals, one of the most recognized charities in the United States that meets the needs of both children and adults with various types of disabilities. The company continued its sponsorships of 75 individual wheelchair athletes and teams, including several of the top-ranked male and female racers, hand cyclists, and wheelchair tennis players in the world. Invacare was the title sponsor for the ninth year in a row of the Invacare World Team Cup of Wheelchair Tennis Tournament, which took place in January in Christchurch, New Zealand. The company also continued its support of disabled veterans through its sponsorship of the 24th National Veterans Wheelchair Games, the largest annual wheelchair sports event in the world, which was held in St. Louis, Missouri. The games bring a competitive and recreational sports experience to military service veterans who use wheelchairs for their mobility needs due to spinal cord injury, neurological conditions or amputation. The year 2004 also was a Paralympic year. Team Invacare had more than 30 athletes participating in the competition who brought home more than 30 gold, silver and bronze medals at the games, which were held in September in Athens, Greece, following the Olympic Games.

The company's top 10 customers accounted for approximately 14% of 2004 net sales. The loss of business of one or more of these customers or buying groups may have a significant impact on the company, although no single customer accounted for more than 5% of the company's 2004 net sales. Providers, who are part of a buying group, generally make individual purchasing decisions and are invoiced directly by the company.

Europe
The company's European operations consist primarily of manufacturing, marketing and distribution operations in Western Europe and export sales activities through local distributors elsewhere in the world. The company has a sales force and where appropriate, distribution centers, in the United Kingdom, France, Germany, Belgium, Portugal, Spain, Italy, Denmark, Sweden, Switzerland, Norway and the Netherlands, and sells through distributors elsewhere in Europe. In markets where the company has its own sales force, product sales are typically made through dealers of medical equipment and, in certain markets, directly to government agencies. In most markets, government health care and reimbursement policies play an important role in determining the types of equipment sold and price levels for such products.
I-8

PRODUCT LIABILITY COSTS
The company's captive insurance company, Invatection Insurance Co., currently has a policy year that runs from September 1 to August 31 and insures annual policy losses of $10,000,000 per occurrence and $11,000,000 in the aggregate of the company's North American product liability exposure. The company also has additional layers of external insurance coverage insuring $100,000,000 in annual aggregate losses arising from individual claims anywhere in the world that exceed the captive insurance company policy limits. There can be no assurance that Invacare's current insurance levels will continue to be adequate or available at affordable rates.

Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and indications from the third-party actuary. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon third-party actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the third-party actuary to estimate the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate. Estimates made are adjusted on a regular basis and can be impacted by actual loss award settlements on claims. While actuarial analysis is used to help determine adequate reserves, the company accepts responsibility for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices.

PRODUCT DEVELOPMENT AND ENGINEERING
Invacare is committed to continuously improving, expanding and broadening its existing product lines. In 2004, new product development continued to receive an even stronger emphasis as part of Invacare's strategy to gain market share and maintain competitive advantage. To this end, the company introduced 53 new products. The following are some of the most significant product introductions:

North America
The At'm Take Along Chair, Invacare's newest power wheelchair, provides consumers a light-weight and compact chair to fit in the trunk of a car and assemble easily in just 60 seconds. The consumer's caregiver can open the seat, snap it on the lightweight base, and add the battery. Assembly requires absolutely no tools.

Formula(TM) Powered Seating, combines three systems: the Formula(TM) PTO Plus, the Formula(TM) Invisible Super Low(TM) Tilt, and Formula(TM) TRE to meet the rehab positioning needs of consumers from simple to complex. This all-new Formula Powered Seating package offers the best integration of powered seating upon the number-one bases with the number-one electronics in the HME industry, all from a single company, Invacare.

The Zoom 220 HMV(TM), the newest entrant to the Zoom family of HMVs (Highly Maneuverable Vehicles), is compact, portable, lightweight and economical for active consumers. The Zoom line combines the power wheelchair technology of center-wheel drive with the aesthetics of traditional scooter products for indoor maneuverability and outdoor performance.

The HomeFill(TM) II Patient Convenience Pack ML4, is an all-new portable oxygen supply system that is lightweight -- 3 1/2 pounds - and easy to transport for oxygen patients. The HomeFill Oxygen System offers HME providers 3-to-1 cost savings in servicing their ambulatory oxygen patients since the patient can fill cylinders themselves in their own home, which gives them freedom and independence - they no longer have to wait for cylinder deliveries.

The Polaris(TM) EX(TM) with SoftX(TM) Technology and the Polaris(TM) EX(TM) Heated Humidifier have been integrated as one product rather than two separate units. The Polaris EX CPAP features Invacare's SoftX technology, which tracks the patient's breathing pattern and reduces the patient's work of breathing during exhalation, providing effortless exhalation for the patient.

Web Ox is a PC-based, high-tech solution to the oxygen qualification problem facing the industry today. For a minimal quarterly fee, Web Ox allows providers to subscribe to an unlimited number of tests, allowing faster Medicare billing for oxygen patients, thus improving the provider's cash flow.

A new Bariatrics Program offers a complete solutions approach for the bariatric provider and their clients, and features the full line of Invacare bariatric products. Making it easy to find the right product, the bariatric catalog employs color-coding to sort products by weight capacity. The catalog also offers cross-selling or complementary product suggestions to help educate providers, clinicians and consumers about additional product they may need, and at the same time establishes Invacare as the leading manufacturer offering bariatric solutions.

I-9

Court-Side Glides(TM) for Invacare walkers are an innovative product that takes the homemade tennis ball solution for walker glide tips a step further. For years, consumers and therapists have been slashing tennis balls, sometimes injuring themselves in the process, to create makeshift walker glide tips that are durable for indoor and outdoor use and safe for flooring surfaces. Invacare has enhanced the homemade tennis ball solution to create a walker glide tip that is longer lasting, easy to install and replace.

The Invacare Full Electric Low Bed is ideal for circumstances where rails are not desirable or appropriate, but injuries from falling out of bed are still a concern. It is the newest split-spring low bed available on the market today, allowing easy, one-person delivery to home or long-term care locations. The split-spring design, which Invacare pioneered, combines easy, one-person delivery with the benefits of a low bed.

Asia/Pacific
Dynamic Controls continued various range extensions and design improvements to products during 2004. Additionally, design work was continued on a New Generation Scooter Controller to be introduced in late 2005 and extending functionality in the "Shark" wheelchair controller, which was introduced in 2004.

Europe
During 2004, European operations introduced less new products than in 2003, but updated a number of existing products as required by the market. Key introductions and updates in 2004 included:

The Invacare(R) Dragon is a rear wheel drive power wheelchair designed and manufactured in Europe. It is a solid and cost efficient power wheelchair that provides excellent indoor and outdoor mobility in the suburban environment. It is easy to drive, and the seat can be adjusted to the physical requirements of the user.

The Invacare(R) Robin is a ceiling hoist designed in Europe. It provides the most innovative way of transfer with care for nursing staff. Ensuring excellent personal contact, the two-strap design offers comfort and efficiency in a safe patient handling environment. Without the need for a spreader bar, a secure and dignified transfer can be achieved.

The Invacare(R) Clematis is a manual wheelchair primarily for use in the French market. Excellent comfort, quality and elegance describe this folding chair equipped with pneumatic actuators. The seat positioning of the Clematis offers the user a real sensation of relaxation and wellbeing.

The Invacare(R) Mistral3 power wheelchair is an updated folding chair with seat positioning. It replaces the Mistral and Mistral Plus.

The Invacare(R) Mistral3 Junior power wheelchair is a version of the Mistral3 with a reclining rigid seat base which is width and length adjustable from 30cm to 36cm and provides ultimate comfort to children or younger teenagers whether they are installed in a shell or not.

The Invacare(R) Action3 manual wheelchair, which was released in 2002 has been improved with the following; new locking pin on hanger and elevating leg-rest, folding backrest, reclining backrest with gas spring, leg-rest adaptor, angle adjustable backrest and hemi motion armrest.

The Invacare(R) Action 2000 & MB2 manual wheelchairs have been improved with the following; new arm-pads - short and long and shorter brake shoe.

MANUFACTURING AND SUPPLIERS
The company's objective is to be the highest quality and lowest-cost manufacturer in its industry. The company believes that it can achieve this objective not only through improved product design, but also by taking a number of steps to lower manufacturing costs. During 2004, the company opened manufacturing locations in China at Suzhou Industrial Park and Kunshan City, both of which are near Shanghai, to manufacture components, including bases for consumer power wheelchairs. The company has plans to further utilize its Hong Kong office to increase local sourcing of components in China in order to lower costs. With these actions, Invacare expects to regain its position as one of the lowest cost producers of standard products in the industry.

Of the many opportunities to reduce overall costs, the short-term emphasis will be on building the professional disciplines in the areas of sourcing, quality and logistics, with particular focus on sourcing components and finished goods for each of the business segments.

I-10

North America / Asia/Pacific
The company has vertically integrated its manufacturing processes by fabricating, coating, plating and assembling many of the components of each product. The company designs and manufactures electronics for power wheelchairs, from insertion of components into printed circuit boards to final assembly and testing.

Invacare has focused on value engineering which reduces manufacturing costs by eliminating product complexity and using common components. Value engineering has been applied to all product introductions in the last three years, including the latest generation of oxygen concentrators, electronic controls, wheelchairs, patient lifts, beds and bath safety products.

The company continues to make investments in manufacturing automation. The company has initiated lean manufacturing programs to reduce manufacturing lead times, shorten production cycles, increase associate training, encourage employee involvement in decision-making and improve manufacturing quality. Associate involvement teams participate in engineering, production and processing strategies and associates have been given responsibility for their own quality assurance.

The manufacturing of wheelchairs, replacement parts, patient aids and home care beds consists of a variety of metal fabricating procedures, electronics production, coating, plating and assembly operations. Manufacturing of oxygen concentrators, nebulizer compressors, and seating and positioning products consists primarily of assembly operations. The company purchases raw materials, fabricated components and services from a variety of suppliers. Where appropriate, Invacare does employ long-term contracts with its suppliers, both domestically and from the Far East. In those situations in which long-term contracts are not advantageous, the company believes that its relationships with those suppliers are satisfactory and that alternative sources of supply are readily available.

Europe
As in other areas, manufacturing and operational issues faced in the U.S. are also present in Europe. The European manufacturing operations have streamlined, allowing for the realization of significant synergies and additional cost reductions and improved efficiencies are planned going forward. This process will continue and will now include the integration of the Domus businesses.

ACQUISITIONS
In 2004, Invacare acquired for cash the following six businesses at a total cost of $343,554,000:

o The assets of ACS, a New York distributor of medical supplies with a focus on infusion therapy.
o The assets of Decpac, an Australian company that designs and manufactures portable folding access ramps for use with wheelchairs and scooters.
o Freedom Designs, Inc., a California-based company that designs and manufactures seating products and wheelchairs with a particular focus on the pediatric marketplace.
o WP Domus GmbH, a European-based holding company which manufactures several complementary product lines to Invacare's product lines.
o Champion Manufacturing, LLC , an Indiana company that designs and manufactures medical recliners.
o The assets of Premier Designs, a California company from which Invacare acquired assets and designs for a lightweight, easily transportable power wheelchair.

On September 9, 2004 the company finalized the acquisition of 100% of the shares of WP Domus GmbH, a European-based holding company that manufactures several complementary product lines to Invacare's product lines, including power add-on products, bath lifts and walking aids, from WP Domus LLC. Domus has three divisions: Alber, Aquatec and Dolomite. The acquisition allows the company to expand its product line and reach new markets. The preliminary purchase price was $227,382,000 including acquisition costs of $3,670,000, which was paid in cash, and is subject to final determination of the estimated costs of possible office closures, sales agency transfers and other consolidation efforts expected to be finalized by the end of the third quarter of 2005. The acquisition was consummated after satisfaction of certain conditions, including receipt of all requisite regulatory approvals. Invacare entered into a 100,000,000 Euro bridge loan agreement and utilized its existing revolving credit line to fund the acquisition. Invacare's reported results reflect the operating results of Domus since the date of the acquisition.

Carroll Healthcare, Inc. was purchased in 2003 and as part of the purchase agreement, the company agreed to pay additional consideration based upon earnings before interest, taxes, depreciation and amortization from September 1, 2003 through August 31, 2004 calculated under Canadian generally accepted accounting principles (U.S. GAAP has been used for company reporting purposes) in accordance with the purchase agreement, with no defined maximum amount. The payment amount was finalized and paid in October 2004 at 74,667,000 Canadian Dollars, or $60,992,335 U.S. Dollars, which increased goodwill.

I-11

Motion Concepts, Inc. ("Motion") also was purchased in 2003 and pursuant to the Motion purchase agreement, the Company agreed to pay contingent consideration based upon earnings before interest and taxes over the three years subsequent to the acquisition up to a maximum of approximately $16,000,000. Based upon 2004 results, no additional consideration was paid. When the contingency calculations are completed in 2005 and 2006 related to the acquisition, any additional consideration paid will increase the purchase price and reported goodwill.

As a result of the company's ongoing search for opportunities, coupled with the industry trend toward consolidation, other acquisitions were evaluated in 2004. The company focuses on acquisitions intended to fulfill the following objectives:

Tactical. Grow market share or extend current product lines. Strategic. Enter new market segments that complement existing businesses or utilize the company's distribution strengths. Geographic. Enable rapid entry into new foreign markets.

GOVERNMENT REGULATION
The company is directly affected by government regulation and reimbursement policies in virtually every country in which it operates. Government regulations and health care policy differ from country to country and within some countries, most notably the U.S., Australia and Canada, from state to state or province to province. Changes in regulations and health care policy take place frequently and can impact the size, growth potential and profitability of products sold in each market.

In the U.S., the growth of health care costs has increased at rates in excess of the rate of inflation and as a percentage of GDP for several decades. A number of efforts to control the federal deficit have impacted reimbursement levels for government sponsored health care programs and private insurance companies often imitate changes made in federal programs. Reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain and, thus, affect the product mix, pricing and payment patterns of the company's customers who are the HME providers.

The company continues its pro-active efforts to shape public policy that impacts home and community-based, non-acute health care. We are currently very active with federal legislation and regulatory policy makers. Invacare believes that these efforts give the company a competitive advantage in two ways. First, customers frequently express appreciation for our efforts on behalf of the entire industry. Second, sometimes we have the ability to anticipate and plan for changes in public policy, unlike most other HME manufacturers who must react to change after it occurs.

The Safe Medical Devices Act of 1990 and Medical Device Amendments of 1976 to the Federal Food, Drug and Cosmetics Act of 1938 (the Acts) provide for regulation by the United States Food and Drug Administration (the FDA) of the manufacture and sale of medical devices. Under the Acts, medical devices are classified as Class I, Class II or Class III devices. The company principal products are designated as Class I or Class II devices. In general, Class I devices must comply with labeling and record keeping requirements and are subject to other general controls. In addition to general controls, certain Class II devices must comply with product design and manufacturing controls established by the FDA. Domestic and foreign manufacturers of medical devices distributed commercially in the U.S. are subject to periodic inspections by the FDA. Furthermore, state, local and foreign governments have adopted regulations relating to the manufacture and marketing of health care products. During the past year, the company was inspected by the FDA at multiple locations and found to be acceptable, with only minor inspectional findings needing attention. From time to time, the company may undertake voluntary recalls of its products to maintain ongoing customer relationships and to enhance its reputation for adhering to high standards of quality and safety. The company continues to strengthen its programs to better ensure compliance with applicable regulations for which the failure to comply would have a material adverse effect.

Although there are a number of reimbursement related issues in most of the countries in which Invacare competes, the issues of primary importance are currently in the United States. There are two critical issues for Invacare:
eligibility for reimbursement of power wheelchairs for elderly patients and the provisions of the legislation related to prescription drug coverage under Medicare. With regard to power wheelchairs, there has been a regulatory push by the Centers for Medicare and Medicaid Services (CMS) towards limiting eligibility to patients who cannot take a single step on their own. This limitation has confined many elderly patients, who could be mobile in power wheelchairs, to their beds. Invacare and the home care industry are working hard to convince CMS and the Bush administration that this change does not benefit the elderly and is leading to less active patients who could end up in costly nursing homes and hospitals, and thereby would counteract any cost savings attributable to limiting the eligibility for power wheelchairs. The Administration is scheduled to soon issue new power wheelchair eligibility criteria, which we expect to provide more predictability and improved access to this benefit.

I-12

In November of 2003, Congress passed legislation related to providing prescription drug coverage for the elderly under the Medicare program. As part of funding the costs of this new program, a number of changes to Medicare home care reimbursement rules will take effect over the next few years. First, the home care provider, who is Invacare's customer, did not receive a cost-of-living adjustment in 2004 and will not receive an update in 2005 and 2006. Second, in 2005, Medicare reimbursement for oxygen, along with certain types of home care beds, wheelchairs, nebulizers and supplies, will be lowered to the median reimbursement levels in the Federal Employee Health Benefit Plans. Third, starting in 2007, Congress has authorized competitive bidding in ten of the largest metropolitan regions of the U.S. for home medical items and services. In 2009, the program would be extended to eighty of the largest metropolitan regions.

Although none of these changes are beneficial to the home care industry, Invacare believes that it can still grow and thrive in this environment. The home care industry has not received any cost-of-living adjustments over the last few years and will try to respond with improved productivity to address the lack of support from Congress. In terms of the 2005 price reductions, although we do not yet know what price reduction will be applied to oxygen reimbursement, it is anticipated that the blended cut for all items will be approximately 8%. If we estimate the impact that the 2005 cuts could have on our revenue stream, they are expected to be around 1% of consolidated net sales.

However, Invacare's new products (for example, the low cost oxygen delivery system of HomeFill(TM)), can help address the cuts the home care provider has to endure. We will continue to focus on developing products that help the provider improve profitability. With such products, Invacare believes that it can grow and offset the risks. Additionally, Invacare will accelerate its activities in China to make sure that we are one of the lowest cost manufacturers and distributors to the home care provider.

In terms of competitive bidding, Invacare has strong positions with the likely consolidators who will probably gain share as we approach 2007 and enter the new reimbursement environment. We believe that we are well positioned to combat pricing pressures with volume gains and productivity improvements. Nevertheless, there will be ongoing uncertainty in the industry over the extent and depth of these cuts to the home care industry. Invacare is concerned that, once implemented, competitive bidding will likely generate poorer service in the home care arena as providers look to remain profitable. Likewise, it will likely lead to further consolidation of the provider base as small entrepreneurs may look to exit a less profitable business model. Invacare will keep a close watch on its extension of credit in this environment and will work with the industry to pressure Congress to reconsider its actions. We believe that home care is the least costly and most preferred environment in which an individual can recover from an operation or illness and that government actions should encourage home care rather than lead to more expensive alternatives.

BACKLOG
The company generally manufactures most of its products to meet near-term demands by shipping from stock or by building to order based on the specialty nature of certain products. Therefore, the company does not have substantial backlog of orders of any particular product nor does it believe that backlog is a significant factor for its business.

EMPLOYEES
As of December 31, 2004, the company had approximately 6,100 employees.

FOREIGN OPERATIONS AND EXPORT SALES
The company also markets its products for export to other foreign countries. The company had product sales in over 80 countries worldwide. For information relating to net sales, operating income and identifiable assets of the company's foreign operations, see Business Segments in the Notes to the Consolidated Financial Statements.

AVAILABLE INFORMATION
The company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments thereto, as well as proxy statements and other documents with the Securities and Exchange Commission (SEC). The public may read and copy any material that the company files with the SEC at the SEC's Public Reference Room located at 450 Fifth Street, NW, Washington D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website, www.sec.gov, that contains all reports, proxy statements and other information filed by the company with the SEC.

Additionally, Invacare's filings with the SEC are available on or through the company's website, www.invacare.com, as soon as reasonably practicable after they are filed electronically with, or furnished to, the SEC. Copies of the company's filings also can be requested, free of charge, by writing to:
Shareholder Relations Department, Invacare Corporation, One Invacare Way, P.O. Box 4028, Elyria, OH 44036-2125.

I-13

Item 2. Properties.
The company owns or leases its warehouses, offices and manufacturing facilities and believes that these facilities are well maintained, adequately insured and suitable for their present and intended uses. Information concerning certain leased facilities of the company as of December 31, 2004 is set forth in Leases and Commitments in the Notes to the Consolidated Financial Statements of the company and in the table below:

                                                     Ownership
                                                     Or Expiration        Renewal
North American Operations            Square Feet     Date of Lease        Options                  Use
-------------------------            -----------     -------------        -------                  ---
Alexandria, Virginia                     230         September 2005       None                     Office

Apharetta, Georgia                     9,000         June 2006            None                     Warehouse and Offices

Atlanta, Georgia                     137,284         February 2008        One (3 yr.)              Warehouse and Offices

Atlanta, Georgia                      48,000         August 2006          None                     Sublet

Beltsville, Maryland                  33,329         February 2005        One (3 yr.)              Manufacturing, Offices, and
                                                                                                   Warehouse

Delta, British Columbia               12,000         January 2008         One (3 yr.)              Warehouse and Offices

Deer Park, New York                    5,100         January 2006         None                     Warehouse and Offices

Edison, New Jersey                   105,014         March 2010           None                     Warehouse and Offices

Elyria, Ohio
- Taylor Street                      251,656         Own                  -                        Manufacturing and Offices

- Cleveland Street                   107,052         November 2007        One (3 yr.)              Warehouse

- One Invacare Way                    50,000         Own                  -                        Headquarters

- 1320 Taylor Street                  30,000         January 2010         One (5 yr.)              Offices

- 1160 Taylor Street                   4,800         Own                  -                        Warehouse and Offices

Fresno, California                     2,500         August 2005          -                        Warehouse and Offices

Grand Prairie, Texas                  43,754         April 2008           One (3 yr.)              Warehouse and Offices

Holliston, Massachusetts              57,420         August 2006          None                     Warehouse and Offices

Kirkland, Quebec                      26,196         November 2010        One (5 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

Jamesburg, New Jersey                 83,200         November 2009        One (5 yr.)              Warehouse and Offices

Kunshan City, China                    4,800         May 2006             One (2 yr.)              Manufacturing and Offices

Longmont, Colorado                     2,400         December 2006        -                        Offices

London, Ontario                      103,200         Own                  -                        Manufacturing and Offices

Marlboro, New Jersey                   2,100         June 2005            None                     Office

Mississauga, Ontario                  81,004         January 2005         One (5 yr.)              Sublet

Mississauga, Ontario                  26,530         November 2011        Two (5 yr.)              Warehouse and Offices

North Ridgeville, Ohio               152,861         Own                  -                        Manufacturing, Warehouses and
                                                                                                   Offices

I-14

                                                     Ownership
                                                     Or Expiration        Renewal
North American Operations            Square Feet     Date of Lease        Options                  Use
-------------------------            -----------     -------------        -------                  ---

North Ridgeville, Ohio                66,724         September 2007       Two (3 yr.)              Office

Overland, Missouri                    67,500         May 2007             Two (3 yr.)              Manufacturing, Warehouses and
                                                                                                   Offices

Pharr, Texas                           2,672         Month to Month       -                        Warehouse

Pinellas Park, Florida                11,400         July 2005            Three (1 yr.)            Manufacturing and Offices

Rancho Cucamonga, California          55,890         June 2009            One (60 day)             Warehouse

Reynosa, Mexico                      129,690         Own                  -                        Manufacturing and Offices

Sacramento, California                26,900         May 2008             One (3 yr.)              Manufacturing, Warehouse
                                                                                                   and Offices

Sanford, Florida                     117,108         Own                  -                        Manufacturing and Offices

Sanford, Florida                     100,000         Own                  -                        Manufacturing and Offices

Scarborough, Ontario                   5,428         February 2005        None                     Manufacturing and Offices

Simi Valley, California               38,501         February 2009        Two (5 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

South Bend, Indiana                   48,000         September 2008       Two (5 yr.)              Warehouse

Spicewood, Texas                       6,500         Month to Month       None                     Manufacturing and Offices

Suzhou, China                          5,000         May 2006             None                     Manufacturing and Offices

Tonawanda, New York                    7,515         March 2008           None                     Warehouse and Offices

Traverse City, Michigan               15,850         April 2006           None                     Manufacturing and Offices

Vaughan, Ontario                      12,000         June 2008            None                     Manufacturing and Offices

Asia/Pacific Operations
-----------------------
Adelaide, Australia                   21,668         April 2006           One (5 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

Adelaide, Australia                   24,000         August 2007          One (5 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

Auckland, New Zealand                 27,000         September 2008       Two (3 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

Birmingham, United Kingdom            15,845         July 2013            None                     Warehouse and Offices

Christchurch, New Zealand             57,682         December 2005        Two (3 yr.)              Manufacturing and Offices

Hong Kong, China                         600         February 2007        None                     Offices

Hong Kong, China                         600         April 2007           None                     Offices

I-15

                                                     Ownership
                                                     Or Expiration        Renewal
Asia/Pacific Operations              Square Feet     Date of Lease        Options                  Use
-------------------------            -----------     -------------        -------                  ---
Melbourne, Australia                  19,629         July 2006            One (2 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

Napier, New Zealand                    4,844         March 2009           Two (3 yr.)              Warehouse and Offices

North Olmsted, Ohio                    2,280         October 2008         None                     Warehouse and Offices

Sydney, Australia                     16,000         February 2009        Two (3 yr.)              Warehouse and Offices

European Operations
-------------------
Albstadt-Tailfi, Germany              78,495         January 2018         Two (5 yr.)              Manufacturing, Warehouse and
                                                                                                   Offices

Allschwil, Switzerland                36,000         Own                  -                        Manufacturing, Warehouse and
                                                                                                   Offices

Anderstorp, Sweden                    47,527         Own                  -                        Manufacturing, Warehouse and
                                                                                                   Offices

Bergen, Norway                         1,000         May 2009             One (5 yr.)              Warehouse and Offices

Bridgend, Wales                      131,522         Own                  -                        Manufacturing, Warehouse and
                                                                                                   Offices

Brondby, Denmark                      16,142         December 2005        One (1 yr.)              Warehouse and Offices

Dio, Sweden                          107,600         Own                  -                        Manufacturing and Offices

Dublin, Ireland                        5,000         December 2009        Three (5 yr.)            Warehouse and Offices

Ede, The Netherlands                  16,000         May 2009             One (5 yr.)              Warehouse and Offices

Fondettes, France                    106,412         November 2007        None                     Manufacturing, Warehouse, and
                                                                                                   Offices

Girona, Spain                         13,600         November 2005        One (1 yr.)              Warehouse and Offices

Gland, Switzerland                     4,306         September 2007       One (5 yr.)              Offices

Gland, Switzerland                     1,173         September 2007       One (4 yr.)              Offices

Goteberg, Sweden                       7,500         June 2006            One (3 yr.)              Warehouse and Offices

Hong, Denmark                        155,541         Own                  -                        Manufacturing, Warehouse and
                                                                                                   Offices

Isny, Germany                        197,581         Own                  -                        Manufacturing, Warehouse and
                                                                                                   Offices

Loppem, Belgium                        6,000         December 2009        One (3 yr.)              Warehouse and Offices

Landskrona, Sweden                     3,099         April 2005           One (3 yr.)              Warehouse

Mondsee, Austria                       1,505         March 2005           Unlimited                Warehouse and Offices

Munchen, Germany                       2,022         July 2005            None                     Offices

I-16

                                                     Ownership
                                                     Or Expiration        Renewal
European Operations                  Square Feet     Date of Lease        Options                  Use
-------------------------            -----------     -------------        -------                  ---
Ontario, Canada                      14,394          May 2007             None                     Offices

Oporto, Portugal                     27,800          Own                  -                        Manufacturing, Warehouse and
                                                                                                   Offices

Oskarshamn, Sweden                   3,551           December 2005        One (1 yr.)              Warehouse

Oslo, Norway                         30,650          September 2006       None                     Warehouse and Offices

Porta Westfalica, Germany            134,563         October 2021         None                     Manufacturing, Warehouse and
                                                                                                   Offices

Spanga, Sweden                       3,228           June 2007            One (3 yr.)              Warehouse and Offices

Spanga, Sweden                       16,140          Own                  -                        Warehouse and Offices

Thiene, Italy                        21,520          Own                  -                        Warehouse and Offices

Marano, Italy                        21,528          May 2005             One (6 yr.)              Manufacturing

Fondettes, France                    106,412         November 2007        None                     Manufacturing, Warehouse, and
                                                                                                   Offices

Trondheim, Norway                    3,000           December 2007        One (3 yr.)              Services and Offices

Venissieux, France                   1,409           October 2006         None                     Offices

Witterswil, Switzerland              40,301          March 2015           Various (5 year)         Manufacturing, Warehouse, and
                                                                                                   Offices

Wurenlos, Switzerland                3,935           June 2009            One (to be determined)   Offices

Item 3. Legal Proceedings.
In the ordinary course of its business, Invacare is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits have been referred to the company's insurance carriers and are being contested vigorously. Coverage territory is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. Management does not believe that the outcome of any of these actions will have a material adverse effect upon its business or financial condition.

Item 4. Submission of Matters to a Vote of Security Holders.
During the fourth quarter of 2004, no matter was submitted to a vote of our security holders.

Executive Officers of the Registrant.*
The following table sets forth the names of the executive officers of Invacare, each of whom serves at the pleasure of the Board of Directors, as well as certain other information.
Name                                           Age               Position
----                                           ---               --------
A. Malachi Mixon, III                          64                Chairman of the Board of Directors and Chief Executive Officer

Gerald B. Blouch                               58                President, Chief Operating Officer and Director

Gregory C. Thompson                            49                President - HME Group and Chief Financial Officer

I-17

Name                                           Age               Position
----                                           ---               --------
Joseph B. Richey, II                           68                President - Invacare Technologies, Senior Vice
                                                                 President - Electronics and Design Engineering and Director

Louis F.J. Slangen                             57                Senior Vice President - Global Market Development

Joseph Usaj                                    53                Senior Vice President - Human Resources

A. Malachi Mixon, III has been a Director since 1979. Mr. Mixon has been Chief Executive Officer since 1979 and Chairman of the Board since 1983 and also served as President until 1996, when Gerald B. Blouch, Chief Operating Officer, was elected President.

Gerald B. Blouch has been President and a Director of Invacare since November 1996. Mr. Blouch has been Chief Operating Officer since December 1994 and Chairman-Invacare International since December 1993. Previously, Mr. Blouch was President-Homecare Division from March 1994 to December 1994 and Senior Vice President-Homecare Division from September 1992 to March 1994. Mr. Blouch served as Chief Financial Officer of Invacare from May 1990 to May 1993 and Treasurer of Invacare from March 1991 to May 1993. Mr. Blouch is also a director of NeuroControl Corporation, Cleveland, Ohio, a privately held company, which develops and markets electromedical stimulation systems for stroke patients.

Gregory C. Thompson was named Senior Vice President and Chief Financial Officer in November 2002. In January 2005, he was assigned the additional position of President - Home Medical Equipment Group. Before coming to Invacare, Mr. Thompson served as Senior Vice President and Chief Financial Officer of Sensormatic Electronics Corporation, a global manufacturer of electronic security products, from October 2000 to January 2002 and was Vice President and Controller from February 1997 to October 2000. Previously, Mr. Thompson was Vice President and Corporate Controller for Wang Laboratories from August 1994 to February 1997 and Assistant Corporate Controller from October 1990 to August 1994.

Joseph B. Richey, II has been a Director since 1980 and in September 1992 was named President - Invacare Technologies and Senior Vice President - Electronics and Design Engineering. Previously, Mr. Richey was Senior Vice President of Product Development from July 1984 to September 1992 and Senior Vice President and General Manager of North American Operations from September 1989 to September 1992. Mr. Richey is also a director of NeuroControl Corporation, Cleveland, Ohio, a privately held company, which develops and markets electromedical stimulation systems for stroke patients.

Louis F. J. Slangen was named Senior Vice President - Global Market Development in June 2004. Previously, Mr. Slangen was Senior Vice President - Sales & Marketing from December 1994 to June 2004 and from September 1989 to December 1994 was Vice President - Sales and Marketing. Mr. Slangen was previously President - Rehab Division from March 1994 to December 1994 and Vice President and General Manager - Rehab Division from September 1992 to March 1994.

Joseph Usaj has been the Senior Vice President - Human Resources since May 2004. Before coming to Invacare, Mr. Usaj served as Vice President - Human Resources for Ferro Corporation, a global manufacturer of performance materials in the electronics, automotive, consumer products and pharmaceutical industries, from August 2002 to December 2003. Previously, Mr. Usaj was Vice President - Human Resources for Phillips Medical Systems from 1998 to 2002.

* The description of executive officers is included pursuant to Instruction 3 to Section (b) of Item 401 of Regulation S-K.

I-18

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Repurchases of Equity Securities.

Invacare Common Shares, without par value, trade on the New York Stock Exchange (NYSE) under the symbol IVC. Ownership of the company Class B Common Shares (which are not listed on NYSE) cannot be transferred, except, in general, to family members. Class B Common Shares may be converted into Common Shares at any time on a share-for-share basis. The approximate number of record holders of the company Common Shares and Class B Common Shares at February 24, 2005 was 4,813 and 27, respectively. The closing sale price for the Common Shares on February 24, 2005 as reported by NYSE, was $46.57. The prices set forth below do not include retail markups, markdowns or commissions.

The range of high and low quarterly prices of the Common Shares in each of the two most recent fiscal years were as follows:

                                          2004                 2003
                                          ----                 ----
Quarter Ended:                       High       Low      High       Low
-------------                        ----       ---      ----       ---
December 31                         $52.00    $43.72    $43.74    $38.78
September 30                         47.16     39.74     40.00     32.99
June 30                              46.50     39.34     34.00     30.29
March 31                             46.50     39.63     34.15     30.02

During 2004 and 2003, the Board of Directors declared dividends of $0.05 per Common Share and $0.045 per Class B Common Share. For information regarding limitations on the payment of dividends in the company loan and note agreements, see Long Term Debt in the Notes to the Consolidated Financial Statements. The Common Shares are entitled to receive cash dividends at a rate of at least 110% of cash dividends paid on the Class B Common Shares.

Information regarding the securities authorized for issuance under equity compensation plans is incorporated by reference to the information set forth under the captions Compensation of Executive Officers and Compensation of Directors in the company's definitive Proxy Statement for the 2005 Annual Meeting of Shareholders.

I-19

Item 6.  Selected Financial Data
                                               2004          2003          2002          2001*         2000
                                               ----          ----          ----          ----          ----
                                             (In thousands, except per share and ratio data)
Earnings
Net Sales                                $1,403,327    $1,247,176    $1,089,161    $1,053,639    $1,013,162
Net Earnings **                              75,197        71,409        64,770        35,190        59,911
Net Earnings per Share - Basic                 2.41          2.31          2.10          1.15          1.99
Net Earnings per Share -
    Assuming Dilution                          2.33          2.25          2.05          1.11          1.95
Dividends per Common Share                  0.05000       0.05000       0.05000       0.05000       0.05000
Dividends per Class B Common Share          0.04545       0.04545       0.04545       0.04545       0.04545


                                               2004          2003          2002          2001*         2000
                                               ----          ----          ----          ----          ----
Balance Sheet
Current Assets                             $565,151      $474,722      $398,812     $ 428,401      $432,408
Total Assets                              1,628,124     1,108,213       906,703       914,537       951,855
Current Liabilities                         258,141       223,488       168,226       167,453       197,387
Working Capital                             307,010       251,234       230,586       260,948       235,021
Long-Term Debt                              547,974       232,038       234,134       342,724       384,316
Shareholders' Equity                        753,438       618,304       480,312       381,550       349,773

Other Data
Research and Development
   Expenditures                             $21,638       $19,130       $17,934       $17,394       $16,231
Capital Expenditures, net of
   Disposals                                 41,400        30,129        19,718        19,486        26,268
Depreciation and Amortization                32,316        27,235        26,638        33,448        31,469

Key Ratios
Return on Sales                                5.4%          5.7%          5.9%          3.3%          5.9%
Return on Average Assets                       5.5%          7.1%          7.1%          3.8%          6.3%
Return on Beginning
   Shareholders' Equity                       12.2%         14.9%         17.0%         10.1%          18.8%
Current Ratio                                 2.2:1         2.1:1         2.4:1         2.6:1          2.2:1
Debt-to-Equity Ratio                          0.7:1         0.4:1         0.5:1         0.9:1          1.1:1

* Reflects non-recurring and unusual charge of $31,950 ($25,250 after tax or $0.80 per share assuming dilution).

** Amortization of goodwill ceased in 2002, net earnings in 2001 and 2002 include amortization expense of $8,972 and $8,899, respectively.

The comparability of the Selected Financial Data provided in the above table is limited as acquisitions made, in particular, the Domus acquisition in 2004, materially impacted the company's reported results. See Acquisitions in the Notes to the Consolidated Financial Statements, which provides pro-forma results.

I-20

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

OUTLOOK
Uncertainty related to Medicare's reimbursement policies for power wheelchairs is now expected to continue throughout 2005. The new proposed criteria from CMS require public comment before implementation. The resulting ambiguity that is impacting the consumer power wheelchair market likely will not be clarified until late 2005, although CMS has recently indicated it will try and finalize the new criteria in the first half of 2005. Adding to the problems arising from the reimbursement difficulties, there will be additional confusion resulting from Medicare's plan to expand coding of the power wheelchair reimbursement system from 4 codes to 49 codes in January 2006. Despite the reimbursement pressures, the Company believes that it will have a net sales increase of between 18% and 20%, with acquisitions contributing between 11% and 13% and currency translation contributing a minimal amount. Earnings per share is expected to be between $2.75 and $2.90 in 2005, excluding the impact from the stock option accounting standard recently announced by the Financial Accounting Standards Board.

Invacare believes it can still grow and thrive despite the fact that the home care industry has not received any cost-of-living adjustments over the last few years and government regulatory landscape is uncertain. The company expects that the blended cut for the items affected by recent government regulations will be around 8%, which should negatively affect consolidated net sales by around 1%. However, Invacare's new products, (for example, the low cost oxygen delivery system of HomeFill(TM)), can help address the cuts the home care provider has to endure. We will continue to focus on developing products that help the provider improve profitability. With such products, Invacare believes it can grow and offset the risks. Additionally, Invacare will accelerate its activities in China to make sure that we are one of the lowest cost manufacturers and distributors to the home care provider.

RESULTS OF OPERATIONS
2004 Versus 2003

Reclassifications. The following Management's Discussion and Analysis of Financial Condition and Results of Operations reflect certain reclassifications made to the prior years' consolidated financial statements to conform to the presentation used for the year ended December 31, 2004.

Net Sales. Consolidated net sales for 2004 increased 13% for the year, to $1,403,327,000 from $1,247,176,000. Acquisitions accounted for 8 percentage points of the net sales increase while foreign currency translation contributed an additional 3 percentage points. The overall growth was primarily driven by volume increases in North America.

North American Operations

North American net sales, increased 12% over the prior year, with acquisitions accounting for 8% of the increase and currency translation having less than a one percentage point impact. These sales consist of Rehab (power wheelchairs, custom manual wheelchairs, personal mobility and seating and positioning), Standard (manual wheelchairs, personal care, home care beds, low air loss therapy and patient transport), Continuing Care (beds and furniture), Respiratory (oxygen concentrators, aerosol therapy, sleep, homefill and associated respiratory) and Distributed (ostomy, incontinence, diabetic, wound care and other medical supplies) products.

For the year, the net sales increase was attributable to volume increases in:
Respiratory products (37%), largely due to continued strong performance in the Homefill(TM) oxygen system product line; Distributed products (26%), with acquisitions contributing 15 percentage points of the improvement; and Continuing Care products (59%) with acquisitions contributing 52 percentage points of the improvement. These were partially offset by declines in Standard products (6%) as a result of reduced pricing and flat Rehab product sales. Sales of Rehab products were negatively impacted by Medicare and Medicaid related reimbursement pressures. In particular, CMS was expected to release new guidelines for power chairs in the fourth quarter of 2004, it instead circulated proposed criteria that required public comment before implementation. While the proposed criteria are favorable and are based on CMS' own medical study, the ambiguity that is impacting the power wheelchair market has resulted in significant declines in this market segment.

Other products, consisting primarily of the company's Canadian and aftermarket parts businesses, had a 10% net sales increase principally as a result of volume increases.

European Operations

European net sales increased 20% over the prior year to $336,792,000 from $279,782,000. Acquisitions contributed 12 percentage points of the increase and foreign currency accounted for 10 percentage points of the increase. The decline in organic growth was primarily due to reduced volumes in the Nordic countries and continued reimbursement pressures in Germany.

I-21

Asia/Pacific Operations

Asia/Pacific net sales declined 8% from the prior year to $64,262,000 from $70,186,000. Excluding the impact of foreign exchange, net sales declined 18% for the year. The decline was primarily the result of reduced volumes of microprocessor controllers, resulting from the global slowdown in the production of power wheelchairs caused in large part by the Medicare reimbursement challenges in the United States described above. The Asia/Pacific segment transacts a substantial amount of its business with customers outside of their region in various currencies other than their functional currency, the New Zealand Dollar. As a result, changes in exchange rates particularly with the Euro and U.S. Dollar can have a significant impact on sales and cost of sales.

Gross Profit. Consolidated gross profit as a percentage of net sales was 29.8% in 2004 and 30.0% in 2003. The margin decline was attributable to continued competitive pricing pressures and increased freight costs partially offset by continued cost reduction initiatives.

North American gross profit as a percentage of net sales was 30.2% in 2004 versus 30.3% in 2003. The decline was primarily attributable to reduced pricing in Standard products partially offset by continued cost reduction efforts.

Gross profit in Europe as a percentage of net sales declined .7 of a percentage point from the prior year. The decline is attributable to unfavorable sales mix toward lower margin products and additional costs related to new product introductions.

Gross profit in Asia/Pacific as a percentage of net sales decreased by 3.5 percentage points from the prior year. The decline was due in part to increased sales of lower margin products in the company's Dynamic Controls subsidiary, reduced volumes and unfavorable foreign currency associated with normal operating transactions.

Selling, General and Administrative. Consolidated selling, general and administrative expenses as a percentage of net sales were 21.2% in 2004 and 21.0% in 2003. The overall dollar increase was $35,109,000 or 13%, with acquisitions increasing selling, general and administrative costs by approximately $20,263,000 or 8% and currency translation by $9,409,000 or 4%. Selling, general and administrative expenses also increased as a result of increased distribution and commission costs related to increased volumes, continued investments in marketing and branding programs, and increased legal costs. These were partially offset by reduced bad debt expense and management bonuses as a result of reduced profitability from plan.

Selling, general and administrative expenses for North American operations increased 9% or $16,562,000 compared to 2003 with acquisitions accounting for 7 percentage points of the increase. The remaining increase is primarily attributable to continued investments in marketing and branding programs, increased distribution and commission costs related to increased volume and higher legal costs. These increases were partially offset by reduced bad debt expense and management bonuses.

European operations' selling, general and administrative expenses increased 26% or $17,290,000 from the prior year. European selling, general and administrative expenses increased due to acquisitions and foreign currency translation. Increases, primarily for acquisitions, were $7,791,000 or 12% and for currency translation totaled $7,305,000 or 11%. The remaining increase was primarily attributable to additional programs to re-establish sales growth.

Asia/Pacific operations' selling, general and administrative expenses increased 16% or $1,257,000 with foreign currency increasing the expense by $961,000 or 12%. The remaining increase was primarily attributable to additional systems costs related to an Enterprise Resource Planning (ERP) implementation and sales and marketing costs associated with the development of the Asia market.

Interest. Interest expense increased to $16,282,000 in 2004 from $11,710,000 in 2003, representing a 39% increase. This increase was attributable to increased borrowings under the Company's revolving credit facility, and to new borrowings under an interim bridge loan financing facility. The company's debt-to-equity ratio increased to 0.7:1 as of December 31, 2004 from 0.4:1 as of the end of the prior year. Interest income in 2004 was $5,186,000, which was comparable to $5,473,000 in the prior year. Since December 2000, Invacare customers primarily utilize the third-party financing arrangement with DLL, a subsidiary of Rabo Bank of the Netherlands, to provide financing.

Income Taxes. The company had an effective tax rate of 31.9% in 2004 and 32.9% in 2003. The effective tax rate declined due to a change in the mix of earnings and permanent deductions. The Company's effective tax rate is lower than the federal statutory rate primarily due to tax credits and earnings abroad being taxed at rates lower than the federal statutory rate.

I-22

Research and Development. The company continues to increase its research and development activities to maintain its competitive advantage. The company dedicates dollars to applied research activities to ensure that new and enhanced design concepts are available to its businesses. Research and development expenditures, which are included in costs of products sold, increased to $21,638,000 in 2004 from $19,130,000 in 2003. The expenditures, as a percentage of net sales, were 1.5% in 2004 and 1.5% in the prior year.

2003 Versus 2002

Net Sales. Consolidated net sales for 2003 increased 15% for the year, to $1,247,176,000 from $1,089,161,000, with net sales increasing in all business segments on a reported basis. Foreign currency translation accounted for 6% of the net sales increase, while acquisitions contributed an additional 3%. The overall growth was primarily driven by volume increases in North America and Asia/Pacific.

North American Operations

North American net sales, consisting of Rehab (power wheelchairs, custom manual wheelchairs, personal mobility and seating and positioning), Standard (manual wheelchairs, personal care, home care beds, low air loss therapy and patient transport), Continuing Care (beds and furniture), Respiratory (oxygen concentrators, aerosol therapy, sleep, homefill and associated respiratory) and Distributed (ostomy, incontinence, diabetic, wound care and other medical supplies) products increased 13% over the prior year, with currency translation having less than a one percentage point impact and acquisitions accounting for 3%.

For the year, the net sales increase was attributable to increases in Respiratory products (43%), Rehab products (30%), Distributed products (11%) and Continuing Care products (20%), which were partially offset by declines in Standard products (6%). Excluding acquisitions, Rehab product net sales increased by 26% and Continuing Care product net sales declined by 4%. The net sales improvements were led by strong sales growth in oxygen concentrators, the HomeFill(TM) product line and consumer power products. Declines were primarily attributable to continued pricing pressures in Standard products and weaker sales to nursing homes through Invacare Continuing Care Group as a result of the continued uncertainty surrounding government reimbursement programs.

Other products, consisting primarily of the company's Canadian and aftermarket parts businesses, had an 8% net sales increase primarily as a result of volume increases.

European Operations

European net sales increased 11% over the prior year to $279,782,000 from $251,443,000. Foreign currency and acquisitions contributed 16 percentage points and 3 percentage points, respectively, of the net sales increase. The organic decline of 8% was primarily due to slower than expected sales in the Nordic region and reimbursement pressures in Germany.

Asia/Pacific Operations

Asia/Pacific net sales increased 59% from the prior year to $70,186,000 from $44,254,000. Excluding the impact of foreign exchange, net sales increased 27% for the year. The increase was primarily the result of sales at Dynamic Controls due in part to a significant increase in sales to a non-healthcare customer.

Gross Profit. Consolidated gross profit as a percentage of net sales were 30.0% in 2003 and 30.1% in 2002. Margins remained relatively flat, as the company was able to offset pricing pressures with improved manufacturing performance.

North American gross profit as a percentage of net sales was 30.3% in 2003 versus 30.0% in 2002. The increase was primarily attributable to continued cost reduction efforts and improved product and customer mix.

Gross profit in Europe as a percentage of net sales improved 1.0 percentage point from the prior year. The improvement is attributable to favorable sales mix towards higher margin products and cost reduction efforts.

Gross profit in Asia/Pacific as a percentage of net sales decreased by 6.1 percentage points from last year. The decline was due in part to increased sales of lower margin products in the company's Dynamic Controls subsidiary and increased costs to support the growth in the business.

I-23

Selling, General and Administrative. Consolidated selling, general and administrative expenses as a percentage of net sales were 21.0% in 2003 and 20.2% in 2002. The overall dollar increase was $41,719,000 or 19% with currency translation increasing selling, general and administrative costs by approximately $13,103,000 or 6% and acquisitions by $6,800,000 or 3%. Selling, general and administrative expenses also increased as a result of accruals for management bonuses as a result of improved profitability, increased distribution and commission costs related to increased volumes, continued investments in marketing and branding programs, and increased insurance costs.

North American operations selling, general and administrative expenses increased 15% or $21,789,000 compared to 2002. The increase is primarily attributable to acquisitions, continued investments in marketing and branding programs, additional provisions for bad debt and increases in insurance costs.

European operations selling, general and administrative expenses increased 30% or $15,721,000 from the prior year. European selling, general and administrative expenses were negatively impacted by foreign currency translation and acquisitions, which increased expenses, reported in dollars by $9,993,000 or 19% and $1,547,000 or 3%, respectively. The remaining increase was primarily attributable to additional programs to re-establish sales growth.

Asia/Pacific operations' selling, general and administrative expenses increased 40% or $2,264,000 with foreign currency increasing the expense by $1,522,000 or 27%. Asia/Pacific selling, general and administrative costs grew at a slower rate than sales principally as a result of aggressive expense control.

Interest. Interest expense decreased to $11,710,000 in 2003 from $15,122,000 in 2002, representing a 23% decrease. This decrease was attributable to the continued favorable interest rate environment in 2003 and to a decrease in the company's average borrowings outstanding under the company's revolving credit facility. The company's debt-to-equity ratio decreased to 0.4:1 as of December 31, 2003 from 0.5:1 as of the end of the prior year. Interest income increased in 2003 to $5,473,000 from $4,550,000 in the prior year, primarily attributable to an increase in loan origination fees received from De Lage Landen Inc. (DLL). Since December 2000, Invacare customers primarily utilize the third-party financing arrangement with DLL, a subsidiary of Rabo Bank of the Netherlands, to provide financing.

Income Taxes. The company had an effective tax rate of 32.9% in both 2003 and 2002, which is lower than the United States federal statutory rate as a significant portion of the company earnings are outside of the United States and taxed at lower rates.

Research and Development. The company continues to increase its research and development activities to maintain its competitive advantage. The company dedicates dollars to applied research activities to ensure that new and enhanced design concepts are available to its businesses. Research and development expenditures, which are included in costs of products sold, increased to $19,130,000 in 2003 from $17,934,000 in 2002. The expenditures, as a percentage of net sales, were 1.5% in 2003 and 1.6% in the prior year.

INFLATION
Although the company cannot determine the precise effects of inflation, management believes that inflation does continue to have an influence on the cost of materials, salaries and benefits, utilities and outside services. The company attempts to minimize or offset the effects through increased sales volume, capital expenditure programs designed to improve productivity, alternative sourcing of material and other cost control measures. In 2004 and 2003, the company was able to offset the majority of the impact of price increases from suppliers by productivity improvements and other cost reduction activities.

LIQUIDITY AND CAPITAL RESOURCES
The company continues to maintain an adequate liquidity position through its unused bank lines of credit (see Long-Term Debt in the Notes to Consolidated Financial Statements) and working capital management. The company maintains various bank lines of credit to finance its worldwide operations. In 2003, the company issued $100,000,000 in senior notes, which are due between 2007 and 2010. In 2001, the company completed a $325,000,000 multi-currency, long-term revolving credit agreement, which was replaced on January 14, 2005, along with a 100,000,000 Euro bridge agreement entered into in 2004, by a new $450,000,000 multi-currency, long-term revolving credit agreement. In February 2005, the new $450,000,000 multi-currency, long-term revolving credit agreement was also used to pay off the $20,000,000 senior notes at 6.60%. Additionally, the company maintains various other demand lines of credit totaling a U.S. dollar equivalent of approximately $4,229,000 as of December 31, 2004. The lines of credit along with cash generated from operations have been and will continue to be used to fund the company's domestic and foreign working capital, capital expenditures and acquisition requirements. As of December 31, 2004, the company had approximately $126,734,000 available under its various lines of credit, excluding debt covenant restrictions.

I-24

The company's borrowing arrangements contain covenants with respect to, among other items, interest coverage, net worth, dividend payments, working capital, and funded debt to capitalization, as defined in the company's bank agreements and agreement with its note holders. The company is in compliance with all covenant requirements. Under the most restrictive covenant of the company's borrowing arrangements, the company has the capacity to borrow up to an additional $60,800,000 as of December 31, 2004 and up to $108,000,000, effective February 2005, pursuant to the covenants of the company's new $450,000,000 multi-currency, long-term revolving credit agreement.

While there is general concern about the potential for rising interest rates, exposure to interest rate fluctuations is manageable given that a portion of the debt is at fixed rates through 2010. In addition, the ability to terminate existing swaps that exchange fixed rate debt to variable and to utilize interest rate swaps to fix a higher percentage of the company's debt coupled with free cash flow should allow Invacare to absorb the expected modest rate increases in the months ahead without any material impact on our liquidity or capital resources. As of December 31, 2004, the weighted average floating interest rate on U.S. borrowings was 3.36%.

CAPITAL EXPENDITURES
There are no individually material capital expenditure commitments outstanding as of December 31, 2004. The company estimates that capital investments for 2005 could approximate up $37,000,000, compared to actual capital expenditures of $41,403,000 in 2004. The company believes that its balances of cash and cash equivalents, together with funds generated from operations and existing borrowing facilities, will be sufficient to meet its operating cash requirements and fund required capital expenditures for the foreseeable future.

CASH FLOWS
Cash flows provided by operating activities were $98,324,000 in 2004, compared to $116,204,000 last year. The decrease is due primarily to increases in installment receivables and inventory and a decline in accrued expenses primarily related to reduced customer rebates. These were partially offset by an increase in accounts payable.

Cash flows used for investing activities were $389,022,000 in 2004, compared to $101,558,000 in 2003. The increase was primarily attributable to costs associated with acquired businesses with the Domus acquisition being the most significant. In addition, purchases of property and equipment activity in 2004 was higher compared to the prior year as the company is in the process of implementing Enterprise Resource Planning Systems in North America, Europe and Asia/Pacific.

Cash flows provided by financing activities in 2004 were $307,051,000, compared to cash flows required of $13,955,000 in 2003. Financing activities for 2004 were impacted by an increase in the company's borrowings of $303,188,000 primarily related to acquisitions. In addition to acquisition activities, the effect of foreign currency translation results in amounts being shown in the Consolidated Statement of Cash Flows that are different from the changes reflected in the respective balance sheet captions.

During 2004, the company generated free cash flow of $56,921,000 compared to free cash flow of $85,544,000 in 2003. The decrease was primarily attributable to additional capital expenditures made in 2004, primarily for enterprise resource planning systems as well as increases in installment receivables and inventory coupled with a decline in accrued expenses, primarily related to reduced customer rebates. Free cash flow is a non-GAAP financial measure that is comprised of net cash provided by operating activities less purchases of property and equipment. Management believes that this financial measure provides meaningful information for evaluating the overall financial performance of the Company and its ability to repay debt or make future investments (including acquisitions, etc.). The non-GAAP financial measure is reconciled to the GAAP measure as follows (in thousands):

                                                      Twelve Months Ended
                                                          December 31,
                                                      2004           2003
----------------------------------------------------------------------------
Net cash provided by operating activities          $98,324       $116,204
Adjusted for:
Purchases of property and equipment                (41,403)       (30,660)
                                                   -------        -------
Free Cash Flow                                     $56,921        $85,544
                                                   =======        =======

I-25

CONTRACTUAL OBLIGATIONS
-----------------------
 (In thousands)                                                            Payments due by period
                                           Total      Less than 1 year           1-3 years          3-5 years     More than 5 years
                                        --------      ----------------           ---------          ---------     -----------------
Long-term debt obligations
   Senior Notes                         $234,595                $8,054             $68,065           $116,629               $41,847
   Revolving credit agreements           382,755                10,647              20,648             20,648               330,812
   Other notes                             1,415                   162                 324                324                   605
Operating lease obligations               37,354                15,680              14,909              5,050                 1,715
Capital lease obligations                 21,539                 1,751               3,285              3,064                13,439
Purchase obligations
   (primarily computer systems             6,975                 6,468                 507                  -                     -
    contracts)
Other long-term obligations
   Product liability                      17,045                 2,595               7,263              3,227                 3,960
   SERP                                   13,371                   424               1,658              1,559                 9,730
   Other, principally deferred
     compensation                         16,680                   339               3,068                612                12,661
                                        --------               -------            --------           --------              ---------
Total                                   $731,729               $46,120            $119,727           $151,113              $414,769
                                        ========               =======            ========           ========              ========

DIVIDEND POLICY
It is the company's policy to pay a nominal dividend in order for its stock to be more attractive to a broader range of investors. The current annual dividend rate remains at $0.05 per Common Share and $0.045 per Class B Common Share. It is not anticipated that this will change materially as the company continues to have available significant growth opportunities through internal development and acquisitions. For 2004, dividends of $0.05 per Common Share and $0.045 per Class B Common Share were declared and paid.

CRITICAL ACCOUNTING POLICIES
The consolidated financial statements include accounts of the company and all majority-owned subsidiaries. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions in certain circumstances that affect amounts reported in the accompanying consolidated financial statements and related footnotes. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. However, application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates.

Revenue Recognition
Invacare's revenues are recognized when products are shipped to unaffiliated customers. The Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 101, "Revenue Recognition," as updated by SAB No. 104, provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. The company has concluded that its revenue recognition policy is appropriate and in accordance with generally accepted accounting principles and SAB No. 101.

Sales are only made to customers with whom the company believes collection is reasonably assured based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts.

The company offers discounts and rebates, which are accounted for as reductions to revenue in the period in which the sale is recognized. Discounts offered include: cash discounts for prompt payment, base and trade discounts based on contract level for specific classes of customers. Volume discounts and rebates are given based on large purchases and the achievement of certain sales volumes. Product returns are accounted for as a reduction to reported sales with estimates recorded for anticipated returns at the time of sale. The company does not sell any goods on consignment.

Distributed products sold by the company are accounted for in accordance with EITF 99-19 Reporting Revenue Gross as a Principal versus Net as an Agent. The company records Distributed product sales gross as a principal since the company takes title to the products and has the risks of loss for collections, delivery and returns.

I-26

Product sales that give rise to installment receivables are recorded at the time of sale when the risks and rewards of ownership are transferred. In December 2000, the company entered into an agreement with DLL, a third party financing company, to provide the majority of future lease financing to Invacare customers. As such, interest income is recognized based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments, interest income is no longer recognized. All installment accounts are accounted for using the same methodology, regardless of duration of the installment agreements.

Allowance for Uncollectible Accounts Receivable Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the company's receivables are due from health care, medical equipment dealers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. In addition, the company has seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts is based primarily on management's evaluation of the financial condition of the customer. In addition, as a result of the third party financing arrangement with DLL, management monitors the collection status of these contracts in accordance with the company's limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts.

Inventories and Related Allowance for Obsolete and Excess Inventory Inventories are stated at the lower of cost or market with cost principally determined for domestic manufacturing inventories by the last-in, first-out (LIFO) method and for non-domestic inventories and domestic finished products purchased for resale by the first-in, first-out (FIFO) method.

Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management's review of inventories on hand compared to estimated future usage and sales. A provision for excess and obsolete inventory is recorded as needed based upon the discontinuation of products, redesigning of existing products, new product introductions, market changes and safety issues. Both raw materials and finished goods are reserved for on the balance sheet.

In general, we review inventory turns as an indicator of obsolescence or slow moving product as well as the impact of new product introductions. Depending on the situation, the individual item may be partially or fully reserved for. No inventory that was reserved for has been sold at prices above their new cost basis. In 2004, individual items were both partially and fully written down. The company continued to increase its overseas sourcing efforts, increase its emphasis on the development and introduction of new products, and decrease the cycle time to bring new product offerings to market. These initiatives are sources of inventory obsolescence for both raw material and finished goods.

Goodwill, Intangible and Other Long-Lived Assets Property, equipment, intangibles and certain other long-lived assets are amortized over their useful lives. Useful lives are based on management's estimates of the period that the assets will generate revenue. As a result of the adoption of Statement of Financial Accounting Standard (SFAS) No. 142, Goodwill and Other Intangible Assets in 2002, goodwill and intangible assets deemed to have indefinite lives are subject to annual impairment tests in accordance with the Statement. Furthermore, goodwill and other long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The company completed the required initial analysis of goodwill as of January 1, 2002 as well the annual impairment tests in the fourth quarter of 2002, 2003 and 2004. The results of these analyses indicated no impairment of goodwill.

Product Liability
The company's captive insurance company, Invatection Insurance Co., currently has a policy year that runs from September 1 to August 31 and insures annual policy losses of $10,000,000 per occurrence and $11,000,000 in the aggregate of the company's North American product liability exposure. The company also has additional layers of external insurance coverage insuring $100,000,000 in annual aggregate losses arising from individual claims anywhere in the world that exceed the captive insurance company policy limits. There can be no assurance that Invacare's current insurance levels will continue to be adequate or available at affordable rates.

Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and indications from the third-party actuary. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon third-party actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the third-party actuary to estimate the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate. Estimates made are adjusted on a regular basis and can be impacted by actual loss award settlements on claims. While actuarial analysis is used to help determine adequate reserves, the company accepts responsibility for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices.

I-27

Warranty
Generally, the company's products are covered by warranties against defects in material and workmanship for periods up to six years from the date of sale to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. No material adjustments to warranty reserves were necessary in the current year. See Current Liabilities in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual.

Accounting for Stock-Based Compensation
The company accounts for options under its stock-based compensation plans using the intrinsic value method proscribed in Accounting Principles Board Opinion (APBO) No. 25, Accounting for Stock Issued to Employees, and related Interpretations. The majority of the options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant; thus, no compensation cost has been reflected in the Consolidated Statement of Earnings for these options. In addition, restricted stock awards have been granted without cost to the recipients and are being expensed on a straight-line basis over the vesting periods. If the company had applied the fair value recognition provisions of SFAS No. 123, Accounting for Stock-Based Compensation, for all stock options granted, net earnings per share assuming dilution would have been reduced by $0.14 in 2004, $0.14 in 2003 and $0.15 in 2002.

In December 2002, the Financial Accounting Standards Board (FASB) issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure. This statement provides guidance for those companies wishing to voluntarily change to the fair value based method of accounting for stock-based compensation. The statement also amends the disclosure requirements of SFAS No. 123. While Invacare continues to utilize the disclosure-only provisions of SFAS No. 123, the company has modified its disclosures to comply with the new statement. See the company's Accounting Policies and Shareholders' Equity Transactions in the Notes to the Consolidated Financial Statements.

Income Taxes
As part of the process of preparing our financial statements, we are required to estimate income taxes in various jurisdictions. The process requires estimating our current tax exposure, including assessing the risks associated with tax audits, as well as estimating temporary differences due to the different treatment of items for tax and accounting policies. The temporary differences are reported as deferred tax assets and or liabilities. The company also must estimate the likelihood that its deferred tax assets will be recovered from future taxable income and whether or not valuation allowances should be established. In the event that actual results differ from our estimates, the company's provision for income taxes could be materially impacted.

The company does not believe that there is a substantial likelihood that materially different amounts would be reported related to its critical accounting policies.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In December 2004, FASB issued Statement of Financial Accounting Standards ("SFAS") No. 123 (Revised 2004), Share-Based Payment ("SFAS 123R"), which requires companies to expense stock options and other share-based payments. SFAS 123R supersedes SFAS No. 123, which permitted either expensing stock options or providing pro forma disclosure. The provisions of this Statement, which is effective July 1, 2005, apply to all awards granted, modified, cancelled or repurchased after July 1, 2005 as well as the unvested portion of prior awards. The company will adopt the standard as of the effective date and estimates that the impact to the company's reported results will be similar to the pro forma results shown in the company's Accounting Policy Note to the Consolidated Financial Statements.

The American Jobs Creation Act of 2004 (the Act) was signed into law in October 2004. The Act provides for a tax deduction on qualified production activities and introduced a special one-time dividends received deduction on the repatriation of certain foreign earnings to a U.S. taxpayer, provided certain criteria are met. The FASB issued FASB Staff Position 109-1 to provide guidance on the application of SFAS No. 109, Accounting for Income Taxes, and FASB Staff Position 109-2 to provide accounting and disclosure guidance for the repatriation provision. The company is reviewing the implication of the new Act, recently released treasury guidance, and the FASB staff positions but does not intend to repatriate any foreign earnings under the Act and does not expect the Act will have a material impact on the company's financial position, results of operations or cash flows.

I-28

Item 7a. Quantitative and Qualitative Disclosure about Market Risk.
The company is exposed to market risk through various financial instruments, including fixed rate and floating rate debt instruments. The company uses interest swap agreements to mitigate its exposure to interest rate fluctuations. Based on December 31, 2004 debt levels, a 1% change in interest rates would impact interest expense by approximately $5,107,000. Additionally, the company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans, and third party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized. The company does not believe that any potential loss related to these financial instruments would have a material adverse effect on the company's financial condition or results of operations.

PRIVATE SECURITIES LITIGATION REFORM ACT
The statements contained in this Form 10-K constitute forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Terms such as as "will," "should," "plan," "intend," "expect," "continue," "forecast", "believe," "anticipate" and "seek," as well as similar comments, are forward-looking in nature. Actual results and events may differ significantly from those expressed or anticipated as a result of risks and uncertainties which include, but are not limited to, the following:
pricing pressures, the success of the Company's ongoing efforts to reduce costs, increasing raw material costs, the consolidations of health care customers and competitors, government reimbursement issues (including those that affect the sales of and margins on products, along with the viability of customers)both at the federal and state level, the ability to design, manufacture, distribute and achieve market acceptance of new products with higher functionality and lower costs, the effect of offering customers competitive financing terms, Invacare's ability to successfully identify, acquire and integrate strategic acquisition candidates, the difficulties in managing and operating businesses in many different foreign jurisdictions (including the recent Domus acquisition), the timely completion of facility consolidations, the vagaries of any litigation or regulatory investigations that the Company may be or become involved in at any time (including the previously-disclosed litigation with Respironics), the difficulties in acquiring and maintaining a proprietary intellectual property ownership position, the overall economic, market and industry growth conditions (including the impact that acts of terrorism may have on such growth conditions), foreign currency and interest rate risks, Invacare's ability to improve financing terms and reduce working capital, as well as the risks described from time to time in Invacare's reports as filed with the Securities and Exchange Commission. We undertake no obligation to review or update these forward-looking statements or other information contained herein.

Item 8. Financial Statements and Supplementary Data

Reference is made to the Report of Independent Registered Public Accounting Firm, Consolidated Balance Sheet, Consolidated Statement of Earnings, Consolidated Statement of Cash Flows, Consolidated Statement of Shareholders' Equity, Notes to Consolidated Financial Statements and Financial Statement Schedule, which appear on pages FS-1 to FS-27 of this Annual Report on Form 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.
(a) Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of the company's management, including the Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the company's management, including the Chief Executive Officer and Chief Financial Officer, concluded that the company's disclosure controls and procedures were effective to provide reasonable assurance that we record, process, summarize and report the information we must disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended, within the time periods specified by the SEC.

I-29

(b) Management's Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining a system of adequate internal control over financial reporting that provides reasonable assurance that assets are safeguarded and that transactions are authorized, recorded and reported properly. The system includes self-monitoring mechanisms; regular testing by the Company's internal auditors; a Code of Conduct; written policies and procedures; and a careful selection and training of employees. Actions are taken to correct deficiencies as they are identified. An effective internal control system, no matter how well designed, has inherent limitations - including the possibility of the circumvention or overriding of controls - and therefore can provide only reasonable assurance that errors and fraud that can be material to the financial statements are prevented or would be detected on a timely basis. Further, because of changes in conditions, internal control system effectiveness may vary over time.

Management's assessment of the effectiveness of the company's internal control over financial reporting is based on the Internal Control -Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission and was limited as explained in the Scope of Management's Report, which follows this report.

In management's opinion, internal control over financial reporting is effective as of December 31, 2004.

The Company's independent registered public accounting firm, Ernst & Young LLP, audited management's assessment of internal control over financial reporting and, based on that audit, issued their report included in this Annual Report.

Scope of Management's Report
Management's assessment of the effectiveness of internal control over financial reporting excludes the WP Domus GmbH acquisition, which was finalized on September 9, 2004. WP Domus GmbH represents approximately 19% of the total assets and approximately 2% of the net sales, respectively, of the consolidated financial statements as of December 31, 2004 and the year ended December 31, 2004.

(c) Changes in Internal Control Over Financial Reporting
There have been no significant changes in the company's internal control over financial reporting that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

PART III

Item 10. Directors and Executive Officers of the Registrant.
We have adopted a Code of Business Conduct and Ethics that applies to all Directors, officers and employees. We also have adopted a separate Financial Code of Ethics that applies to our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer and principal accounting officer). You can find both codes on our website at www.invacare.com by clicking on the link for Investor Relations. We will post any amendments to the codes, as well as any waivers that are required to be disclosed pursuant to the rules of the Securities and Exchange Commission and the New York Stock Exchange, on our website.

Our Board of Directors has adopted Corporate Governance Guidelines and charters for the Audit Committee, Compensation, Management Development and Corporate Governance Committee, Nominating Committee and Investment Committee of the Board of Directors. These documents can be found on our website at www.invacare.com by clicking on the link for Investor Relations.

You also can obtain printed copies of any of the materials referred to above, free of charge, by writing to: Shareholder Relations Department, Invacare Corporation, One Invacare Way, P.O. Box 4028, Elyria, OH 44036-2125.

We submitted the New York Stock Exchange ('NYSE') Section 12(a) Annual CEO Certification as to our compliance with the NYSE corporate governance listing standards to the NYSE in June 2004. In addition, we have filed the certifications of our Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 regarding the quality of our public disclosures as exhibits to this Annual Report on Form 10-K.

Information required by Item 10 as to the executive officers of the company is included in Part I of this Annual Report on Form 10-K, the other information required by Item 10 as to the directors of the company is incorporated herein by reference to the information set forth under the caption "Election of Directors" in the company's definitive Proxy Statement for the 2005 Annual Meeting of Shareholders.

Item 11. Executive Compensation.
The information required by Item 11 is incorporated by reference to the information set forth under the captions "Compensation of Executive Officers" and "Compensation of Directors" in the company's definitive Proxy Statement for the 2005 Annual Meeting of Shareholders.
I-30

Item. 12. Security Ownership of Certain Beneficial Owners and Management.
The information required by Item 12 is incorporated by reference to the information set forth under the caption "Share Ownership of Principal Holders and Management" in the company's definitive Proxy Statement for the 2005 Annual Meeting of Shareholders.

Item 13. Certain Relationships and Related Transactions.
The information required by Item 13 is incorporated by reference to the information set forth under the caption "Compensation Committee Interlocks and Insider Participation" in the company's definitive Proxy Statement for the 2005 Annual Meeting of Shareholders.

Item 14. Principal Accounting Fees and Services.
The information required by Item 14 is incorporated by reference to the information set forth under the caption "Independent Auditors" in the company's definitive Proxy Statement for the 2005 Annual Meeting of Shareholders.

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a)(1) Financial Statements The following financial statements of the company are included in Part II, Item 8:

Consolidated Statement of Earnings - years ended December 31, 2004, 2003 and 2002

Consolidated Balance Sheet - December 31, 2004 and 2003

Consolidated Statement of Cash Flows - years ended December 31, 2004, 2003, and 2002

Consolidated Statement of Shareholders' Equity - years ended December 31, 2004, 2003, and 2002

Notes to Consolidated Financial Statements

(a)(2) Financial Statement Schedules The following financial statement schedule of the company is included in Part II, Item 8:

Schedule II - Valuation and Qualifying Accounts

All other schedules have been omitted because they are not applicable or not required, or because the required information is included in the Consolidated Financial Statements or notes thereto.

(a)(3) Exhibits. See Exhibit Index at page number I-33 of this Report on Form 10-K.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized as of March 11, 2005.

INVACARE CORPORATION

By:  /S/ A. Malachi Mixon, III
     -------------------------------------
     A. Malachi Mixon, III Chairman of the Board of
     Directors and Chief Executive Officer

I-31

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated as of March 11, 2005.

Signature                            Title
---------                            -----

/s/ A. Malachi Mixon, III            Chairman of the Board of Directors and
------------------------------       Chief Executive Officer
    A. Malachi Mixon, III           (Principal Executive Officer)

/s/ Gerald B. Blouch                 President, Chief Operating Officer and
------------------------------       Director
    Gerald B. Blouch

/s/ Gregory C. Thompson              Chief Financial Officer
------------------------------      (Principal Financial and Accounting Officer)
    Gregory C. Thompson

/s/ James C. Boland                  Director
------------------------------
    James C. Boland

/s/ Michael F. Delaney               Director
------------------------------
    Michael F. Delaney

/s/ Whitney Evans                    Director
------------------------------
    Whitney Evans

/s/ C. Martin Harris, M.D.           Director
------------------------------
    C. Martin Harris, M.D.

/s/ Bernadine P. Healy, M.D.         Director
------------------------------
    Bernadine P. Healy, M.D.

/s/ John R. Kasich                   Director
------------------------------
    John R. Kasich

/s/ Dan T. Moore, III                Director
------------------------------
    Dan T. Moore, III

/s/ Joseph B. Richey, II             Director
------------------------------
    Joseph B. Richey, II

/s/ William M. Weber                 Director
------------------------------
    William M. Weber

I-32

INVACARE CORPORATION

Report on Form 10-K for the fiscal year ended December 31, 2004.

                                  Exhibit Index
Official                                                                                                              Sequential
Exhibit No         Description                                                                                        Page No.
----------         -----------                                                                                        ----------
2.1                Sale and Purchase Agreement Regarding the Sale and Purchase of All Shares in WP Domus GmbH by      (A)
                   and among WP Domus LLC, Mr. Peter  Schultz and Mr.  Wilhelm  Kaiser,  Invacare  GmbH & Co. KG and
                   Invacare Corporation dated as of July 31, 2004

2.2                Guarantee Letter Agreement of Warburg,  Pincus Ventures,  L.P. and Warburg, Pincus International,  (A)
                   L.P. dated as of September 9, 2004

3(a) **            Amended and Restated Articles of Incorporation, as amended through February 2, 1996

3(b) **            Code of Regulations, as amended on May 22, 1996

4(a)               Specimen Share Certificate for Common Shares, as revised                                           (B)

4(b)               Specimen Share Certificate for Class B Common Shares                                               (B)

4(c)               Rights agreement between Invacare Corporation and Rights Agent dated as of July 7, 1995            (C)

10(a)              Assignment  of Patent  Application  and  License of  Know-how  dated  January  14,  1981,  and an  (D)
                   amendment  thereto dated October 12, 1981, with respect to certain royalty payments to be made to
                   the former owners of the company's home care bed subsidiary

10(b) **           1992 Non-Employee Directors Stock Option Plan adopted in May 1992

10(c) **           Deferred Compensation Plan for Non-Employee Directors, adopted in May 1992

10(d) **           Invacare Corporation 1994 Performance Plan approved January 28, 1994

10(e)              Amendment No. 3 to the Invacare Corporation 1994 Performance Plan                                  (H)*

10(f) **           Note Purchase Agreement dated as of February 27, 1998 for $80,000,000 6.71% Series A Senior
                   Notes Due February 27, 2008 and $20,000,000 6.60% Series B Senior Notes Due February 27, 2005

10(g) **           Amendment No. 1 to the Invacare Corporation 1994 Performance Plan approved May 28, 1998            *

10(h)              Amendment No. 2 to the Invacare Corporation 1994 Performance Plan approved May 24, 2000            (E)*

10(i)              Invacare Retirement Savings Plan, effective January 1, 2001                                        (F)

10(j)              Employment Agreement entered into by and between the company and Chief Operating Officer           (G)*

10(k)              Amendment No. 1 to Invacare Corporation 401(K) Plus Benefit Equalization Plan                      (L)

10(l)              Invacare  Corporation  401(K) Plus Benefit  Equalization Plan (As amended and restated  effective  (L)
                   January 1, 2003)

10(m)              Invacare  Corporation Note Purchase  Agreement dated as of October 1, 2003 for $50,000,000  3.97%  (J)
                   Series A Senior  Notes Due October 1, 2007;  $30,000,000  4.74% Series B Senior Notes Due October
                   1, 2009 and $20,000,000 5.05% Series C Senior Notes Due October 1, 2010

I-33

Official                                                                                                              Sequential
Exhibit No         Description                                                                                        Page No.
----------         -----------                                                                                        ----------
10(n)              First  Amendment,  dated as of October 1, 2003, to Note Purchase  Agreement  dated as of February  (K)
                   27, 1998 for $80,000,000  6.71% Series A Senior Notes Due February 27, 2008 and $20,000,000 6.60%
                   Series B Senior Notes Due February 27, 2005

10(o)              Invacare Corporation 2003 Performance Plan                                                         (I)*

10(p)              Form of Change of Control Agreement entered into by and between the company and certain of         (G)*
                   its executive officers and Schedule of all such agreements with current executive officers

10(q)              Form of Indemnity  Agreement entered into by and between the company and certain of its Directors  (G)*
                   and executive  officers and Schedule of all such Agreements with current  Directors and executive
                   officers

10(r)              Employment Agreement entered into by and between the company and Chief Financial Officer           (G)*

10(s)              Credit  Agreement dated as of January 14, 2005 among Invacare  Corporation and Certain  Borrowing  (M)
                   Subsidiaries,  the Banks named therein,  and JPMorgan Chase Bank, N.A. as Agent, Keybank National
                   Association as Syndication Agent, J.P. Morgan Securities,  Inc. and Keybank National Association,
                   as Co-Lead Arrangers.

10(t)**            Invacare Corporation Deferred Compensation Plus Plan, effective January 1, 2005                    *

10(u)**            Invacare Corporation Death Benefit Only Plan, effective January 1, 2005                            *

10(v)**            A. Malachi Mixon, III 10b5-1 Plan, effective February 14, 2005                                     *

10(w)**            Gerald B. Blouch 10b5-1 Plan, effective February 22, 2005                                          *

10(x)**            Gregory C. Thompson 10b5-1 Plan, effective February 21, 2005                                       *

10(y) **           Supplemental Executive Retirement Plan (As amended and restated effective February 1, 2000)        *

10(z)**            Form of Director Stock Option Award under Invacare Corporation 1994 Performance Plan               *

10(aa)**           Form of Director Stock Option Award under Invacare Corporation 2003 Performance Plan               *

10(ab)**           Form of Director Deferred Option Award under Invacare Corporation 2003 Performance Plan            *

10(ac)**           Form of Restricted Stock Option Award under Invacare Corporation 2003 Performance Plan             *

10(ad)**           Form of Stock Option Award under Invacare Corporation 2003 Performance Plan                        *

10(ae)**           Director Compensation Schedule                                                                     *

21                 Subsidiaries of the company

23                 Consent of Independent Registered Public Accounting Firm

31.1 **            Certification of the Chief Executive  Officer pursuant to Section 302 of the  Sarbanes-Oxley  Act
                   of 2002

31.2 **            Certification of the Chief Financial  Officer pursuant to Section 302 of the  Sarbanes-Oxley  Act
                   of 2002

I-34

Official                                                                                                              Sequential
Exhibit No         Description                                                                                        Page No.
----------         -----------                                                                                        ----------
32.1 **            Certification  of the Chief  Executive  Officer  pursuant to 18 U.S.C.  Section  1350, as adopted
                   pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 **            Certification  of the Chief  Financial  Officer  pursuant to 18 U.S.C.  Section  1350, as adopted
                   pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Management contract, compensatory plan or arrangement ** Filed herein.

(A) Reference is made to the appropriate Exhibit to the company report on Form 8-K, dated September 9, 2004, which Exhibit is incorporated herein by reference.

(B) Reference is made to the appropriate Exhibit of the company Registration Statement on Form S-3 (Reg. No. 33-40168), effective as of April 26, 1991, which Exhibit is incorporated herein by reference.

(C) Reference is made to Exhibit 1 of the company report on Form 8-A, dated July 18, 1995, which Exhibit is incorporated herein by reference.

(D) Reference is made to the appropriate Exhibit of the company Form 8 Amendment No. 1 (filed on September 23, 1987) to its Registration Statement on Form 8-A (Reg. No. 0-12938, effective as of October 21, 1986), which Exhibit is incorporated herein by reference.

(E) Reference is made to the appropriate Exhibit of the company report on Form S-8, dated March 30, 2001, which Exhibit is incorporated herein by reference.

(F) Reference is made to Exhibit 10.1 of the company report on Form 10-Q, dated September 30, 2002, which Exhibit is incorporated herein by reference.

(G) Reference is made to the appropriate Exhibit of the company report on Form 10-K for the fiscal year ended December 31, 2002, which Exhibit is incorporated herein by reference.

(H) Reference is made to the appropriate Exhibit of the company report on Form 10-Q for the quarter ended March 31, 2003, which Exhibit is incorporated herein by reference.

(I) Reference is made to Exhibit 4.5 of Invacare Corporation Form S-8 filed on October 17, 2003.

(J) Reference is made to the appropriate Exhibit of the company report on Form 10-Q for the quarter ended September 30, 2003, which Exhibit is incorporated herein by reference.

(K) Reference is made to the appropriate Exhibit of the company report on Form 10-K for the fiscal year ended December 31, 2003, which Exhibit is incorporated herein by reference.

(L) Reference is made to the appropriate Exhibit of the company report on Form 10-Q for the quarter ended June 30, 2004, which Exhibit is incorporated herein by reference.

(M) Reference is made to the appropriate Exhibit of the company report on Form 8-K, dated January 14, 2005, which is incorporated herein by reference.

I-35

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Shareholders and Board of Directors
Invacare Corporation

We have audited the accompanying consolidated balance sheets of Invacare Corporation and subsidiaries as of December 31, 2004 and 2003, and the related consolidated statements of earnings, cash flows and shareholders' equity for each of the three years in the period ended December 31, 2004. Our audits also included the financial statement schedule listed in the Index at Item 15 (a)(2). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Invacare Corporation and subsidiaries at December 31, 2004 and 2003, and the consolidated results of their operations and their cash flows for each of the three years in the period ended December 31, 2004, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Invacare Corporation's internal control over financial reporting as of December 31, 2004, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 4, 2005 expressed an unqualified opinion thereon.

                                                           /s/ ERNST & YOUNG LLP



Cleveland, Ohio
March 4, 2005

FS-1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Shareholders and Board of Directors
Invacare Corporation

We have audited management's assessment, included in the accompanying Management Report on Internal Control Over Financial Reporting, that Invacare Corporation maintained effective internal control over financial reporting as of December 31, 2004, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Invacare Corporation's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management's assessment and an opinion on the effectiveness of the company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management's assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As indicated in the accompanying Management Report on Internal Control Over Financial Reporting, management's assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of WP Domus GmbH, which is included in the 2004 consolidated financial statements of Invacare Corporation and constituted 19% of total assets as of December 31, 2004 and 2% of net sales for the year then ended. Our audit of internal control over financial reporting of Invacare Corporation also did not include an evaluation of the internal control over financial reporting of WP Domus GmbH.

In our opinion, management's assessment that Invacare Corporation maintained effective internal control over financial reporting as of December 31, 2004, is fairly stated, in all material respects, based on the COSO criteria. Also, in our opinion, Invacare Corporation maintained, in all material respects, effective internal control over financial reporting as of December 31, 2004, based on the COSO criteria.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Invacare Corporation as of December 31, 2004 and 2003 and the related consolidated statements of earnings, cash flows and shareholders' equity for each of the three years in the period ended December 31, 2004 of Invacare Corporation and our report dated March 4, 2005 expressed an unqualified opinion thereon.

                                                           /s/ ERNST & YOUNG LLP

Cleveland, Ohio
March 4, 2005
                                      FS-2


CONSOLIDATED STATEMENT OF EARNINGS

INVACARE CORPORATION AND SUBSIDIARIES

                                                                          Years Ended December 31,
                                                                    2004            2003            2002
                                                                    ----            ----            ----
                                                                   (In thousands, except per share data)

Net sales                                                     $1,403,327      $1,247,176      $1,089,161
Cost of products sold                                            984,735         872,515         761,763
                                                                 -------         -------         -------

     Gross Profit                                                418,592         374,661         327,398

Selling, general and administrative expenses                     297,124         262,015         220,296
Interest expense                                                  16,282          11,710          15,122
Interest income                                                   (5,186)         (5,473)         (4,550)
                                                                 -------         -------         -------

     Earnings before Income Taxes                                110,372         106,409          96,530

Income taxes                                                      35,175          35,000          31,760
                                                                 -------         -------         -------

     Net Earnings                                                $75,197         $71,409         $64,770
                                                                 =======         =======         =======

     Net Earnings per Share - Basic                                $2.41           $2.31           $2.10
                                                                 =======         =======         =======

Weighted Average Shares Outstanding - Basic                       31,153          30,862          30,867
                                                                 =======         =======         =======

     Net Earnings per Share - Assuming Dilution                    $2.33           $2.25           $2.05
                                                                 =======         =======         =======

Weighted Average Shares Outstanding -
  Assuming Dilution                                               32,347          31,729          31,664
                                                                 =======         =======         =======

See notes to consolidated financial statements.

FS-3


CONSOLIDATED BALANCE SHEETS

INVACARE CORPORATION AND SUBSIDIARIES

                                                                                  December 31,            December 31,
                                                                                         2004                    2003
                                                                                      -------                 -------
                                                                                              (In thousands)
Assets
------
Current Assets
   Cash and cash equivalents                                                          $32,567                 $16,074
   Marketable securities                                                                  199                     214
   Trade receivables, net                                                             287,950                 255,534
   Installment receivables, net                                                        13,422                   7,755
   Inventories, net                                                                   175,883                 130,979
   Deferred income taxes                                                               21,730                  24,573
   Other current assets                                                                33,400                  39,593
                                                                                      -------                 -------
     Total Current Assets                                                             565,151                 474,722

Other Assets                                                                           55,634                  53,263
Other Intangibles                                                                      98,212                  14,678
Property and Equipment, net                                                           191,163                 150,051
Goodwill                                                                              717,964                 415,499
                                                                                      -------                 -------
     Total Assets                                                                  $1,628,124              $1,108,213
                                                                                   ==========              ==========


Liabilities and Shareholders' Equity
------------------------------------
Current Liabilities
   Accounts payable                                                                  $149,413                $110,178
   Accrued expenses                                                                    98,850                  92,032
   Accrued income taxes                                                                 7,816                  19,107
   Current maturities of long-term debt                                                 2,062                   2,171
                                                                                      -------                 -------
     Total Current Liabilities                                                        258,141                 223,488

Long-Term Debt                                                                        547,974                 232,038

Other Long-Term Obligations                                                            68,571                  34,383

Shareholders' Equity
   Preferred Shares (Authorized 300 shares; none outstanding)                               -                       -
   Common Shares (Authorized 100,000 shares; 31,209 and
         30,739 issued in 2004 and 2003, respectively) - par $0.25                      7,803                   7,686
   Class B Common Shares (Authorized 12,000 shares; 1,112, issued and
         outstanding) - par $0.25                                                         278                     278
   Additional paid-in-capital                                                         123,793                 109,015
   Retained earnings                                                                  550,753                 477,113
   Accumulated other comprehensive earnings                                           104,629                  51,057
   Unearned compensation on stock awards                                               (1,557)                 (1,458)
   Treasury shares (934 and 770 shares in
         2004 and 2003, respectively)                                                 (32,261)                (25,387)
                                                                                      -------                 -------
     Total Shareholders' Equity                                                       753,438                 618,304
                                                                                      -------                 -------

Total Liabilities and Shareholders' Equity                                         $1,628,124              $1,108,213
                                                                                   ==========              ==========

See notes to consolidated financial statements.

FS-4


CONSOLIDATED STATEMENT OF CASH FLOWS

INVACARE CORPORATION AND SUBSIDIARIES

                                                                                          Years Ended December 31,
                                                                                     2004           2003            2002
                                                                                     ----           ----            ----
                                                                                               (In thousands)
Operating Activities
Net earnings                                                                      $75,197        $71,409         $64,770
Adjustments to reconcile net earnings to net cash provided
  by operating activities:
    Depreciation and amortization                                                  32,316         27,235          26,638
    Provision for losses on trade and installment receivables                      11,222         13,760          10,792
    Provision for deferred income taxes                                             4,250          3,205          (3,050)
    Provision for other deferred liabilities                                        4,091          2,587           3,342
Changes in operating assets and liabilities:
    Trade receivables                                                             (19,978)       (37,122)         19,740
    Installment sales contracts, net                                               (2,911)         6,678          11,435
    Inventories                                                                   (15,781)        (4,607)          6,208
    Other current assets                                                             (516)        (3,447)         (4,193)
    Accounts payable                                                               19,718         13,351           2,576
    Accrued expenses                                                              (11,281)        17,943          (2,534)
    Other long-term liabilities                                                     1,997          5,212            (108)
                                                                                  -------        -------         -------
              Net Cash Provided by Operating Activities                            98,324        116,204         135,616

Investing Activities
    Purchases of property and equipment                                           (41,403)       (30,660)        (22,109)
    Proceeds from sale of property and equipment                                        3            531           2,391
    Marketable securities                                                               -          1,130             (43)
    Business acquisitions, net of cash acquired                                  (343,554)       (70,555)              -
    Increase in other investments                                                    (603)           (64)           (317)
    Increase in other long-term assets                                             (3,133)        (1,898)         (1,834)
    Other                                                                            (332)           (42)          1,079
                                                                                  -------         ------         -------
              Net Cash Required for Investing Activities                         (389,022)      (101,558)        (20,833)

Financing Activities
    Proceeds from revolving lines of credit and
      long-term borrowings                                                        844,432        474,583         254,512
    Payments on revolving lines of credit and
      long-term borrowings                                                       (541,244)      (483,725)       (377,582)
    Proceeds from exercise of stock options                                         9,850          5,063           6,154
    Payment of dividends                                                           (1,557)        (1,531)         (1,567)
    Purchase of treasury stock                                                     (4,430)        (8,345)         (1,674)
                                                                                  -------        -------         -------
              Net Cash Provided (Required) by Financing Activities                307,051        (13,955)       (120,157)

    Effect of exchange rate changes on cash                                           140          2,297           1,777
                                                                                  -------        -------         -------

    Increase (decrease) in cash and cash equivalents                               16,493          2,988          (3,597)

    Cash and cash equivalents at beginning of year                                 16,074         13,086          16,683
                                                                                  -------        -------         -------

    Cash and cash equivalents at end of year                                      $32,567        $16,074         $13,086
                                                                                  =======        =======         =======

See notes to consolidated financial statements.

FS-5


CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

INVACARE CORPORATION AND SUBSIDIARIES
(In thousands)

                                                                                  Accumulated
                                                           Additional             Other
                                        Common   Class B   Paid-in-    Retained   Comprehensive   Unearned      Treasury
                                        Stock    Stock     Capital     Earnings   Earnings(Loss)  Compensation  Stock      Total
                                        ------   -------   ----------  --------   --------------  ------------  ---------  ---------
January 1, 2002 Balance                 $7,466    $278     $87,980     $344,032     $(48,129)        $(771)     $(9,306)   $381,550
Exercise of stock options, including
  tax benefit                              105               9,834                                               (2,863)      7,076
Restricted stock awards                      9               1,181                                  (1,190)                       -
Restricted stock award expense                                                                         757                      757

Net earnings                                                             64,770                                              64,770
Foreign currency translation
  adjustments                                                                         28,214                                 28,214
Unrealized gains on cash flow hedges                                                   1,349                                  1,349
Marketable securities holding loss                                                      (163)                                  (163)
                                                                                                                              -----
Total comprehensive income                                                                                                   94,170

Dividends                                                                (1,567)                                             (1,567)
Purchase of treasury shares                                                                                      (1,674)     (1,674)
------------------------------------------------------------------------------------------------------------------------------------
December 31, 2002 Balance                 7,580    278      98,995      407,235      (18,729)       (1,204)     (13,843)    480,312

Exercise of stock options, including
  tax benefit                                99              9,130                                               (3,199)      6,030
Restricted stock awards                       7                890                                    (897)                       -
Restricted stock award expense                                                                         643                      643

Net earnings                                                             71,409                                              71,409
Foreign currency translation
  adjustments                                                                         66,185                                 66,185
Unrealized gains on cash flow hedges                                                   3,506                                  3,506
Marketable securities holding gain                                                        95                                     95
                                                                                                                              -----
Total comprehensive income                                                                                                  141,195

Dividends                                                                (1,531)                                             (1,531)
Purchase of treasury shares                                                                                      (8,345)     (8,345)
------------------------------------------------------------------------------------------------------------------------------------
December 31, 2003 Balance                 7,686    278     109,015      477,113       51,057        (1,458)     (25,387)    618,304

Exercise of stock options, including
  tax benefit                               112             13,872                                               (2,444)     11,540
Restricted stock awards                       5                906                                    (911)                       -
Restricted stock award expense                                                                         812                      812

Net earnings                                                             75,197                                              75,197
Foreign currency translation
  adjustments                                                                         57,903                                 57,903
Unrealized losses on cash flow hedges                                                 (4,322)                                (4,322)
Marketable securities holding loss                                                        (9)                                    (9)
                                                                                                                              -----
Total comprehensive income                                                                                                  128,769

Dividends                                                                (1,557)                                             (1,557)
Purchase of treasury shares                                                                                      (4,430)     (4,430)
------------------------------------------------------------------------------------------------------------------------------------
December 31, 2004 Balance                $7,803   $278    $123,793     $550,753     $104,629       $(1,557)    $(32,261)   $753,438
                                         ======   ====    ========     ========     ========       =======      =======    ========

See notes to consolidated financial statements.

FS-6


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTING POLICIES

Nature of Operations: Invacare Corporation and its subsidiaries ("Invacare" or the "company") is the leading home medical equipment manufacturer in the world based on its distribution channels, the breadth of its product line and net sales. The company designs, manufactures and distributes an extensive line of medical equipment for the home health care, retail and extended care markets. The company's products include standard manual wheelchairs, motorized and lightweight prescription wheelchairs, seating and positioning systems, motorized scooters, patient aids, home care beds, low air loss therapy products, respiratory products and distributed products.

Principles of Consolidation: The consolidated financial statements include the accounts of the company and its majority owned subsidiaries. Certain foreign subsidiaries, represented by the European segment, are consolidated using a November 30 fiscal year end. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated.

Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

Marketable Securities: Marketable securities consist of short-term investments in repurchase agreements, government and corporate securities, certificates of deposit and equity securities. Marketable securities with original maturities of less than three months are treated as cash equivalents. The company has classified its marketable securities as available for sale. The securities are carried at their fair value and net unrealized holding gains and losses, net of tax, are carried as a component of accumulated other comprehensive earnings (loss).

Inventories: Inventories are stated at the lower of cost or market with cost principally determined for domestic manufacturing inventories by the last-in, first-out method and for non-domestic inventories and domestic finished products purchased for resale ($138,845,000 and $99,607,000 at December 2004 and 2003, respectively) by the first-in, first-out method. Market costs are based on the lower of replacement cost or estimated net realizable value. The value of inventory on the LIFO method is approximately equal to its current cost as of December 31, 2004 and 2003. Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management's review of inventories on hand compared to estimated future usage and sales.

Property and Equipment: Property and equipment are stated on the basis of cost. The company principally uses the straight-line method of depreciation for financial reporting purposes based on annual rates sufficient to amortize the cost of the assets over their estimated useful lives. Accelerated methods of depreciation are used for federal income tax purposes. Expenditures for maintenance and repairs are charged to expense as incurred.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. The asset would be considered impaired when the future net undiscounted cash flows generated by the asset are less than its carrying value. An impairment loss would be recognized based on the amount by which the carrying value of the asset exceeds its fair value.

Goodwill and Other Intangibles: Effective January 1, 2002, Invacare adopted SFAS No. 142, Goodwill and Other Intangible Assets, and accordingly, discontinued amortization of goodwill. SFAS No. 142 changed the accounting for goodwill from an amortization approach to a non-amortization approach requiring periodic testing for impairment. For purposes of the impairment test, the fair value of each reporting unit is estimated by forecasting cash flows and discounting those cash flows using appropriate discount rates. The fair values are then compared to the carrying value of the net assets of each reporting unit. The company completed the required initial analysis as of January 1, 2002 as well as the annual impairment tests in the fourth quarter of 2002, 2003 and 2004. The results of these tests indicated no impairment of goodwill.

FS-7


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

ACCOUNTING POLICIES--Continued

Accrued Warranty Cost: Generally, the company's products are covered by warranties against defects in material and workmanship for periods up to six years from the date of sale to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. No material adjustments to warranty reserves were necessary in the current year. See Current Liabilities in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual.

Product Liability Cost: The company's captive insurance company, Invatection Insurance Co., currently has a policy year that runs from September 1 to August 31 and insures annual policy losses of $10,000,000 per occurrence and $11,000,000 in the aggregate of the company's North American product liability exposure. The company also has additional layers of external insurance coverage insuring $100,000,000 in annual aggregate losses arising from individual claims anywhere in the world that exceed the captive insurance company policy limits. There can be no assurance that Invacare's current insurance levels will continue to be adequate or available at affordable rates.

Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and indications from the third-party actuary. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon third-party actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the third-party actuary to estimate the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate. Estimates made are adjusted on a regular basis and can be impacted by actual loss award settlements on claims. While actuarial analysis is used to help determine adequate reserves, the company accepts responsibility for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices.

Revenue Recognition: Invacare's revenues are recognized when products are shipped to unaffiliated customers. The Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 101, "Revenue Recognition," as updated by SAB No. 104, provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. The company has concluded that its revenue recognition policy is appropriate and in accordance with generally accepted accounting principles and SAB No. 101.

Sales are only made to customers with whom the company believes collection is reasonably assured based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts.

The company offers discounts and rebates, which are accounted for as reductions to revenue in the period in which the sale is recognized. Discounts offered include: cash discounts for prompt payment, base and trade discounts based on contract level for specific classes of customers. Volume discounts and rebates are given based on large purchases and the achievement of certain sales volumes. Product returns are accounted for as a reduction to reported sales with estimates recorded for anticipated returns at the time of sale. The company does not sell any goods on consignment.

Distributed products sold by the company are accounted for in accordance with EITF 99-19 Reporting Revenue Gross as a Principal versus Net as an Agent. The company records Distributed product sales gross as a principal since the company takes title to the products and has the risks of loss for collections, delivery and returns.

FS-8


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

ACCOUNTING POLICIES--Continued

Product sales that give rise to installment receivables are recorded at the time of sale when the risks and rewards of ownership are transferred. In December 2000, the company entered into an agreement with DLL, a third party financing company, to provide the majority of future lease financing to Invacare customers. As such, interest income is recognized based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments, interest income is no longer recognized. All installment accounts are accounted for using the same methodology, regardless of duration of the installment agreements.

Research and Development: Research and development costs are expensed as incurred and included in cost of products sold. The company's annual expenditures for product development and engineering were approximately $21,638,000, $19,130,000, and $17,934,000 for 2004, 2003, and 2002, respectively.

Advertising: Advertising costs are expensed as incurred and included in selling, general and administrative expenses. The company has a co-op advertising program in which the company reimburses customers up to 50% of their costs of qualifying advertising expenditures. Invacare product, brand logos and corporate spokesperson, Arnold Palmer, must appear in all advertising. Invacare requires customers to submit proof of advertising with their claims for reimbursement. Invacare receives advertising and in return reimburses customers for a portion of their advertising costs. The company's cost of the program is included in SG&A expense on the consolidated statement of earnings at the time the liability is estimated. Reimbursement is made on an annual basis and within 3 months of submission and approval of the documentation. The company receives monthly reporting from those in the program of their qualified advertising dollars spent and accrues based upon information received. Advertising expenses amounted to $24,999,000, $22,806,000 and $20,905,000 for 2004, 2003 and 2002, respectively.

Stock-Based Compensation Plans: The company accounts for options under its stock-based compensation plans using the intrinsic value method proscribed in APBO No. 25, Accounting for Stock Issued to Employees, and related Interpretations. The majority of the options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant, thus no compensation cost has been reflected in the consolidated statement of earnings for these options. In addition, restricted stock awards have been granted without cost to the recipients and are being expensed on a straight-line basis over the vesting periods. Invacare continues to utilize the disclosure-only provisions of SFAS No. 123, Accounting for Stock Based Compensation. If the company had applied the fair value recognition provisions of SFAS No. 123, the company's net earnings and earnings per share in 2004, 2003 and 2002 would have been reduced to the pro forma amounts indicated below (in thousands except per share data):

                                                                   2004               2003                2002
                                                                   ----               ----                ----
Net earnings - as reported *                                    $75,197            $71,409             $64,770
Less:  compensation expense determined based on the
       fair-value method for all awards granted at
       market value, net of related tax effects                   4,226              4,529               4,504
                                                                -------            -------             -------
Net earnings - pro forma                                        $70,971            $66,880             $60,266
                                                                =======            =======             =======

Earnings per share as reported - basic                            $2.41              $2.31               $2.10
Earnings per share as reported - assuming dilution                $2.33              $2.25               $2.05

Pro forma earnings per share - basic                              $2.28              $2.17               $1.95
Pro forma earnings per share - assuming dilution                  $2.19              $2.11               $1.90

* Includes stock compensation expense, net of tax, on
  restricted awards granted without cost of:                       $528               $418                $492

Income Taxes: The company uses the liability method in measuring the provision for income taxes and recognizing deferred tax assets and liabilities on the balance sheet. The liability method requires that deferred income taxes reflect the tax consequences of currently enacted rates for differences between the tax and financial reporting bases of assets and liabilities. Undistributed earnings of the company's foreign subsidiaries are considered to be indefinitely reinvested and, accordingly, no provision for United States federal income taxes has been provided.

FS-9


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

ACCOUNTING POLICIES--Continued

Derivative Instruments: The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company's derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. The derivatives designated as fair value hedges are perfectly effective; thus, the entire gain or loss associated with the derivative instrument directly affects the value of the debt by increasing or decreasing its carrying value.

The company has entered into interest rate swap agreements that qualify as fair value hedges and effectively convert $180,000,000 of fixed-rate debt to floating-rate debt, so the company can avoid paying higher than market interest rates. The company also had interest rate swap agreements, which expired in 2004, that qualified as cash flow hedges and effectively converted $20,000,000 of its floating-rate debt to a fixed-rate basis, thus reducing the impact of interest-rate changes on future interest expense. The company recognized net gains of $4,577,000, $2,872,000 and $773,000, respectively, related to its swap agreements in 2004, 2003 and 2002, which is reflected in interest expense on the consolidated statement of earnings.

To protect against decreases/increases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes cash flow hedges to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The company recognized net gains in 2004, 2003 and 2002 of $6,961,000, $1,410,000 and $1,252,000, respectively on foreign currency cash flow hedges. The gains are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of earnings.

The company has used forward contracts that do not qualify for special hedging treatment, but do effectively limit the company's exposure to foreign currency fluctuations between the Mexican Peso and U.S. Dollar. During 2003 and 2002, the company recognized losses of $118,000 and $68,000 related to these forward contracts, which are included in costs of products sold on the consolidated statement of earnings. No Mexican Peso forward contracts were entered into in 2004.

The company recognized no gain or loss related to hedge ineffectiveness or discontinued cash flow hedges. If it is later determined that a hedged forecasted transaction is unlikely to occur, any gains or losses on the forward contracts would be reclassified from other comprehensive income into earnings. The company does not expect this to occur during the next twelve months.

Foreign Currency Translation: The functional currency of the company's subsidiaries outside the United States is the applicable local currency. The assets and liabilities of the company's foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Revenues and expenses are translated at weighted average exchange rates. Gains and losses resulting from translation are included in accumulated other comprehensive earnings (loss).

Net Earnings Per Share: Basic earnings per share are computed based on the weighted-average number of Common Shares and Class B Common Shares outstanding during the year. Diluted earnings per share are computed based on the weighted-average number of Common Shares and Class B Common Shares outstanding plus the effects of dilutive stock options outstanding during the year.

Reclassifications: Certain reclassifications have been made to the prior years' consolidated financial statements to conform to the presentation used for the year ended December 31, 2004.

Recently Issued Accounting Pronouncements: In December 2004, FASB issued Statement of Financial Accounting Standards ("SFAS") No. 123 (Revised 2004), Share-Based Payment ("SFAS 123R"), which requires companies to expense stock options and other share-based payments. SFAS 123R supersedes SFAS No. 123, which permitted either expensing stock options or providing pro forma disclosure. The provisions of this Statement, which is effective July 1, 2005, apply to all awards granted, modified, cancelled or repurchased after July 1, 2005 as well as the unvested portion of prior awards. The company will adopt the standard as of the effective date and estimates that the impact to the company's reported results will be similar to the pro forma results shown in the company's Accounting Policy Note to the Consolidated Financial Statements.

FS-10


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

ACCOUNTING POLICIES--Continued

The American Jobs Creation Act of 2004 (the Act) was signed into law in October 2004. The Act provides, among other things, for a tax deduction on qualified domestic production activities and introduced a special one-time dividends received deduction on the repatriation of certain foreign earnings to a U.S. taxpayer, provided certain criteria are met. The FASB issued FASB Staff Positions 109-1 to provide guidance on the application of SFAS No. 109, Accounting for Income Taxes, and FASB Staff Positions 109-2 to provide accounting and disclosure guidance for the repatriation provision. The company is reviewing the implication of the new Act, recently released treasury guidance, and the FASB staff positions but does not intend to repatriate any foreign earnings under the Act and does not expect the Act will have a material impact on the company's financial position, results of operations or cash flows.

RECEIVABLES

Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the company's receivables are due from health care, medical equipment dealers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. In addition, the company has seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts ($9,857,000 in 2004 and $16,775,000 in 2003) is based primarily on management's evaluation of the financial condition of the customer. The decrease in the allowance for uncollectible accounts in 2004 compared to 2003 is primarily attributable to significant write-offs of accounts previously reserved for as all collection efforts were exhausted in 2004.

Installment receivables as of December 31, 2004 and 2003 consist of the following (in thousands):

                                                                  2004                                   2003
                                                                  ----                                   -----
                                                    Current    Long-Term      Total         Current    Long-Term      Total
                                                    -------    ----------    -------        -------    ---------    -------
Installment receivables                             $19,576       $1,324     $20,900        $18,930        $578     $19,508
Less:
     Unearned interest                                 (435)           -        (435)          (246)        (54)       (300)
     Allowance for doubtful accounts                 (5,719)           -      (5,719)       (10,929)          -     (10,929)
                                                    -------       ------     -------         ------      ------      ------
                                                    $13,422       $1,324     $14,746         $7,755        $524      $8,279
                                                    =======       ======     =======         ======       =====      ======

In addition, as a result of the third party financing arrangement with DLL, management monitors the collection status of these contracts in accordance with the company's limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts. See the "Concentration of Credit Risk" footnote for a description of the financing arrangement. Long-term installment receivables are included in "Other Assets" on the consolidated balance sheet.

INVENTORIES

Inventories as of December 31, 2004 and 2003 consist of the following (in thousands):

                                     2004                2003
                                   ------             -------
Raw materials                     $60,548             $41,573
Work in process                    16,156              18,711
Finished goods                     99,179              70,695
                                   ------             -------
                                 $175,883            $130,979
                                  =======            ========

PROPERTY AND EQUIPMENT

Property and equipment as of December 31, 2004 and 2003 consist of the following (in thousands):

                                     2004                2003
                                   ------             -------
Machinery and equipment          $243,335            $216,459
Land, buildings and improvements   95,041              67,364
Furniture and fixtures             27,494              20,737
Leasehold improvements             14,275              14,946
                                  -------             -------
                                  380,145             319,506
Less allowance for depreciation  (188,982)           (169,455)
                                   ------             -------
                                 $191,163            $150,051
                                  =======             =======
                    FS-11



INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

ACQUISITIONS

In 2004, Invacare acquired for cash the following six businesses at a total cost of $343,554,000:

o The assets of ACS, a New York distributor of medical supplies with a focus on infusion therapy.
o The assets of Decpac, an Australian company that designs and manufactures portable folding access ramps for use with wheelchairs and scooters.
o Freedom Designs, Inc., a California-based company that designs and manufactures seating products and wheelchairs with a particular focus on the pediatric marketplace.
o WP Domus GmbH, a European-based holding company which manufactures several complementary product lines to Invacare's product lines.
o Champion Manufacturing, LLC , an Indiana company that designs and manufactures medical recliners.
o The assets of Premier Designs, a California company from which Invacare acquired assets and designs for a lightweight, easily transportable power wheelchair.

Carroll Healthcare, Inc. was purchased in 2003 and as part of the purchase agreement, the company agreed to pay additional consideration based upon earnings before interest, taxes, depreciation and amortization from September 1, 2003 through August 31, 2004 calculated under Canadian generally accepted accounting principles (U.S. GAAP used for company reporting purposes) in accordance with the purchase agreement with no defined maximum amount. The payment amount was finalized and paid in October 2004 at 74,667,000 Canadian Dollars, $60,992,000 U.S. Dollars, which increased goodwill.

Motion Concepts, Inc. ("Motion") was also purchased in 2003 and pursuant to the Motion purchase agreement, the Company agreed to pay contingent consideration based upon earnings before interest and taxes over the three years subsequent to the acquisition up to a maximum of approximately $16,000,000. Based upon 2004 results, no additional consideration was paid. When the contingency related to the acquisitions is settled, any additional consideration paid will increase the purchase price and reported goodwill.

On September 9, 2004 the company finalized the acquisition of 100% of the shares of WP Domus GmbH, a European-based holding company that manufactures several complementary product lines to Invacare's product lines, including power add-on products, bath lifts and walking aids, from WP Domus LLC. Domus has three divisions: Alber, Aquatec and Dolomite. The acquisition allows the company to expand its product line and reach new markets. The preliminary purchase price was $227,382,000 including acquisition costs of $3,670,000, which was paid in cash, and is subject to final determination of the estimated costs of possible office closures, sales agency transfers and other consolidation efforts expected to be finalized by the end of the third quarter of 2005. The acquisition was consummated after satisfaction of certain conditions, including receipt of all requisite regulatory approvals. Invacare entered into a 100,000,000 Euro bridge loan agreement and utilized its existing revolving credit line to fund the acquisition. Invacare's reported results reflect the operating results of Domus since the date of the acquisition.

Supplemental pro forma information is presented below as though the business combination had been completed as of the beginning of the period being reported on. The pro forma information does not necessarily reflect the results of operations that would have occurred if Domus had been a wholly owned entity of Invacare as of the beginning of the periods presented (in thousands).

                                      Years Ended December 31
                                     2004                  2003
                               ----------             ----------
Net sales                      $1,490,140            $1,363,763
Net earnings                       80,410                75,859
Earnings per share - assuming
  dilution                          $2.49                 $2.39

The pro forma results for 2004 included non-recurring stock option plan expense of $1,410,000. The pro forma results for 2003 included non-recurring stock option plan expense of $2,208,000 and a one-time shipment to a Japanese distributor of approximately $9,512,000.

FS-12


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

ACQUISITIONS--Continued

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition (in thousands):

Trade receivables                               $10,845
Inventories                                       8,470
Other current assets                              5,380
Other intangibles                                68,965
Property and equipment                           17,673
Goodwill                                        161,486
                                                -------
   Total assets acquired                        272,819

Accounts payable                                 (3,985)
Accrued expenses                                (17,655)
Long-term debt                                   (7,771)
Other long-term obligations                     (16,026)
                                               --------
   Total liabilities assumed                    (45,437)
                                               --------
Net assets acquired                            $227,382
                                               ========

GOODWILL

The carrying amount of goodwill by operating segment is as follows (in thousands):

                                          2004                                                      2003
                   ----------------------------------------------------       ----------------------------------------------------
                     North                                                      North
                    America      Europe    Asia/Pacific    Consolidated        America      Europe     Asia/Pacific   Consolidated
                   --------      ------    ------------    ------------        -------      ------     ------------   ------------
Balance as of
 January 1          $210,047    $192,508        $12,944        $415,499       $153,683    $157,325       $10,110        $321,118
Acquisitions          95,344     161,486             71         256,901         49,723       3,397             -          53,120
Foreign
 currency
 translation           7,936      36,617          1,011          45,564          6,641      31,786         2,834          41,261
                    --------    --------       --------        --------       --------    --------      --------        --------
Balance as of
 December 31        $313,327    $390,611        $14,026        $717,964       $210,047    $192,508       $12,944        $415,499
                    ========    ========        =======        ========       ========    ========       =======        ========

Of the $256,901,000 in goodwill recorded from acquisitions, $67,557,000 is expected to be deductible for tax purposes, of which $53,716,000 is deductible related to the acquisition of Domus.

All of the company's other intangible assets have definite lives and continue to be amortized over their useful lives, except for $27,732,000 related to trademarks, which have indefinite lives. The company's intangibles consist of the following (in thousands):

                                             December 31, 2004                December 31, 2003
                                             -----------------                -----------------
                                                        Accumulated                         Accumulated
                                     Historical Cost    Amortization     Historical Cost    Amortization
                                     ---------------    ------------     ---------------    ------------
Customer Lists                               $57,788          $2,737              $6,105           $ 936
Trademarks                                    27,732               -               4,268               -
License agreements                             6,518           5,051               6,455           4,464
Developed Technology                           5,842              80                   -               -
Patents                                        4,137           1,443               2,180           1,109
Other                                          7,348           1,842               3,406           1,227
                                             -------         -------             -------          ------
                                            $109,365         $11,153             $22,414          $7,736
                                             =======         =======             =======          ======

FS-13


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

OTHER INTANGIBLES

The intangibles recorded on the date of acquisition due to the Domus acquisition were as follows (in thousands):

                                                       Weighted Average
                                   Fair Value          Amortization Period
                                   ----------          -------------------
Customer relationships              $  42,731               13 years
Trademarks - Indefinite lives          20,521              Indefinite
Developed Technology                    5,311               17 years
Other                                     402                5 years
                                    ---------
Total                               $  68,965               13 years
                                    =========

Amortization expense related to other intangibles was $3,417,000 and $1,506,000 for 2004 and 2003, respectively. Estimated amortization expense for each of the next five years is expected to be $7,333,000 for 2005, $6,591,000 in 2006, $6,427,000 in 2007, $6,128,000 in 2008 and $5,868,000 in 2009.

INVESTMENT IN AFFILIATED COMPANY

In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities (FIN 46), which was revised in December 2003 and, which among other things, deferred the implementation date of FIN 46 until periods after March 15, 2004. This interpretation requires consolidation of an entity if the company is subject to a majority of the risk of loss from the variable interest entity's (VIE) activities or entitled to receive a majority of the entity's residual returns, or both. A company that consolidates a VIE is known as the primary beneficiary of that entity.

As of December 31, 2004, the company had an investment in a development stage company, which is currently pursuing FDA approval to market a product focused on the treatment of post-stroke shoulder pain in the United States. The amount of net advances and investment recorded on the company's books is approximately $3,000,000 at December 31, 2004. Certain of the Company's officers and directors have small minority equity ownership positions in this company. Based on the provisions of FIN 46 and the company's preliminary analysis, the company does not believe that its investment is a VIE as of December 31, 2004. Subsequent to December 31, 2004, the company's board of directors approved an additional funding commitment. Accordingly, the company will be required to consolidate this investment on a prospective basis for the quarter ended March 31, 2005 as the company will be deemed the primary beneficiary of this variable interest entity.

CURRENT LIABILITIES

Accrued expenses as of December 31, 2004 and 2003 consist of the following (in thousands):

                                                 2004           2003
                                               ------         ------
Accrued salaries and wages                    $35,280        $31,960
Accrued warranty cost                          13,998         12,688
Accrued rebates                                 7,427         13,595
Accrued taxes other than income taxes           6,419          3,661
Accrued interest                                5,274          3,998
Accrued legal and professional                  4,761          2,029
Accrued freight                                 2,894          4,524
Accrued insurance                               2,656          2,470
Accrued product liability, current portion      2,595          2,245
Other accrued items                            17,546         14,862
                                               ------         ------
                                              $98,850        $92,032
                                               ======         ======

Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold in accordance with the guidance in EITF 01-09:
Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor's Products). The company has experienced significant pricing pressure in the U.S. market for standard products in recent years and has partially reduced prices to our customers in the form of a volume rebate such that the rebates would typically apply only if customers increased their standard product purchases from the company. The decrease in rebates from December 31, 2003 to December 31, 2004 is attributable to the fact that rebate programs in place at December 31, 2003 targeted at Standard Products customers in the U.S. expired during 2004 and were not renewed.

FS-14


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

CURRENT LIABILITIES --Continued

Changes in accrued warranty costs were as follows (in thousands):

                                                2004          2003
                                              ------        ------
Balance as of January 1                      $12,688       $11,448
Warranties provided during the period          8,665         8,557
Settlements made during the period            (7,977)       (8,288)
Changes in liability for pre-existing
   warranties during the period,
   including expirations                         622           971
                                              ------        ------
Balance as of December 31                    $13,998       $12,688
                                              ======        ======

LONG-TERM DEBT

Long-term debt as of December 31, 2004 and 2003 consist of the following (in thousands):

                                                                                           2004             2003
                                                                                         ------           ------
$80,000,000 senior notes at 6.71%, due in February 2008                                 $83,304          $85,462
$20,000,000 senior notes at 6.60%, due in February 2005                                  20,000           20,000
$50,000,000 senior notes at 3.97%, due in October 2007                                   50,081           50,560
$30,000,000 senior notes at 4.74%, due in October 2009                                   30,485           30,532
$20,000,000 senior notes at 5.05%, due in October 2010                                   20,433           20,386
Revolving credit agreement ($325,000,000 multi-currency), at 0.675% to
     1.40% above local interbank offered rates, expires October 17, 2006                230,382           20,002
Bridge Credit Agreement                                                                 100,000                -
Other notes                                                                              15,351            7,267
                                                                                         ------           ------
                                                                                        550,036          234,209
Less current maturities                                                                  (2,062)          (2,171)
                                                                                         ------           ------
                                                                                       $547,974         $232,038
                                                                                       ========         ========

The carrying values of the senior notes have been increased by the gains on the interest rate swaps accounted for as fair value hedges.

On January 14, 2005, Invacare Corporation entered into a $450,000,000 multi-currency revolving credit agreement, which expires on January 14, 2010. The facility provides that Invacare, may, upon consent of its lenders, increase the amount of the facility by an additional $100,000,000. The borrowing rates under the revolving credit agreement are determined based on the ratio of debt to earnings before interest, taxes, depreciation and amortization (EBITDA) of the company as defined in the agreement, and ranges from LIBOR plus 0.35% to 0.675%.

On September 1, 2004, Invacare Corporation entered into a 364-day, multi-currency bridge credit agreement with a group of commercial banks, with an expiration date of August 31, 2005 or such later date as mutually agreed upon by the company and the banks. Pursuant to the agreement, the company borrowed 100,000,000 Euros in order to provide funds for the company's general corporate purposes, including financing the Domus acquisition and expenses incurred in connection therewith.

In October 2003, Invacare Corporation issued $100,000,000 in senior notes, maturing between 2007 and 2010. In 2001, the company entered into a $325,000,000 5-year, multi-currency revolving credit agreement with a group of commercial banks. The multi-currency revolving credit agreement was to expire on October 17, 2006 or such later date as mutually agreed upon by the company and the banks.

In January 2005, amounts outstanding under both the $325,000,000 revolving credit agreement and the 100,000,000 Euro bridge credit agreement were paid off with the $450,000,000 multi-currency revolving credit agreement described above. In addition, the $20,000,000 senior notes at 6.60%, due in February 2005 were paid off with the new $450,000,000 facility and thus were classified as long-term as of December 31, 2004 as the company had the intent and the ability to pay-off the notes with long-term debt.

Borrowings denominated in foreign currencies aggregated $179,084,000 at December 31, 2004 and $872,000 at December 31, 2003. The borrowing rates under the revolving credit agreement are determined based on the ratio of debt to EBITDA of the company as defined in the agreement and range from 0.675% to 1.40% above the various interbank offered rates. As of December 31, 2004 and 2003, the weighted average floating interest rate on U.S. borrowings was 3.36% and 2.69%, respectively.

FS-15


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

LONG-TERM DEBT --Continued

The revolving credit agreement, as amended, bridge credit agreement and senior notes all require the company to maintain certain conditions with respect to net worth, funded debt to capitalization, and interest coverage as defined in the agreements. Under the most restrictive covenants of the company's borrowing arrangements, the company has the capacity to borrow up to an additional $60,800,000 as of December 31, 2004 and up to $108,000,000, effective February 2005, pursuant to the covenants of the new $450,000,000 multi-currency, long-term revolving credit agreement.

In October 2003, the company exchanged the fixed rates of 3.97%, 4.74% and 5.05% on the $50,000,000, $30,000,000 and $20,000,000 Senior Notes due in October 2007, October 2009 and October 2010 for variable rates based on LIBOR plus 0.01%, LIBOR plus 0.14% and LIBOR plus 0.26%, respectively. The effect of these swaps is to exchange fixed rates for the lower floating rates currently available.

In December 2001, the company exchanged the fixed rate of 6.71% on $50,000,000 of the $80,000,000 in Senior Notes due in February 2008. The three agreements for $25,000,000, $15,000,000 and $10,000,000 exchanged the fixed rate for variable rates equal to LIBOR plus 1.9%, 1.71% and 1.62%, respectively. In January 2002, the company exchanged the fixed rate of 6.71% on the remaining $30,000,000 of the $80,000,000 in Senior Notes due in February 2008. The two agreements for $10,000,000 and $20,000,000 exchanged the fixed rate for variable rates equal to LIBOR plus 1.05% and 1.08%, respectively. The effect of these swaps is to exchange a fixed rate of 6.71% for the lower floating rates currently available.

The aggregate minimum maturities of long-term debt for each of the next five years are as follows: $2,062,000 in 2005, $1,308,000 in 2006, $217,578,000 in 2007, $81,089,000 in 2008, and $31,108,000 in 2009. Interest paid on borrowings was $15,348,000, $9,450,000 and $13,465,000 in 2004, 2003 and 2002, respectively.

Other long-term obligations as of December 31, 2004 and 2003 consist of the following (in thousands):

                                                          2004             2003
                                                        ------           ------
Supplemental Executive Retirement Plan liability       $12,947          $11,048
Product liability                                       14,450            9,664
Deferred federal income taxes                           24,833            2,337
Other, principally deferred compensation                16,341           11,334
                                                        ------           ------
Total long-term obligations                            $68,571          $34,383
                                                       =======          =======

LEASES AND COMMITMENTS

The company leases a substantial portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms of up to 18 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses of operating the facilities and equipment. As of December 31, 2004, the company is committed under non-cancelable operating leases, which have initial or remaining terms in excess of one year and expire on various dates through 2014. Lease expenses were approximately $18,663,000 in 2004, $15,803,000 in 2003, and $12,575,000 in 2002.

The amount of buildings and equipment capitalized in connection with capital leases was $16,545,000 and $7,767,000 at December 31, 2004 and 2003, respectively. At December 31, 2004 and 2003, accumulated amortization was $3,590,000 and $3,003,000, respectively.

Future minimum operating and capital lease commitments as of December 31, 2004, are as follow (in thousands):

                                   Year      Capital Leases     Operating Leases
                                   ----      --------------     ----------------
                                   2005              $1,751              $15,680
                                   2006               1,699                9,039
                                   2007               1,586                5,870
                                   2008               1,538                3,178
                                   2009               1,526                1,872
                             Thereafter              13,439                1,715
                                                    -------              -------
    Total future minimum lease payments              21,539              $37,354
                                                    =======
          Amounts representing interest              (8,262)
Present value of minimum lease payments             $13,277
                                                    =======
                                      FS-16



INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

RETIREMENT AND BENEFIT PLANS

Substantially all full-time salaried and hourly domestic employees are included in the Invacare Retirement Savings Plan sponsored by the company. The company makes matching cash contributions up to 66.7% of employees' contributions up to 3% of compensation, quarterly contributions based upon 4% of qualified wages and may make discretionary contributions to the domestic plans based on an annual resolution by the Directors.

The company also sponsors a non-qualified 401(k) Plus Benefit Equalization Plan covering certain employees, which provides for employee elective deferrals and company retirement deferrals so that the total retirement deferrals equal amounts that would have been contributed to the company's principal retirement plans if it were not for limitations imposed by income tax regulations. Contribution expense for the plans in 2004, 2003 and 2002 was $5,860,000, $5,619,000, and $5,444,000, respectively.

The company also sponsors a non-qualified defined benefit Supplemental Executive Retirement Plan for certain key executives. The projected benefit obligation related to this unfunded plan was $30,631,000 and $27,618,000 at December 31, 2004 and 2003, respectively, of which approximately $13,371,000 and $11,517,000, at December 31, 2004 and 2003, respectively, has been accrued. Expense for the plan in 2004, 2003, and 2002 was $2,278,000, $2,108,000, and $2,147,000, respectively.

In conjunction with these non-qualified plans, the company has invested in life insurance policies related to certain employees to satisfy certain of these future obligations. The current cash surrender value of the policies approximates the current benefit obligations. In addition, the projected policy benefits exceed the projected benefit obligations.

SHAREHOLDERS' EQUITY TRANSACTIONS

The Common Shares and the Class B Common Shares generally have identical rights, terms and conditions and vote together as a single class on most issues, except that the Class B Common Shares have ten votes per share, carry a 10% lower cash dividend rate and, in general, can only be transferred to family members. Holders of Class B Common Shares are entitled to convert their shares into Common Shares at any time on a share-for-share basis.

The 2003 Performance Plan (the "2003 Plan") allows the Compensation Committee of the Board of Directors (the "Committee") to grant up to 2,000,000 Common Shares in connection with incentive stock options, non-qualified stock options, stock appreciation rights and stock awards (including the use of restricted stock). The 1994 Performance Plan (the "1994 Plan"), as amended, expired in 2004 and allowed the Compensation Committee of the Board of Directors (the "Committee") to grant up to 5,500,000 Common Shares. The Committee has the authority to determine which employees and directors will receive awards, the amount of the awards and the other terms and conditions of the awards. During 2004, the Committee granted 615,450 and 11,000 non-qualified stock options for a term of ten years at the fair market value of the company's Common Shares on the date of grant under the 2003 Plan and the 1994 Plan, respectively. There were no stock appreciation rights outstanding at December 31, 2004, 2003 or 2002.

Restricted stock awards for 20,510, 28,894 and 37,289 shares were granted in years 2004, 2003 and 2002 without cost to the recipients. Under the terms of the restricted stock awards, which were initially granted in 2001, 104,213 of the shares granted vest ratably over the four years after the award date and 6,500 of the shares granted vest ratably over the 2 years after the award date. Unearned restricted stock compensation of $911,000 in 2004, $897,000 in 2003 and $1,190,000 in 2002, determined as the market value of the shares at the date of grant, is being amortized on a straight-line basis over the vesting period. Compensation expense of $812,000, $643,000 and $757,000 was recognized in 2004, 2003 and 2002, respectively, related to restricted stock awards granted since 2001.

The 1994 Plan and the 2003 Plan have provisions that allow employees to exchange mature shares to pay the exercise price and surrender shares for the options to cover the minimum tax withholding obligation. Under these provisions, the company acquired approximately 53,000 treasury shares for $2,444,000 in 2004, 110,000 treasury shares for $3,199,000 in 2003 and 85,000 treasury shares for $2,863,000 in 2002.

FS-17


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

SHAREHOLDERS' EQUITY TRANSACTIONS--(Continued)

As of December 31, 2004, an aggregate of 10,389,393 Common Shares were reserved for conversion of Class B Common Shares, future rights (as defined below) and the exercise and future grant of options.

                                                                Weighted                   Weighted                   Weighted
                                                                 Average                    Average                    Average
                                                                Exercise                   Exercise                   Exercise
                                                      2004         Price          2003        Price          2002        Price
                                                      ----         -----          ----        -----          ----        -----
Options outstanding at January 1                 4,518,890        $27.34     4,257,422       $25.23     4,201,943       $23.27
Granted                                            626,450         43.89       704,617        36.73       619,868        33.59
Exercised                                         (449,374)        24.13      (340,665)       19.08      (418,432)       18.28
Canceled                                           (57,561)        34.75      (102,484)       33.02      (145,957)       27.32
                                                 ---------        ------     ---------       ------     ---------       ------
Options outstanding at December 31               4,638,405        $29.81     4,518,890       $27.34     4,257,422       $25.23
                                                 =========        ======     =========       ======     =========       ======

Options price range at December 31               $16.03 to                   $15.13 to                  $11.88 to
                                                    $47.35                      $43.37                     $36.84

Options exercisable at December 31               2,963,385                   2,796,100                  2,347,721
Options available for grant at December 31*      1,033,858                   1,670,600                    296,860

* Options available for grant as of December 31, 2004 reduced by net restricted stock award activity of 108,713.

The following table summarizes information about stock options outstanding at December 31, 2004:

                                          Options Outstanding                                      Options Exercisable
                                          -------------------                                      -------------------
                          Number            Weighted Average                                  Number
                        Outstanding             Remaining          Weighted Average         Exercisable         Weighted Average
Exercise Prices         At 12/31/04         Contractual Life        Exercise Price          At 12/31/04          Exercise Price
---------------         -----------         ----------------        --------------          -----------          --------------
$16.03 - $19.50            513,873              3.8 years               $18.25                 513,873               $18.25
$20.06 - $24.75          1,266,484                 3.9                  $23.67               1,066,484               $23.72
$25.13 - $29.85            723,042                 4.4                  $25.30                 723,042               $25.30
$30.02 - $34.54            694,753                 7.4                  $32.54                 387,718               $32.82
$36.10 - $37.70            823,891                 8.3                  $37.29                 272,268               $37.06
$40.07 - $47.35            616,362                 9.7                  $44.29                       -                    -
                         ---------                 ---                  ------               ---------               ------
     Total               4,638,405                 6.0                  $29.41               2,963,385               $25.57

The company utilizes the disclosure-only provisions of SFAS No. 123. Accordingly, no compensation cost has been recognized for the stock option plans, except the expense recorded related to the 110,713 restricted stock awards granted in years 2001 through 2004.

The assumption regarding the stock options issued in 2004, 2003 and 2002 was that 25% of such options vested in the year following issuance. The stock options awarded during such years provided a four-year vesting period whereby options vest equally in each year. Current and prior years' pro forma disclosures may be adjusted for forfeitures of awards that will not vest because service or employment requirements have not been met.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

                                         2004          2003         2002
                                         ----          ----         ----
Expected dividend yield                  .63%          .75%         .80%
Expected stock price volatility         28.8%         29.6%        31.4%
Risk-free interest rate                 3.67%         3.31%        3.26%
Expected life (years)                    5.6           5.5          5.4

The weighted-average fair value of options granted during 2004, 2003 and 2002, based upon an expected exercise year of 2010, was $13.58, $11.03 and $10.71, respectively.

FS-18


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

SHAREHOLDERS' EQUITY TRANSACTIONS --Continued

The plans provide that shares granted come from the company's authorized but unissued Common Shares or treasury shares. Pursuant to the plans, the Committee has established that the 2004 grants may not be exercised within one year from the date granted and options must be exercised within ten years from the date granted. The weighted-average remaining contractual life of options outstanding at December 31, 2004 is 6.0 years.

On July 7, 1995, the company adopted a Rights Plan whereby each holder of a Common Share and a Class B Common Share received one purchase right (the "Rights") for each share owned. Under certain conditions, each Right may be exercised to purchase one-tenth of one Common Share at a price of $8.00 per one-tenth of a share. The Rights may only be exercised 10 days after a third party has acquired 30% or more of the company's outstanding voting power or 10 days after a third party commences a tender offer for 30% or more of the voting power (an "Acquiring Party"). In addition, if an Acquiring Party merges with the company and the company's Common Shares are not changed or exchanged, or if an Acquiring Party engages in one of a number of self-dealing transactions, each holder of a Right (other than the Acquiring Party) will have the right to receive that number of Common Shares or similar securities of the resulting entity having a market value equal to two times the exercise price of the Right. The company may redeem the Rights at a price of $0.005 per Right at any time prior to 10 days following a public announcement that an Acquiring Party has acquired beneficial ownership of 30% or more of the company's outstanding voting power, and in certain other circumstances as approved by the Board of Directors. The Rights will expire on July 7, 2005.

CAPITAL STOCK

Capital stock activity for 2004, 2003 and 2002 consisted of the following (in thousands of shares):

                                                                      Common Stock      Class B      Treasury
                                                                         Shares         Shares        Shares
                                                                      ----------------------------------------
January 1, 2002 Balance                                                       29,838      1,112          (249)
Exercise of stock options                                                        419          -           (85)
Stock awards                                                                      37          -             -
Repurchase of treasury shares                                                      -          -           (53)
--------------------------------------------------------------------------------------------------------------
December 31, 2002 Balance                                                     30,294      1,112          (387)
Exercise of stock options                                                        416          -          (110)
Stock awards                                                                      29          -             -
Repurchase of treasury shares                                                      -          -          (273)
--------------------------------------------------------------------------------------------------------------
December 31, 2003 Balance                                                     30,739      1,112          (770)
Exercise of stock options                                                        449          -           (53)
Stock awards                                                                      21          -             -
Repurchase of treasury shares                                                      -          -          (111)
--------------------------------------------------------------------------------------------------------------
December 31, 2004 Balance                                                     31,209      1,112          (934)
                                                                              ======      =====         =====

Stock option exercises in 2003 include deferred share activity, which increased common shares by 75,000 shares and treasury shares by 5,000 shares.

FS-19


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--Continued

OTHER COMPREHENSIVE EARNINGS (LOSS)

The components of other comprehensive earnings (loss) are as follows (in thousands):

                                                                                                       Unrealized Gain
                                                                                    Unrealized Gain       (Loss) on
                                                                      Currency         (Loss) on          Derivative
                                                                     Translation    Available-for-Sale    Financial
                                                                     Adjustments       Securities         Instruments        Total
                                                                     ---------------------------------------------------------------
Balance at January 1, 2002                                            $(47,832)          $ 743             $(1,040)        $(48,129)
Foreign currency translation adjustments                                28,214                                               28,214
Unrealized loss on available for sale securities                                          (251)                                (251)
Deferred  tax benefit  relating to  unrealized  loss on available
    for sale securities                                                                     88                                   88
Current period unrealized gain on cash flow hedges, net of
    reclassifications                                                                                        2,074            2,074
Deferred tax expense  relating to  unrealized  gain on derivative
    financial instruments                                                                                     (725)            (725)
                                                                     ---------------------------------------------------------------
Balance at December 31, 2002                                           (19,618)            580                 309          (18,729)

Foreign currency translation adjustments                                66,185                                               66,185
Unrealized gain on available for sale securities                                           146                                  146
Deferred tax liability relating to unrealized gain on available
     for sale securities                                                                   (51)                                 (51)
Current period unrealized gain on cash flow hedges, net of
     reclassifications                                                                                       5,394            5,394
Deferred tax expense  relating to  unrealized  gain on derivative
     financial instruments                                                                                  (1,888)          (1,888)
                                                                     ---------------------------------------------------------------
Balance at December 31, 2003                                            46,567             675               3,815           51,057

Foreign currency translation adjustments                                57,903                                               57,903
Unrealized loss on available for sale securities                                           (14)                                 (14)
Deferred  tax benefit  relating to  unrealized  loss on available
     for sale securities                                                                     5                                    5
Current period unrealized loss on cash flow hedges, net of
     reclassifications                                                                                      (6,649)          (6,649)
Deferred tax benefit  relating to  unrealized  loss on derivative
     financial instruments                                                                                   2,327            2,327
                                                                     ---------------------------------------------------------------
Balance at December 31, 2004                                          $104,470            $666               $(507)        $104,629
                                                                     ===============================================================

Net gains of $6,650,000 and $500,000 and a net loss of $402,000 were reclassified into earnings related to derivative instruments designated and qualifying as cash flow hedges in 2004, 2003 and 2002, respectively.

INCOME TAXES

Earnings before income taxes consist of the following (in thousands):

                           2004                2003              2002
                        -------             -------           -------
Domestic                $57,557             $59,027           $51,512
Foreign                  52,815              47,382            45,018
                        -------             -------           -------
                       $110,372            $106,409           $96,530
                        =======             =======            ======

FS-20


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

INCOME TAXES --Continued

The company has provided for income taxes as follows (in thousands):

                          2004                2003              2002
                       -------             -------           -------
Current:
  Federal              $14,075             $16,635           $21,415
  State                  2,800               3,200             2,200
  Foreign               14,050              11,960            11,195
                       -------             -------           -------
                        30,925              31,795            34,810

Deferred:
  Federal                2,225               1,625            (4,620)
  Foreign                2,025               1,580             1,570
                       -------             -------           -------
                         4,250               3,205            (3,050)
                       -------             -------           -------
Income Taxes           $35,175             $35,000           $31,760
                       =======             =======           =======

A reconciliation to the effective income tax rate from the federal statutory rate follows:

                                        2004       2003       2002
                                        ----       ----       ----
Statutory federal income tax rate       35.0%      35.0%      35.0%
State and local income taxes, net of
  federal income tax benefit             1.6        2.0        1.5
Tax credits                             (1.6)      (1.4)      (2.3)
Foreign taxes at less than the federal
  statutory rate                        (2.1)      (2.9)      (2.6)
Other, net                              (1 0)        .2        1.3
                                        ----       ----       ----
                                        31.9%      32.9%      32.9%
                                        ====       ====       ====

Significant components of deferred income tax assets and liabilities at December 31, 2004 and 2003 are as follows (in thousands):

                                                 2004            2003
                                                -----           -----
Current deferred income tax assets, net:
     Loss carryforwards                        $7,620          $1,162
     Bad debt                                   4,366           7,773
     Warranty                                   3,157           3,094
     State and local taxes                      3,048           2,422
     Other accrued expenses and reserves        2,219           2,118
     Inventory                                  1,816           1,931
     Litigation reserves                            -           2,177
     Compensation and benefits                  1,240             968
     Product liability                            292             291
     Other, net                                (2,028)          2,637
                                                -----           -----
                                              $21,730         $24,573

FS-21


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

INCOME TAXES --Continued
                                                          2004             2003
                                                         -----            -----
                                                             (In thousands)
          Long-term deferred income tax assets
         (liabilities), net:
               Goodwill & intangibles                  (35,431)          (3,310)
               Fixed assets                            (15,169)         (11,003)
               Compensation and benefits                 9,642            8,219
               Loss carryforwards                        6,429            1,001
               Product liability                         3,391            1,282
               State and local taxes                     2,400            2,400
               Valuation reserve                             -           (1,001)
               Other, net                                3,905               75
                                                         -----            -----
                                                     $ (24,833)        $ (2,337)
                                                         -----            -----
          Net Deferred Income Taxes                    $(3,103)         $22,236
                                                        ======           ======

At December 31, 2004, the company had federal foreign tax loss carryforwards of approximately $47,625,000 of which $43,990,000 are non-expiring, $890,000 are expiring in 2009 and $2,745,000 are expiring in 2010. At December 31, 2004 the company also has $17,550,000 of local foreign tax loss carryforwards, which are non-expiring. The loss carryforward amounts include $43,200,000 of federal and $17,550,000 of local loss carryforwards acquired in 2004 acquisitions. The company made income tax payments of $30,180,000, $25,173,000 and $28,769,000 during the years ended December 31, 2004, 2003 and 2002, respectively.

NET EARNINGS PER COMMON SHARE

The following table sets forth the computation of basic and diluted net earnings per common share.

                                             2004       2003       2002
                                             ----       ----       ----
                                        (In thousands except per share data)
Basic
  Average common shares outstanding        31,153     30,862      30,867

  Net earnings                            $75,197    $71,409     $64,770

  Net earnings per common share             $2.41      $2.31       $2.10

Diluted
  Average common shares outstanding        31,153     30,862      30,867
  Stock options                             1,194        867         797
                                             ----       ----        ----
  Average common shares assuming dilution  32,347     31,729      31,664

  Net earnings                            $75,197    $71,409     $64,770

  Net earnings per common share             $2.33      $2.25       $2.05

At December 31, 2004 and 2003, 21,167 and 501,067 shares, respectively were excluded from the average common shares assuming dilution, as they were anti-dilutive. In 2004, the majority of the anti-dilutive shares were granted at an exercise price of $47.35, which was higher than the average fair market value price of $44.39 for 2004. In 2003, the majority of the anti-dilutive shares were granted at an exercise price of $37.70, which was higher than the average fair market value price of $35.29 for 2003.

FS-22


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

CONCENTRATION OF CREDIT RISK

The company manufactures and distributes durable medical equipment and supplies to the home health care, retail and extended care markets. The company performs credit evaluations of its customers' financial condition. Prior to December 2000, the company financed equipment to certain customers for periods ranging from 6 to 39 months. In December 2000, Invacare entered into an agreement with DLL, a third party financing company, to provide the majority of future lease financing to Invacare's customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a limited recourse obligation ($50,010,000 at December 31, 2004) to DLL for events of default under the contracts (total balance outstanding of $104,447,000 at December 31, 2004). Financial Accounting Standards Board (FASB) Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, requires the company to record a guarantee liability as it relates to the limited recourse obligation. As such, the company has recorded a liability for this guarantee obligation. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with SFAS No. 5, Accounting for Contingencies. Credit losses are provided for in the financial statements.

Substantially all of the company's receivables are due from health care, medical equipment dealers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. In addition, the company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company's customers.

FAIR VALUES OF FINANCIAL INSTRUMENTS

The company in estimating its fair value disclosures for financial instruments used the following methods and assumptions:

Cash, cash equivalents and marketable securities: The carrying amount reported in the balance sheet for cash, cash equivalents and marketable securities approximates its fair value.

Installment receivables: The carrying amount reported in the balance sheet for installment receivables approximates its fair value. The majority of the portfolio contains receivables, which are due in less than one year. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value.

Long-term debt: Fair values for the company's senior notes are estimated using discounted cash flow analyses, based on the company's current incremental borrowing rate for similar borrowing arrangements.

Interest Rate Swaps: The company is a party to interest rate swap agreements, which are entered into, in the normal course of business to reduce exposure to fluctuations in interest rates. The agreements are with major financial institutions, which are expected to fully perform under the terms of the agreements thereby mitigating the credit risk from the transactions. The agreements are contracts to exchange fixed rate payments for floating rate payments over the life of the agreements without the exchange of the underlying notional amounts. The notional amounts of such agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The amounts to be paid or received under the interest rate swap agreements are accrued consistent with the terms of the agreements and market interest rates. Fair value for the company's interest rate swaps are based on independent pricing models.

Other investments: The company has made other investments in limited partnerships and non-marketable equity securities, which are accounted for using the cost method, adjusted for any estimated declines in value. These investments were acquired in private placements and there are no quoted market prices or stated rates of return.

FS-23


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

FAIR VALUES OF FINANCIAL INSTRUMENTS --Continued

The carrying amounts and fair values of the company's financial instruments at December 31, 2004 and 2003 are as follows (in thousands):

                                    2004                      2003
                                    ----                      ----
                           Carrying        Fair      Carrying         Fair
                              Value       Value         Value        Value
                            -------      ------       -------       ------
Cash and cash equivalents   $32,567     $32,567       $16,074      $16,074
Marketable securities           199         199           214          214
Other investments             8,213       8,213         7,642        7,642
Installment receivables      14,746      14,746         8,279        8,279
Long-term debt (including
  current maturities)       550,036     551,431       234,209      237,584
Interest rate swaps           4,302       4,302         6,615        6,615
Forward contracts              (780)       (780)        6,196        6,196

Forward Contracts: The company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are entered into to hedge the following currencies: USD, NZD, CAD, EUR, SEK, DKK and AUD. The company does not use derivative financial instruments for speculative purposes.

The gains and losses that result from the majority of the forward contracts are deferred and recognized when the offsetting gains and losses for the identified transactions are recognized. The company recognized gains of $6,961,000 in 2004, $1,292,000 in 2003, and $1,184,000 in 2002, which were recognized in cost of products sold and selling, general and administrative expenses.

BUSINESS SEGMENTS

The company operates in three primary business segments based on geographical area: North America, Europe and Asia/Pacific. The three reportable segments represent operating groups, which offer products to different geographic regions.

The North America segment sells each of five primary product lines, which includes: standard, rehab, distributed, respiratory, and continuing care products. Europe and Asia/Pacific sell the same product lines with the exception of distributed products. Each business segment sells to the home health care, retail and extended care markets.

The company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company's consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance. Intersegment revenue for reportable segments are $83,135,000, $74,835,000 and $61,178,000 for the years ended December 31, 2004, 2003 and 2002, respectively.

FS-24


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

BUSINESS SEGMENTS--Continued

The information by segment is as follows (in thousands):

                                           2004          2003          2002
----------------------------------------------------------------------------
Revenues from external customers
     North America                   $1,002,273      $897,208      $793,464
     Europe                             336,792       279,782       251,443
     Asia/Pacific                        64,262        70,186        44,254
                                      ---------     ---------     ---------
     Consolidated                    $1,403,327    $1,247,176    $1,089,161
                                      =========     =========     =========

Depreciation and amortization
     North America                      $20,644       $18,551       $19,232
     Europe                               8,687         6,315         5,699
     Asia/Pacific                         2,911         2,261         1,623
     All Other (1)                           74           108            84
                                      ---------     ---------     ---------
     Consolidated                       $32,316       $27,235       $26,638
                                      =========     =========     =========

Net interest expense (income)
     North America                       $8,940        $7,780       $11,910
     Europe                               4,924         4,220         5,256
     Asia/Pacific                          (664)         (602)         (282)
     All Other (1)                       (2,104)       (5,161)       (6,312)
                                      ---------     ---------     ---------
     Consolidated                       $11,096        $6,237       $10,572
                                      =========     =========     =========

Earnings (loss) before income taxes
     North America                      $95,883       $88,299       $76,548
     Europe                              18,705        19,132        19,020
     Asia/Pacific                         1,430         5,997         5,740
     All Other (1)                       (5,646)       (7,019)       (4,778)
                                      ---------     ---------     ---------
     Consolidated                      $110,372      $106,409       $96,530
                                      =========     =========     =========

Assets
     North America                     $778,820      $616,352      $510,135
     Europe                             710,510       348,063       295,085
     Asia/Pacific                        69,685        56,403        41,185
     All Other (1)                       69,109        87,395        60,298
                                      ---------     ---------     ---------
     Consolidated                    $1,628,124    $1,108,213      $906,703
                                      =========     =========     =========

Long-lived assets
     North America                     $428,308      $307,736      $252,624
     Europe                             548,843       236,591       194,212
     Asia/Pacific                        31,797        24,492        15,831
     All Other (1)                       53,905        64,672        45,224
                                      ---------     ---------     ---------
     Consolidated                    $1,062,853      $633,491      $507,891
                                      =========     =========     =========

Expenditures for assets
     North America                      $14,897       $12,513       $11,172
     Europe                              20,064        11,933         7,956
     Asia/Pacific                         6,441         6,203         2,381
     All Other (1)                            1            11           600
                                      ---------     ---------     ---------
     Consolidated                       $41,403       $30,660       $22,109
                                      =========     =========     =========

(1) Consists of the domestic export unit, un-allocated corporate selling, general and administrative costs, the Invacare captive insurance unit and inter-company profits, which do not meet the quantitative criteria for determining reportable segments.

FS-25


INVACARE CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

BUSINESS SEGMENTS--Continued

Net sales by product, are as follows (in thousands):

North America                           2004          2003          2002
-------------                      ---------      --------      --------
Standard                            $257,668      $274,959      $282,627
Rehab                                280,339       273,063       211,096
Distributed                          205,130       162,645       146,573
Respiratory                          161,247       118,115        82,528
Continuing Care                       76,578        48,321        40,452
Other                                 21,311        20,105        30,188
                                   ---------      --------      --------
                                  $1,002,273      $897,208      $793,464
                                   =========      ========      ========

Europe                                  2004          2003          2002
------                             ---------      --------      --------
Standard                            $200,064      $142,777      $130,617
Rehab                                128,316       129,167       113,162
Respiratory                            8,412         7,838         7,664
                                   ---------      --------      --------
                                    $336,792      $279,782      $251,443
                                   =========      ========      ========

Asia/Pacific                            2004          2003          2002
------------                       ---------      --------      --------
Rehab                                $34,273       $46,832       $32,752
Respiratory                            8,162         6,584         4,207
Standard                               7,721         6,427         4,680
Other                                 14,106        10,343         2,615
                                   ---------      --------      --------
                                     $64,262       $70,186       $44,254
                                   =========      ========      ========

Total Consolidated                $1,403,327    $1,247,176    $1,089,161
                                   =========     =========     =========

No single customer accounted for more than 5% of the company's sales.

INTERIM FINANCIAL INFORMATION (UNAUDITED)

                                                                            QUARTER ENDED
                                                                            -------------
                                                                  (In thousands, except per share data)
                    2004                             March 31,         June 30,     September 30,      December 31,
                    ----                            ---------        ---------         ---------         ---------
Net sales                                            $321,343         $339,288          $349,507          $393,189
Gross profit                                           93,379          102,124           106,076           117,013
Earnings before income taxes                           21,041           26,698            32,614            30,019
Net earnings                                           14,201           18,023            22,529            20,444
Net earnings per share - basic                            .46              .58               .72               .65
Net earnings per share - assuming
   dilution                                               .44              .56               .70               .63

                    2003                             March 31,         June 30,     September 30,      December 31,
                    ----                            ---------         ---------        ---------         ---------
Net sales                                            $276,673         $300,114          $327,366          $343,023
Gross profit                                           80,451           87,834            98,452           107,924
Earnings before income taxes                           18,267           23,022            29,812            35,308
Net earnings                                           12,257           15,447            20,007            23,698
Net earnings per share - basic                            .40              .50               .65               .76
Net earnings per share - assuming
   dilution                                               .39              .49               .63               .74

FS-26


INVACARE CORPORATION AND SUBSIDIARIES

SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS

            (In thousands)                  COL A.          COL B.         COL C.          COL D.
                                            ------          ------         ------          ------

                                            Balance       Charged To                     Balance
                                         At Beginning      Cost And    Deductions         At End
                                           Of Period       Expenses     Describe        Of Period
Year Ended December 31, 2004             ------------      --------    ----------       ---------
----------------------------
Deducted from asset accounts -

     Allowance for doubtful accounts        $27,704         $11,222    $(23,350)(A)       $15,576

     Inventory obsolescence reserve           8,715           2,609      (1,792)(B)         9,532

     Investments and related notes           29,540               -           -            29,540
       receivable

Accrued warranty cost                        12,688           9,287      (7,977)(B)        13,998

Accrued product liability                    11,909           8,202      (3,066)(C)        17,045

Year Ended December 31, 2003
----------------------------
Deducted from asset accounts -

     Allowance for doubtful accounts        $32,732         $13,760    $(18,788)(A)       $27,704

     Inventory obsolescence reserve           5,337           6,623      (3,245)(B)         8,715

     Investments and related notes           29,000             540           -            29,540
       receivable

Accrued warranty cost                        11,448           9,528      (8,288)(B)        12,688

Accrued product liability                     8,272           8,058      (4,421)(C)        11,909

Year Ended December 31, 2002
----------------------------
Deducted from asset accounts -

    Allowance for doubtful accounts         $28,797         $10,792     $(6,857)(A)       $32,732

    Inventory obsolescence reserve            5,463           2,137      (2,263)(B)         5,337

    Investments and related notes            29,000               -           -            29,000
       receivable

Accrued warranty cost                         7,607          11,695      (7,854)(B)        11,448

Accrued product liability                     5,816           5,086      (2,630)(C)         8,272

Note (A) - Uncollectible accounts written off, net of recoveries.

Note (B) - Amounts written off or payments incurred.

Note (C) - Loss and loss adjustment.

FS-27


Exhibit 21 Invacare Corporation Subsidiaries
1. 2030604 Ontario, Inc., an Ontario corporation and wholly owned subsidiary.

2. 3080359 Nova Scotia Company, a Nova Scotia corporation and wholly owned subsidiary.

3. 6123449 Canada, Inc., a Canadian corporation and wholly owned subsidiary.

4. Adaptive Switch Laboratories, Inc., a Texas corporation and wholly owned subsidiary.

5. Alber GmbH, Wurenlos, a Swiss corporation and wholly owned subsidiary.

6. Aquatec GmbH, Isny, a German limited liability company.

7. Carroll Healthcare (USA) Inc., a Nevada corporation and wholly owned subsidiary.

8. Carroll Healthcare Inc. (Chile) Limitada, a Chilean corporation and wholly owned subsidiary.

9. Carroll Healthcare, Inc., an Ontario corporation and wholly owned subsidiary.

10. Champion Manufacturing Inc., a Delaware corporation.

11. Dolomite AB, Gislaved, a Swedish corporation and wholly owned subsidiary.

12. Dolomite Holding AB, Gislaved, a Swedish corporation and wholly owned subsidiary.

13. Dynamic Controls, a New Zealand corporation and wholly owned subsidiary.

14. Dynamic Europe Limited, a U.K. corporation and wholly owned subsidiary.

15. EC-Hong AS, a Danish corporation and wholly owned subsidiary.

16. Freedom Designs, Inc., a California corporation and wholly owned subsidiary

17. Garden City Medical Inc., a Delaware corporation and wholly owned subsidiary.

18. Groas A/S, a Norwegian corporation and wholly owned subsidiary.

19. Healthtech, Inc., a Missouri corporation and wholly owned subsidiary.

20. Invacare AB, a Swedish corporation and wholly owned subsidiary.

21. Invacare AG, a Swiss corporation and wholly owned subsidiary.

22. Invacare AS, a Danish corporation and wholly owned subsidiary.

23. Invacare AS, a Norwegian corporation and wholly owned subsidiary.

24. Invacare Australia Pty Limited, an Australian corporation and wholly owned subsidiary.

25. Invacare Bencraft, a U.K. corporation and wholly owned subsidiary.

26. Invacare BV, a Netherlands corporation and wholly owned subsidiary.

27. Invacare Canada Holdings, Inc., a Canadian corporation and wholly owned subsidiary.

I-36

Invacare Corporation Subsidiaries
28. Invacare Canada Inc., an Ontario corporation and wholly owned subsidiary.

29. Invacare Canadian Holdings, Inc., a Delaware corporation and wholly owned subsidiary.

30. Invacare Credit Corporation, an Ohio corporation and wholly owned subsidiary.

31. Invacare Deutschland GmbH, a German corporation and wholly owned subsidiary.

32. Invacare Florida Corporation, a Delaware corporation and wholly owned subsidiary.

33. Invacare Germany Holding GmbH, a German corporation and wholly owned subsidiary

34. Invacare GmbH and Co. KG, a German corporation and wholly owned subsidiary.

35. Invacare Holding AB, a Swedish corporation and wholly owned subsidiary.

36. Invacare Holding BV, a Netherlands corporation and wholly owned subsidiary.

37. Invacare Holding Two AB, a Swedish corporation and wholly owned subsidiary.

38. Invacare Holdings AS, a Norwegian corporation and wholly owned subsidiary.

39. Invacare Holdings CV, a Netherlands wholly owned partnership subsidiary.

40. Invacare Holdings LLC, an Ohio limited liability corporation and wholly owned subsidiary.

41. Invacare Holdings New Zealand, a New Zealand corporation and wholly owned subsidiary.

42. Invacare Holdings Two BV, a Netherlands corporation and wholly owned subsidiary.

43. Invacare International Corporation, an Ohio corporation and wholly owned subsidiary.

44. Invacare International SARL, a Swiss corporation and wholly owned subsidiary.

45. Invacare Ltd., a U.K. corporation and wholly owned subsidiary.

46. Invacare Mauritius Holdings, a Republic of Mauritius Company and wholly owned subsidiary.

47. Invacare MeccSan SrL, an Italian corporation and wholly owned subsidiary.

48. Invacare Medical Equipment (Kunshan) Company, Ltd., a Chinese company and wholly owned subsidiary.

49. Invacare Medical Equipment (Suzhou) Company, Ltd., a Chinese company and wholly owned subsidiary.

50. Invacare New Zealand, a New Zealand corporation and wholly owned subsidiary.

51. Invacare NV, a Belgium corporation and wholly owned subsidiary.

52. Invacare Poirier SAS, a French corporation and wholly owned subsidiary.

53. Invacare Rea AB, a Swedish corporation and wholly owned subsidiary.

54. Invacare Supply Group, Inc. (formerly Suburban Ostomy Supply Company, Inc.), a Massachusetts corporation and wholly owned subsidiary.

55. Invacare Trading Company, Inc., a United States Territory of the Virgin Islands corporation and wholly owned subsidiary.

I-37

Invacare Corporation Subsidiaries
56. Invacare Verwaltungs GmbH, a German corporation and wholly owned subsidiary.

57. Invacare(Portugual) - Sociedade Industrial e Comercial de Ortopedia., Lda., a Portugal company and wholly owned subsidiary.

58. Invacare, S.A., a Spanish corporation and wholly owned subsidiary.

59. Invamex S.A. de R.L. de C.V., a Mexican corporation and wholly owned subsidiary.

60. Invatection Insurance Company, a Vermont corporation and wholly owned subsidiary.

61. Medbloc, Inc., a Delaware corporation and wholly owned subsidiary.

62. Mobilite Building Corporation, a Florida corporation and wholly owned subsidiary.

63. Mobitec Mobilitatshilfen Ges.m.b.H., Tiefgraben, an Austrian corporation and wholly owned subsidiary.

64. Mobitec Rehab AG, Wurenlos, a Swiss corporation and wholly owned subsidiary.

65. Mobitec S.a.r.l., Venissieux, A French corporation and wholly owned subsidiary.

66. Motion Concepts, L.P., an Ontario wholly owned partnership.

67. Perpetual Motion Enterprises Inc., an Ontario corporation and wholly owned subsidiary.

68. Pro-Med Australia Pty. Limited., an Australian corporation and wholly owned subsidiary.

69. Pro-Med Equipment Pty. Limited, an Australian corporation and wholly owned subsidiary.

70. Roller Chair Pty. Limited, an Australian corporation and wholly owned subsidiary.

71. Samarite B.V., a Netherlands corporation and wholly owned subsidiary.

72. Scandinavian Mobility GmbH, a German corporation and wholly owned subsidiary.

73. Scandinavian Mobility International AS, a Danish corporation and wholly owned subsidiary.

74. Sci Des Hautes Roches, a French partnership and wholly owned subsidiary.

75. Silcraft Corporation, a Michigan corporation and wholly owned subsidiary.

76. The Aftermarket Group, Inc., a Delaware corporation and wholly owned subsidiary.

77. Ulrich Alber GmbH, Albstadt, a German limited liability company.

78. WP Domus GmbH, a German corporation and wholly owned subsidiary.

79. WP Gesundheits Verwaltungs GmbH, a German limited liability company .


Note, "Wholly owned subsidiary" refers to indirect, as well as direct, wholly owned subsidiaries.

I-38

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Forms S-8, No. 33-45993 dated February 24, 1992, No. 33-87052 dated December 5, 1994, No. 33-57978 dated March 30, 2001 and No. 333-109794 dated October 17, 2003) pertaining to the Invacare Corporation stock option plans of our reports dated March 4, 2005, with respect to the consolidated financial statements and schedule of Invacare Corporation and subsidiaries, Invacare Corporation management's assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Invacare Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2004.

                                                           /S/ ERNST & YOUNG LLP



Cleveland, Ohio
March 4, 2005

I-39

Exhibit 3(a)

CERTIFICATE OF AMENDMENT
TO THE
ARTICLES OF INCORPORATION
OF
INVACARE CORPORATION

A. MALACHI MIXON, III, President, and DALE C. LaPORTE, Secretary, of INVACARE CORPORATION, an Ohio corporation (the "Corporation"), do hereby certify that at a meeting of shareholders duly called and held on May 28, 1987, at which meeting a quorum of shareholders was present in person or by proxy, the following resolutions to amend and restate the Articles of Incorporation of the Corporation as set forth in Exhibit A to the Company's Definitive Proxy Statement dated April 30, 1987 and as attached hereto as Exhibit A, were duly adopted by the affirmative vote of holders of shares entitling them to exercise a majority of the voting power of the Corporation.
RESOLVED: That the Articles of Incorporation of Invacare Corporation be amended and restated to restate Article IV as set forth in Subdivisions A and B to Article IV in Exhibit A to the Company's Definitive Proxy Statement dated April 30, 1987, and that it be

FURTHER RESOLVED: That the President and Secretary of Invacare Corporation be and they are hereby authorized and directed to execute and file in the Office of the Secretary of State of Ohio an appropriate Certificate of Amendment in order to carry out the intent and purposes of the preceding resolution and render effective said amendment and restatement of the Articles of Incorporation; and

RESOLVED: That the Articles of Incorporation of Invacare Corporation be amended and restated to add a new provision to Article IV as set forth in Subdivision C to Article IV in Exhibit A to the Company's Definitive Proxy Statement dated April 30, 1987, and that it be


FURTHER RESOLVED: That the President and Secretary of Invacare Corporation be and they are hereby authorized and directed to execute and file in the Office of the Secretary of State of Ohio an appropriate Certificate of Amendment in order to carry out the intent and purposes of the preceding resolution and render effective said amendment and restatement of the Articles of Incorporation.

IN WITNESS WHEREOF, said A. Malachi Mixon, III, President and Dale C. LaPorte, Secretary, acting for and on behalf of the Corporation, have hereunto subscribed their names this 28th day of May, 1987.

INVACARE CORPORATION

                                         By:          /s/ A. Malachi Mixon, III
                                                      ------------------------
                                                      A. Malachi Mixon,
III, President

                                         And:         /s/ Dale C. LaPorte
                                                      -----------------------
                                                      Dale C. LaPorte, Secretary

2

AMENDED AND RESTATED

ARTICLES OF INCORPORATION
OF
INVACARE CORPORATION

ARTICLE I

The name of the Corporation shall be Invacare Corporation.

ARTICLE II

The principal office of the Corporation shall be located in Elyria, Lorain County, Ohio.

ARTICLE III

The purposes of the Corporation shall be:

(1) To manufacture, assemble, sell, lease, and distribute wheelchairs, patient aids and other health care products of every kind and nature; and

(2) To enter into, promote or conduct any other kind of business, contract or undertaking permitted to corporations for profit organized under the General Corporation Law of the State of Ohio, to engage in any lawful act or activity for which corporations may be formed under Sections 1701.01 to 1701.98, inclusive, of the Revised Code of Ohio. and, in connection therewith, to exercise all express and incidental powers normally permitted such corporations.

ARTICLE IV

The authorized number of shares of capital stock of the Corporation shall be Thirty Million Three Hundred Thousand (30,300,000), of which Eighteen Million (18,000,000) shall be Common Shares, without par value, Twelve Million (12,000,000) shall be Class S Common Shares, without par value, and Three Hundred Thousand (300,000) shall be Serial Preferred Shares, without par value.

SUBDIVISION A

Provisions Applicable to Serial Preferred Shares

The Serial Preferred Shares may be issued, from time to time, in one or more series, with such designations. preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, as shall be stated and expressed in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors. The Board of Directors, in such resolution or resolutions (a copy of which shall be filed and recorded as required by law), is also expressly authorized to fix:

(a) The distinctive serial designations and the division of such shares Into series and the number of shares of a particular series, which may be Increased or decreased, but not below the number of shares thereof then outstanding, by a certificate made. Signed, filed and recorded as required by law;

3

(b) The annual dividend rate for the particular series, and the date or dates from which dividends on all shares of such series shall be cumulative, if dividends on shares of the particular series shall be cumulative.

(c) The redemption price or prices, if any, for the particular series:

(d) The right, if any, of the holders of a particular series to convert such stock into other classes of shares (except for Class B Common Shares), and the terms and conditions of such conversions: and

(e) The obligation, if any, of the Corporation to purchase and retire and redeem shares of a particular series as a sinking fund or redemption or purchase account, the terms thereof and the redemption price or prices per share for such series redeemed pursuant to the sinking fund or redemption or purchase account.

All shares of any one series of Serial Preferred Shares shall be alike in every particular and all series shall rank equally and be identical in all respects except insofar as they may vary with respect to the matters which the Board of Directors is hereby expressly authorized to determine in the resolution or resolutions providing for the issue of any series of the Serial Preferred Shares.

In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, then before any distribution or payment shall have been made to the holders of the Common Shares or me Class Es Common Shares, the holders of the Serial Preferred Shares of each series shall be entitled to be paid, or to have set apart in trust for payment, an amount from the net assets of the Corporation equal to that stated and expressed in the resolution or resolutions adopted by the Board of Directors which provide for the issue of such series, respectively. The remaining net assets of the Corporation shall be distributed solely among the holders of the Common Shares and the Class B Common Shares according to their respective shares.

The holders of Serial Preferred Shares shall be entitled to one vote for each Serial Preferred Share upon all matters presented to the shareholders, and, except as otherwise provided by these Amended and Restated Articles of Incorporation or required by law, the holders of Serial Preferred Shares, the holders of Common Shares and the holders of Class B Common Shares shall vote together as one class on all matters. No adjustment of the voting rights of holders of Serial Preferred Shares shall be made in the event of an increase or decrease in the number of Common Shares or Class B Common Shares authorized or issued or in the event of a stock split or combination of the Common Shares or Class B Common Shares or in the event of a stock dividend on any class of stock payable solely in Common Shares or Class B Common Shares.

The affirmative vote of the holders of at least two-thirds of the Serial Preferred Shares at the time outstanding, given in person or by proxy at a meeting called for the purpose at which the holders of Serial Preferred Shares shall vote separately as a class, shall be necessary to adopt any amendment to

4

the Amended and Restated Articles of Incorporation (but so far as the holders of Serial Preferred Shares are concerned, such amendment may be adopted with such vote) which:

(i) changes issued shares of Serial Preferred Shares of all series then outstanding into a lesser number of shares of the Corporation of the same class and series or into the same or a different number of shares of the Corporation of any other class or series; or

(ii) changes the express terms of the Serial Preferred Shares in any manner substantially prejudicial to the holders of all series thereof then outstanding; or

(iii) authorizes shares of any class, or any security convertible into shares of any class, or authorizes the conversion of any security into shares of any class, ranking prior to the Serial Preferred Shares; or

(iv) changes the express terms of issued shares of any class ranking prior to the Serial Preferred Shares in any manner substantially prejudicial to the holders of all series of Serial Preferred Shares then outstanding:

and the affirmative vote of the holders of at least two-thirds of the shares of each affected series of Serial Preferred Shares at the time outstanding, given in person or by proxy at a meeting called for the purpose at which the holders of each affected series of Serial Preferred Shares shall vote separately as a series, shall be necessary to adopt any amendment to the Amended and Restated Articles of Incorporation (but so far as the holders of each such series of Serial Preferred Shares are concerned, such amendment may be adopted with such vote) which:

(i) changes issued shares of Serial Preferred Shares of one or more but not all series then outstanding into a lesser number of shares of the Corporation of the same series or into the same or a different number of shares of the Corporation of any other class or series; or

(ii) changes the express terms of any series of the Serial Preferred Shares in any manner substantially prejudicial to the holders of one or more but not all series thereof then outstanding; or

(iii) changes the express terms of issued shares of any class ranking prior to the Serial Preferred Shares in any manner substantially prejudicial to the holders of one or more but not all series of Serial Preferred Shares then outstanding.

Whenever reference is made herein to shares "ranking prior to the Serial Preferred Shares," such reference shall mean and include all shares of the Corporation in respect of which the rights of the holders thereof either as to the payment of dividends or as to distributions in the event of a voluntary or involuntary liquidation, dissolution or winding up of the Corporation are given preference over the rights of the holders of Serial Preferred Shares; whenever reference is made to shares "on a parity with the Serial Preferred Shares," such reference shall mean and include all shares of the Corporation in respect of which the rights of the holders thereof (i) neither as to the payment of dividends nor as to distributions in the event of a voluntary or involuntary liquidation, dissolution or winding up of the Corporation are given preference

5

over the rights of the holders of Serial Preferred Shares and (ii) either as to the payment of dividends or as to distributions in the event of a voluntary or involuntary liquidation, dissolution or winding up of the Corporation rank on an equality (except as to the amounts fixed therefor) with the rights of the holders of Serial Preferred Shares; and whenever reference is made to shares "ranking junior to the Serial Preferred Shares," such reference shall mean and include all shares of the Corporation in respect of which the rights of the holders thereof both as to the payment of dividends and as to distributions in the event of a voluntary or involuntary liquidation, dissolution or winding up of the Corporation are junior and subordinate to the rights of the holders of the Serial Preferred Shares.

Subdivision B

Provisions Applicable to Common Shares and Class a Common Shares

In this Subdivision B of Article IV, any reference to a section or paragraph, without further attribution, within a provision relating to a particular class of shares is intended to refer solely to the specified section or paragraph of the other provisions relating to the same class of shares.

The Common Shares and Class B Common Shares shall be subject to the express terms of the Serial Preferred Shares and of any series thereof and shall have the following voting powers, designations, preferences and relative, participating, optional and other special rights, and qualifications, limitations or restrictions thereof:

1. Dividends.

1.1 Whenever the full dividends upon any outstanding Serial Preferred Shares for all past dividend periods shall have been paid and the full dividends thereon for the then current respective dividend periods shall have been paid, or declared and a sum sufficient for the respective payments thereof set apart, the holders of the Common Shares and Class B Common Shares shall be entitled to receive such dividends and distributions, payable in cash or otherwise, as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefor, provided that no cash dividend shall be declared and paid on the Class B Common Shares unless, simultaneously therewith, a cash dividend per share of at least one hundred and ten percent (110% of the amount per share of the dividend on the Class B Common Shares is declared and paid on the Common Shares. Notwithstanding the foregoing, in the event that any dividend shall be declared in Common Shares or Class B Common Shares, such dividend shall be declared at the same rate per share on Common Shares and Class B Common Shares, but the dividend payable on Common Shares shall be payable in Common Shares and the dividend payable on Class B Common Shares shall be payable in Class B Common Shares. If the Corporation shall in any manner split, subdivide or combine the outstanding Common Shares or Class B Common Shares, the outstanding shares of the other such class of shares shall be split, subdivided or combined in the same manner proportionately and on the same basis per share.

6

2. Issuance of the Class B Common Shares.

2.1 The Board of Directors may authorize by resolution the manner in which Class B Common Shares shall initially be issued (the "Initial Issuance") and may set such terms and conditions (including the determination of the record date for the Initial Issuance and to "Initial Issuance Date" for all purposes hereunder) as it deems appropriate or advisable with respect thereto, without any vote or other action by the shareholders, except as otherwise required by law.

2.2 Following the Initial Issuance, the Board of Directors may only issue Class B Common Shares in the form of a distribution or distributions pursuant to a stock dividend on or split-up of the Class B Common Shares and only to the then holders of the outstanding Class B Common Shares et conjunction with and in the same ratio as a stock dividend on or split-up of the Common Shares.

3. Rights on Liquidation.

In the event of any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, after the payment or setting apart for payment to the holders of any outstanding Serial Preferred Shares of the full preferential amounts to which such holders are entitled as herein provided or referred to, all of the remaining assets of the Corporation shall belong to and be distributable in equal amounts per share to the holders of the Common Shares and the holders of Class B Common Shares, as if such classes constituted a single class. For purposes of this paragraph 3, a consolidation or merger of the Corporation with any other corporation, or the sale, transfer or lease of all or substantially all its assets shall not constitute or be deemed a liquidation, dissolution or winding up of the Corporation.

4. Conversion of Class B Common Shares.

4.1 The holders of Class B Common Shares shall have the right, at their option, to convert any or all such shares into Common Shares of the Corporation on the following terms and conditions:

(i) Each Class B Common Share shall be convertible, at any time, at the office of any transfer agent for the Common Shares of the Corporation, and at such other place or places, if any, as the Board of Directors may determine, into one fully paid and nonassessable Common Share of the Corporation upon surrender at such office or other place of the certificate or certificates representing the Class B Common Shares so to be converted. In no event, upon conversion of any Class B Common Shares into Common Shares, shall any allowance or adjustment be made in respect of dividends on the Class B Common Snares or the Common Shares.

(ii) Class B Common Shares shall be deemed to have been converted and the person converting the same shall become a holder of Common Shares for the purpose of receiving dividends and for all other purposes whatsoever as of the date when the certificate or certificates for the Class B Common Shares to be converted are surrendered to the Corporation as provided in paragraph 4.1(v).

7

(iii) A number of Common Shares sufficient to provide, upon the basis hereinbefore set forth, for the conversion of all Class B Common Shares outstanding shall at all times be reserved by the Corporation for the exercise of the conversion rights of the holders of Class B Common Shares.

(iv) If the Corporation shall, at any time, be consolidated or merged with, or shall sell its property as an entirety or substantially as an entirety to, any other corporation or corporations, or in the event of any recapitalization or reclassification of its shares, proper provisions shall be made as a part of the terms of each such consolidation., merger, sale, recapitalization or reclassification so that the holder of any of the Class B Common Shares outstanding immediately prior to such consolidation, merger, sale, recapitalization or reclassification shall thereafter be entitled to and only entitled to conversion rights upon the terms and with respect to such securities of the consolidated, merged or purchasing corporation, or with respect to such securities issued upon such recapitalization or reclassification, as such holder would have been entitled to receive upon such consolidation, merger, sale, recapitalization or reclassification if such holder had exercised the conversion privilege immediately prior thereto. The provisions of this paragraph 4.1(iv) shall similarly apply to successive consolidations, mergers, sales, recapitalizations or reclassifications.

(v) Before any holder of Class B Common Shares shall be entitled to convert the same into Common Shares, he shall surrender his certificate or certificates for such Class B Common Shares to the Corporation at the office of a transfer agent for the Common Shares, or at such other piece or places, if any, as the Board of Directors may determine, duly endorsed or accompanied if appropriate by duly executed instruments of transfer and shall give written notice to the Corporation at said office or place that he elects so to convert the Class B Common Shares represented by _____ certificate or certificates so surrendered. Unless the Common Shares are to be issued in the name of the registered owner of the certificates surrendered, the holder shall state in writing the name or names in which he wishes the certificate or certificates for Common Shares to be issued, and shall furnish all requisite stock transfer and stock issuance tax stamps, or funds therefor. The Corporation shall as soon as practicable after such deposit of certificates for Class B Common Shares, accompanied by the written notice above prescribed, issue and deliver, at the office or place at which such certificates were deposited, to the person for whose account Class B Common Shares were so surrendered, or to his assignee or assignees, certificates for the number of full Common Shares to which he shall be entitled as aforesaid.

4.2 All outstanding Class B Common Shares shall automatically, without any act or deed on the part of the Corporation or any other person, be converted into Common Shares on a share-for-share basis (i) if at any time the Board of Directors, in its sole discretion, determines that there has been a material adverse change in the liquidity, marketability or market value of the outstanding Common Shares due to an actual or threatened delisting of the Common Shares from a national securities exchange or a national over-the-counter listing or due to requirements under applicable state securities laws in any such case attributable to the existence of the Class B Common Shares; or (ii) if the Board of Directors, in its sole discretion, elects to effect a conversion in connection with its approval of any sale or lease of all or substantially all of the Corporation's assets or any merger, consolidation, liquidation or

8

dissolution of the Corporation. In the event of any such automatic conversion, each stock certificate theretofore representing Class B Common Shares will thereafter represent the same number of Common Shares.

4.3 The provisions of this paragraph 4 shall be in addition to the provisions of paragraphs 6.1(i) (A) (4), 6.1 (ii) and 6.1 (iv), which require automatic conversion of Class B Common Shares in the circumstances provided therein.

4.4 The Class B Common Shares converted into Common Shares as provided in paragraph 4 or paragraph 6 shall resume the status of authorized but unissued Class B Common Shares. Upon the automatic conversion of Class B Common Shares into Common Shares pursuant to paragraph 4.2, the Class B Common Shares shall no longer be authorized for issuance.

5. Voting.

5.1 Each Common Share shall entitle the holder thereof to one vote.

5.2 Each Class B Common Share shall entitle the holder thereof to ten votes. Except as otherwise provided herein or required by law, holders of Common Shares, Class B Common Shares and Serial Preferred Shares shall at all times vote on all matters (including the election of directors) together as one class and together with the holders of any other series or class of shares of the Corporation accorded such class voting right.

5.3 The affirmative vote of the holders of a majority of the outstanding Common Shares and of Class B Common Shares, each voting separately as a class, shall be required to:

(i) authorize additional Class B Common Shares;

(ii) modify or eliminate paragraph 2 above; or

(iii) adopt any other amendment hereof that alters or changes the designations or powers or the preferences, qualifications, limitations, restrictions or the relative or special rights of either the Common Shares or the Class B Common Shares so as to affect holders of shares of such class adversely; provided, that an increase in the number of authorized Common Shares shall not be deemed to affect the holders of Common Shares adversely for purposes of this paragraph 5.3(iii).

6. Limitations on Transfer and issuance of Class B Common Shares.

6.1 (i) Subject to the provisions of paragraph 6.5, no person holding any Class B Common Share may transfer, and the Corporation shall not register the transfer of, such Class B Common Share or any interest therein, whether by sale, assignment, gift, bequest, appointment or otherwise, except to a "Permitted Transferee" of such person. The term "Permitted Transferee" shall mean only,

9

(A) In the case of a holder of Class B Common Shares (a "Holder") who is a natural person and the holder of record and beneficial owner of shares subject to a proposed transfer, "Permitted Transferee" means:

(1) The Holder, the spouse of such Holder, any lineal descendant of a grandparent of such Holder, or any spouse of such lineal descendant (herein collectively referred to as "such Holder's Family Members");

(2) The trustee of a trust solely for the benefit of such Holder or such Holder's Family Members, provided that such trust may also grant a general or special power of appointment to one or more of such Holder's Family Members and may permit trust assets to be used to pay taxes, legacies and other obligations of the trust or of the estates of one or more of such Holder's Family Members payable by reason of the death of any of such Family Members;

(3) The trustee of a trust which is not solely for the benefit of such Holder or such Holder's Family Members so long as such Holder and/or one or more of such Holder's Permitted Transferees (determined under this paragraph 6.1 (i) (A)) possess the power to vote or direct the vote of the Class B Common Shares held by such trustee:

(4) A corporation if all of the outstanding capital stock of such corporation is beneficially owned by, or a partnership if all of the partners are and all of the partnership interests are beneficially owned by, the Holder and his Permitted Transferees determined under this paragraph 6.1(1)(A). provided that if by reason of any change in the ownership of such stock or partners or partnership interests, such corporation or partnership would no longer qualify as a Permitted Transferee of such Holder or his Permitted Transferees, all Class B Common Shares then held by such corporation or partnership shall immediately and automatically, without further act or deed on the part of the Corporation or any other person, be converted into Common Shares on a share-for-share basis, and stock certificates formerly representing such Class B Common Shares shall thereupon and thereafter be deemed to represent the like number of Common Shares;

(5) An organization established by the Holder or such Holder's Family Members, contributions to which are deductible for federal income, estate or gift tax purposes; or

(6) The executor, administrator or personal representative of the estate of such Holder or the guardian or conservator of such Holder adjudged disabled by a court of competent jurisdiction, acting in his capacity as such.

(B) In the case of a Holder holding the shares subject to a proposed transfer as trustee pursuant to a trust (ether than a trust described in paragraph 6.1(i) (C) below or a trust for an employee benefit or employee stock ownership plan), "Permitted Transferee" means (1) the person who established such trust and (2) any Permitted Transferee of any such person determined pursuant to paragraph 6.1(i) (A) above.

(C) In the case of a Holder holding shares subject to a proposed transfer as trustee pursuant to a trust which was irrevocable on the Initial

10

Issuance Date, "Permitted Transferee" means (1) any person to whom or for whose benefit principal may be distributed either during or at the end of the term of such trust whether by power of appointment or otherwise (excluding beneficiaries of any employee benefit plan) and (2) any Permitted Transferee of any such person determined pursuant to paragraph 6.1(i) (A) above.

(D) In the case of a Holder which is a partnership holding shares subject to a proposed transfer, "Permitted Transferee" means (i) any partner owning more than ten percent (10%) of the equity of such partnership as of the Initial Issuance Date and (ii) any Permitted Transferee of such partner.

(E) In the case of a Holder which is a corporation (other than an organization described in subsection 6.1 (i) (A) (5) above) holding shares subject to a proposed transfer, "Permitted Transferee" means (1) any stockholder owning more than ten percent (10%) of the equity of such corporation as of the Initial Issuance Date, (2) any Permitted Transferee of such stockholder, (3) the survivor of a merger or consolidation of such corporation or (4) any person who transferred to such corporation the Class B Common Shares that are the subject of the proposed transfer.

(F) In the case of a Holder which is an employee benefit or employee stock ownership plan or a trustee therefor, "Permitted Transferee" shall include any beneficiary of such plan (or the Permitted Transferee of such beneficiary) but only as to shares distributable to such beneficiary pursuant to the plan.

(G) In the case of a Holder who is the executor, administrator or personal representative of the estate of a deceased Holder, guardian or conservator of the estate of a disabled Holder or who is a trustee of the estate of a bankrupt or insolvent Holder, "Permitted Transferee" means a Permitted Transferee of such deceased, disabled, bankrupt or insolvent Holder as determined pursuant to this paragraph 6.1(i).

(ii) Notwithstanding anything to the contrary set forth herein, any holder of Class B Common Shares may pledge his Class B Common Shares to a pledgee pursuant to a bona fide pledge of such shares as collateral security for indebtedness due to the pledgee, provided that such shares may not be transferred to or registered in the name of the pledgee unless such pledgee is a Permitted Transferee. In the event of foreclosure or other similar action by the pledgee. such pledged Class B Common Shares shall automatically, without any act or deed on the part of the Corporation or any other person, be converted into Common Shares on a share-for-share basis, unless within five business days after such foreclosure or similar event such pledged shares are returned to the pledger or transferred to a Permitted Transferee of the pledger.

(iii) For purposes of this paragraph 6.1.

(A) The relationship of any person that is derived by or through legal adoption shall be considered a natural one.

(B) Each joint owner of Class B Common Shares shall be considered a Holder of such shares.

11

(C) A minor for whom Class B Common Shares are held pursuant to a Uniform Gifts to Minors Act or similar law shall be considered a Holder of such shares.

(D) Unless otherwise specified, the term "person" means both natural persons and legal entities.

(E) The giving of a proxy in connection with a solicitation of proxies subject to the provisions of Section 14 of the Securities Exchange Act of 1934 (or any successor provision thereof) and the rules and regulations promulgated thereunder shall not be deemed to constitute the transfer of an interest in the Class B Common Shares which are the subject of such proxy.

(iv) Any purported transfer of Class B Common Shares other than to a Permitted Transferee shall automatically, without any further act or deed on the part of the Corporation or any other person, result in the conversion of such shares into Common Shares on a share-for-share basis, effective on the date of such purported transfer. The Corporation may, as a condition to transfer or registration of transfer of Class B Common Shares to a purported Permitted Transferee, require that the record holder establish to the satisfaction of the Corporation, by filing with the transfer agent an appropriate affidavit or certificate or such other proof as the Corporation shall deem necessary, that such transferee is a Permitted Transferee.

6.2 Anything in this Article IV to the contrary notwithstanding but subject to the provisions of paragraph 6.5, no Class B Common Share may be held of record but not beneficially by a broker or dealer in securities, a bank or voting trustee or a nominee of any such, or otherwise held of record but not beneficially by a nominee of the beneficial owner of such share other than (i) by an employee benefit or employee stock ownership plan or a trustee therefor or
(ii) by a trustee of a trust which would be a Permitted Transferee pursuant to paragraph 6.1(i) (A) (2) or 6.1(i) (A) (3) (any such form of prohibited holding being referred to herein as holding in "street" or nominee name); provided, however, that if any person establishes to the satisfaction of the Corporation in accordance with this paragraph 6.2 that he is the beneficial owner of any such Class B Common Shares, the Corporation shall issue such share in the name of such beneficial owner. Any such beneficial owner who desires to have Class B Common Shares issued in his name in the circumstances described in this paragraph 6.2 shall file an affidavit or certificate with the Secretary of the Corporation setting forth the name and address of such beneficial owner and certifying that he is the beneficial owner of the Class B Common Shares in question.

6.3 The Corporation shall note on the certificates representing the Class B Common Shares that there are restrictions on transfer and registration of transfer to the extent imposed by paragraph 6.1.

6.4 (i) For purposes of this paragraph 6, "beneficial ownership" shall mean possession of the power to vote or to direct the vote or to dispose of or to direct the disposition of the Class B Common Share in question, and a beneficial owner" of a Class B Common Share shall be the person having beneficial ownership thereof.

12

(ii) The Board of Directors may, from time to time, establish practices and procedures and promulgate rules and regulations, in addition to those set forth in this Article IV, and amend or revoke any such, regarding the evidence necessary to establish entitlement of any transferee or purported transferee of Class B Common Shares to be registered as a Permitted Transferee. Should tee transferee or purported transferee of any share wish to contest any decision of the Corporation on the question whether the transferee or purported transferee has established entitlement to be registered as a Permitted Transferee of Class B Common Shares, then the Board of Directors shall in its sole discretion make the final determination.

6.5 The restrictions on transfer set forth in paragraph 6.1 and the remaining provisions of paragraph 6 (other than this paragraph 6.5) shall automatically, without any act or deed on the part of the Corporation or any other person, be cancelled (as to all but not less than all Class B Common Shares then outstanding or thereafter issued) and of no further force and effect if at any time the Board of Directors, in its sole discretion, determines that the restrictions oil transfer set forth in paragraph 6.1 have a material adverse effect on the liquidity, marketability or market value of the outstanding Common Shares. Such cancellation shall be effective as of the date of such determination by the Board of Directors or as of such later date as the Board may determine. Written notice of such determination and rescission shall be given to all holders of Class B Common Shares as of such date as shown on the records of the Company or its transfer agent. No such determination by the Board of Directors shall affect the validity of any act or the effect of any provision of this Article IV which occurred prior to the effective date of such cancellation. In the event that a holder of Class B Common Shares transfers such shares after the effective date of such cancellation to a non-Permitted Transferee, such transfer shall presumptively be deemed to be an election by such holder to convert such Class B Common Shares into Common Shares immediately prior to the effectiveness of such transfer unless the transferring holder or his agent shall give written notice to the Company or its transfer agent at the time of delivery of the certificates representing the Class B Common Shares to be transferred that the holder and the transferee of such Class B Common Shares intend to transfer the Class B Common Shares and that no such conversion is intended.

7. Other Matters.

7.1 In case the Corporation shall at any time issue to the holders of its Common Shares as such options or rights to subscribe for Common Shares (including shares held in the Corporation's treasury) or any other security (whether of the Corporation or otherwise), the Corporation shall issue such options or rights to the holders of the Class B Common Shares in the respective amounts equal to the amounts that such holders would have been entitled to receive had their respective Class B Common Shares been converted into Common Shares on the day prior to the date for the determination of the holders of Common Shares entitled to receive such options or rights.

13

Subdivision C

Cumulative Voting

Notwithstanding the respective voting rights of the holders of the Common Shares, Class B Common Shares and Serial Preferred Shares, no holder of shares of any class shall have the right to vote cumulatively in the election of Directors.

ARTICLE V

The Corporation may purchase, from time to time, and to the extent permitted by the laws of Ohio, shares of any class of stock issued by it. Such purchases may be made either in the open market or at private or public sale, in such manner and amount, from such holder or holders and at such prices as the Board of Directors of the Corporation shall from time to time determine, and the Board of Directors is hereby empowered to authorize such purchases from time to time without any vote of the holders of any class of shares now or hereafter authorized and outstanding at the time of any such purchase.

ARTICLE VI

(a) Notwithstanding any provisions of the laws of the State of Ohio now or hereafter in force requiring, for any purpose, the vote of the holders of shares entitling them to exercise two-thirds or any other proportion (but less than all) of the voting power of the Corporation or of any class or classes of shares thereof and subject to the provisions of Article VI (b) hereof, such action (unless otherwise expressly prohibited by statute) may be taken by a vote of the holders of shares entitling them to exercise a majority of the voting power of the Corporation or of such class or classes.

(b) If a shareholder vote is required by law, then except as provided in the last paragraph of this Article VI (b) the affirmative vote of the holders of shares entitling them to exercise at least two-thirds of the voting power of the Corporation, given in person or by proxy at a meeting called for the purpose, shall be necessary:

(i) to approve the lease, sale, exchange, transfer or other disposition by the Corporation of all, or substantially all, of its assets or business to a Related Person (as hereinafter defined ), an affiliate of a Related Person or an associated person of a Related Person; or the lease, sale, exchange, transfer or other disposition to the Corporation or a subsidiary of the Corporation of all, or substantially all, of the assets of a Related Person, an affiliate of a Related Person or an associated person of a Related Person: or the consolidation of the Corporation with or its merger into a Related Person, an affiliate of a Related Person or an associated person of a Related Person; or the merger into the Corporation or a subsidiary of the Corporation of a Related Person, an affiliate of a Related Person or an associated person of a Related Person; or a combination or a majority share acquisition in which the Corporation is the acquiring corporation and its voting shares are issued or transferred to a Related Person, an affiliate of a Related Person, shareholders of a Related Person or an associated person,

14

(ii) to approve any agreement, contract or other arrangement with a Related Person or an affiliate of a Related Person or an associated person of a Related Person providing for any of the transactions described in subparagraph (i) above;

(iii) to adopt any amendment of the Amended and Restated Articles of Incorporation of the Corporation which changes the provisions of this Article VI (b ).

For the purpose of this Article VI (b), a "Related Person" in respect of a given transaction shall be any person, partnership, corporation or firm which, together with its affiliates and associated persons, owns of record or beneficially, directly or indirectly, ten percent (10%) or more of the shares of any outstanding class of shares of the Corporation entitled to vote upon such transaction, as of the record date used to determine the shareholders of the Corporation entitled to vote upon such transactions; and "affiliate" of a Related Person shall be any person, individual, joint venture, trust, partnership or corporation which, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, the Related Person; and "associated person" of a Related Person shall be any officer or Director or any beneficial owner, directly or indirectly, of ten percent (10%) or more of any class of equity security of such Related Person or any of its affiliates; and the terms "persons," "combinations," "majority share acquisition" and "acquiring corporation" shall have the same meaning as that contained in Section 1701.01 of the Ohio General Corporation Law or any similar provision hereafter Mooted. The determination of the Board of Directors of the Corporation, based on information known to the Board of Directors and made in good faith, shall be conclusive as to whether any person, partnership, corporation or firm is a Related Person or affiliate or associated person as defined in this Article VI (b).

The provisions of this Article VI(b) shall not apply to any proposal submitted to shareholders if (i) such proposal has been approved and recommended by written resolution of the Board of Directors of the Corporation adopted prior to the acquisition of the ten percent (10%) interest in shares of the Corporation, as aforesaid, by the Related Person or its affiliates or associated persons, and (ii) the terms of any inducements made to officers or Directors of the Corporation, if any, which are not made available to an shareholders have been disclosed to all shareholders.

ARTICLE VII

The preemptive right to purchase additional shares or any other securities of the Corporation is hereby expressly denied to holders of shares of all classes.

ARTICLE VIII

These Amended and Restated Articles of Incorporation shall supersede the existing Articles of Incorporation of the Corporation.

15

CERTIFICATE OF AMENDMENT

TO THE
AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF
INVACARE CORPORATION

A. MALACHI MIXON III, Chairman, President and Chief Executive Officer, and DALE C. LaPORTE, Secretary, of INVACARE CORPORATION, an Ohio corporation (the "Company"), do hereby certify that at a meeting of the Company's shareholders duly called and held on May 24, 1991, at which meeting a quorum of shareholders was present in person or by proxy, the following resolutions to amend the Amended and Restated Articles of Incorporation of the Company were duly adopted by the affirmative vote of holders of shares entitling them to exercise a majority of the voting power of the Company:
RESOLVED, That Article IV of the Company's Amended and Restated Articles of Incorporation is hereby amended to increase the number of authorized Common Shares, without par value, of the Company from Eighteen Million (18,000,000) to Twenty-Five Million (25,000,000) by deleting in its entirety the current first full, introductory paragraph of Article IV and replacing it with the following:

"The authorized number of shares of capital stock of the Corporation shall be Thirty-Seven Million Three Hundred Thousand (37,300,000), of which Twenty-Five Million (25,000,000) shall be Common Shares, without par value, Twelve Million (12,000,000) shall be Class B Common Shares, without par value, and Three Hundred Thousand (300,000) shall be Serial Preferred Shares, without par value."

RESOLVED FURTHER, That the President and Secretary of the Company be and they are hereby authorized and directed to execute and file in the office of the Secretary of State of Ohio an appropriate Certificate of Amendment, pay any filing fees and take any and all other actions in order to carry out the intent and purposes of the preceding resolution and render effective such amendment to the Amended and Restated Articles of Incorporation.

IN WITNESS WHEREOF, said A. Malachi Mixon III, Chairman, President and Chief Executive Officer, and Dale C. LaPorte, Secretary, acting for and on behalf of the Corporation, have hereunto subscribed their names this 24th day of May, 1991.

16

INVACARE CORPORATION

By:          /s/ A. Malachi Mixon, III
             --------------------------------
             A. Malachi Mixon, III, Chairman,
             President and Chief Executive
             Officer

And:         /s/ Dale C. LaPorte
             --------------------------------
             Dale C. LaPorte, Secretary

17

CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED ARTICLES OF INCORPORATION
INVACARE CORPORATION

A. MALACHI MIXON III, Chairman, President and Chief Executive Officer, and DALE C. LaPORTE, Secretary, of INVACARE CORPORATION, an Ohio corporation (the "Company"), do hereby certify that at a meeting of the Company's shareholders duly called and held on May 27, 1992, at which meeting a quorum of shareholders was present in person or by proxy, the following resolutions to amend the Amended and Restated Articles of Incorporation of the Company were duly adopted by the affirmative vote of holders of shares entitling them to exercise a majority of the voting power of the Company:
RESOLVED, That Article IV of the Company's Amended and Restated Articles of Incorporation is hereby amended to increase the number of authorized Common Shares, without par value, of the Company from Twenty-Five Million (25,000,000) to Fifty Million (50,000,000) by deleting in its entirety the current first full, introductory paragraph of Article IV and replacing it with the following:

"The authorized number of shares of capital stock of the Corporation shall be Sixty-Two Million Three Hundred Thousand (62,300,000), of which Fifty Million (50,000,000) shall be Common Shares, without par value, Twelve Million (12,000,000) shall be Class B Common Shares, without par value, and Three Hundred- Thousand (300,000) shall be Serial Preferred Shares, without par value."

RESOLVED FURTHER, That the President and Secretary of the Company be and they are hereby authorized and directed to execute and file in the office of the Secretary of Ste of Ohio an appropriate Certificate of Amendment, pay any filing fees and take any and all other actions in order to carry out the intent and purposes of the preceding resolution and render effective such amendment to the Amended and Restated Articles of Incorporation.

IN WITNESS WHEREOF, said A. Malachi Nixon III, Chairman, President and Chief Executive Officer, and Dale C. LaPorte, Secretary, `acting for and on behalf of the Corporation, have hereunto subscribed their names this 27th day of May, 1992.

18

INVACARE CORPORATION

By:          /s/ A. Malachi Mixon, III
             --------------------------------
             A. Malachi Mixon, III, Chairman,
             President and Chief Executive
             Officer

 And:         /s/ Dale C. LaPorte
              -------------------------------
              Dale C. LaPorte, Secretary

19

CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF
INVACARE CORPORATION

A. MALACHI MIXON III, Chairman, President and Chief Executive Officer, and THOMAS R. MIKLICH, Secretary, of INVACARE CORPORATION, an Ohio corporation (the "Company"), do hereby certify that at a meeting of the Company's shareholders duly called and held on May 22, 1996, at which meeting a quorum of shareholders was present in person or by proxy , the following resolutions to amend the Amended and Restated Articles of Incorporation of the Company were duly adopted in accordance with the Ohio Revised Code by the affirmative vote of holders of shares entitling them to exercise a majority of the voting power of the Company:
RESOLVED, that Article IV of the Company's Amended and Restated Articles of Incorporation is hereby amended to increase the number of authorized Common Shares, without par value, of the Company from Fifty Million (50,000,000) to One Hundred Million (100,000,000) by deleting in its entirety the current first full, introductory paragraph of Article IV and replacing it with the following:

"The authorized number of shares of capital stock of the Corporation shall be One Hundred Twelve Million Three Hundred Thousand (112,300,000), of which One Hundred Million (100,000,000) shall be Common Shares, without par value, Twelve Million (12,000,000) shall be Class B Common Shares, without par value, and Three Hundred Thousand (300,000) shall be Serial Preferred Shares, without par value."

RESOLVED FURTHER, that the President and Secretary of the Company be and they are hereby authorized and directed to execute and file in the office of the Secretary of State of Ohio an appropriate Certificate of Amendment, pay any filing fees and take any and all other actions in order to carry out the intent and purposes of the preceding resolution and render effective such amendment to the Amended and Restated Articles of Incorporation.

IN WITNESS WHEREOF, said A. Malachi Mixon III, Chairman, President and Chief Executive Officer, and Thomas R. Miklich, Secretary, acting for and on behalf of the Corporation, have hereunto subscribed their names this 10th day of June, 1996.
INVACARE CORPORATION

By:      /s/ A. Malachi Mixon, III
         ---------------------------------
         A. Malachi Mixon, III, Chairman,
         President and Chief Executive
         Officer

And:     /s/ Thomas R. Miklich
         ---------------------------------
         Thomas R. Miklich, Secretary

20

Exhibit 3(b)

CODE OF REGULATIONS

OF

INVACARE CORPORATION

Adopted December 28, 1979
Amended and Restated as of April 7, 1984
Amended May 22, 1996

ARTICLE I

Fiscal Year

The fiscal year of the Corporation shall be the calendar year, or such other period as the Board of Directors may designate by resolution.

ARTICLE II

Shareholders

Section 1. Meetings of Shareholders.

(a) Annual Meeting. The annual meeting of the Shareholders of this Corporation, for the election of Directors, the consideration of financial statements and other reports, and the transaction of such other business as may properly be brought before such meeting, shall be held at such time on such date within six (6) months after the close of the Corporation's fiscal year as the Board of Directors shall designate by appropriate notice. Upon due notice there may also be considered and acted upon at an annual meeting any matter which could properly be considered and acted upon at a special meeting, in which case and for which purpose the annual meeting shall also be considered as, and shall be, a special meeting. In the event that the annual meeting is not held or if Directors are not elected thereat, a special meeting may be called and held for that purpose. (1701.39, 1701.38(A))

(b) Special Meeting. Special meetings of the Shareholders may be held on any business day when called by any person or persons who may be authorized by law to do so. Calls for special meetings shall specify the purpose or purposes thereof, and no business shall be considered at any such meeting other than that specified in the call therefor. (1701.40(A), 1701.41)

(c) Place of Meetings. Any meeting of Shareholders may be held at such place within or without the State of Ohio as may be designated in the Notice of said meeting. (1701.40(B))

(d) Notice of Meeting and Waiver of Notice.

(1) Notice. Written notice of the time, place and purposes of any meeting of Shareholders shall be given to each Shareholder entitled thereto not less than seven (7) days nor more than sixty (60) days before the date fixed for the meeting and as prescribed by law. Such notice shall be given either by personal delivery or mailed to each Shareholder entitled to notice of or to vote at such meeting. If


Page 2 of 10

such notice is mailed, it shall be directed, postage prepaid, to the Shareholders at their respective addresses as they appear upon the records of the Corporation, and notice shall be deemed to have been given on the day so mailed. If any meeting is adjourned to another time or place, no notice as to such adjourned meeting need be given other than by announcement at the meeting at which such an adjournment is taken. No business shall be transacted at any such adjourned meeting except as might have been lawfully transacted at the meeting at which such adjournment was taken. (1701.41(A), 1701.02)

(2) Notice to Joint Owners. All notices with respect to any shares to which persons are entitled by joint or common ownership may be given to that one of such persons who is named first upon the books of this Corporation, and notice so given shall be sufficient notice to all the holders of such shares.

(3) Waiver. Notice of any meeting, however, may be waived in writing by any Shareholder either before or after any meeting of Shareholders, or by attendance at such meeting without protest prior to the commencement thereof. (1701.42)

(e) Shareholders Entitled to Notice and to Vote. If a record date shall not be fixed or the books of the Corporation shall not be closed against transfers of shares pursuant to statutory authority, the record date for the determination of Shareholders entitled to notice of or to vote at any meeting of Shareholders shall be the close of business on the twentieth day prior to the date of the meeting and only Shareholders of record at such record date shall be entitled to notice of and to vote at such meeting. Such record date shall continue to be the record date for all adjournments of such meeting unless a new record date shall be fixed and notice thereof and of the date of the adjourned meeting be given to all Shareholders entitled to notice in accordance with the new record date so fixed. (1701.45(A)(C)(E))

(f) Quorum. At any meeting of Shareholders, the holders of shares entitling them to exercise a majority of the voting power of the Corporation, present in person or by proxy, shall constitute a quorum for such meeting; provided, however, that no action required by law, the Articles, or these Regulations to be authorized or taken by the holders of a designated proportion of the shares of the Corporation may be authorized or taken by a lesser proportion. The Shareholders present in person or by proxy, whether or not a quorum be present, may adjourn the meeting from time to time without notice other than by announcement at the meeting. (1701.51)

(g) Organization of Meetings:

(1) Presiding Officer. The Chairman of the Board, or in his absence, the President, or in the absence of both of them, a Vice President of the Corporation shall call all meetings of the Shareholders to order and shall act as Chairman thereof. If all are absent, the Shareholders shall select a Chairman.

(2) Minutes. The Secretary of the Corporation, or, in his absence, an Assistant Secretary, or, in the absence of both, a person appointed by the Chairman of the meeting, shall act as Secretary of the meeting and shall keep and make a record of the proceedings thereat.

(h) Order of Business. The order of business at all meetings of the Shareholders, unless waived or otherwise determined by a vote of the holder or holders of the majority of the number of shares entitled to vote present in person or represented by proxy, shall be as follows:


Page 3 of 10

1. Call meeting to order.

2. Selection of Chairman and/or Secretary, if necessary.

3. Proof of notice of meeting and presentment of affidavit thereof.

4. Roll call, including filing of proxies with Secretary.

5. Upon appropriate demand, appointment of inspectors of election (1701.50)

6. Reading, correction and approval of previously unapproved minutes.

7. Reports of officers and committees.

8. If annual meeting, or meeting called for that purpose, election of Directors.

9. Unfinished business, if adjourned meeting.

10. Consideration in sequence of all other matters set forth in the call for and written notice of the meeting.

11. Adjournment.

(i) Voting. Except as provided by statute or in the Articles, every Shareholder entitled to vote shall be entitled to cast one vote on each proposal submitted to the meeting for each share held of record by him on the record date for the determination of the Shareholders entitled to vote at the meeting. At any meeting at which a quorum is present, all questions and business which may come before the meeting shall be determined by a majority of votes cast, except when a greater proportion is required by law, the Articles, or these Regulations. (1701.44(A))

(j) Proxies. A person who is entitled to attend a Shareholders' meeting, to vote thereat, or to execute consents, waivers and releases, may be represented at such meeting or vote thereat, and execute consents, waivers, and releases, and exercise any of his rights, by proxy or proxies appointed by a writing signed by such person, or by his duly authorized attorney, as provided by the laws of the State of Ohio. (1701.48)

(k) List of Shareholders. At any meeting of Shareholders a list of Shareholders, alphabetically arranged, showing the number and classes of shares held by each on the record date applicable to such meeting shall be produced on the request of any Shareholder. (1701.37(B))

Section 2. Action of Shareholders Without a Meeting.

Any action which may be taken at a meeting of Shareholders may be taken without a meeting if authorized by a writing or writings signed by all of the holders of shares who would be entitled to notice of a meeting for such purpose, which writing or writings shall be filed or entered upon the records of the Corporation. (1701.54)


Page 4 of 10

ARTICLE III

Directors

Section 1. General Powers.

The business, power and authority of this Corporation shall be exercised, conducted and controlled by a Board of Directors, except where the law, the Articles or these Regulations require action to be authorized or taken by the Shareholders. (1071.59)

Section 2. Number, Classification, Election and Qualification of Directors.

(a) Number. The Board of Directors shall consist of not less than five nor more than fifteen members. At any Shareholders meeting called for the purpose of electing Directors, the Shareholders, by a vote of the holders of a majority of the voting power represented at the meeting, may fix or change the total number of Directors within the above limitation. In the event that the Shareholders fail to fix or change the number of Directors, the number of Directors then serving in office shall constitute the total number of Directors until further changed in accordance with this Section. In addition to the authority of the Shareholders to fix or change the number of Directors, the total number of Directors so determined may be increased or decreased by not more than two between Shareholders' meetings by the Board of Directors at a meeting or by action without a meeting, and the total number of Directors as so changed shall be the total number of Directors until further changed in accordance with this Section. In the event that the Directors increase the total number of Directors, the Directors who are then in office may fill any vacancy created thereby. No reduction in the total number of Directors shall of itself have the effect of shortening the term of any incumbent Director.

(b) Classification. The Directors shall be classified in respect of the time for which they shall severally hold office by dividing them into three classes, each class to be as nearly equal in number as possible. Subject to the preceding sentence, in the event the total number of Directors (whether determined by the Shareholders or by the Directors in accordance with
Section 2(a)) is not divisible by three (3), the extra Director or Directors shall be assigned to a particular class or classes, at the time of election of such Director or Directors, by the Shareholders or by the Directors, whichever have elected the new Director or Directors. The term of any Director elected to fill a vacancy in a class, however created, shall end at the expiration of the term of such class and upon the election and qualification of the successor of such Director.

(c) Election. Subject to the rights of Directors to elect additional Directors in accordance with Section 2(a) or Section 3(d), the Directors of the appropriate class shall be elected at the Annual Meeting of Shareholders, or if not so elected, at a Special Meeting of Shareholders called for that purpose. The Directors to be elected at each such Annual or Special Meeting of Shareholders shall be the class whose term of office then expires; provided, however that the Shareholders may, in their discretion, also elect Directors to fill any vacancies in other classes without regard to how such vacancies were created. At any meeting of Shareholders at which Directors are to be elected, only persons nominated as candidates shall be eligible for election, and the candidates receiving the greatest number of votes shall be elected.


Page 5 of 10

(d) Qualification. Directors need not be Shareholders of the Corporation.

Section 3. Term of Office of Directors.

(a) Term. The term of office of each class of Directors shall be three (3) years (so that the term of one class of Directors shall expire each year), and the Directors shall hold office for the respective terms to which elected and until their respective successors are elected and qualified, subject only to prior resignation, death or removal by the Directors as provided by law, and subject to the provisions of the Articles.

(b) Removal. Other than as heretofore stated, no Director may be removed from office except for cause. With prior notice thereof, all the Directors or all the Directors of a particular class, or any individual Director may be removed for cause by a majority vote at any Special Meeting of Shareholders properly called for that purpose, provided that unless all the Directors, or all the Directors of a particular class, are removed, no individual Director shall be removed in case the votes of a sufficient number of shares are cast against his removal which, if cumulatively voted at an election of all the Directors, or all the Directors of a particular class, as the case may be, would be sufficient to elect at least one Director.

(c) Resignation. A resignation from the Board of Directors shall be deemed to take effect immediately or at such other time as the Director may specify.

(d) Vacancy. If any vacancy shall occur in the Board of Directors by death, resignation or as provided by law, the Articles or these Regulations, the remaining Directors shall constitute the Board of Directors until such vacancy is filled. The remaining Directors may fill any vacancy in the Board for the unexpired term.

Section 4. Meetings of Directors.

(a) Regular Meetings. A regular meeting of the Board of Directors shall be held immediately following the adjournment of the annual meeting of the Shareholders or a special meeting of the Shareholders at which Directors are elected. The holding of such Shareholders' meeting shall constitute notice of such Directors' meeting and such meeting may be held without further notice. Other regular meetings shall be held at such other times and places as may be fixed by the Directors. (1701.61)

(b) Special Meetings. Special meetings of the Board of Directors may be held at any time upon call of the Chairman of the Board, the President, any Vice President, or any two Directors. (1701.61(A))

(c) Place of Meeting. Any meeting of Directors may be held at any place within or without the State of Ohio in person and/or through any communications equipment if all persons participating in the meeting can hear each other.
(1701.61(B))

(d) Notice of Meeting and Waiver of Notice. Notice of the time and place of any regular or special meeting of the Board of Directors (other than the regular meeting of Directors following the adjournment of the annual meeting of the Shareholders or following any special meeting of the


Page 6 of 10

Shareholders at which Directors are elected) shall be given to each Director by personal delivery, telephone, mail, telegram or cablegram at least forty-eight
(48) hours before the meeting, which notice need

not specify the purpose of the meeting. Such notice, however, may be waived in writing by any Director either before or after any such meeting, or by attendance at such meeting (including attendance (presence) by means of participation through any communications equipment as above provided) without protest prior to the commencement thereof.
(1701.61(B)(C), 1701.42)

Section 5. Quorum and Voting.

At any meeting of Directors, not less than one-half of the whole authorized number of Directors is necessary to constitute a quorum for such meeting, except that a majority of the remaining Directors in office constitutes a quorum for filling a vacancy in the Board. At any meeting at which a quorum is present, all acts, questions and business which may come before the meeting shall be determined by a majority of votes cast by the Directors present at such meeting, unless the vote of a greater number is required by the Articles, Regulations or By-Laws. (1701.62)

Section 6. Committees.

(a) Appointment. The Board of Directors may from time to time appoint certain of its members (but in no event less than three) to act as a committee or committees in the intervals between meetings of the Board and may delegate to such committee or committees powers to be exercised under the control and direction of the Board. Each such committee and each member thereof shall serve at the pleasure of the Board.

(b) Executive Committee. In particular, the Board of Directors may create from its membership and define the powers and duties of an Executive Committee. During the intervals between meetings of the Board of Directors the Executive Committee shall possess and may exercise all of the powers of the Board of Directors in the management and control of the business of the Corporation to the extent permitted by law. All action taken by the Executive Committee shall be reported to the Board of Directors at its first meeting thereafter.

(c) Committee Action. Unless otherwise provided by the Board of Directors, a majority of the members of any committee appointed by the Board of Directors pursuant to this Section shall constitute a quorum at any meeting thereof and the act of a majority of the members present at a meeting at which a quorum is present shall be the act of such committee. Action may be taken by any such committee without a meeting by a writing signed by all its members. Any such committee shall prescribe its own rules for calling and holding meetings and its method of procedure, subject to any rules prescribed by the Board of Directors, and shall keep a written record of all action taken by it. (1701.63)

Section 7. Action of Directors Without a Meeting.

Any action which may be taken at a meeting of Directors may be taken without a meeting if authorized by a writing or writings signed by all the Directors, which writing or writings shall be filed or entered upon the records of the Corporation. (1701.54)


Page 7 of 10

Section 8. Compensation of Directors.

The Board of Directors may allow compensation for attendance at meetings or for any special services, may allow compensation to members of any committee, and may reimburse any Director for his expenses in connection with attending any Board or committee meeting. (1701.60)

Section 9. Attendance at Meetings of Persons Who Are Not Directors.

Unless waived by a majority of Directors in attendance, not less than twenty-four (24) hours before any regular or special meeting of the Board of Directors any Director who desires the presence at such meeting of not more than one person who is not a Director shall so notify all other Directors, request the presence of such person at the meeting, and state the reason in writing. Such person will not be permitted to attend the Directors' meeting unless a majority of the Directors in attendance vote to admit such person to the meeting. Such vote shall constitute the first order or business for any such meeting of the Board of Directors. Such right to attend, whether granted by waiver or vote, may be revoked at any time during any such meeting by the vote of a majority of the Directors in attendance.

ARTICLE IV

Officers

Section 1. General Provisions.

The Board of Directors shall elect a President, a Secretary and a Treasurer, and may elect a Chairman of the Board, one or more Vice-Presidents, and such other officers and assistant officers as the Board may from time to time deem necessary. The Chairman of the Board, if any, and the President shall be Directors, but no one of the other officers need be a Director. Any two or more offices may be held by the same person, but no officer shall execute, acknowledge or verify any instrument in more than one capacity if such instrument is required to be executed, acknowledged or verified by two or more officers. (1701.64(A))

Section 2. Powers and Duties.

All officers, as between themselves and the Corporation, shall respectively have such authority and perform such duties as are customarily incident to their respective offices, and as may be specified from time to time by the Board of Directors, regardless of whether such authority and duties are customarily incident to such office. In the absence of any officer of the Corporation, or for any other reason the Board of Directors may deem sufficient, the Board of Directors may delegate for the time being, the powers or duties of such officer, or any of them, to any other officer or to any Director. The Board of Directors may from time to time delegate to any officer authority to appoint and remove subordinate officers and to prescribe their authority and duties. Since the lawful purposes of this Corporation include the acquisition and ownership of real property, personal property and property in the nature of patents, copyrights, and trademarks and the protection of the Corporation's property rights in its patents, copyrights and trademarks, each of the officers of this Corporation is empowered to execute any power of attorney necessary to protect, secure, or vest the Corporation's interest in and to real property, personal property and its property protectable by patents, trademarks and copyright registration and to secure such patents, copyrights and trademark registrations.
(1701.64(B)(1))


Page 8 of 10

Section 3. Term of Office and Removal.

(a) Term. Each officer of the Corporation shall hold office during the pleasure of the Board of Directors, and unless sooner removed by the Board of Directors, until the meeting of the Board of Directors following the date of their election and until his successor is elected and qualified. (1701.64(A))

(b) Removal. The Board of Directors may remove any officer at any time, with or without cause by the affirmative vote of a majority of Directors in office. (1701.64(B)(2))

Section 4. Compensation of Officers.

Unless compensation is otherwise determined by a majority of the Directors at a regular or special meeting of the Board of Directors, or unless such determination is delegated by the Board of Directors to another officer or officers, the President of the Corporation from time to time shall determine the compensation to be paid to all officers and other employees for services rendered to the Corporation. (1701.60)

ARTICLE V

Indemnification of Directors, Officers, Employees, and Others

(a) Right of Indemnification. The Corporation shall indemnify any Director, officer, employee or other person, to the fullest extent provided by, or permissible under, Section 1701.13(E), Ohio Revised Code; and the Corporation is hereby specifically authorized to take any and all further action to effectuate any indemnification of any person which any Ohio corporation may have power to take (permissible under Section 1701.13(E)(6) or under any other statute or under general law), by any vote of the Shareholders, vote of disinterested Directors, by any Agreement, or otherwise. This Section of the Code of Regulations of the Corporation shall be interpreted in all respects to expand such power to indemnify to the maximum extent permissible to any Ohio Corporation with regard to the particular facts of each case, and not in any way to limit any statutory or other power to indemnify, or right of any individual to indemnification.

(b) Insurance for Indemnification. The Corporation may purchase and maintain insurance for protection of the Corporation and for protection of any Director, officer, employee and/or any other person for whose protection, and to the fullest extent, such insurance may be purchased and maintained under Section 1701.13(E)(7), Ohio Revised Code, or otherwise. Such policy or policies of insurance may provide such coverage and be upon such terms and conditions as shall be authorized or approved from time to time by the Board of Directors or the Shareholders of the Corporation.


Page 9 of 10

ARTICLE VI

Securities Held by the Corporation

Section 1. Transfer of Securities Owned by the Corporation.

All endorsements, assignments, transfers, stock powers, share powers or other instruments of transfer of securities standing in the name of the Corporation shall be executed for and in the name of the Corporation by the President, by a Vice President, by the Secretary or by the Treasurer or by any other person or persons as may be thereunto authorized by the Board of Directors.

Section 2. Voting Securities Held by the Corporation.

The Chairman of the Board, President, any Vice President,Secretary or Treasurer, in person or by another person thereunto authorized by the Board of Directors, in person or by proxy or proxies appointed by him, shall have full power and authority on behalf of the Corporation to vote, act and consent with respect to any securities issued by other corporations which the Corporation may own. (1701.47(A))

ARTICLE VII

Share Certificates

Section 1. Transfer and Registration of Certificates.

The Board of Directors shall have authority to make such rules and regulations, not inconsistent with law, the Articles or these Regulations, as it deems expedient concerning the issuance, transfer and registration of certificates for shares and the shares represented thereby and may appoint transfer agents and registrars thereof. (1701.14(A), 1701.26)

Section 2. Substituted Certificates.

Any person claiming that a certificate for shares has been lost, stolen or destroyed, shall make an affidavit or affirmation of that fact and, if required, shall give the Corporation (and its registrar or registrars and its transfer agent or agents, if any) a bond of indemnity, in such form and with one or more sureties satisfactory to the Board, and, if required by the Board of Directors, shall advertise the same in such manner as the Board of Directors may require, whereupon a new certificate may be executed and delivered of the same tenor and for the same number of shares as the one alleged to have been lost, stolen or destroyed. (1701.27, 1308.35)


Page 10 of 10

ARTICLE VIII

Seal

The Directors may adopt a seal for the Corporation which shall be in such form and of such style as is determined by the Directors. Failure to affix any such corporate seal shall not affect the validity of any instrument.
(1701.13(B))

ARTICLE IX

Consistency with Articles of Incorporation

If any provision of these Regulations shall be inconsistent with the Corporation's Articles of Incorporation (and as they may be amended from time to time), the Articles of Incorporation (as so amended at the time) shall govern.

ARTICLE X

Section Headings

The headings contained in this Code of Regulations are for reference purposes only and shall not be construed to be part of and/or shall not affect in any way the meaning or interpretation of this Code of Regulations.

ARTICLE XI

Amendments

This Code of Regulations of the Corporation (and as it may be amended from time to time) may be amended or added to by the affirmative vote or the written consent of the Shareholders of record entitled to exercise a majority of the voting power on such proposal; provided, however, that if an amendment or addition is adopted by written consent without a meeting of the Shareholders, it shall be the duty of the Secretary to enter the amendment or addition in the records of the Corporation, and to mail a copy of such amendment or addition to each Shareholder of record who would be entitled to vote thereon and did not

participate in the adoption thereof. (1701.11)


Exhibit 10(b)

1992 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN

Invacare Corporation, hereinafter called the "Company," hereby adopts a stock option plan for eligible Directors of the Company pursuant to the following terms and provisions:

1. Purpose of the Plan. The purpose of this plan, hereinafter called the "Plan," is to provide additional incentive to those Directors of the Company who are not employees of the Company or any of its subsidiaries or affiliates and who have not received options to purchase the Company's Common Shares, without par value (the "Common Shares"), under any other option plan of the Company, by encouraging them to acquire a new or an additional share ownership in the Company, thus increasing their proprietary interest in the Company's business and providing them with an increased personal interest in the Company's continued success and progress. These objectives will be promoted through the grant of options to acquire Common Shares of the Company pursuant to the terms of the Plan. Only those Directors who meet the qualifications stated above are eligible for and shall receive options under this Plan.

2. Effective Date of the Plan. The Plan shall become effective on May 27, 1992, subject to approval by holders of shares representing a majority of the outstanding votes of the Company present at the shareholders meeting called for that purpose. In the event that such shareholder approval has not occurred on or before March 2, 1993, the Plan and any options granted hereunder shall be null and void.

3. Shares Subject to the Plan. The shares to be issued upon the exercise of the options granted under the Plan shall be Common Shares of the Company. Either treasury or authorized and unissued Common Shares, or both, as the Board of Directors shall from time to time determine, may be so issued. Common Shares which are the subject of any lapsed, expired or terminated options may be made available for reoffering under the Plan. If an option granted under this Plan is exercised pursuant to the terms and conditions of subsection 5(b), any Common Shares which are the subject thereof shall not thereafter be available for reoffering under the Plan.

Subject to the provisions of the next succeeding paragraph of this Section 3, the aggregate number of Common Shares for which options may be granted under the Plan shall be Fifty Thousand (50,000) Common Shares.

In the event that subsequent to the date of adoption of the Plan by the Board of Directors the Common Shares should, as a result of a stock split, stock dividend, combination or exchange of shares, exchange for other securities, reclassification, reorganization, redesignation, merger, consolidation, recapitalization or other such change, be increased or decreased or changed into or exchanged for a different number or kind of shares of stock or other securities of the Company or of another corporation, then (i) there shall automatically be substituted for each Common Share subject to an unexercised option (in whole or in part) granted under the Plan, each Common Share available for additional grants of options under the Plan and each Common Share made available for grant to each eligible Director pursuant to Section 4 hereof, the number and kind of shares of stock or other securities into which each outstanding Common Share shall be changed or for which each such Common Share shall be exchanged, (ii) the option price per Common Share or unit of securities


shall be increased or decreased proportionately so that the aggregate purchase price for the securities subject to the option shall remain the same as immediately prior to such event, and (iii) the Board shall make such other adjustments as may be appropriate and equitable to prevent enlargement or dilution of option rights. Any such adjustment may provide for the elimination of fractional shares.

4. Grant of Options. Subject to the terms of the Plan, a one-time option automatically shall be granted to each person who (i) becomes a Director of the Company for the first time from and after the effective date of the Plan and
(ii) is eligible under the Plan. The option shall be exercisable for that number of Common Shares (rounded to the nearest whole share) determined by dividing $150,000 by the fair market value of one Common Share on the date of grant. The date of grant of such option shall be the date that such optionee is elected or appointed to the Board as an eligible Director. The option shall be granted at an option price per share equal to the fair market value of a Common Share of the Company on the date said option is granted. Subject to the provisions of paragraph 5(c), each such option granted shall be exercisable for a period of ten (10) years from the date of grant but shall not be exercisable during the first year of said period. Thereafter, during each succeeding year each such option may be exercised for up to a maximum of thirty three and one-third percent (33/3%) of the total number of Common Shares subject to the option, which annual rights of exercise shall be cumulative.

5. Option Provisions.

a. Limitation on Exercise and Transfer of Options. Only the Director to whom the option is granted may exercise the same except where a guardian or other legal representative has been duly appointed for such Director and except as otherwise provided in the case of such Director's death. No option granted hereunder shall be transferable otherwise than by the Last Will and Testament of the Director to whom it is granted or, if the Director dies intestate, by the applicable laws of descent and distribution. No option granted hereunder may be pledged or hypothecated, nor shall any such option be subject to execution, attachment or similar process.

b. Exercise of Option. Each option granted hereunder may be exercised in whole or in part (to the maximum extent then exercisable) from time to time during the option period, but this right of exercise shall be limited to whole shares. Options shall be exercised by the optionee giving written notice to the Treasurer of the Company at its principal business office, by certified mail, return receipt requested, of the optionee's intention to exercise the same and the number of shares with respect to which the option is being exercised (the "Notice of Exercise of Option") accompanied by full payment of the purchase price in cash or in whole or in part in Common Shares having a fair market value on the date the option is exercised equal to that portion of the purchase price for which payment in cash is not made. Such Notice of Exercise of Option shall be deemed delivered upon deposit into the mails.

c. Termination of Directorship. If the optionee ceases to be a Director of the Company, his or her option shall terminate three (3) months after the effective date of termination of his or her directorship and neither he nor she nor any other person shall have any right after such date to exercise all or any part of such option. If the termination of the directorship is due to death, then the option may be exercised within one


(1) year after the optionee's death by the optionee's estate or by the person designated in the optionee's Last Will and Testament or to whom transferred by the applicable laws of descent and distribution (the "Personal Representative"). Notwithstanding the foregoing, in no event shall any option be exercisable after the expiration of the ten-year option period and no option shall be exercisable to any greater extent than the optionee would have been entitled to exercise the option at the time of termination or death.

d. Acceleration of Exercise of Options in Certain Events. Notwithstanding anything to the contrary described in the Plan, in the event of a "change in control," the eligible Director shall have the immediate right and option (notwithstanding the provisions of paragraph 4 hereof) to exercise the option with respect to all Common Shares covered by the option, which exercise, if made, shall be irrevocable. The term "change in control" shall include, but not be limited to: (i) the first purchase of shares pursuant to a tender offer or exchange (other than a tender offer or exchange by the Company) for all or part of the Company's common shares of any class or any securities convertible into such common shares; (ii) the receipt by the Company of a Schedule 13D or other advice indicating that a person is the "beneficial owner" (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) of twenty percent (20%) or more of the voting power of the Company; (iii) the date of the approval by shareholders of the Company of an agreement providing for any consolidation or merger of the Company in which the Company will not be the continuing or surviving corporation or pursuant to which shares of capital stock of any class, or any securities convertible into such capital stock, of the Company would be converted into cash, securities, or other property, other than a merger of the Company in which the holders of shares of all classes of the Company's capital stock immediately prior to the merger would own at least a majority of the voting power of the surviving corporation (or the parent company of the surviving corporation) immediately after the merger;
(iv) the date of the approval by shareholders of the Company of any sale, lease, exchange, or other transfer (in one transaction or a series of related transactions) of all or substantially all the assets of the Company (other than a sale, lease, exchange or other transfer of such assets to an affiliate of the Company): or (v) the adoption of any plan or proposal for the liquidation (but not a partial liquidation) or dissolution of the Company.

e. Option Agreements. Options granted under the Plan shall be subject to the further terms and provisions of an Option Agreement, a copy of which is attached hereto as Exhibit A, the execution of which by each optionee shall be a condition to the receipt of an option.

6. Investment Representation; Approvals and Listing. The options to be granted hereunder shall be further conditioned upon receipt of the following investment representation from the optionee:

"I further agree that any Common Shares of Invacare Corporation which I may acquire by virtue of this option shall be acquired for investment purposes only and not with a view to distribution or resale; provided, however, that this restriction shall become inoperative in the event that the


said Common Shares subject to this option shall be registered under the Securities Act of 1933, as amended, or in the event that the offer or sale of the Common Shares subject to this option may be lawfully made without registration of the said Common Shares under the Securities Act of 1933, as amended."

The Company shall not be required to issue any certificate or certificates for Common Shares upon the exercise of an option granted under the Plan prior to (i) the obtaining of any approval from any governmental agency which the Company shall, in its sole discretion, determine to be necessary or advisable, (ii) the admission of such Common Shares to listing on any national securities exchange on which the Common Shares may be listed, (iii) the completion of any registration or other qualification of the Common Shares under any state or federal law or ruling or regulations of any governmental body which the Company shall, in its sole discretion, determine to be necessary or advisable or the determination by the Company, in its sole discretion, that any registration or other qualification of the Common Shares is not necessary or advisable and (iv) the obtaining of an investment representation from the optionee in the form stated above or in such other form as the Company, in its sole discretion, shall determine to be adequate.

7. General Provisions. For all purposes of this Plan, the fair market value of a Common Share shall be determined as follows: so long as the Common Shares of the Company are listed upon an established stock exchange or exchanges or contained in the NASDAQ National Market System, such fair market value shall be determined to be the highest closing sale price of such Common Shares on such stock exchange or exchanges on the day the option is granted (or the date the Common Shares are tendered as payment, in the case of determining fair market value for that purpose) or if no sale of such Common Shares shall have been made on any stock exchange on that day, then on the closest preceding day on which there was a sale of such Common Shares; and during any period of time as such Common Shares are not listed upon an established stock exchange or contained in the NASDAQ National Market System, the fair market value per share shall be the mean between dealer "Bid" and "Ask" prices of such Common Shares in the over-the-counter market on the day the option is granted (or the day the Common Shares are tendered as payment, in the case of determining fair market value for that purpose), as reported by the National Association of Securities Dealers, Inc.

The liability of the Company under the Plan and any distribution of Common Shares made hereunder is limited to the obligations set forth herein with respect to such distribution and no term or provision of the Plan shall be construed to impose any liability on the Company in favor of any person with respect to any loss, cost or expense which the person may incur in connection with or arising out of any transaction in connection with the Plan, including, but not limited to, any liability to any Federal, state, or local tax authority and/or any securities regulatory authority.


Nothing in the Plan or in any option agreement shall confer upon any optionee any right to continue as a Director of the Company, or to be entitled to any remuneration or benefits not set forth in the Plan or such option.

Nothing contained in the Plan or in any option agreement shall be construed as entitling any optionee to any of the rights of a shareholder as a result of the grant of an option until such time as Common Shares are actually issued to such optionee pursuant to the exercise of an option.

The Plan may be assumed by the successors and assigns of the Company.

The Plan shall not be amended more than once every six months, other than to comport with changes in the Internal Revenue Code, the Employee Retirement Income Security Act, or the rules thereunder.

The cash proceeds received by the Company from the issuance of Common Shares pursuant to the Plan will be used for general corporate purposes or in such other manner as the Board of Directors deems appropriate.

The expense of administering the Plan shall be borne by the Company.

The captions and section numbers appearing in the Plan are inserted only as a matter of convenience. They do not define, limit, construe or describe the scope or intent of the provisions of the Plan.

8. Termination of the Plan. The Plan shall terminate ten (10) years from the date of its adoption by the Board of Directors of the Company and thereafter no options shall be granted hereunder. All options outstanding at the time of termination of the Plan shall continue in full force and effect in accordance with and subject to their terms and the terms and conditions of the Plan.

9. Taxes. Appropriate provisions shall be made for all taxes required to be withheld and for paid in connection with the Options or the exercise thereof, and the transfer of Common Shares pursuant thereto, under the applicable laws or other regulations of any governmental authority, whether federal, state, or local and whether domestic or foreign. In its discretion, the Company may permit the optionee to satisfy such withholding requirements by (a) the Company withholding from issuance to the optionee such number of Common Shares other-wise issuable upon exercise of the option as the Company and the optionee may agree, provided, however, that the optionee must have had on file with the Committee, for at least six (6) months prior thereto, an effective standing election to satisfy said optionee's tax withholding obligations in such a fashion, which election form by its terms shall not be revocable or amendable for at least six (6) months, or (b) with the consent of the Board, in whole or in part, in Common Shares having a fair market value on the date the option is exercised equal to that portion of the withholding obligation for which payment in cash is not made.

10. Changes in Governing Rules and Regulations. All references herein to the Internal Revenue Code of 1986, as amended, or sections thereof, or to rules and regulations of the Department of Treasury or of the Securities and Exchange Commission, shall mean and include the Code sections thereof and such rules and regulations as are now in effect or as they may be subsequently amended, modified, substituted or superseded.


IN WITNESS WHEREOF, INVACARE CORPORATION, by its appropriate officers duly authorized, has executed this instrument this _____ day of ________________, 1992.

INVACARE CORPORATION

By:

And:

Exhibit 10(c)
INVACARE CORPORATION

DEFERRED COMPENSATION PLAN
FOR NONEMPLOYEE DIRECTORS
(effective January 1, 1993)

(1)

Purpose of the Plan

The purpose of the Invacare Corporation Deferred Compensation Plan for Nonemployee Directors is to provide any Director of the Company with the option to defer receipt of the compensation payable to him or her for services as a Director and to help build loyalty through increased investment in Company stock.

(2)

Definitions

As used herein, the following words shall have the meanings stated after them unless otherwise specifically provided.

(A) "Committee" shall mean the Administrative Committee described in Section 7.1 hereof.

(B) "Company" shall mean Invacare Corporation.

(C) "Director" shall mean any director of the Company that is not an employee of the Company or any of its subsidiaries or affiliates.

(D) "Trust Agreement" shall mean the Trust Agreement dated as of ___________________, 1992 entered into between the Company and the Trustee in connection with the Plan.

(E) "Trustee" shall mean ______________________________ any corporate successor to a majority of its trust business, or any successor Trustee hereunder.

(3)

Elections by Directors

(A) Election to Defer. No later than June 30 of any year, a Director may elect to defer payment, of all or any specified portion of the compensation payable to him or her for future services as a Director commencing January 1 of the following year. If a Director becomes a Director after the beginning of any calendar year, the Director may elect to defer payment of the compensation payable to him or her for future services as a Director occurring at least six
(6) months following the date of such election. Such election must be made within ninety (90) days after he or she becomes a Director and shall be made on an election form specified by the Committee (the "Election Form"). Once an


election becomes effective pursuant to this Article, the election shall be irrevocable and remain in effect until the electing Director amends or terminates the election in accordance with Section 3.3.

(B) Effectiveness of Elections. Elections shall be effective six months after the delivery of an Election Form to the Committee except for elections made prior to the effective date of this Plan, which shall be effective as of January 1, 1993. Subject to the provisions of Article V, amounts deferred pursuant to such elections shall be distributed at the time and in the manner set forth in such election.

(C) Amendment and Termination of Elections. A Director may terminate or amend his or her election to defer payments of compensation in a written notice delivered to the Committee. Either a termination or amendment shall apply to all compensation payable for services as a Director after the expiration of six (6) months from the date such amendment or termination was made. Amendments which serve only to change the beneficiary designation shall be permitted to be effective immediately. Amounts credited to a Director's account pursuant to
Section 4.2 hereof prior to the effective date of any termination or amendment shall not be affected thereby and shall be paid at the time and in the manner specified in the election form in effect when the deferral occurred.

(4)

Accounts and Investments

(A) Contributions. The Company shall transfer an amount equal to one hundred percent (100%) of the compensation deferred pursuant to this Plan to the Trustee if the Director elects to have such compensation invested in a money market fund. In the event that a Director elects to have his or her compensation invested in Company stock then the Company shall transfer an amount equal to one hundred twenty five percent (125%) of such compensation to the Trustee. Such transfer shall be made within thirty days after such deferred amounts would otherwise have been paid to the Director.

(B) Establishment of Accounts. The Trustee shall establish a separate "Deferred Compensation Account" for any Director who defers compensation pursuant to the Plan. Amounts deferred by each Director shall be paid in cash to the Trustee by the Company and credited to such Director's Deferred Compensation Account.

(C) Adjustment of Accounts. As of December 31 of each year and on such other dates as the Committee directs, the fair market value of the assets of the Trust allocated to all Deferred Compensation Accounts (the "Trust Fund") shall be determined by the Trustee.

(D) Investment of Assets. The assets of the Trust Fund shall be held by the Trustee in the name of the Trust. As amounts are received by the Trustee, it shall invest the funds pursuant to the Trust Agreement.

(E) Assets Held in Cash. The Trustee may, in its sole discretion, maintain in cash such amounts as it deems necessary. Amounts maintained in cash by the


Trustee shall be kept to a minimum consistent with the duties and obligations of the Trustee as set forth in the Trust Agreement and shall not be required to be invested at interest.

(5)

Payment of Accounts

(A) Time and Payment. Distribution of a Director's account shall commence upon the earlier of: ( i ) a date within thirty days after the date the Director attains either age fifty-five, age sixty, age sixty-five or age seventy, as specified by the Director on the Election Form, or (ii) a date within thirty days after the Director's termination as a Director due to resignation, retirement, death or otherwise.

(B) Method of Distribution. Each deferred Compensation Account shall be distributed to the Director either in a lump sum or in equal annual installments over a period of not more than ten years as specified in each Director's Election Form. Deferred Compensation Accounts shall be distributed in kind.

(C) Hardship Distributions. Prior to the time a Director's account becomes payable, the Committee, in its sole discretion, may elect to distribute all or a portion of a Director's account in the event that such Director requests a distribution on account of severe financial hardship. For purposes of this Plan, severe financial hardship shall be deemed to exist in the event that the Committee determines that a Director needs a distribution to meet immediate and heavy financial needs resulting from a sudden or unexpected illness or accident of the Director or a member of his or her family, loss of the Director's property due to casualty, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Director. A distribution based on financial hardship shall not exceed the amount required to meet the immediate financial need created by the hardship.

(D) Designation of Beneficiary. Upon the death of a Director, his or her account shall be paid to the beneficiary or beneficiaries designated by him or her. If there is no designated beneficiary, or no designated beneficiary surviving at a Director's death, payment of a Director's account shall be made to his or her estate. Beneficiary designations shall be made in writing. A Director may designate a new beneficiary or beneficiaries at any time by notifying the Committee in writing.

(E) Taxes. In the event that taxes are required by law to be withheld or paid from any payments made pursuant to the Plan, the Trustee shall deduct such amounts from such payments and shall transmit the withheld amounts to the appropriate taxing authority.

(6)

Creditors and Insolvency

(A) Claims of the Company's Creditors. All assets held in trust pursuant to the provisions of this Plan, and any payment to be made by the Trustee pursuant to the terms and conditions of the Trust, shall be subject to the claims of general creditors of the Company, including judgment creditors and bankruptcy creditors.


The rights of a Director or his or her beneficiaries to any assets of the Trust Fund shall be no greater than the rights of an unsecured creditor of the Company.

(B) Notification of Insolvency. In the event that the Company becomes insolvent, the Board of Directors of the Company and the chief executive officer of the Company shall immediately notify the Trustee of that fact. The Trustee shall not make any payments from the Trust Fund to any Director or any beneficiary under the Plan after such notification is received or at any time after the Trustee has knowledge of such insolvency. Under any circumstance, the Trustee shall deliver any property held in the Trust Fund only as a court of competent jurisdiction may direct to satisfy the claims of the Company's creditors. For purposes of this Plan, the Company shall be deemed to be insolvent if the Company is subject to a pending or involuntary proceeding as a debtor under the United States Bankruptcy Code, as amended, or is unable to pay its debts as they mature.

(7)

Administration

(A) Appointment of Committee. The Plan shall be administered by an Administrative Commit-tee consisting of the President and the Chief Financial Officer, unless additional or different persons are appointed by the Board of Directors. Members of the Committee shall hold office at the pleasure of the Board of Directors and may be dismissed at any time with or without cause. Such persons serving on the Committee need not be members of the Board of Directors of the Company.

(B) Powers of the Committee. The Committee shall administer the Plan and resolve all questions of interpretation arising under the Plan with the help of legal counsel, if necessary. Whenever directions, designations, applications, requests or other notices are to be given by a Director under the Plan, they shall be filed with the Committee. The Committee shall have no discretion with respect to the Plan contributions or distributions but shall act in an administrative capacity only.

(8)

Miscellaneous

(A) Term of Plan. The Company reserves the right to amend or terminate the Plan at any time; provided, however, that no amendment or termination shall affect the rights of Directors to amounts previously credited to their accounts pursuant to Section 4.2. The Trust shall remain in effect until such time as the entire corpus of the Trust Fund has been distributed pursuant to the terms of the Plan.

(B) Assignment. No right or interest of any Director (or any person claiming through or under such Director) other than the surviving spouse of such Director after he or she is deceased in any benefit or payment herefrom shall be assignable or transferable in any manner or be subject to alienation, anticipation, sale, pledge, encumbrance or other legal process or in any manner be liable for or subject to the debts or liabilities of such Director. If any Director or any such person (other than the surviving spouse of such Director after he or she is deceased) shall attempt to or shall transfer, assign,


alienate, anticipate, sell, pledge or otherwise encumber his or her benefits hereunder or any part thereof, or if by reason of his or her bankruptcy or other event happening at any time such benefits would devolve upon anyone else or would not be enjoyed by him or her, then the Committee, in its sole discretion, may terminate his or her interest in any such benefit to the extent the Committee considers necessary or advisable in order to prevent or limit the effects of such occurrence. Termination shall be effected by filing a written "termination declaration" with the Committee records and making reasonable efforts to deliver a copy to such Director or his or her legal representative.

As long as any Director is alive, any benefits affected by that termination pursuant to this Section 8.2 shall be retained by the Trust and, in the Committee's sole and absolute judgment, may be paid to or expended for the benefit of such Director, his or her spouse, his or her children or any other person or persons in fact dependent upon him or her in such manner as the Committee shall deem proper. Upon the death of any Director, all benefits withheld from him or her and not paid to others in accordance with the preceding sentence shall be distributed to such Director's estate or to his or her creditors and if such Director shall have descendants, including adopted children, then living, distribution shall be made to such Director's then living descendants, including adopted children, per stirpes.

In addition, a Director or beneficiary shall have no rights against or security interest in the assets of the Trust Fund and shall have only the Company's unsecured promise to pay benefits. All assets of the Trust Fund shall remain subject to the claims of the Company's general creditors.

(C) Taxes. This Plan is intended to be treated as an unfunded deferred compensation plan under the Internal Revenue Code. It is the intention of the Company that the amounts deferred pursuant to this Plan shall not be included in the gross income of the Directors or their beneficiaries until such time as the deferred amounts are distributed from the Plan. If, at any time, it is determined that amounts deferred pursuant to the Plan are currently taxable to the Directors or their beneficiaries, the Trust shall terminate and .any amounts held in the Trust Fund shall be distributed immediately to the Directors or their beneficiaries. (D) Effective Date of Plan. The Plan shall be effective as of January 1, 1993, subject to prior approval by the shareholders of the Company.

(D) Effecitve Date of Plan. The Plan shall be effective as of January 1, 1993,

subject to prior approval by the shareholders of the company.


Exhibit 10(d)
INVACARE CORPORATION

1994 PERFORMANCE PLAN

1. Purpose

The Invacare Corporation 1994 Performance Plan, as the same may be amended (the "Plan"), is designed to foster the long-term growth and performance of the Company by: (a) enhancing the Company's ability to attract and retain highly qualified employees and (b) motivating employees to serve and promote the long-term interests of the Company and its shareholders through stock ownership and performance-based incentives. To achieve this purpose, the Plan provides authority for the grant of Stock Options, Restricted Stock, Stock Equivalent Units, Stock Appreciation Rights, and other stock and performance-based incentives.

2. Definitions

(a) "Affiliate" -- means the same definition as under Rule 12b-2 under the Exchange Act.

(b) "Award" -- means the grant of Stock Options, Restricted Stock, Stock Equivalent Units, Stock Appreciation Rights, Cash Awards, and other stock and performance-based incentives under this Plan.

(c) "Award Agreement" -- means any agreement between the Company and a Participant that sets forth terms, conditions, and restrictions applicable to an Award.

(d) "Board of Directors" -- means the Board of Directors of the Company.

(e) "Cash Award" -- is defined in Section 6(b) (iv).

(f) "Change in Control" -- means, at any time after the date of the adoption of this Plan, the occurrence of any one or more of the following:

(i) Any Person (other than any employee benefit plan or employee stock ownership plan of the Company, or any Person organized, appointed, or established by the Company, for or pursuant to the terms of any such plan), alone or together with any of its Affiliates or Associates, becomes the Beneficial Owner of 30% or more of the total outstanding voting power of the Company, as reflected by the power to vote in connection with the election of Directors, or commences or publicly announces an intent to commence a tender offer or exchange offer the consummation of which would result in the Person becoming the Beneficial Owner of 30% or more of the total outstanding voting power of the Company as reflected by the power to vote in connection with the election of Directors. For purposes of this Section 2 (f) (i), the terms "Affiliates," "Associates," and "Beneficial Owner," will have the meanings given to them in the Rights Agreement, dated as of April 2, 1991, between Invacare Corporation and National City Bank, as Rights Agent, as amended from time to time.

(ii) At any time during a period of 24 consecutive months, individuals who were Directors at the beginning of the period no longer constitute a majority of the members of the Board of Directors, unless the election, or the nomination for election by the Company's shareholders, of each Director who was not a Director at the beginning of the period is approved by at least a majority of the Directors who are in office at the time of the election or nomination and were either Directors at the beginning of the period or are Continuing Directors.

(iii)A record date is established for determining shareholders entitled to vote upon (A) a merger or consolidation of Invacare Corporation with another corporation (which is not an affiliate of Invacare Corporation) in which Invacare Corporation is not the surviving or continuing corporation or in which all or part of the outstanding Common Shares are to be converted into or exchanged for cash, securities, or other property, (B) a sale or other disposition of all or substantially all of the assets of Invacare Corporation, or (C) the dissolution or liquidation (but not partial liquidation) of Invacare Corporation.

(g) "Class B Common Shares" -- means Class B Common Shares, without par value, of Invacare Corporation, including authorized and unissued Common Shares.

(h) "Code" -- means the Internal Revenue Code of 1986, or any law that supersedes or replaces it, as amended from time to time.

(i) "Committee" -- means the Compensation Committee of the Board of Directors, or any other committee of the Board of Directors that the Board of Directors authorizes to administer this Plan. The Committee will be constituted in a manner that satisfies the disinterested administration standard set forth in Rule 16b-3.

(j) "Common Shares" -- means Common Shares, without par value, of Invacare Corporation, including authorized and unissued Common Shares and treasury Common Shares.

(k) "Company" -- means Invacare Corporation, an Ohio corporation, and its direct and indirect subsidiaries.

(l) "Continuing Director" -- means a Director who was a Director prior to a Change in Control or was recommended or elected to succeed a Continuing Director by a majority of the Continuing Directors then in office.

(m) "Director" -- means a director of Invacare Corporation.

(n) "Exchange Act" -- means the Securities Exchange Act of 1934, and any law that supersedes or replaces it, as amended from time to time.

(o) "Fair Market Value" of Common Shares -- means the value of the Common Shares determined by the Committee, or pursuant to rules established by the Committee on a basis consistent with regulations under the Code.

(p) "Incentive Stock Option" -- means a Stock Option that meets the requirements of Section 422 of the Code.

(q) "Notice of Award" -- means any notice by the Committee to a Participant that advises the Participant of the grant of an Award or sets forth terms, conditions, and restrictions applicable to an Award.

(r) "Participant" -- means any person to whom an Award has been granted under this Plan.

(s) "Person" -- means an individual, partnership, corporation (including a business trust), joint stock company, trust, unincorporated association, joint venture or other entity, or a governmental authority.

(t) "Restricted Stock" -- means an Award of Common Shares that are subject to restrictions or risk of forfeiture.

(u) "Rule 16b-3" -- means Rule 16b-3 under the Exchange Act, or any rule that supersedes or replaces it, as amended from time to time.

(v) "Stock Appreciation Right" -- is defined in Section 6(b) (ii).

(w) "Stock Award" -- is defined in Section 6(b) (ii).

(x) "Stock Equivalent Unit" -- means an Award that is valued by reference to the value of Common Shares.

(y) "Stock Option" -- is defined in Section 6(b) (iii).

3. Eligibility

All employees of the Company and its Affiliates, whether or not Directors, are eligible for the grant of Awards. The selection of any such employees to receive Awards will be within the discretion of the Committee. More than one Award may be granted to the same employee.

Notwithstanding the foregoing, any individual that renounces in writing any right that he or she may have to receive Awards under the Plan shall not be eligible to receive any Awards hereunder.

4. Common Shares Available for Awards; Adjustment

(a) Number of Common Shares. The aggregate number of Common Shares that may be subject to Awards, including Stock Options, granted under this Plan during the term of this Plan will be equal to One Million (1,000,000) Common Shares, subject to any adjustments made in accordance with the terms of this Section 4.

The assumption of obligations in respect of awards granted by an organization acquired by the Company, or the grant of Awards under this Plan in substitution for any such awards, will not reduce the number of Common Shares available in any fiscal year for the grant of Awards under this Plan.

Common Shares subject to an Award that is forfeited, terminated, or canceled without having been exercised (other than Common Shares subject to a Stock Option that is canceled upon the exercise of a related Stock Appreciation Right) will again be available for grant under this Plan, without reducing the number of Common Shares available in any fiscal year for grant of Awards under this Plan, except to the extent that the availability of those Common Shares would cause this Plan or any Awards granted under this Plan to fail to qualify for the exemption provided by Rule 16b-3. In addition, any Common Shares which are retained to satisfy a Participant's withholding tax obligations or which are transferred to the Company by a Participant to satisfy such obligations or to pay all or any portion of the exercise price of the Award in accordance with the terms of the Plan, the Award Agreement or the Notice of Award, may be made available for reoffering under the Plan to any Participant, except to the extent that the availability of those Common Shares would cause this Plan or any Awards granted under this Plan to fail to qualify for the exemption provided by Rule 16b-3.

(b) No Fractional Common Shares. No fractional Common Shares will be issued, and the Committee will determine the manner in which the value of fractional Common Shares will be treated.

(c) Adjustment. In the event of any change in the Common Shares by reason of a merger, consolidation, reorganization, recapitalization, or similar transaction, including any transaction described under Section 424(a) of the Code, or in the event of a stock dividend, stock split, or distribution to shareholders (other than normal cash dividends), the Committee will have authority to adjust, in any manner that it deems equitable, the number and class of Common Shares that may be issued under this Plan, the number and class of Common Shares subject to outstanding Awards, the exercise price applicable to outstanding Awards, and the Fair Market Value of the Common Shares and other value determinations applicable to outstanding Awards, including as may be allowed or required under Section 424(a) of the Code.

5. Administration

(a) Committee. This Plan will be administered by the Committee. The Committee will, subject to the terms of this Plan, have the authority to: (i) select the eligible employees who will receive Awards, (ii) grant Awards, (iii) determine the number and types of Awards to be granted to eligible employees,
(iv) determine the terms, conditions, vesting periods, and restrictions applicable to Awards, including timing and price, (v) adopt, alter, and repeal administrative rules and practices governing this Plan, (vi) interpret the terms and provisions of this Plan and any Awards granted under this Plan, including, where applicable, determining the method of valuing any Award and certifying as to the satisfaction of such Awards, (vii) prescribe the forms of any Notices of Award, Award Agreements, or other instruments relating to Awards, and (viii) otherwise supervise the administration of this Plan.

(b) Delegation. The Committee may delegate any of its authority to any other person or persons that it deems appropriate, provided the delegation does not cause this Plan or any Awards granted under this Plan to fail to qualify for the exemption provided by Rule 16b-3 or for the exemption from Section 162(m) of the Code for performance-based compensation.

(c) Decisions Final. All decisions by the Committee, and by any other Person or Persons to whom the Committee has delegated authority, to the extent permitted by law, will be final and binding on all Persons.

(d) No Liability. Neither the Committee nor any of its members shall be liable for any act taken by the Committee pursuant to the Plan. No member of the Committee shall be liable for the act of any other member.

6. Awards

(a) Grant of Awards. The Committee will determine the type or types of Awards to be granted to each Participant and will set forth in the related Notice of Award or Award Agreement the terms, conditions, vesting periods, and restrictions applicable to each Award. Awards may be granted singly or in combination or tandem with other Awards. Awards may also be granted in replacement of, or in substitution for, other awards granted by the Company, whether or not granted under this Plan; without limiting the foregoing, if a Participant pays all or part of the exercise price or taxes associated with an Award by the transfer of Common Shares or the surrender of all or part of an Award (including the Award being exercised), the Committee may, in its discretion, grant a new Award to replace the Common Shares that were transferred or the Award that was surrendered. The Company may assume obligations in respect of awards granted by any Person acquired by the Company or may grant Awards in replacement of, or in substitution for, any such awards.

(b) Types of Awards. Awards may include, but are not limited to, the following:

(i) Stock Appreciation Right -- means a right to receive a payment, in cash or Common Shares, equal to the excess of (A) the Fair Market Value, or other specified valuation, of a specified number of Common Shares on the date the right is exercised over (B) the Fair Market Value, or other specified valuation, of such Common Shares on the date the right is granted, all as determined by the Committee. The right may be conditioned upon the occurrence of certain events, such as a Change in Control of the Company, or may be unconditional, as determined by the Committee.

(ii) Stock Award -- means an Award that is made in Common Shares, Restricted Stock, or Stock Equivalent Units or that is otherwise based on, or valued in whole or in part by reference to, the Common Shares. All or part of any Stock Award may be subject to conditions, restrictions, and risks of forfeiture, as and to the extent established by the Committee. Stock Awards may be based on the Fair Market Value of the Common Shares, or on other specified values or methods of valuation, as determined by the Committee.

(iii)Stock Option -- means a right to purchase a specified number of Common Shares, during a specified period, and at a specified exercise price, all as determined by the Committee. A Stock Option may be an Incentive Stock Option or a Stock Option that does not qualify as an Incentive Stock Option. In addition to the terms, conditions, vesting periods, and restrictions established by the Committee, Incentive Stock Options must comply with the requirements of Section 422 of the Code. The exercise price of a Stock Option that does not qualify as an Incentive Stock Option may be more or less than the Fair Market Value of the Common Shares on the date the Stock Option is granted.

(iv) Cash Award -- An Award denominated in cash. All or part of any Cash Award may be subject to conditions established by the Committee, including but not limited to future service with the Company or the achievement of specific performance objectives.

(c) Limits on Awards. The maximum aggregate number of Common Shares (i) for which Stock Options may be granted, and (ii) with respect to which Stock Appreciation Rights may be granted, to any particular employee during any calendar year during the term of this Plan is 200,000 Common Shares, subject to adjustment in accordance with Section 4(c).

7. Deferral of Payment

With the approval of the Committee, the delivery of the Common Shares, cash, or any combination thereof subject to an Award may be deferred, either in the form of installments or a single future delivery. The Committee may also permit selected Participants to defer the receipt of some or all of their Awards, as well as other compensation, in accordance with procedures established by the Committee to assure that the recognition of taxable income is deferred under the Code. Deferred amounts may, to the extent permitted by the Committee, be credited as cash or Stock Equivalent Units. The Committee may also establish rules and procedures for the crediting of interest on deferred cash payments and dividend equivalents on Stock Equivalent Units.

8. Payment of Exercise Price

The exercise price of a Stock Option (other than an Incentive Stock Option) and any Stock Award for which the Committee has established an exercise price may be paid in cash, by the transfer of Common Shares, by the surrender of all or part of an Award (including the Award being exercised), or by a combination of these methods, as and to the extent permitted by the Committee. The exercise price of an Incentive Stock Option may be paid in cash, by the transfer of Common Shares, or by a combination of these methods, as and to the extent permitted by the Committee but may not be paid by the surrender of all or part of an Award. The Committee may prescribe any other method of paying the exercise price that it determines to be consistent with applicable law and the purpose of this Plan.

In the event Common Shares that are Restricted Stock are used to pay the exercise price of a Stock Award, that number of the Common Shares issued upon the exercise of the Award equal to the number of Common Shares that are Restricted Stock that have been used to pay the exercise price will be subject to the same restrictions as the Restricted Stock.

9. Taxes Associated with Award

Prior to the payment of an Award or upon the exercise or release thereof, the Company may withhold, or require a Participant to remit to the Company, an amount sufficient to pay any Federal, state, and local taxes associated with the Award. The Committee may, in its discretion and subject to such rules as the Committee may adopt, permit a Participant to pay any or all taxes associated with the Award (other than an Incentive Stock Option) in cash, by the transfer of Common Shares, by the surrender of all or part of an Award (including the Award being exercised), or by a combination of these methods. The Committee may permit a Participant to pay any or all taxes associated with an Incentive Stock Option in cash, by the transfer of Common Shares, or by a combination of these methods or by any other method which does not disqualify the option as an Incentive Stock Option under applicable provisions of the Code.

10. Termination of Employment

If the employment of a Participant terminates for any reason, all unexercised, deferred, and unpaid Awards may be exercisable or paid only in accordance with rules established by the Committee or as specified in the particular Award Agreement or Notice of Award. Such rules may provide, as the Committee deems appropriate, for the expiration, continuation, or acceleration of the vesting of all or part of the Awards.

11. Termination of Awards Under Certain Conditions

The Committee may cancel any unexpired, unpaid, or deferred Awards at any time if the Participant is not in compliance with all applicable provisions of this Plan or with any Notice of Award or Award Agreement or if the Participant, without the prior written consent of the Company, engages in any of the following activities:

(i) Renders services for an organization, or engages in a business, that is, in the judgment of the Committee, in competition with the Company.

(ii) Discloses to anyone outside of the Company, or uses for any purpose other than the Company's business any confidential information or material relating to the Company, whether acquired by the Participant during or after employment with the Company, in a fashion or with a result that the Committee, in its judgment, deems is or may be injurious to the best interests of the Company.

The Committee may, in its discretion and as a condition to the exercise of an Award, require a Participant to acknowledge in writing that he or she is in compliance with all applicable provisions of this Plan and of any Notice of Award or Award Agreement and has not engaged in any activities referred to in clauses (i) and (ii) above.

12. Change in Control

In the event of a Change in Control of the Company, unless and to the extent otherwise determined by the Board of Directors, (i) all Stock Appreciation Rights and Stock Options then outstanding will become fully exercisable as of the date of the Change in Control, (ii) all restrictions and conditions applicable to Restricted Stock and other Stock Awards will be deemed to have been satisfied as of the date of the Change in Control, and (iii) all Cash Awards will be deemed to have been fully earned as of the date of the Change in Control. Any such determination by the Board of Directors that is made after the occurrence of a Change in Control will not be effective unless a majority of the Directors then in office are Continuing Directors and the determination is approved by a majority of the Continuing Directors.

13. Amendment, Suspension, or Termination of this Plan; Amendment of Outstanding Awards

(a) Amendment, Suspension, or Termination of this Plan. The Board of Directors may amend, suspend, or terminate this Plan at any time; provided, however, that in no event, without the approval of the Company's shareholders, shall any action of the Committee or the Board of Directors result in:

(i) Increasing, except as provided in Section 4(c) hereof, the maximum number of Common Shares that may be subject to Awards granted under the Plan;

(ii) Making any change which would cause any option granted under the Plan as an Incentive Stock Option not to qualify as an Incentive Stock Option within the meaning of Section 422 of the Code; or

(iii)Making any change which would eliminate the exemption provided by Rule 16b-3 for this Plan and for Awards granted under this Plan.

(b) Amendment of Outstanding Awards. The Committee may, in its discretion, amend the terms of any Award, prospectively or retroactively, but no such amendment may impair the rights of any Participant without his or her consent. The Committee may, in whole or in part, waive any restrictions or conditions applicable to, or accelerate the vesting of, any Award.

14. Awards to Foreign Nationals and Employees Outside the United States

To the extent that the Committee deems appropriate to comply with foreign law or practice and to further the purpose of this Plan, the Committee may, without amending this Plan, (i) establish special rules applicable to Awards granted to Participants who are foreign nationals, are employed outside the United States, or both, including rules that differ from those established under this Plan, and (ii) grant Awards to such Participants in accordance with those rules.

15. Nonassignability

Unless otherwise determined by the Committee, (i) no award granted under the Plan may be transferred or assigned by the Participant to whom it is granted other than by will, pursuant to the laws of descent and distribution, and (ii) an Award granted under this Plan may be exercised, during the Participant's lifetime, only by the Participant or by the Participant's guardian or legal representative; except that, no Incentive Stock Option may be transferred or assigned pursuant to a qualified domestic relations order or exercised, during the Participant's lifetime, by the Participant's guardian or legal representative.

16. Governing Law

The interpretation, validity, and enforcement of this Plan will, to the extent not otherwise governed by the Code or the securities laws of the United States, be governed by the laws of the State of Ohio.

17. No Rights as Employees/Shareholders

Nothing in the Plan or in any Award Agreement or Notice of Award shall confer upon any Participant any right to continue in the employ of the Company or an Affiliate, or to serve as a member of the Board of Directors or to be entitled to receive any remuneration or benefits not set forth in the Plan or such Award Agreement or Notice of Award, or to interfere with or limit either the right of the Company or an Affiliate to terminate the employment of such Participant at any time or the right of the shareholders of the Company to remove him or her as a member of the Board of Directors with or without cause. Nothing contained in the Plan or in any Award Agreement or Notice of Award shall be construed as entitling any Participant to any rights of a shareholder as a result of the grant of an Award until such time as Common Shares are actually issued to such Participant pursuant to the exercise of a Stock Option, Stock Appreciation Right or other Stock Award.

18. Effective and Termination Dates

(a) Effective Date. This Plan was approved by the Board of Directors on January 28, 1994 and becomes effective upon adoption by the affirmative vote of the holders of a majority of the voting power of the Company represented by the Class A and Class B Common Shares, represented in person or by proxy, at any annual or special meeting of shareholders at which a quorum is present. The Plan shall be deemed to be adopted on the date of such shareholder meeting.

(b) Termination Date. This Plan will continue in effect until midnight on May 23, 2004; provided, however, that Awards granted on or before that date may extend beyond that date and restrictions and other terms and conditions imposed on Restricted Stock or any other Award granted on or before that date may extend beyond such date.

IN WITNESS WHEREOF, the undersigned by its duly authorized officer, has hereunto set forth its signatures as of the effective date of the Plan.

INVACARE CORPORATION

By: /s/ A.M. Mixon
--------------------------------------------
A.M. Mixon, Chairman, Chief Executive Officer and
President


By: /s/ Thomas R. Miklich
 -------------------------------------------
Thomas R. Miklich, Chief Financial Officer and
Treasurer


Exhibit 10(f)

INVACARE CORPORATION

Note Purchase Agreement

DATED AS OF FEBRUARY 27, 1998

$80,000,000 6.71% SERIES A SENIOR NOTES DUE FEBRUARY 27, 2008
$20,000,000 6.60% SERIES B SENIOR NOTES DUE FEBRUARY 27, 2005


TABLE OF CONTENTS

PAGE

1. AUTHORIZATION OF NOTES.............................................. 1

2. SALE AND PURCHASE OF NOTES.......................................... 2

3. CLOSING............................................................. 2

4. CONDITIONS TO CLOSING............................................... 2

         4.1      Representations and Warranties.............................  2
         4.2      Performance; No Default....................................  2
         4.3      Compliance Certificates....................................  3
         4.4      Opinions of Counsel........................................  3
         4.5      Purchase Permitted By Applicable Law, etc..................  3
         4.6      Sale of Other Notes........................................  4
         4.7      Payment of Special Counsel Fees............................  4
         4.8      Private Placement Numbers..................................  4
         4.9      Changes in Structure.......................................  4
         4.10     Proceedings and Documents..................................  4

5.       REPRESENTATIONS AND WARRANTIES OF THE COMPANY.......................  4
         5.1      Organization; Power and Authority..........................  4
         5.2      Authorization, etc.........................................  5
         5.3      Disclosure.................................................  5
         5.4      Organization and Ownership of Shares of Subsidiaries;
                    Affiliates...............................................  6
         5.5      Financial Statements.......................................  6
         5.6      Compliance with Laws, Other Instruments, etc...............  7
         5.7      Governmental Authorizations, etc...........................  7
         5.8      Litigation; Observance of Agreements, Statutes and Orders..  7
         5.9      Taxes......................................................  8
         5.10     Title to Property; Leases..................................  8
         5.11     Licenses, Permits, etc.....................................  8
         5.12     Pension Plans..............................................  9
         5.13     Private Offering by the Company............................ 10
         5.14     Use of Proceeds; Margin Regulations........................ 10
         5.15     Existing Debt; Future Liens................................ 10
         5.16     Foreign Assets Control Regulations, etc.................... 11
         5.17     Status under Certain Statutes.............................. 11
         5.18     Environmental Matters...................................... 11

6. REPRESENTATIONS OF THE PURCHASER.................................... 12
6.1 Purchase for Investment.................................... 12
6.2 Source of Funds............................................ 12

7. INFORMATION AS TO COMPANY........................................... 13
7.1 Financial and Business Information......................... 13


TABLE OF CONTENTS (cont.)

7.2 Officer's Certificate...................................... 16
7.3 Inspection................................................. 16

8. PREPAYMENT OF THE NOTES............................................. 17

8.1      Required Prepayments....................................... 17
8.2      Optional Prepayments of Notes with Make-Whole Amount....... 17
8.3      Allocation of Note Partial Prepayments..................... 18
8.4      Notes; Maturity; Surrender, etc............................ 18
8.5      Purchase of Notes.......................................... 19
8.6      Offer to Prepay upon Change in Control, etc................ 19
8.7      Make-Whole Amount.......................................... 21

9. INTEREST ON THE NOTES............................................... 22
9.1 Series A Notes............................................. 22
9.2 Series B Notes............................................. 22

10. AFFIRMATIVE COVENANTS............................................... 22

         10.1     Compliance with Law........................................ 23
         10.2     Insurance.................................................. 23
         10.3     Maintenance of Properties.................................. 23
         10.4     Payment of Taxes and Claims................................ 23
         10.5     Corporate Existence, etc................................... 24
         10.6     Pari Passu Obligations..................................... 24

11.      NEGATIVE COVENANTS.................................................. 24
         11.1     Transactions with Affiliates............................... 24
         11.2     Merger, Consolidation, etc................................. 24
         11.3     Maximum Amount of Consolidated Debt........................ 25
         11.4     Incurrence of Priority Debt................................ 26
         11.5     Consolidated Net Worth..................................... 26
         11.6     Liens...................................................... 27
         11.7     Sale of Assets, etc........................................ 30
         11.8     Line of Business........................................... 32

12. EVENTS OF DEFAULT................................................... 32

13. REMEDIES ON DEFAULT, ETC............................................ 34

13.1     Acceleration............................................... 34
13.2     Other Remedies............................................. 35
13.3     Rescission................................................. 35
13.4     No Waivers or Election of Remedies, Expenses, etc.......... 36

14. REGISTRATION; EXCHANGE; SUBSTITUTION OF NOTES....................... 36
14.1 Registration of Notes...................................... 36


TABLE OF CONTENTS (cont.)

14.2 Transfer and Exchange of Notes............................. 36
14.3 Replacement of Notes....................................... 37

15. PAYMENTS ON NOTES................................................... 37
15.1 Place of Payment........................................... 37
15.2 Home Office Payment........................................ 37

16. EXPENSES, ETC....................................................... 38
16.1 Transaction Expenses....................................... 38
16.2 Survival................................................... 38

17. SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE AGREEMENT........ 38

18. AMENDMENT AND WAIVER................................................ 39

         18.1     Requirements............................................... 39
         18.2     Solicitation of Holders of Notes........................... 39
         18.3     Binding Effect, etc........................................ 39
         18.4     Notes held by Company, etc................................. 40

19.      NOTICES............................................................. 40

20. REPRODUCTION OF DOCUMENTS........................................... 40

21. CONFIDENTIAL INFORMATION............................................ 41

22. SUBSTITUTION OF PURCHASER........................................... 42

23. ADDITIONAL NOTE PROVISIONS.......................................... 43

24. MISCELLANEOUS....................................................... 43

24.1     Successors and Assigns..................................... 43
24.2     Payments Due on Non-Business Days.......................... 43
24.3     Severability............................................... 43
24.4     Construction............................................... 43
24.5     Counterparts............................................... 43
24.6     Governing Law.............................................. 44


SCHEDULES:

SCHEDULE A        --       Information Relating to Purchasers

SCHEDULE B        --       Defined Terms

SCHEDULE C        --       Payment Instructions at Closing

SCHEDULE 4.9      --       Changes in Corporate Structure

SCHEDULE 5.3      --       Disclosure Materials

SCHEDULE 5.4      --       Ownership of the Company; Affiliates

SCHEDULE 5.5      --       Financial Statements

SCHEDULE 5.8      --       Certain Litigation

SCHEDULE 5.11     --       Licenses, Permits, etc.

SCHEDULE 5.12(g)  --       Certain Pension Plans

SCHEDULE 5.14     --       Use of Proceeds; Margin Stock

SCHEDULE 5.15     --       Existing Indebtedness

SCHEDULE 11.6     --       Existing Liens

SCHEDULE B-C      --       Competitors

SCHEDULE B-MT     --       Management Team


EXHIBITS:

EXHIBIT 1A        --       Form of 6.71% Series A Senior Note due
                               February 27, 2008

EXHIBIT 1B        --       Form of 6.60% Series B Senior Note due
                               February 27, 2005

EXHIBIT 4.4(a)    --       Form of Opinion of General Counsel of the
                               Company

EXHIBIT 4.4(b) -- Form of Opinion of Special Counsel for the Company


INVACARE CORPORATION
One Invacare Way
Elyria, Ohio 44035

$80,000,000 6.71% SERIES A SENIOR NOTES DUE FEBRUARY 27, 2008
$20,000,000 6.60% SERIES B SENIOR NOTES DUE FEBRUARY 27, 2005

Dated as of February 27, 1998

[Separately addressed to each of
the Purchasers identified on Schedule A]

Ladies and Gentlemen:

INVACARE CORPORATION, an Ohio corporation (together with its permitted successors, the "Company"), hereby agrees with you as follows:

1. AUTHORIZATION OF NOTES

The Company will authorize the issue and sale of

(a) $80,000,000 aggregate principal amount of its 6.71% Series A Senior Notes due February 27, 2008 (the "Series A Notes") and

(b) $20,000,000 aggregate principal amount of its 6.60% Series B Senior Notes due February 27, 2005 (the "Series B Notes").

The term "Series A Notes" as used in this Agreement shall include each Series A Note delivered pursuant to this Agreement and the Other Agreements (as hereinafter defined) and any such notes issued in substitution therefor pursuant to Section 14 of this Agreement or the Other Agreements, and the term "Series B Notes" as used in this Agreement shall include each Series B Note delivered pursuant to this Agreement and the Other Agreements and any such notes issued in substitution therefor pursuant to Section 14 of this Agreement or the Other Agreements. The term "Notes" as used in this Agreement shall include each Series A Note and each Series B Note. The Series A Notes and the Series B Notes shall be substantially in the forms set out in Exhibits 1A and 1B, respectively, with such changes therefrom, if any, as may be approved by you, the Other Purchasers (as hereinafter defined) and the Company. Certain capitalized terms used in this Agreement are defined in Schedule B; references to a "Schedule" or an "Exhibit" are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.


2. SALE AND PURCHASE OF NOTES

Subject to the terms and conditions of this Agreement, the Company will issue and sell to you and you will purchase from the Company, at the Closing provided for in Section 3, Notes in the principal amount and of the Series specified below your name in Schedule A at the purchase price of 100% of the principal amount thereof. Contemporaneously with entering into this Agreement, the Company is entering into separate Note Purchase Agreements (the "Other Agreements") identical with this Agreement with each of the other purchasers named in Schedule A (the "Other Purchasers"), providing for the sale at such Closing to each of the Other Purchasers of Notes in the principal amount and of the Series specified below its name in Schedule A. Your obligation hereunder and the obligations of the Other Purchasers under the Other Agreements are several and not joint obligations and you shall have no obligation under any Other Agreement and no liability to any Person for the performance or non-performance by any Other Purchaser thereunder.

3. CLOSING

The sale and purchase of the Notes to be purchased by you and the Other Purchasers shall occur at the offices of Chapman and Cutler, at 10:00 a.m., local time, at a closing (the "Closing") on March 4, 1998 or on such other Business Day thereafter as may be agreed upon by the Company and you and the Other Purchasers. At the Closing the Company will deliver to you the Notes of the Series to be purchased by you in the form of a single Note (or such greater number of Notes in denominations of at least $500,000 as you may request), dated the date of the Closing and registered in your name (or in the name of your nominee), against delivery by you to the Company or its order of immediately available funds in the amount of the purchase price therefor by wire transfer of immediately available funds for the account of the Company as indicated on Schedule C. If at the Closing the Company shall fail to tender such Notes to you as provided above in this Section 3, or any of the conditions specified in
Section 4 shall not have been fulfilled to your satisfaction, you shall, at your election, be relieved of all further obligations under this Agreement, without thereby waiving any rights you may have by reason of such failure or such nonfulfillment.

4. CONDITIONS TO CLOSING

Your obligation to purchase and pay for the Notes to be sold to you at the Closing is subject to the fulfillment to your satisfaction, prior to or at the Closing, of the following conditions:

4.1 Representations and Warranties

The representations and warranties of the Company in this Agreement shall be correct when made and at the time of the Closing.

4.2 Performance; No Default

The Company shall have performed and complied with all agreements and conditions contained in this Agreement required to be performed or complied with by it prior to or at the Closing and, after giving effect to the issue and sale of the Notes (and the application of the proceeds thereof as contemplated by Schedule 5.14 ) no Default or Event of Default shall have occurred and be

2

continuing. Neither the Company nor any Subsidiary shall have entered into any transaction since the date of the Memorandum that would have been prohibited by Sections 11.1 through 11.3 or Sections 11.5 through 11.8 had such Sections applied since such date and, with respect to Section 11.4, a Subsidiary shall be able to borrow at least One Dollar of Debt under said Section 11.4 as of the date of Closing.

4.3 Compliance Certificates

(a) Officer's Certificates. The Company shall have delivered to you an Officer's Certificate, dated the date of the Closing, certifying that the conditions specified in Section 4.1, Section 4.2 and Section 4.9 have been fulfilled.

(b) Secretary's Certificates. The Company shall have delivered to you a certificate of its Secretary or one of its Assistant Secretaries, dated the date of the Closing, certifying as to the resolutions attached thereto and other proceedings relating to the authorization, execution and delivery of the Notes, this Agreement and the Other Agreements.

4.4 Opinions of Counsel

You shall have received opinions in form and substance satisfactory to you, dated the date of the Closing,

(a) from Thomas R. Miklich, General Counsel of the Company, substantially in the form set out in Exhibit 4.4(a) and covering such other matters incident to the transactions contemplated hereby as you or your counsel may reasonably request (and the Company hereby instructs its counsel to deliver such opinion to you),

(b) from Hebb & Gitlin, special counsel for the Company, substantially in the form set out in Exhibit 4.4(b) and covering such other matters incident to the transactions contemplated hereby as you or your counsel may reasonably request (and the Company hereby instructs its counsel to deliver such opinion to you) and

(c) from Chapman and Cutler, your special counsel in connection with the transactions contemplated hereby.

4.5 Purchase Permitted By Applicable Law, etc.

On the date of the Closing your purchase of Notes shall (a) be permitted by the laws and regulations of each jurisdiction to which you are subject, without recourse to provisions (such as section 1405(a)(8) of the New York Insurance Law) permitting limited investments by insurance companies without restriction as to the character of the particular investment, (b) not violate any applicable law or regulation (including, without limitation, Regulation G, T or X of the Board of Governors of the Federal Reserve System) and (c) not subject you to any tax, penalty or liability under or pursuant to any applicable law or regulation, which law or regulation was not in effect on the date of your execution and delivery of this Agreement. If requested by you, you shall have received an Officer's Certificate certifying as to such matters of fact as you may reasonably specify to enable you to determine whether such purchase is so permitted.

3

4.6 Sale of Other Notes

Contemporaneously with the Closing the Company shall sell to the Other Purchasers and the Other Purchasers shall purchase the Notes to be purchased by them at the Closing, as specified in Schedule A.

4.7 Payment of Special Counsel Fees

Without limiting the provisions of Section 16.1, the Company shall have paid on or before the Closing, the fees, charges and disbursements of your special counsel referred to in Section 4.4 to the extent reflected in a statement of such counsel rendered to the Company at least one Business Day prior to the date of the Closing.

4.8 Private Placement Numbers

A Private Placement Number issued by Standard & Poor's CUSIP Service Bureau (in cooperation with the Securities Valuation Office of the National Association of Insurance Commissioners) shall have been obtained for each Series of the Notes.

4.9 Changes in Structure

Except as specified in Schedule 4.9, the Company shall not have changed its jurisdiction of incorporation or been a party to any merger or consolidation and shall not have succeeded to all or any substantial part of the liabilities of any other entity, at any time following the date of the most recent financial statements referred to in Schedule 5.5.

4.10 Proceedings and Documents

All corporate and other proceedings in connection with the transactions contemplated by this Agreement and all documents and instruments incident to such transactions shall be satisfactory to you and your special counsel, and you and your special counsel shall have received all such counterpart originals or certified or other copies of such documents as you or they may reasonably request.

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company represents and warrants to you, as of the date of this Agreement, that:

5.1 Organization; Power and Authority

The Company is a corporation, duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation, and is duly qualified as a foreign corporation and is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which the failure to be so qualified or in good standing could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has the corporate power and authority to own or hold under lease the properties it purports to own or hold under lease, to transact the business it transacts and proposes to transact, to execute and deliver this

4

Agreement, the Other Agreements and the Notes and to perform the provisions hereof and thereof.

5.2 Authorization, etc.

This Agreement, the Other Agreements and the Notes have been duly authorized by all necessary corporate action on the part of the Company, and this Agreement constitutes, and upon execution and delivery thereof each Note will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors' rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law or in respect of specific performance).

5.3 Disclosure

(a) The Company, through the Placement Agents, has delivered to you and each Other Purchaser a copy of a Confidential Private Placement Memorandum, dated January 1998 (the "Memorandum"), relating to the transactions contemplated hereby. The Memorandum fairly describes, in all material respects, the general nature of the business and principal properties of the Company and its Subsidiaries. Except as disclosed in Schedule 5.3, this Agreement, the Memorandum, the documents, certificates or other writings delivered to you by or on behalf of the Company in connection with the transactions contemplated hereby and the financial statements listed in Schedule 5.5, taken as a whole, do not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein (taken as a whole) not misleading in light of the circumstances under which they were made. Except as disclosed in the Memorandum or as expressly described in Schedule 5.3, or in one of the documents, certificates or other writings identified therein, or in the financial statements listed in Schedule 5.5, since December 31, 1996, there has been no change in the financial condition, operations, business, properties or prospects of the Company and its Subsidiaries except changes that individually or in the aggregate could not reasonably be expected to have a Material Adverse Effect. There is no fact known to a Senior Financial Officer that could reasonably be expected to have a Material Adverse Effect that has not been set forth herein or in the Memorandum or in the other documents, certificates and other writings delivered to you by or on behalf of the Company specifically for use in connection with the transactions contemplated hereby, provided that no representation is made as to general economic conditions.

(b) The material assumptions used in the preparation of the projected information with respect to the Company and its Subsidiaries included in the Memorandum, taken as a whole, were made in good faith, were believed to be reasonable when made and the Company believes such assumptions continue to be reasonable. All material assumptions and principles of accounting on which such projections were based are disclosed therein. Such projections were prepared in good faith, have a reasonable basis and represent the good faith opinion of the Company as to the projected results of the operations of the Company and its Subsidiaries after giving effect to the transactions contemplated hereby. The estimates of future performance and financial condition set

5

forth in such projections, taken as a whole, are, in the Company's opinion, reasonable; however, actual events or results may differ materially from such estimates. There is no fact known to a Senior Financial Officer that has occurred since the preparation of such projections that could materially affect such projections, except such facts that the Memorandum or other written statements delivered to you disclose have occurred or may occur.

5.4 Organization and Ownership of Shares of Subsidiaries; Affiliates

(a) Schedule 5.4 contains (except as noted therein) complete and correct lists (i) of the Company's Subsidiaries, showing, as to each Subsidiary, the correct name thereof, the jurisdiction of its organization and the percentage of shares of each class of its capital stock or similar equity interests outstanding owned by the Company and each other Subsidiary, (ii) of the Company's Affiliates, other than Subsidiaries, and (iii) of the Company's directors and senior officers.

(b) All of the outstanding shares of capital stock or similar equity interests of each Subsidiary shown in Schedule 5.4 as being owned by the Company and its Subsidiaries have been validly issued, are fully paid and nonassessable and are owned by the Company or another Subsidiary free and clear of any Lien (except as otherwise disclosed in Schedule 5.4).

(c) Each Subsidiary identified in Schedule 5.4 is a corporation or other legal entity duly organized, validly existing and in good standing (to the extent such concept is recognized) under the laws of its jurisdiction of organization, and is duly qualified as a foreign corporation or other legal entity and is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which the failure to be so qualified or in good standing could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each such Subsidiary has the corporate or other power and authority to own or hold under lease the properties it purports to own or hold under lease and to transact the business it transacts and proposes to transact.

(d) No Subsidiary is a party to, or otherwise subject to any legal restriction or any agreement (other than this Agreement, the agreements listed on Schedule 5.4 and customary limitations imposed by corporate law statutes) restricting the ability of such Subsidiary to pay dividends out of profits or make any other similar distributions of profits to the Company or any of its Subsidiaries that owns outstanding shares of capital stock or similar equity interests of such Subsidiary.

5.5 Financial Statements

The Company has delivered to you and each Other Purchaser copies of the financial statements of the Company and its Subsidiaries listed on Schedule 5.5. All of said financial statements (including in each case the related schedules and notes) fairly present, in all material respects, the consolidated financial position of the Company and its Subsidiaries as of the respective dates specified in such Schedule and the consolidated results of their operations and cash flows for the respective periods so specified and have been prepared in accordance with GAAP consistently applied throughout the periods involved except

6

as set forth in the notes thereto (subject, in the case of any interim financial statements, to normal year-end adjustments).

5.6 Compliance with Laws, Other Instruments, etc.

The execution, delivery and performance by the Company of this Agreement and the Notes will not

(a) contravene, result in any breach of, or constitute a default under, or result in the creation of any Lien in respect of any property of the Company or any Subsidiary under, any indenture, mortgage, deed of trust, loan, purchase or credit agreement, lease, corporate charter, bylaws or other constitutive document, or any other agreement or instrument to which the Company or any Subsidiary is bound or by which the Company or any Subsidiary or any of their respective properties may be bound or affected,

(b) conflict with or result in a breach of any of the terms, conditions or provisions of any order, judgment, decree, or ruling of any court, arbitrator or Governmental Authority applicable to the Company or any Subsidiary, or

(c) violate any provision of any statute or other rule or regulation of any Governmental Authority applicable to the Company or any Subsidiary.

5.7 Governmental Authorizations, etc.

No consent, approval or authorization of, or registration, filing or declaration with, any Governmental Authority is required in connection with the execution, delivery or performance by the Company of this Agreement or the Notes.

5.8 Litigation; Observance of Agreements, Statutes and Orders

(a) Except as disclosed in Schedule 5.8, there are no actions, suits or proceedings pending or, to the knowledge of the Company, threatened against or affecting the Company or any Subsidiary or any property of the Company or any Subsidiary in any court or before any arbitrator of any kind or before or by any Governmental Authority that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.

(b) Neither the Company nor any Subsidiary is in default under any term of any agreement or instrument to which it is a party or by which it is bound, or any order, judgment, decree or ruling of any court, arbitrator or Governmental Authority or is in violation of any applicable law, ordinance, rule or regulation (including, without limitation, Environmental Laws) of any Governmental Authority, which default or violation, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.

7

5.9 Taxes

The Company and its Subsidiaries have filed all tax returns that are required to have been filed in any jurisdiction, and have paid all taxes shown to be due and payable on such returns and all other taxes and assessments levied upon them or their properties, assets, income or franchises, to the extent such taxes and assessments have become due and payable and before they have become delinquent, except for any taxes and assessments (a) the amount of which is not individually or in the aggregate Material or (b) the amount, applicability or validity of which is currently being contested in good faith by appropriate proceedings and with respect to which the Company or any Subsidiary, as the case may be, has established adequate reserves in accordance with GAAP. The Company knows of no basis for any other tax or assessment that could reasonably be expected to have a Material Adverse Effect. The charges, accruals and reserves on the books of the Company and its Subsidiaries in respect of Federal, state or other taxes for all fiscal periods are adequate. The Federal income tax liabilities of the Company and its Subsidiaries have been determined by the Internal Revenue Service and paid for all fiscal years up to and including the fiscal year ended December 31, 1994.

5.10 Title to Property; Leases

The Company and its Subsidiaries have good and sufficient title to their respective properties that individually or in the aggregate are Material, including all such properties reflected in the most recent audited balance sheet referred to in Section 5.5 or purported to have been acquired by the Company or any Subsidiary after said date (except as sold or otherwise disposed of in the ordinary course of business), in each case free and clear of Liens prohibited by this Agreement. All leases that individually or in the aggregate are Material are valid and subsisting and are in full force and effect in all material respects.

5.11 Licenses, Permits, etc.

Except as disclosed in Schedule 5.11,

(a) to the best knowledge of the Company, the Company and its Subsidiaries own or possess all licenses, permits, franchises, authorizations, patents, copyrights, service marks, trademarks and trade names, or rights thereto, that individually or in the aggregate are Material, without known conflict with the rights of others;

(b) to the best knowledge of the Company, no product or practice of the Company or any Subsidiary infringes in any material respect any license, permit, franchise, authorization, patent, copyright, service mark, trademark, trade name or other right owned by any other Person, which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect; and

(c) to the best knowledge of the Company, there is no Material violation by any Person of any right of the Company or any Subsidiary with respect to any patent, copyright, service mark, trademark, trade name or other right owned or used by the Company or any of its Subsidiaries.

8

5.12 Pension Plans

(a) The Company and each ERISA Affiliate have operated and administered each Plan (other than any Multiemployer Plan) in compliance with all applicable laws except for such instances of noncompliance as have not resulted in and could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any ERISA Affiliate has incurred any liability in the nature of a penalty, excise tax or fine pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans (as defined in Section 3 of ERISA), and no event, transaction or condition has occurred or exists that could reasonably be expected to result in the incurrence of any such liability by the Company or any ERISA Affiliate, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate, in either case pursuant to Title I or IV of ERISA or to such penalty or excise tax provisions or to section 401(a)(29) or 412 of the Code, other than such liabilities or Liens as would not be individually or in the aggregate Material.

(b) The present value of the aggregate benefit liabilities under each of the Plans subject to Title IV of ERISA (other than Multiemployer Plans), determined as of the end of each such Plan's most recently ended plan year on the basis of the actuarial assumptions specified for funding purposes in such Plan's most recent actuarial valuation report, did not exceed the aggregate current value of the assets of such Plan allocable to such benefit liabilities by more than $10,000,000 in the case of any single Plan and by more than $10,000,000 in the aggregate for all Plans. The term "benefit liabilities" has the meaning specified in section 4001 of ERISA and the terms "current value" and "present value" have the meaning specified in section 3 of ERISA.

(c) The Company and its ERISA Affiliates have not incurred withdrawal liabilities (and are not subject to contingent withdrawal liabilities) under section 4201 or 4204 of ERISA in respect of Multiemployer Plans that individually or in the aggregate are Material.

(d) The unfunded expected postretirement benefit obligation (determined as of the last day of the Company's most recently ended fiscal year in accordance with Financial Accounting Standards Board Statement No. 106, without regard to liabilities attributable to continuation coverage mandated by section 4980B of the Code) of the Company and its Subsidiaries is not Material.

(e) The execution and delivery of this Agreement and the issuance and sale of the Notes hereunder will not involve any transaction that is subject to the prohibitions of section 406 of ERISA or in connection with which a tax could be imposed pursuant to section 4975(c)(1)(A)-(D) of the Code. The representation by the Company in the first sentence of this Section 5.12(e) is made in reliance upon and subject to the accuracy of your representation in Section 6.2 as to the sources of the funds used to pay the purchase price of the Notes to be purchased by you.

(f) All Non-US Pension Plans have been established, operated, administered and maintained in material compliance with all laws, regulations and orders applicable thereto, except where any failure to

9

so comply could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except where they could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, all premiums, contributions and any other amounts required to be paid pursuant to applicable Non-US Pension Plan documents or applicable laws governing such Non-US Pension Plans have been paid or accrued as required.

(g) The Multiemployer Plans in respect of which the Company or any ERISA Affiliate makes contributions or has any liability or obligation are set forth on Schedule 5.12(g). The Plans constituting "defined benefit plans" (as defined in section (3)(35) of ERISA) are set forth on Schedule 5.12(g).

5.13 Private Offering by the Company

Neither the Company nor anyone acting on its behalf has offered the Notes or any similar securities for sale to, or solicited any offer to buy any of the same from, or otherwise approached or negotiated in respect thereof with, any Person other than you, the Other Purchasers and not more than 77 other Institutional Investors, each of which has been offered the Notes at a private sale for investment. Neither the Company nor anyone acting on its behalf has taken, or will take, any action that would subject the issuance or sale of the Notes to the registration requirements of section 5 of the Securities Act.

5.14 Use of Proceeds; Margin Regulations

The Company will apply the proceeds of the sale of the Notes as set forth in Schedule 5.14. No part of the proceeds from the sale of the Notes hereunder will be used, directly or indirectly, for the purpose of buying or carrying any margin stock within the meaning of Regulation G of the Board of Governors of the Federal Reserve System (12 CFR 207), or for the purpose of buying or carrying or trading in any securities under such circumstances as to involve the Company in a violation of Regulation X of said Board (12 CFR 224) or to involve any broker or dealer in a violation of Regulation T of said Board (12 CFR 220). Margin stock does not constitute more than 5% of the value of the consolidated assets of the Company and its Subsidiaries and the Company does not have any present intention that margin stock will constitute more than 5% of the value of such assets. As used in this Section, the terms "margin stock" and "purpose of buying or carrying" shall have the meanings assigned to them in said Regulation G.

5.15 Existing Debt; Future Liens

(a) Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Debt of the Company and its Subsidiaries as of December 31, 1997, since which date there has been no material change in the amounts, interest rates, sinking funds, installment payments or maturities of the Debt of the Company and its Subsidiaries except as described in Schedule 5.15. Neither the Company nor any of its Subsidiaries is in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Debt of the Company or such Subsidiary and no event or condition exists with respect to any Debt of the Company or such Subsidiary that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Debt to become due and

10

payable before its stated maturity or before its regularly scheduled dates of payment.

(b) Except as disclosed in Schedule 5.15, neither the Company nor any Subsidiary has agreed or consented to cause or permit in the future (upon the happening of a contingency or otherwise) any of its property, whether now owned or hereafter acquired, to be subject to a Lien not permitted by Section 11.6.

5.16 Foreign Assets Control Regulations, etc.

Neither the sale of the Notes by the Company hereunder nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended, or any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto.

5.17 Status under Certain Statutes

Neither the Company nor any Subsidiary is subject to regulation under the Investment Company Act of 1940, as amended, the Public Utility Holding Company Act of 1935, as amended, the ICC Termination Act of 1995, as amended, or the Federal Power Act, as amended.

5.18 Environmental Matters

Neither the Company nor any Subsidiary has knowledge of any claim or has received any notice of any claim, and no proceeding has been instituted raising any claim against the Company or any of its Subsidiaries or any of their respective real properties now or formerly owned, leased or operated by any of them or other assets, alleging any damage to the environment or violation of any Environmental Laws, except, in each case, such as could not reasonably be expected to result in a Material Adverse Effect. Except as otherwise disclosed to you in writing,

(a) neither the Company nor any Subsidiary has knowledge of any facts which would give rise to any claim, public or private, of violation of Environmental Laws or damage to the environment emanating from, occurring on or in any way related to real properties now or formerly owned, leased or operated by any of them or to other assets or their use, except, in each case, such as could not reasonably be expected to result in a Material Adverse Effect;

(b) neither the Company nor any of its Subsidiaries has stored any Hazardous Materials on real properties now or formerly owned, leased or operated by any of them in a manner contrary to any Environmental Laws and has not transported or disposed of any Hazardous Materials in a manner contrary to any Environmental Laws in each case in any manner that could reasonably be expected to result in a Material Adverse Effect; and

(c) all buildings on all real properties now owned, leased or operated by the Company or any of its Subsidiaries are in compliance

11

with applicable Environmental Laws, except where failure to comply could not reasonably be expected to result in a Material Adverse Effect.

REPRESENTATIONS OF THE PURCHASER

6.1 Purchase for Investment

You represent that you are purchasing the Notes for your own account or for one or more separate accounts maintained by you or for the account of one or more pension or trust funds (or commingled pension trust funds) or for the account of one or more "accredited investors" within the meaning of Regulation D under the Securities Act for whom you are acting as investment manager, agent or investment adviser, and not with a view to the distribution thereof, provided that the disposition of your or their property shall at all times be within your or their control. You understand that the Notes have not been registered under the Securities Act and may be resold only if registered pursuant to the provisions of the Securities Act or if an exemption from registration is available, except under circumstances where neither such registration nor such an exemption is required by law, and that the Company is not required to register the Notes.

6.2 Source of Funds

You represent that at least one of the following statements is an accurate representation as to each source of funds (a "Source") to be used by you to pay the purchase price of the Notes to be purchased by you hereunder:

(a) the Source is an "insurance company general account" as defined in Department of Labor Prohibited Transaction Exemption ("PTE") 95-60 (60 FR 35925, July 12, 1995) and in respect thereof you represent that there is no "employee benefit plan" (as defined in section 3(3) of ERISA and section 4975(e)(1) of the Code, treating as a single plan all plans maintained by the same employer or employee organization or affiliate thereof) with respect to which the amount of the general account reserves and liabilities of all contracts held by or on behalf of such plan exceed 10% of the total reserves and liabilities of such general account (exclusive of separate account liabilities) plus surplus, as set forth in the NAIC Annual Statement filed with your state of domicile; or

(b) if you are an insurance company, the Source does not include assets allocated to any separate account maintained by you in which any employee benefit plan (or its related trust) has any interest, other than a separate account that is maintained solely in connection with your fixed contractual obligations under which the amounts payable, or credited, to such plan and to any participant or beneficiary of such plan (including any annuitant) are not affected in any manner by the investment performance of the separate account; or

(c) the Source is either (i) an insurance company pooled separate account, within the meaning of PTE 90-1 (issued January 29, 1990), or (ii) a bank collective investment fund, within the meaning of the PTE 91-38 (issued July 12, 1991) and, except as you have disclosed

12

to the Company in writing pursuant to this paragraph (c), no employee benefit plan or group of plans maintained by the same employer, affiliate of such employer or employee organization beneficially owns more than 10% of all assets allocated to such pooled separate account or collective investment fund; or

(d) (i) the Source constitutes assets of an "investment fund" (within the meaning of Part V of the QPAM Exemption) managed by a "qualified professional asset manager" or "QPAM" (within the meaning of Part V of the QPAM Exemption), (ii) no employee benefit plan's assets that are included in such investment fund, when combined with the assets of all other employee benefit plans established or maintained by the same employer or by an affiliate (within the meaning of Section V(c)(1) of the QPAM Exemption) of such employer or by the same employee organization and managed by such QPAM, exceed 20% of the total client assets managed by such QPAM, (iii) the conditions of Part I(c) and (g) of the QPAM Exemption are satisfied, neither the QPAM nor a person controlling or controlled by the QPAM (applying the definition of "control" in Section V(e) of the QPAM Exemption) owns a 5% or more interest in the Company and (iv) the identity of such QPAM and the names of all employee benefit plans whose assets are included in such investment fund have been disclosed to the Company in writing pursuant to this paragraph (d); or

(e) the Source is a governmental plan; or

(f) the Source is one or more employee benefit plans, or a separate account or trust fund comprised of one or more employee benefit plans, each of which has been identified to the Company in writing pursuant to this paragraph (f); or

(g) the Source does not include assets of any employee benefit plan, other than a plan exempt from the coverage of ERISA.

As used in this Section 6.2, the terms "employee benefit plan", "governmental plan", "party in interest" and "separate account" shall have the respective meanings assigned to such terms in section 3 of ERISA.

INFORMATION AS TO COMPANY

7.1 Financial and Business Information

The Company shall deliver to each holder of Notes that is an Institutional Investor:

(a) Quarterly Statements -- within 50 days after the end of each quarterly fiscal period in each fiscal year of the Company (other than the last quarterly fiscal period of each such fiscal year), duplicate copies of

(i) a consolidated balance sheet of the Company and its Subsidiaries as at the end of such quarter, and

(ii) consolidated statements of earnings and cash flows for the Company and its Subsidiaries for such quarter and (in the case of the second and third quarters) for the portion of the fiscal year ending with such quarter,

13

setting forth in the case of the consolidated statements of earnings and cash flows in comparative form the figures for the corresponding periods in the previous fiscal year of the Company and in the case of the consolidated balance sheet in comparative form the figures for the then most recently completed Fiscal Year, all in reasonable detail, prepared in accordance with GAAP applicable to quarterly financial statements generally, and certified by a Senior Financial Officer as fairly presenting, in all material respects, the financial position of the companies being reported on and their results of operations and cash flows, subject to changes resulting from year-end adjustments, provided that delivery within the time period specified above of copies of the Company's Quarterly Report on Form 10-Q prepared in compliance with the requirements therefor and filed with the Securities and Exchange Commission shall be deemed to satisfy the requirements of this
Section 7.1(a);

(b) Annual Statements -- within 90 days after the end of each fiscal year of the Company, duplicate copies of

(i) a consolidated balance sheet of the Company and its Subsidiaries, as at the end of such year, and

(ii) consolidated statements of earnings, shareholders' equity and cash flows of the Company and its Subsidiaries for such year,

setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail, prepared in accordance with GAAP, and accompanied

(A) by an opinion thereon of independent certified public accountants of recognized national standing, which opinion shall state that such financial statements present fairly, in all material respects, the consolidated financial position of the companies being reported upon and the consolidated results of their operations and cash flows in conformity with GAAP, and that the examination of such accountants in connection with such financial statements has been made in accordance with generally accepted auditing standards, and that such audit provides a reasonable basis for such opinion in the circumstances, and

(B) by a certificate of such accountants stating that in making the examination necessary for their opinion they obtained no knowledge of a Default or an Event of Default, or, if they are aware that any such Default or Event of Default then exists, specifying the nature and period of the existence thereof (it being understood that such accountants shall not be liable, directly or indirectly, for any failure to obtain knowledge of any Default or Event of Default unless such accountants should have obtained knowledge thereof in making an audit in accordance with generally accepted auditing standards or did not make such an audit),

14

provided that the delivery within the time period specified above of the Company's Annual Report on Form 10-K for such fiscal year (together with the Company's annual report to shareholders, if any, prepared pursuant to Rule 14a-3 under the Exchange Act) prepared in accordance with the requirements therefor and filed with the Securities and Exchange Commission, together with the accountant's certificate described in clause (B) above, shall be deemed to satisfy the requirements of this Section 7.1(b);

(c) SEC and Other Reports -- promptly upon their becoming available, one copy of (i) each financial statement, report, notice or proxy statement sent by the Company or any Subsidiary to public securities holders generally, (ii) each regular or periodic report, each registration statement (without exhibits except as expressly requested by such holder), and each prospectus and all amendments thereto filed by the Company or any Subsidiary with the Securities and Exchange Commission and (iii) all other statements made available generally by the Company or any Subsidiary to the public concerning developments that are Material;

(d) Notice of Default or Event of Default -- promptly, and in any event within 5 days after a Responsible Officer becomes aware of the existence of any Default or Event of Default or that any Person has given any notice or taken any action with respect to a claimed default hereunder or that any Person has given any notice or taken any action with respect to a claimed default of the type referred to in Section
12(f), a written notice specifying the nature and period of existence thereof and what action the Company is taking or proposes to take with respect thereto;

(e) ERISA Matters -- promptly, and in any event within 10 days after a Senior Financial Officer becomes aware of any of the following, a written notice setting forth the nature thereof and the action, if any, that the Company or an ERISA Affiliate proposes to take with respect thereto:

(i) with respect to any Plan, any reportable event, as defined in section 4043(c) of ERISA and the regulations thereunder, for which notice thereof has not been waived pursuant to such regulations as in effect on the date of the Closing; or

(ii) the taking by the PBGC of steps to institute, or the threatening by the PBGC of the institution of, proceedings under section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Plan, or the receipt by the Company or any ERISA Affiliate of a notice from a Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer Plan; or

(iii) any event, transaction or condition that could result in the incurrence of any liability by the Company or any ERISA Affiliate pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate pursuant to Title I or IV of ERISA or such penalty or excise tax provisions, if such liability or Lien, taken together with any other such liabilities or Liens then existing, could reasonably be expected to have a Material Adverse Effect;

15

(f) Notices from Governmental Authority -- promptly, and in any event within 30 days of receipt thereof, copies of any notice to the Company or any Subsidiary from any Federal or state Governmental Authority relating to any order, ruling, statute or other law or regulation that could reasonably be expected to have a Material Adverse Effect; and

(g) Requested Information -- with reasonable promptness, such other data and information relating to the business, operations, affairs, financial condition, assets or properties of the Company or any of its Subsidiaries or relating to the ability of the Company to perform its obligations under this Agreement, the Other Agreements and the Notes as from time to time may be reasonably requested by any such holder of Notes.

7.2 Officer's Certificate

Each set of financial statements delivered to a holder of Notes pursuant to Section 7.1(a) or Section 7.1(b) hereof shall be accompanied by a certificate of a Senior Financial Officer setting forth:

(a) Covenant Compliance -- the information (including detailed calculations) required in order to establish whether the Company was in compliance with the requirements of Section 11.2 through Section 11.7, inclusive, during the quarterly or annual period covered by the statements then being furnished (including with respect to each such Section, where applicable, the calculations of the maximum or minimum amount, ratio or percentage, as the case may be, permissible under the terms of such Sections, and the calculation of the amount, ratio or percentage then in existence); and

(b) Event of Default -- a statement that such officer has reviewed the relevant terms hereof and has made, or caused to be made, under his or her supervision, a review of the transactions and conditions of the Company and its Subsidiaries from the beginning of the quarterly or annual period covered by the statements then being furnished to the date of the certificate and that such review shall not have disclosed the existence during such period of any condition or event that constitutes a Default or an Event of Default or, if any such condition or event existed or exists (including, without limitation, any such event or condition resulting from the failure of the Company or any Subsidiary to comply with any Environmental Law), specifying the nature and period of existence thereof and what action the Company shall have taken or proposes to take with respect thereto.

7.3 Inspection

The Company shall permit the representatives of each holder of Notes that is an Institutional Investor:

(a) No Default -- if no Default or Event of Default then exists, at the expense of such holder and upon reasonable prior notice to the Company, to visit the principal executive office of the Company, to discuss the affairs, finances and accounts of the Company and its Subsidiaries with the Company's officers, and (with the consent of the Company, which consent will not be unreasonably withheld) its

16

independent public accountants, and (with the consent of the Company, which consent will not be unreasonably withheld) to visit the other offices and properties of the Company and each Subsidiary, all at such reasonable times and as often as may be reasonably requested in writing; and

(b) Default -- if a Default or Event of Default then exists, at the expense of the Company to visit and inspect any of the offices or properties of the Company or any Subsidiary, to examine all their respective books of account, records, reports and other papers, to make copies and extracts therefrom, and to discuss their respective affairs, finances and accounts with their respective officers and independent public accountants (and by this provision the Company authorizes said accountants to discuss the affairs, finances and accounts of the Company and its Subsidiaries), all at such reasonable times and as often as may be reasonably requested.

PREPAYMENT OF THE NOTES

8.1 Required Prepayments

(a) Series A Notes. There shall be no scheduled principal prepayments on account of the Series A Notes. The unpaid principal amount of each Series A Note, together with accrued unpaid interest thereon, shall be due and payable on February 27, 2008.

(b) Series B Notes. There shall be no scheduled principal prepayments on account of the Series B Notes. The unpaid principal amount of each Series B Note, together with accrued unpaid interest thereon, shall be due and payable on February 27, 2005.

8.2 Optional Prepayments of Notes with Make-Whole Amount

The Company may, at its option, upon notice as provided below, prepay at any time all, or from time to time any part of, the Notes, on a pro rata basis in respect of all Notes outstanding at such time, in an amount not less than 5% of the aggregate principal amount of the Notes then outstanding in the case of a partial prepayment, at 100% of the principal amount so prepaid and accrued interest thereon to the date of prepayment, plus the Make-Whole Amount determined for the prepayment date with respect to the principal amount of Notes being so prepaid. The Company will give each holder of Notes to be prepaid under this Section 8.2 written notice of such optional prepayment not less than 30 days and not more than 60 days prior to the date fixed for such prepayment (which shall be a Business Day). Each such notice shall specify such date, the aggregate principal amount and the Series of the Notes to be prepaid on such date, the principal amount of each Note held by such holder to be prepaid (determined in accordance with Section 8.3), and the interest to be paid on the prepayment date with respect to such principal amount being prepaid, and shall be accompanied by a certificate of a Senior Financial Officer as to the estimated Make-Whole Amount due in connection with such prepayment (calculated as if the date of such notice were the date of the prepayment), setting forth the details of such computation. Two Business Days prior to such prepayment, the Company shall deliver to each holder of a Note to be optionally prepaid under this Section 8.2 a certificate of a Senior Financial Officer specifying the calculation of the Make-Whole Amount in respect of such Notes as of the

17

specified prepayment date. For the purposes of avoidance of doubt, the Company may effect multiple partial prepayments of the Notes pursuant to, and in accordance with the terms of, this Section 8.2 and all optional prepayments under this Section 8.2 shall be on a pro rata basis in respect of all Notes of both Series.

8.3 Allocation of Note Partial Prepayments

In the case of each partial prepayment of Notes pursuant to Section 8.2, the principal amount of the Notes to be prepaid shall be allocated among all of the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid principal amounts thereof not theretofore called for prepayment. All partial prepayments made pursuant to any Debt Offered Prepayment Application or pursuant to Section 8.6 with respect to a Change in Control shall be applied only to the Notes of the holders who have elected to participate in such prepayment.

8.4 Notes; Maturity; Surrender, etc.

In the case of each prepayment of Notes pursuant to this Section 8, the principal amount of each such Note to be prepaid shall mature and become due and payable on the date fixed for such prepayment, together with interest on such principal amount accrued to such date and the applicable Make-Whole Amount, if any. From and after such date, unless the Company shall fail to pay such principal amount when so due and payable, together with the interest and Make-Whole Amount, if any, as aforesaid, interest on such principal amount shall cease to accrue. Any Note paid or prepaid in full shall be surrendered to the Company and cancelled and shall not be reissued, and no Note shall be issued in lieu of any prepaid principal amount of any Note.

Any Debt Offered Prepayment Application in respect of the Notes shall be on terms as set forth in Section 8.2 (other than any requirement in said
Section requiring a minimum prepayment amount or any requirement in said Section that is inconsistent with a requirement in this Section 8.4) and this Section 8.4, provided that only those holders who shall have accepted any offer in respect of such Debt Offered Prepayment Application shall have their Notes prepaid, in whole or part, in connection therewith. Each notice of a Debt Offered Prepayment Application made to the holders of Notes shall be in writing, shall be executed by a Senior Financial Officer, shall reasonably identify the property being Transferred, the portion of the Net Proceeds Amount in respect of such Transferred property being utilized in connection with such Debt Offered Prepayment Application and all other Senior Debt being made subject to such Debt Offered Prepayment Application, shall calculate the Ratable Portion in respect of each holder of Notes with respect to such Net Proceeds Amount and shall specify the date on which such Debt Offered Prepayment Application will be effected, which date will be not less than 35 days and not more than 90 days after the date of notice. To accept or reject a Debt Offered Prepayment Application, a holder of Notes shall cause a written notice of such acceptance or rejection to be delivered to the Company not later than 30 days after the date on which such notice is delivered to such holder. A failure by any holder of Notes to respond in writing to a notice of a Debt Offered Prepayment Application by the deadline set forth above shall be deemed to constitute an acceptance of the same. If a Debt Offered Prepayment Application is accepted or is deemed to have been accepted, the amounts payable in respect thereof shall become due and payable on the date set therefor in the notice in respect thereof.

18

Any prepayment of Notes in respect of a Change in Control under Section 8.6 shall be on terms as set forth in said Section 8.6, provided that only those holders who shall have accepted the offer under said Section 8.6 shall have their Notes prepaid in whole in connection therewith.

8.5 Purchase of Notes

The Company will not and will not permit any Affiliate to purchase, redeem, prepay or otherwise acquire, directly or indirectly, any of the outstanding Notes except upon the payment or prepayment of the Notes in accordance with the terms of this Agreement and the Notes (including, without limitation, any prepayment of the Notes contemplated in connection with a Debt Offered Prepayment Application or a Change in Control accepted by any holder of Notes). The Company will promptly cancel all Notes acquired by it or any Affiliate pursuant to any payment, prepayment or purchase of Notes pursuant to any provision of this Agreement and no Notes may be issued in substitution or exchange for any such Notes.

8.6 Offer to Prepay upon Change in Control, etc.

(a) Notice and Offer. In the event of either

(i) a Change in Control, or

(ii) the obtaining of actual knowledge of a Control Event by a Senior Financial Officer,

the Company will, within five Business Days of the occurrence of either of such events, give written notice of such Change in Control or Control Event to each holder of Notes by facsimile transmission and, simultaneously with the sending of such facsimile notice, send a copy of such notice to each such holder via an overnight courier of national reputation. Such written notice shall contain, and such written notice shall constitute, an irrevocable offer to prepay all, but not less than all, the Notes held by such holder on a date specified in such notice (the "Control Prepayment Date") that is not less than 60 days and not more than 90 days after the date of such notice, provided that, in the case of a Control Event that does not give rise to a Change in Control, such notice shall be null and void and in the case of a Control Event that does give rise to a Change in Control which shall occur more than 90 days following the date the written notice required by this Section 8.6(a) must be given, the Control Prepayment Date may be delayed by the Company to a date not later than the date on which the Change in Control arising from such Control Event shall actually be consummated or finalized. If the Control Prepayment Date shall not be specified in such notice, the Control Prepayment Date shall be the 60th day after the date of such notice; it being understood by the parties hereto, for purposes of the avoidance of doubt, that any such notice shall be dated the date on which it is first given to the holders of Notes and that all notices to all holders of Notes shall bear the same date.

If the Company shall not have received a written response to such written notice from any holder of Notes within 10 days after the date of the facsimile transmission of such notice to such holder, the

19

Company shall use its best efforts to send a second written notice via an overnight courier of national reputation to such holder of Notes but shall be under no obligation to do so.

(b) Acceptance and Payment; Acceptance.

(i) Acceptance and Payment. To accept or reject such offered prepayment, a holder of Notes shall cause a notice of such acceptance or rejection to be delivered to the Company not later than 30 days after the date of the notice constituting such offered prepayment (which, if there shall have been two written notices, shall be deemed to be the first written notice). If so accepted, such offered prepayment in respect of such principal amount of such Notes shall be due and payable on the Control Prepayment Date. Such offered prepayment shall be made at 100% of the principal amount of the Notes held by holders having accepted such offer, together with interest on the Notes then being prepaid accrued to the Control Prepayment Date and the Make-Whole Amount in respect thereof, if any. Two Business Days preceding the Control Prepayment Date, the Company shall deliver to each holder of Notes being prepaid a certificate of a Senior Financial Officer specifying the calculation of the Make-Whole Amount due in connection with such prepayment and setting forth the details of the computation of such amount.

(ii) Acceptance. A failure by any holder of Notes to respond in writing to all written offers of prepayment referred to in Section 8.6(b) by the deadlines set forth therein shall be deemed to constitute an acceptance of such offer by such holder.

(c) Officer's Certificate. Each offer to prepay the Notes pursuant to this Section 8.6 shall be accompanied by a certificate, executed by a Senior Financial Officer and dated the date of such offer, specifying:

(i) the Control Prepayment Date;

(ii) that such offer is being made pursuant to this
Section 8.6 and that failure by a holder to respond to such offer by the deadlines as established by this Section 8.6 shall result in such offer to such holder being deemed accepted;

(iii) the estimated Make-Whole Amount due in connection with such prepayment (calculated as if the date of such notice were the date of the prepayment), setting forth the details of such computation;

(iv) the interest that would be due on each such Note offered to be prepaid, accrued to the date fixed for payment;

(v) that the conditions of this Section 8.6 have been fulfilled; and

(vi) in reasonable detail, a description of the nature and date or proposed date of the Change in Control.

20

(d) Cancellation of Notes. Any Note acquired by the Company under this Section 8.6 shall be cancelled and shall not be reissued.

8.7 Make-Whole Amount

The term "Make-Whole Amount" means, with respect to any Note, an amount equal to the excess, if any, of the Discounted Value with respect to the Called Principal of such Note over the amount of such Called Principal, provided that the Make-Whole Amount may in no event be less than zero. For the avoidance of doubt, the Company and you agree that the determination of Reinvestment Yield and Remaining Average Life in respect of Notes of each Series will be different and will result in different Make-Whole Amounts in respect of the Notes of each Series.

For the purposes of determining the Make-Whole Amount, the following terms have the following meanings:

"Called Principal" means, with respect to any Note, the principal of such Note that is to be prepaid pursuant to
Section 8.2 or Section 8.6 or has become or is declared to be immediately due and payable pursuant to Section 13.1, as the context requires.

"Discounted Value" means, with respect to the Called Principal of any Note, the amount obtained by discounting the amount of such Called Principal and interest payable in respect thereof from, in the case of the Called Principal, the maturity date in respect of such Note to the Settlement Date and, in the case of such interest, the scheduled dates of payment hereunder in respect thereof to the Settlement Date, in accordance with accepted financial practice and at a discount factor (applied on the same periodic basis as that on which interest on such Note is payable) equal to the Reinvestment Yield with respect to such Called Principal.

"Reinvestment Yield" means, with respect to the Called Principal of any Note, the sum of (a) 0.50% per annum plus (b) the yield to maturity implied by (i) the yields reported, as of 10:00 a.m. (New York City time) on the second Business Day preceding the Settlement Date with respect to such Called Principal, on the display designated as "Page U.S.D." of the Bloomberg Financial Markets Services Screen (or, if not available, any other nationally recognized trading screen reporting on-line intraday trading in the U.S. Treasury securities) for actively traded U.S. Treasury securities having a maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date, or (ii) if such yields are not reported as of such time or the yields reported as of such time are not ascertainable (including by interpolation), the Treasury Constant Maturity Series Yields reported, for the latest day for which such yields have been so reported as of the second Business Day preceding the Settlement Date with respect to such Called Principal, in Federal Reserve Statistical Release H.15 (519) (or any comparable successor publication) for actively traded U.S. Treasury securities having a constant maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date. Such implied yield will be determined, if necessary, by (1) converting U.S. Treasury bill quotations to bond-equivalent yields in accordance with accepted financial

21

practice and (2) interpolating linearly between (A) the actively traded U.S. Treasury security with the maturity closest to and greater than the Remaining Average Life and (B) the actively traded U.S. Treasury security with the maturity closest to and less than the Remaining Average Life.

"Remaining Average Life" means, with respect to the Called Principal of any Note, the number of years (calculated to the nearest one-twelfth year) that will elapse between the Settlement Date with respect to such Called Principal and the maturity date of the Note in respect thereof.

"Settlement Date" means, with respect to the Called Principal of any Note, the date on which such Called Principal is to be prepaid pursuant to Section 8.2 or Section 8.6 or has become or is declared to be immediately due and payable pursuant to Section 13.1, as the context requires.

INTEREST ON THE NOTES

9.1 Series A Notes

Interest shall accrue on the unpaid principal balance of the Series A Notes on the basis of a 360-day year of twelve 30-day months at the rate of 6.71% per annum and shall be payable, in arrears, semiannually on February 27 and August 27 in each year, commencing on August 27, 1998, until the principal amount of the Series A Notes in respect of which such interest shall have accrued shall become due and payable, and interest shall accrue on any overdue principal (including any overdue prepayment of principal), Make-Whole Amount, if any, and (to the extent permitted by applicable law) on any overdue installment of interest on the Series A Notes at a rate equal to the Series A Default Rate.

9.2 Series B Notes

Interest shall accrue on the unpaid principal balance of the Series B Notes on the basis of a 360-day year of twelve 30-day months at the rate of 6.60% per annum and shall be payable, in arrears, semiannually on February 27 and August 27 in each year, commencing on August 27, 1998, until the principal amount of the Series B Notes in respect of which such interest shall have accrued shall become due and payable, and interest shall accrue on any overdue principal (including any overdue prepayment of principal), Make-Whole Amount, if any, and (to the extent permitted by applicable law) on any overdue installment of interest on the Series B Notes at a rate equal to the Series B Default Rate.

10. AFFIRMATIVE COVENANTS

The Company covenants that so long as any of the Notes are outstanding:

22

10.1 Compliance with Law

The Company will and will cause each of its Subsidiaries to comply with all laws, ordinances or governmental rules or regulations to which each of them is subject, including, without limitation, Environmental Laws, and will obtain and maintain in effect all licenses, certificates, permits, franchises and other governmental authorizations necessary to the ownership of their respective properties or to the conduct of their respective businesses, in each case to the extent necessary to ensure that non-compliance with such laws, ordinances or governmental rules or regulations or failures to obtain or maintain in effect such licenses, certificates, permits, franchises and other governmental authorizations could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

10.2 Insurance

The Company will and will cause each of its Subsidiaries to, maintain, with financially sound and reputable insurers, insurance with respect to their respective properties and businesses against such casualties and contingencies, of such types, on such terms and in such amounts (including deductibles, co-insurance, self-insurance and insurance provided by captive insurance companies, if adequate reserves are maintained with respect thereto) as is customary in the case of entities of established reputations engaged in the same or a similar business and similarly situated.

10.3 Maintenance of Properties

The Company will and will cause each of its Subsidiaries to maintain and keep, or cause to be maintained and kept, their respective properties in good repair, working order and condition (other than ordinary wear and tear), so that the business carried on in connection therewith may be properly conducted at all times, provided that this Section shall not prevent the Company or any Subsidiary from discontinuing the operation and the maintenance of any of its properties if such discontinuance is desirable in the conduct of its business and the Company has concluded that such discontinuance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

10.4 Payment of Taxes and Claims

The Company will and will cause each of its Subsidiaries to file all tax returns required to be filed in any jurisdiction and to pay and discharge all taxes shown to be due and payable on such returns and all other taxes, assessments, governmental charges, or levies imposed on them or any of their properties, assets, income or franchises, to the extent such taxes and assessments have become due and payable and before they have become delinquent and all claims for which sums have become due and payable that have or might become a Lien on properties or assets of the Company or any Subsidiary (including, without limitation, mechanic's liens or other similar construction liens), provided that neither the Company nor any Subsidiary need pay any such tax or assessment or claims if (a) the amount, applicability or validity thereof is contested by the Company or such Subsidiary on a timely basis in good faith and in appropriate proceedings, and the Company or such Subsidiary has established adequate reserves therefor in accordance with GAAP on the books of the Company or such Subsidiary or (b) the nonpayment of all such taxes and

23

assessments and claims in the aggregate could not reasonably be expected to have a Material Adverse Effect.

10.5 Corporate Existence, etc.

The Company will at all times preserve and keep in full force and effect its corporate existence. Subject to Section 11.2 and Section 11.7, the Company will at all times preserve and keep in full force and effect the corporate or other entity existence of each of its Subsidiaries (unless merged into the Company or a Subsidiary) and all rights and franchises of the Company and its Subsidiaries unless, in the good faith judgment of the Company, the termination of or failure to preserve and keep in full force and effect such corporate existence, right or franchise could not, individually or in the aggregate, have a Material Adverse Effect.

10.6 Pari Passu Obligations

The Company covenants that its obligations under the Notes and under this Agreement and the Other Agreements do and will rank at least pari passu in right of payment with all of its present and future unsecured and unsubordinated indebtedness, except for those obligations that are mandatorily preferred by law.

11 NEGATIVE COVENANTS

The Company covenants that so long as any of the Notes are outstanding:

11.1 Transactions with Affiliates

The Company will not and will not permit any Subsidiary to enter into directly or indirectly any transaction or Material group of related transactions (including, without limitation, the purchase, lease, sale or exchange of properties of any kind or the rendering of any service) with any Affiliate (other than the Company or a Subsidiary), except in the ordinary course and pursuant to the reasonable requirements of the Company's or such Subsidiary's business and upon fair and reasonable terms no less favorable to the Company or such Subsidiary than would be obtainable in a comparable arm's-length transaction with a Person not an Affiliate.

11.2 Merger, Consolidation, etc

The Company will not and will not permit any of its Subsidiaries to consolidate, amalgamate or merge with or into any other Person or convey, transfer or lease all or substantially all of its assets in a single transaction or series of transactions to any Person (except that (x) any Subsidiary may consolidate, amalgamate or merge with or into, or convey, transfer or lease all or substantially all of its assets in a single transaction or series of transactions to, the Company or any Wholly-Owned Subsidiary and (y) any Subsidiary may transfer or lease all or substantially all of its assets if permitted pursuant to Sections 11.7(d) or (e)), provided that the foregoing restrictions do not apply to the consolidation, amalgamation or merger of the Company with or into, or the conveyance, transfer or lease of all or substantially all of the assets of the Company in a single transaction or series of transactions to, any Person so long as:

24

(i) the successor formed by such consolidation or amalgamation or the survivor of such merger or the Person that acquires by conveyance, transfer or lease all or substantially all of the assets of the Company as an entirety, as the case may be (the "Successor Company"), shall be a solvent corporation organized and existing under the laws of the United States of America or any State thereof (including, without limitation, the District of Columbia);

(ii) if the Company is not the Successor Company, such Successor Company shall have executed and delivered to each holder of any Notes its assumption of the due and punctual payment of the principal of and premium, if any, and interest on all of the Notes, according to their tenor, and the due and punctual performance and observance of each covenant and condition of this Agreement, the Other Agreements and the Notes and shall have caused to be delivered to each holder of any Notes an opinion of nationally recognized independent counsel, or other independent counsel reasonably satisfactory to the Required Holders, to the effect that all agreements or instruments effecting such assumption have been duly authorized, executed and delivered and are enforceable in accordance with their terms and comply with the terms hereof; and

(iii) immediately before and after giving effect to such transaction no Default or Event of Default would exist.

11.3 Maximum Amount of Consolidated Debt

The Company will not at any time during the applicable periods set forth below permit Consolidated Debt, determined at such time, to exceed the percentage of Consolidated Total Capitalization, determined at such time, that is set forth below and corresponds to the applicable period:

=========================================================== ========================================================
                 Applicable Time Periods                              Maximum Amount of Consolidated Debt
=========================================================== ========================================================
From and including the date of Closing to (but excluding)        68% of  Consolidated Total Capitalization
the first anniversary of the date of Closing
=========================================================== ========================================================
From and including  the first anniversary  date of Closing       67% of  Consolidated Total  Capitalization
to (but excluding) the second anniversary of the date of
Closing
=========================================================== ========================================================
From and including the second anniversary date of Closing        66% of  Consolidated Total  Capitalization
to (but  excluding) the third anniversary of the date of
Closing
=========================================================== ========================================================
From and after the third  anniversary of the date of             65% of  Consolidated  TotalCapitalization.
Closing
=========================================================== ========================================================

25

11.4 Incurrence of Priority Debt

The Company will not and will not permit any of its Subsidiaries to directly or indirectly create, incur, assume, guarantee, or otherwise become liable in respect of

(a) in the case of the Company, any Debt to be incurred after the date of the Closing and secured by Liens permitted pursuant to clause (h), (i), (j) or (k) of Section 11.6, or

(b) in the case of any Subsidiary, any Debt to be incurred by such Subsidiary after the date of the Closing,

unless, after giving effect to the incurrence of such Debt and the application of the proceeds thereof,

(i) no Default or Event of Default would exist and

(ii) the aggregate principal amount (without duplication) of

(A) all Debt of the Company then outstanding secured by Liens permitted pursuant to clauses (e), (h), (i), (j) or
(k) of Section 11.6 (excluding, in any case, any such Debt owing to a Subsidiary and excluding any duplication of Debt that may arise by virtue of the utilization of clause (j)) and

(B) all Consolidated Subsidiary Debt then outstanding

does not exceed 30% of Consolidated Net Worth, determined as of the last day of the most recently ended Fiscal Quarter.

For the purposes of this Section 11.4, any Person becoming a Subsidiary after the date of the Closing shall be deemed, at the time it becomes such a Subsidiary, to have incurred all of its then outstanding Debt. This Section 11.4 shall have no application to any Debt of a Subsidiary owing to the Company or a Subsidiary.

11.5 Consolidated Net Worth

The Company will not, at any time, permit Consolidated Net Worth to be less than the sum of

(i) $125,000,000, plus

(ii) an aggregate amount equal to 25% of Consolidated Net Earnings (but only if a positive number) for each completed Fiscal Year beginning with the Fiscal Year ending December 31, 1998.

26

11.6 Liens

The Company will not and will not permit any of its Subsidiaries to directly or indirectly create, incur, assume or permit to exist (upon the happening of a contingency or otherwise) any Lien on or with respect to any property or asset (including, without limitation, any document or instrument in respect of goods or accounts receivable) of the Company or such Subsidiary, whether now owned or held or hereafter acquired, or any income or profits therefrom or assign or otherwise convey any right to receive such income or profits (unless it makes, or causes to be made, effective provision whereby the Notes will be equally and ratably secured with any and all other obligations thereby secured, such security to be pursuant to an agreement reasonably satisfactory to the Required Holders providing for such security (including an opinion of counsel to the Company to the effect that the holders of the Notes are so equally and ratably secured) and, in any such case, the Notes shall have the benefit, to the fullest extent that, and with such priority as, the holders of the Notes may be entitled under applicable law, of an equitable Lien on such property), provided that the foregoing restrictions and limitations shall not apply to:

(a) (i) Liens for taxes, assessments or other governmental charges (including ERISA Liens) the payment of which is not at the time required by Section 10.4, and

(ii) statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, materialmen, inventory suppliers and other similar Liens, in each case, incurred in the ordinary course of business for sums not yet due or the payment of which is not at the time required by Section 10.4;

(b) Liens

(i) arising from judicial attachments and judgments,

(ii) securing appeal bonds or supersedeas bonds, or

(iii) arising in connection with court proceedings (including, without limitation, surety bonds and letters of credit or any other instrument serving a similar purpose),

provided that (1) the execution or other enforcement of such Liens is effectively stayed, (2) the claims secured thereby are being actively contested in good faith and by appropriate proceedings and (3) adequate book reserves shall have been established and maintained with respect thereto in accordance with GAAP;

(c) Liens (other than any Lien imposed by ERISA) incurred or deposits made in the ordinary course of business (i) in connection with workers' compensation, unemployment insurance and other types of social security or retirement benefits, or (ii) to secure (or to obtain letters of credit that secure) the performance of tenders, statutory obligations, surety bonds, appeal bonds, bids, leases (other than Capital Leases), performance bonds, purchase, construction or sales contracts, leases and other similar obligations, in each case not incurred or made in connection with the borrowing of money, the

27

obtaining of advances or credit or the payment of the deferred purchase price of property, and which Liens do not, in the aggregate, materially impair the use of the property subject thereto in the operation of the business of the Company and the Subsidiaries, taken as a whole, or the value of such property for the purposes of such business;

(d) leases or subleases granted to others, easements, rights-of-way, restrictions, zoning restrictions, governmental restrictions in respect of any property or property right or franchise of the Company or any Subsidiary and other similar charges or encumbrances, in each case incidental to, and not interfering with, the ordinary conduct of the business of the Company and the Subsidiaries, taken as a whole, provided that such charges and encumbrances do not, in the aggregate, materially detract from the value of such property;

(e) Liens existing on the date of the Closing as set forth on Schedule 11.6;

(f) Liens on property or assets of the Company or any of its Subsidiaries securing Debt owing to the Company or any Subsidiary;

(g) Liens arising from the Transfer by ICC (or any other Subsidiary primarily responsible for providing credit to the customers of the Company and its Subsidiaries) of all or any of its receivables, whether with or without recourse to ICC, the Company or any other Subsidiary, which Liens shall extend solely to such receivables, the proceeds in respect thereof, receivables substituted therefor and books or records in respect thereof, provided that such Transfer is an arm's-length transaction, not accounted for under GAAP as a secured loan and, in the good faith opinion of a Senior Financial Officer, for fair value and in the best interests of the Company and the

Subsidiaries, taken as a whole, and provided further, that recourse to ICC, the Company or any other Subsidiary in connection with any such Transfer shall be limited to (i) liabilities arising from the breach of warranties made by ICC or such other Subsidiary in connection with such Transfer and (ii) an amount, with respect to any such Transfer and in addition to clause (i) above, not in excess of 30% of the proceeds of the disposition of the receivables so transferred in such Transfer;

(h) Liens created to secure all or any part of the purchase price, or to secure Debt incurred or assumed to pay all or any part of the purchase price or cost of construction, of property (or any improvement thereon) acquired or constructed by the Company or any of its Subsidiaries, provided that all of the following conditions are satisfied:

(i) any such Lien shall extend solely to the item or items of such property (or improvement thereon) or proceeds thereof so acquired or constructed and, if required by the terms of the instrument originally creating such Lien, other property (or improvement thereon) which is an improvement to or is acquired for specific use in connection with such acquired or constructed property (or improvement thereon) or which is real property being improved by such acquired or constructed property (or improvement thereon),

28

(ii) the principal amount of the Debt secured by any such Lien shall at no time exceed an amount equal to the lesser of (A) the cost to such Person of the property (or improvement thereon) so acquired or constructed and (B) the Fair Market Value (as determined in good faith by the Board of Directors of the Company) of such property (or improvement thereon) at the time of such acquisition or construction,

(iii) any such Lien shall be created contemporaneously with, or within 180 days after, the acquisition or construction of such property, and

(iv) at the time of creation, incurrence, assumption or guarantee of the Debt secured by such Lien and after giving effect thereto, no Default or Event of Default would exist;

(i) Liens existing on property of a Person immediately prior to its being consolidated or amalgamated with or merged into the Company or any Subsidiary or its becoming a Subsidiary, or any Lien existing on any property acquired by the Company or any Subsidiary at the time such property is so acquired (whether or not the Debt secured thereby shall have been assumed), provided that

(i) no such Lien shall have been created or assumed in contemplation of such consolidation, amalgamation or merger or such Person's becoming a Subsidiary or such acquisition of property,

(ii) each such Lien shall extend solely to the item or items of property so acquired and proceeds thereof and, if required by the terms of the instrument originally creating such Lien, other property which is an improvement to or is acquired for specific use in connection with such acquired property,

(iii) the principal amount of the Debt secured by any such Lien shall at no time exceed an amount equal to the Fair Market Value (as determined in good faith by the Board of Directors of the Company) of such property (or improvement thereon) at the time of such consolidation, merger, becoming a Subsidiary or acquisition, and

(iv) at the time of creation, incurrence, assumption or guarantee of the Debt secured by such Lien and after giving effect thereto, no Default or Event of Default would exist;

(j) Liens renewing, extending or replacing Liens permitted by clauses (e), (h) or (i) above, provided that all of the following conditions are satisfied:

(i) no such new Lien shall extend to any property of the Company or any of its Subsidiaries other than property already encumbered by the existing Lien being so renewed or replaced,

(ii) the principal amount of the underlying obligation secured by such existing Lien outstanding at the time of such renewal or replacement shall not be increased in

29

connection with such renewal or replacement and the average life thereof shall not be reduced, and

(iii) immediately after such extension, renewal or refunding no Default or Event of Default would exist;

(k) any Lien (other than a Lien permitted under clause (a) through clause (j) above) securing any Debt of the Company or any Subsidiary, which Debt, as of the date of the creation of such Lien, does not exceed the remainder of

(i) 30% of Consolidated Net Worth, determined as of the end of the most recently ended Fiscal Quarter, minus

(ii) the sum (without duplication) of (A) the aggregate principal amount of all Consolidated Subsidiary Debt outstanding as of the date of creation of such Lien plus (B) the total amount of Debt of the Company outstanding as of the date of creation of such Lien secured by Liens pursuant to clauses (e), (h), (i) or (j) of this Section 11.6 or pursuant to this clause (k) (excluding any duplication of Debt that may arise pursuant to the utilization of said clause (j)).

For the purposes of this Section 11.6, any Person becoming a Subsidiary after the date of the Closing shall be deemed, at the time it becomes such a Subsidiary, to have incurred all of its then existing Liens securing outstanding Debt.

11.7 Sale of Assets, etc

The Company will not and will not permit any of its Subsidiaries to make any Transfer, provided that the foregoing restriction does not apply to a Transfer if:

(a) the property that is the subject of such Transfer constitutes either (i) inventory or (ii) equipment, fixtures, supplies or materials no longer required in the operation of the business of the Company or any of its Subsidiaries or that is obsolete, and, in each case, such Transfer is in the ordinary course of business;

(b) such Transfer is (i) from a Subsidiary to the Company or a Wholly-Owned Subsidiary or (ii) from the Company to a Wholly-Owned Subsidiary, in each case, so long as immediately before and after giving effect to the consummation of any such Transfer, no Default or Event of Default would exist;

(c) such Transfer is subject to Section 11.2 and satisfies the requirements thereof;

(d) such Transfer is of receivables of ICC (or any other Subsidiary primarily responsible for providing credit to the customers of the Company and its Subsidiaries), whether with or without recourse to ICC, the Company or any other Subsidiary, provided that such Transfer is an arm's-length transaction, not accounted for under GAAP as a secured loan and, in the good faith opinion of a Senior Financial Officer, for fair value and in the best interests of the Company and the Subsidiaries, taken as a whole, and provided further, that recourse

30

to ICC, the Company or any other Subsidiary in connection with any such Transfer shall be limited to (i) liabilities arising from the breach of warranties made by ICC or such other Subsidiary in connection with any such Transfer and (ii) an amount, with respect to any such Transfer and in addition to clause (i) above, not in excess of 30% of the proceeds of the disposition of the receivables so transferred in such Transfer; or

(e) such Transfer is not a Transfer described in clause (a) through clause (d) above (each such Transfer is referred to as a "Basket Transfer"), and all of the following conditions shall have been satisfied with respect to such Transfer:

(i) in the good faith opinion of the Board of Directors of the Company, the Transfer is in exchange for consideration with a Fair Market Value at least equal to that of the property exchanged, and is in the best interests of the Company and its Subsidiaries, taken as a whole,

(ii) immediately before and after giving effect to such transaction no Default or Event of Default would exist, and

(iii) immediately after giving effect to such Transfer, the book value of all property that was the subject of each Basket Transfer occurring after the date of Closing would not exceed 25% of Consolidated Total Assets as of the end of the then most recently ended Fiscal Quarter.

If the Net Proceeds Amount for any Basket Transfer is applied to a Debt Offered Prepayment Application and/or is applied to, or committed in writing to, a Property Reinvestment Application, in each case within 365 days after the consummation of such Transfer (and, in the case of any such commitment, such Property Reinvestment Application is actually consummated within 30 days after the expiration of such 365-day period), then such Basket Transfer, to the extent of such application or applications of such Net Proceeds Amount, shall be excluded from any calculations set forth above in subclause (iii) of this clause (e).

For purposes of determining the book value of any property that is the subject of a Transfer, such book value shall be the book value of such property, as determined in accordance with GAAP, at the time of the consummation of such Transfer, provided that, in the case of a Transfer of any capital stock or other equity interests of a Subsidiary, the book value thereof shall be deemed to be an amount equal to

(A) the remainder (determined after eliminating all intra-company transactions, assets and liabilities in accordance with GAAP) of

(1) the book value of the total net assets of such Subsidiary less

(2) the liabilities of such Subsidiary times

31

(B) a percentage that is equal to the percentage of total equity interests of such Subsidiary attributable to the capital stock or other equity interest being so Transferred.

11.8 Line of Business

The Company will not and will not permit any of its Subsidiaries to engage in any business if, as a result, the general nature of the business in which the Company and its Subsidiaries, taken as a whole, would then be engaged would be substantially changed from the general nature of the business in which the Company and its Subsidiaries, taken as a whole, are engaged on the date of the Closing as described in the Memorandum.

.2. EVENTS OF DEFAULT

An "Event of Default" shall exist if any of the following conditions or events shall occur and be continuing:

(a) the Company defaults in the payment of any principal or Make-Whole Amount, if any, on any Note when the same becomes due and payable, whether at maturity or at a date fixed for prepayment or by declaration or otherwise; or

(b) the Company defaults in the payment of any interest on any Note for more than 5 Business Days after the same becomes due and payable; or

(c) the Company defaults in the performance of or compliance with any term contained in any of Section 11.2 through Section 11.7, inclusive, or Section 7.1(d); or

(d) the Company defaults in the performance of or compliance with any term contained herein or in any Other Agreement (other than those referred to in paragraphs (a), (b) or (c) of this Section 12) and such default is not remedied within 30 days after the earlier of (i) a Senior Financial Officer obtaining actual knowledge of such default and
(ii) the Company's receiving written notice of such default from any holder of a Note (any such written notice to be identified as a "notice of default" and to refer specifically to this paragraph (d) of Section 12); or

(e) any representation or warranty made in writing by or on behalf of the Company or by any officer of the Company in this Agreement, any Other Agreement or in any writing furnished in connection with the transactions contemplated hereby or thereby proves to have been false or incorrect in any material respect on the date as of which made; or

(f) (i) the Company or any Subsidiary is in default (as principal or as guarantor or other surety) in the payment of any principal of or premium or make-whole amount or interest on any Debt (other than Debt under this Agreement, the Other Agreements and the Notes) after notice and beyond any period of grace provided with respect thereto, that individually or together with such other Debt as to which any such failure exists has an aggregate outstanding principal amount of at least $5,000,000 (or its equivalent in other applicable currencies), or

32

(ii) the Company or any Subsidiary is in default in the performance of or compliance with any other term of any evidence of any Debt (other than any term under this Agreement, the Other Agreements and the Notes), that individually or together with such other Debt as to which any such failure exists has an aggregate outstanding principal amount of at least $5,000,000 (or its equivalent in other applicable currencies), or of compliance of any mortgage, indenture or other agreement relating thereto or any other condition exists, and as a consequence of such default or condition such Debt has become, or has been declared, due and payable before its stated maturity or before its regularly scheduled dates of payment, or

(iii) as a consequence of the occurrence or continuation of any event or condition (other than the passage of time, the right of the holder of Debt to convert such Debt into equity interests or in respect of any scheduled or contractually agreed upon payments),

(A) the Company or any Subsidiary has become obligated (other than at the Company's election) to purchase or repay Debt before its regular maturity or before its regularly scheduled dates of payment in an aggregate outstanding principal amount of at least $5,000,000 (or its equivalent in other applicable currencies), or

(B) one or more Persons have the right to require the Company or any Subsidiary to purchase or repay such Debt and have exercised such right; or

(g) the Company or any Material Subsidiary (i) is generally not paying, or admits in writing its inability to pay, its debts as they become due, (ii) files, or consents by answer or otherwise to the filing against it of, a petition for relief or reorganization or arrangement or any other petition in bankruptcy, for liquidation or to take advantage of any bankruptcy, insolvency, reorganization, moratorium or other similar law of any jurisdiction, (iii) makes an assignment for the benefit of its creditors, (iv) consents to the appointment of a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, (v) is adjudicated as insolvent or to be liquidated, or (vi) takes corporate action for the purpose of any of the foregoing; or

(h) a court or governmental authority of competent jurisdiction enters an order appointing, without consent by the Company or any Material Subsidiary, a custodian, receiver, trustee or other officer with similar powers with respect to the Company or any Material Subsidiary or with respect to any substantial part of the property of the Company or any Material Subsidiary, or constituting an order for relief or approving a petition for relief or reorganization or any other petition in bankruptcy or for liquidation or to take advantage of any bankruptcy or insolvency law of any jurisdiction, or ordering the dissolution, winding-up or liquidation of the Company or any Material Subsidiary, or any such petition shall be filed against the Company or any Material Subsidiary and such petition shall not be dismissed within 60 days; or

33

(i) a final judgment or judgments for the payment of money aggregating in excess of $5,000,000 (or its equivalent in other applicable currencies) are rendered against one or more of the Company and the Subsidiaries and which judgments are not, within 60 days after entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within 60 days after the expiration of such stay; or

(j) if (i) any Plan shall fail to satisfy the minimum funding standards of ERISA or the Code for any plan year or part thereof or a waiver of such standards or extension of any amortization period is sought or granted under section 412 of the Code,

(ii) a notice of intent to terminate any Plan shall have been or is reasonably expected to be filed with the PBGC or the PBGC shall have instituted proceedings under ERISA section 4042 to terminate or appoint a trustee to administer any Plan or the PBGC shall have notified the Company or any ERISA Affiliate that a Plan may become a subject of any such proceedings,

(iii) the aggregate "amount of unfunded benefit liabilities" (within the meaning of section 4001(a)(18) of ERISA) under all Plans subject to Title IV of ERISA, determined in accordance with Title IV of ERISA, shall exceed $10,000,000,

(iv) the Company or any ERISA Affiliate shall have incurred or is reasonably expected to incur any liability in the nature of a penalty, excise tax or fine pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans,

(v) the Company or any ERISA Affiliate withdraws from any Multiemployer Plan, or

(vi) the Company or any Subsidiary establishes or amends any employee welfare benefit plan that provides post-employment welfare benefits in a manner that would increase the liability of the Company or such Subsidiary thereunder;

and any such event or events described in clauses (i) through (vi) above, either individually or together with any other such event or events, could reasonably be expected to have a Material Adverse Effect.

As used in Section 12(j), the terms "employee benefit plan" and "employee welfare benefit plan" shall have the respective meanings assigned to such terms in section 3 of ERISA.

13. REMEDIES ON DEFAULT, ETC.

13.1 Acceleration

(a) If an Event of Default with respect to the Company described in paragraph (g) or paragraph (h) of Section 12 (other than an Event of Default described in clause (i) of paragraph (g) or

34

described in clause (vi) of paragraph (g) by virtue of the fact that such clause encompasses clause (i) of paragraph (g)) has occurred, all the Notes then outstanding shall automatically become immediately due and payable.

(b) If any other Event of Default has occurred and is continuing, any holder or holders of more than 50% in principal amount of the Notes at the time outstanding may at any time at its or their option, by notice or notices to the Company, declare all the Notes then outstanding to be immediately due and payable.

(c) If any Event of Default described in paragraph (a) or (b) of Section 12 has occurred and is continuing, any holder or holders of Notes at the time outstanding affected by such Event of Default may at any time, at its or their option, by notice or notices to the Company, declare all the Notes held by it or them to be immediately due and payable.

Upon any Notes becoming due and payable under this Section 13.1, whether automatically or by declaration, such Notes will forthwith mature and the entire unpaid principal amount of such Notes, plus (x) all accrued and unpaid interest thereon and (y) the Make-Whole Amount determined in respect of such principal amount (to the full extent permitted by applicable law), shall all be immediately due and payable, in each and every case without presentment, demand, protest or further notice, all of which are hereby waived. The Company acknowledges, and the parties hereto agree, that each holder of a Note has the right to maintain its investment in such Note free from repayment by the Company (except as herein specifically provided for) and that the provision for payment of a Make-Whole Amount by the Company in the event that such Note is prepaid or is accelerated as a result of an Event of Default, is intended to provide compensation for the deprivation of such right under such circumstances.

13.2 Other Remedies

If any Default or Event of Default has occurred and is continuing, and irrespective of whether any Notes have become or have been declared immediately due and payable under Section 13.1, the holder of any Note at the time outstanding may proceed to protect and enforce the rights of such holder by an action at law, suit in equity or other appropriate proceeding, whether for the specific performance of any agreement contained herein or in any Note, or for an injunction against a violation of any of the terms hereof or thereof, or in aid of the exercise of any power granted hereby or thereby or by law or otherwise.

13.3 Rescission

At any time after any Notes have been declared due and payable pursuant to clause (b) or clause (c) of Section 13.1, the holders of more than 50% in principal amount of the Notes then outstanding, by written notice to the Company, may rescind and annul any such declaration and its consequences if (a) the Company has paid all overdue interest on the Notes, all principal due and payable on any Notes other than by reason of such declaration, and all interest on such overdue principal, if any, and any Make-Whole Amount that is due and payable in respect of the Notes other than by reason of such declaration and any interest thereon and (to the extent permitted by applicable law) any overdue interest in respect of the Notes, at the applicable Default Rate, (b) all Events

35

of Default and Defaults, other than non-payment of amounts that have become due solely by reason of such declaration, have been cured or have been waived pursuant to Section 18, and (c) no judgment or decree has been entered for the payment of any monies due pursuant hereto or to the Notes. No rescission and annulment under this Section 13.3 will extend to or affect any subsequent Event of Default or Default or impair any right consequent thereon.

13.4 No Waivers or Election of Remedies, Expenses, etc.

No course of dealing and no delay on the part of any holder of any Note in exercising any right, power or remedy shall operate as a waiver thereof or otherwise prejudice such holder's rights, powers or remedies. No right, power or remedy conferred by this Agreement or by any Note upon any holder thereof shall be exclusive of any other right, power or remedy referred to herein or therein or now or hereafter available at law, in equity, by statute or otherwise. Without limiting the obligations of the Company under Section 16, the Company will pay to the holder of each Note on demand such further amount as shall be sufficient to cover all reasonable costs and expenses of such holder incurred in any enforcement or collection under this Section 13, including, without limitation, reasonable attorneys' fees, expenses and disbursements.

14. REGISTRATION; EXCHANGE; SUBSTITUTION OF NOTES

14.1 Registration of Notes

The Company shall keep at its principal executive office a register for the registration and registration of transfers of Notes. The name and address of each holder of one or more Notes, each transfer thereof and the name and address of each transferee of one or more Notes shall be registered in such register. Prior to due presentment for registration of transfer, the Person in whose name any Note shall be registered shall be deemed and treated as the owner and holder thereof for all purposes hereof, and the Company shall not be affected by any notice or knowledge to the contrary. The Company shall give to any holder of a Note that is an Institutional Investor promptly upon request therefor, a complete and correct copy of the names and addresses of all registered holders of Notes.

14.2 Transfer and Exchange of Notes

Upon surrender of any Note at the principal executive office of the Company for registration of transfer or exchange (and in the case of a surrender for registration of transfer, duly endorsed or accompanied by a written instrument of transfer duly executed by the registered holder of such Note or his attorney duly authorized in writing and accompanied by the address for notices of each transferee of such Note or part thereof), the Company shall execute and deliver, at the Company's expense (except as provided below), one or more new Notes (as requested by the holder thereof) in exchange therefor, in an aggregate principal amount equal to the unpaid principal amount of the surrendered Note. Each such new Note shall be payable to such Person as such holder may request and shall be substantially in the form of Exhibit 1A or Exhibit 1B. Each such new Note shall be dated and bear interest from the date to which interest shall have been paid on the surrendered Note or dated the date of the surrendered Note if no interest shall have been paid thereon. The Company may require payment of a sum sufficient to cover any stamp tax or governmental charge imposed in respect of any such transfer of Notes. Notes shall not be transferred in denominations of less than $1,000,000, provided that if necessary to enable the registration of transfer by a holder of its entire holding of Notes, one Note may be in a denomination of less than $1,000,000. Any

36

transferee, by its acceptance of a Note registered in its name (or the name of its nominee), shall be deemed to have made the representation set forth in
Section 6.2.

14.3 Replacement of Notes

Upon receipt by the Company of evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note (which evidence shall be, in the case of an Institutional Investor, notice from such Institutional Investor of such ownership and such loss, theft, destruction or mutilation), and

(a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to it (provided that if the holder of such Note is, or is a nominee for, an original Purchaser or another holder of a Note with a minimum net worth of at least $250,000,000, such Person's own unsecured agreement of indemnity shall be deemed to be satisfactory), or

(b) in the case of mutilation, upon surrender and cancellation thereof,

the Company at its own expense shall execute and deliver, in lieu thereof, a new Note, dated and bearing interest from the date to which interest shall have been paid on such lost, stolen, destroyed or mutilated Note or dated the date of such lost, stolen, destroyed or mutilated Note if no interest shall have been paid thereon.

15. PAYMENTS ON NOTES

15.1 Place of Payment

Subject to Section 15.2, payments of principal, Make-Whole Amount, if any, and interest becoming due and payable on the Notes shall be made in Elyria, Ohio at the principal office of the Company in such jurisdiction. The Company may at any time, by notice to each holder of a Note, change the place of payment of the Notes so long as such place of payment shall be either the principal office of the Company in the United States of America or the principal office of a bank or trust company in the United States of America.

15.2 Home Office Payment

So long as you or your nominee shall be the holder of any Note, and notwithstanding anything contained in Section 15.1 or in such Note to the contrary, the Company will pay all sums becoming due on such Note for principal, Make-Whole Amount, if any, and interest by the method and at the address specified for such purpose below your name in Schedule A, or by such other method or at such other address as you shall have from time to time specified to the Company in writing for such purpose, without the presentation or surrender of such Note or the making of any notation thereon, except that upon written request of the Company made concurrently with or reasonably promptly after payment or prepayment in full of any Note, you shall surrender such Note for cancellation, reasonably promptly after any such request, to the Company at its principal executive office or at the place of payment most recently designated by the Company pursuant to Section 15.1. Prior to any sale or other disposition of any Note held by you or your nominee you will, at your election, either endorse thereon the amount of principal paid thereon and the last date to which

37

interest has been paid thereon or surrender such Note to the Company in exchange for a new Note or Notes pursuant to Section 14.2. The Company will afford the benefits of this Section 15.2 to any Institutional Investor that is the direct or indirect transferee of any Note purchased by you under this Agreement and that has made the same agreement relating to such Note as you have made in this
Section 15.2.

16. EXPENSES, ETC.

16.1 Transaction Expenses

Whether or not the transactions contemplated hereby are consummated, the Company will pay all reasonable costs and expenses (including reasonable attorneys' fees of a special counsel and, if reasonably required, local or other counsel) incurred by you and each Other Purchaser or holder of a Note in connection with such transactions and in connection with any amendments, waivers or consents under or in respect of this Agreement or the Notes (whether or not such amendment, waiver or consent becomes effective), including, without limitation: (a) the reasonable costs and expenses incurred in enforcing or defending (or determining whether or how to enforce or defend) any rights under this Agreement or the Notes or in responding to any subpoena or other legal process or informal investigative demand issued in connection with this Agreement or the Notes, or by reason of being a holder of any Note, and (b) the reasonable costs and expenses, including financial advisors' fees, incurred in connection with the insolvency or bankruptcy of the Company or any Subsidiary or in connection with any work-out or restructuring of the transactions contemplated hereby and by the Notes. The Company will pay, and will save you and each other holder of a Note harmless from, all claims in respect of any fees, costs or expenses if any, of brokers and finders (other than those retained by you).

16.2 Survival

The obligations of the Company under this Section 16 will survive the payment or transfer of any Note, the enforcement, amendment or waiver of any provision of this Agreement or the Notes and the termination of this Agreement.

17. SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE AGREEMENT

All representations and warranties contained herein shall survive the execution and delivery of this Agreement and the Notes, the purchase or transfer by you of any Note or portion thereof or interest therein and the payment of any Note, and may be relied upon by any subsequent holder of a Note, regardless of any investigation made at any time by or on behalf of you or any other holder of a Note. All statements contained in any certificate or other instrument delivered by or on behalf of the Company pursuant to this Agreement shall be deemed representations and warranties of the Company under this Agreement. Subject to the preceding sentence, this Agreement and the Notes embody the entire agreement and understanding between you and the Company and supersede all prior agreements and understandings relating to the subject matter hereof.

38

18. AMENDMENT AND WAIVER

18.1 Requirements

This Agreement and the Notes may be amended, and the observance of any term hereof or of the Notes may be waived (either retroactively or prospectively), with (and only with) the written consent of the Company and the Required Holders, except that (a) no amendment or waiver of any of the provisions of any of Sections 1, 2, 3, 4, 5, 6 and 22, or any defined term (as it is used therein), will be effective as to you unless consented to by you in writing, and (b) no such amendment or waiver may, without the written consent of the holder of each Note at the time outstanding affected thereby, (i) subject to the provisions of Section 13 relating to acceleration or rescission, change the amount or time of any prepayment or payment of principal of, or reduce the rate or change the time of payment or method of computation of interest or of the Make-Whole Amount on, the Notes, (ii) change the percentage of the principal amount of the Notes the holders of which are required to consent to any such amendment or waiver, or (iii) amend any of Sections 8, 12(a), 12(b), 13, 18 and 21.

18.2 Solicitation of Holders of Notes

(a) Solicitation. The Company will provide each holder of the Notes (irrespective of the amount of Notes then owned by it) with sufficient information, sufficiently far in advance of the date a decision is required, to enable such holder to make an informed and considered decision with respect to any proposed amendment, waiver or consent in respect of any of the provisions hereof or of the Notes. The Company will deliver executed or true and correct copies of each amendment, waiver or consent effected pursuant to the provisions of this Section 18 to each holder of outstanding Notes promptly following the date on which it is executed and delivered by, or receives the consent or approval of, the requisite holders of Notes.

(b) Payment. The Company will not directly or indirectly pay or cause to be paid any remuneration, whether by way of supplemental or additional interest, fee or otherwise, or grant any security, to any holder of Notes as consideration for or as an inducement to the entering into by any holder of Notes or any waiver or amendment of any of the terms and provisions hereof unless such remuneration is concurrently paid, or security is concurrently granted, on the same terms, ratably to each holder of Notes then outstanding even if such holder did not consent to such waiver or amendment.

18.3 Binding Effect, etc.

Any amendment or waiver consented to as provided in this Section 18 applies equally to all holders of Notes and is binding upon them and upon each future holder of any Note and upon the Company without regard to whether such Note has been marked to indicate such amendment or waiver. No such amendment or waiver will extend to or affect any obligation, covenant, agreement, Default or Event of Default not expressly amended or waived or impair any right consequent thereon. No course of dealing between the Company and the holder of any Note nor any delay in exercising any rights hereunder or under any Note shall operate as a waiver of any rights of any holder of such Note. As used herein, the term

39

"this Agreement" and references thereto shall mean this Agreement as it may from time to time be amended or supplemented.

18.4 Notes held by Company, etc.

Solely for the purpose of determining whether the holders of the requisite percentage of the aggregate principal amount of Notes then outstanding approved or consented to any amendment, waiver or consent to be given under this Agreement or the Notes, or have directed the taking of any action provided herein or in the Notes to be taken upon the direction of the holders of a specified percentage of the aggregate principal amount of Notes then outstanding, Notes directly or indirectly owned by the Company or any of its Affiliates shall be deemed not to be outstanding.

19. NOTICES

All notices and communications provided for hereunder shall be in writing and sent (a) by telecopy if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid), or (b) by registered or certified mail with return receipt requested (postage prepaid), or (c) by a recognized overnight delivery service (with charges prepaid). Any such notice must be sent:

(i) if to you or your nominee, to you or it at the address specified for such communications in Schedule A, or at such other address as you or it shall have specified to the Company in writing,

(ii) if to any other holder of any Note, to such holder at such address as such other holder shall have specified to the Company in writing, or

(iii) if to the Company, to the Company at its address set forth at the beginning hereof to the attention of Chief Financial Officer, or at such other address as the Company shall have specified to the holder of each Note in writing.

Notices under this Section 19 will be deemed given only when actually received.

20. REPRODUCTION OF DOCUMENTS

This Agreement and all documents relating thereto, including, without limitation, (a) consents, waivers and modifications that may hereafter be executed, (b) documents received by you at the Closing (except the Notes themselves), and (c) financial statements, certificates and other information previously or hereafter furnished to you, may be reproduced by you by any photographic, photostatic, microfilm, microcard, miniature photographic or other similar process and you may destroy any original document so reproduced. The Company agrees and stipulates that, to the extent permitted by applicable law, any such reproduction shall be admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the original is in existence and whether or not such reproduction was made by you in the regular course of business) and any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence. This Section 20 shall not prohibit the Company or any other holder of Notes from contesting any such reproduction to the same extent that it could contest the original, or from introducing evidence to demonstrate the inaccuracy of any such reproduction.

40

21. CONFIDENTIAL INFORMATION

For the purposes of this Section 21, "Confidential Information" means information delivered to you by or on behalf of the Company or any of its Subsidiaries in connection with the transactions contemplated by or otherwise pursuant to this Agreement that is proprietary in nature and that was clearly marked or labeled or otherwise adequately identified when received by you as being confidential information of the Company and/or its Subsidiaries, provided that such term does not include information that

(a) was publicly known or otherwise known to you prior to the time of such disclosure,

(b) subsequently becomes publicly known through no act or omission by you or any Person acting on your behalf,

(c) otherwise becomes known to you other than through disclosure by the Company or any of its Subsidiaries, or

(d) constitutes financial statements delivered to you under
Section 7.1 that are otherwise publicly available.

You will maintain the confidentiality of such Confidential Information in accordance with procedures adopted by you in good faith to protect confidential information of third parties delivered to you, provided that you may deliver or disclose Confidential Information to:

(i) your directors, officers, trustees, employees, agents, attorneys and affiliates (to the extent such disclosure reasonably relates to the administration of the investment represented by your Notes),

(ii) your financial advisors and other professional advisors who agree to hold confidential the Confidential Information substantially in accordance with the terms of this Section 21,

(iii) any other holder of any Note other than a Competitor,

(iv) any Institutional Investor to which you sell or offer to sell such Note or any part thereof or any participation therein (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 21),

(v) any Person other than a Competitor from which you offer to purchase any security of the Company (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 21),

(vi) any federal or state regulatory authority having jurisdiction over you,

41

(vii) the National Association of Insurance Commissioners or any similar organization, or any nationally recognized rating agency that requires access to information about your investment portfolio or

(viii) any other Person to which such delivery or disclosure may be necessary or appropriate

(A) to effect compliance with any law, rule, regulation or order applicable to you,

(B) in response to any subpoena or other legal process,

(C) in connection with any litigation to which you are a party, or

(D) if an Event of Default has occurred and is continuing, to the extent you may reasonably determine such delivery and disclosure to be necessary or appropriate in the enforcement or for the protection of the rights and remedies under your Notes and this Agreement.

Each holder of a Note, by its acceptance of a Note, will be deemed to have agreed to be bound by and to be entitled to the benefits of this Section 21 as though it were a party to this Agreement. On reasonable request by the Company in connection with the delivery to any holder of a Note of information required to be delivered to such holder under this Agreement or requested by such holder (other than a holder that is a party to this Agreement or its nominee), such holder will enter into an agreement with the Company embodying the provisions of this Section 21.

22. SUBSTITUTION OF PURCHASER

You shall have the right to substitute any one of your Affiliates as the purchaser of the Notes that you have agreed to purchase hereunder, by written notice to the Company, which notice shall be signed by both you and such Affiliate, shall contain such Affiliate's agreement to be bound by this Agreement and shall contain a confirmation by such Affiliate of the accuracy with respect to it of the representations set forth in Section 6. Upon receipt of such notice, wherever the word "you" is used in this Agreement (other than in this Section 22), such word shall be deemed to refer to such Affiliate in lieu of you. In the event that such Affiliate is so substituted as a purchaser hereunder and such Affiliate thereafter transfers to you all of the Notes then held by such Affiliate, upon receipt by the Company of notice of such transfer, wherever the word "you" is used in this Agreement (other than in this Section 22), such word shall no longer be deemed to refer to such Affiliate, but shall refer to you, and you shall have all the rights of an original holder of the Notes under this Agreement.

42

23. ADDITIONAL NOTE PROVISIONS.

Subject to the terms and provisions hereof (including, but not limited to, Section 11.3), the Company may, from time to time, issue and sell additional promissory notes pursuant to agreements which may incorporate by reference all or certain of the provisions of this Agreement and the Other Agreements. Such incorporation by reference shall not have the effect of constituting such promissory notes as Notes for any purpose, whether for acceleration of the Notes, rescission of such acceleration, or the exercise of any other amendments or waivers of the provisions hereof or of the Other Agreements, or otherwise.

24. MISCELLANEOUS

24.1 Successors and Assigns

All covenants and other agreements contained in this Agreement by or on behalf of any of the parties hereto bind and inure to the benefit of their respective successors and assigns (including, without limitation, any subsequent holder of a Note) whether so expressed or not.

24.2 Payments Due on Non-Business Days

Anything in this Agreement or the Notes to the contrary notwithstanding, any payment of principal of or Make-Whole Amount or interest on any Note that is due on a date other than a Business Day shall be made on the next succeeding Business Day without including the additional days elapsed in the computation of the interest payable on such next succeeding Business Day.

24.3 Severability

Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall (to the full extent permitted by law) not invalidate or render unenforceable such provision in any other jurisdiction.

24.4 Construction

Each covenant contained herein shall be construed (absent express provision to the contrary) as being independent of each other covenant contained herein, so that compliance with any one covenant shall not (absent such an express contrary provision) be deemed to excuse compliance with any other covenant. Where any provision herein refers to action to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or indirectly by such Person.

24.5 Counterparts

This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one

43

instrument. Each counterpart may consist of a number of copies hereof, each signed by less than all, but together signed by all, of the parties hereto.

24.6 Governing Law

THIS AGREEMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE LAW OF THE STATE OF NEW YORK EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE.

[Remainder of page intentionally blank. Next page is signature page.]

44

If you are in agreement with the foregoing, please sign the form of agreement on the accompanying counterpart of this Agreement and return it to the Company, whereupon the foregoing shall become a binding agreement between you and the Company.

Very truly yours,

INVACARE CORPORATION

  By:  /s/ Thomas R. Miklich
        _____________________

 Name:  Thomas R. Miklich
Title:  Chief Financial Officer

The foregoing is hereby
agreed to as of the
date thereof.

General Electric Capital Life
Assurance Company of New York

By       /s/ William D. Koski
         ________________________________
Name:    William D. Koski
Its:     Vice President

The Life Insurance Company of Virginia

By       /s/ William D. Koski
         ________________________________
Name:    William D. Koski
Its:     Vice President

Massachusetts Mutual Life Insurance Company

By       /s/ Mark A. Ahmed
         ________________________________
Name:    Mark A. Ahmed
Its:     Managing Director

Mony Life Insurance Company of America

By       /s/ William D. Goodwin
         ________________________________
Name:    William D. Goodwin
Its:     Authorized Agent

The Mutual Life Insurance Company of New York

By       /s/ Will D. Goodwin
         ________________________________
Name:    William D. Goodwin
Its:     Senior Managing Director

Principal Mutual Life Insurance Company

By       /s/ James C. Fifield
         ________________________________
Name:    James C. Fifield
Its:     Counsel

By       /s/ Christopher J. Henderson
         ________________________________
Name:    Christopher J. Henderson
Its:     Counsel

United Services Automobile Association

By       /s/ Carl Shinsky
         ________________________________
Name:    Carl Shinsky
Its:     Senior Vice President


SCHEDULE A

[List of Purchasers and Purchaser Information]


SCHEDULE B

DEFINED TERMS

As used herein, the following terms have the respective meanings set forth below or set forth in the Section hereof following such term:

Affiliate -- means, at any time, and with respect to any Person,

(a) any other Person that at such time directly or indirectly through one or more intermediaries Controls, or is Controlled by, or is under common Control with, such first Person, and

(b) any Person beneficially owning or holding, directly or indirectly, 10% or more of any class of voting or equity interests of the Company or any Subsidiary or any corporation, company, partnership or other entity of which the Company and its Subsidiaries beneficially own or hold, in the aggregate, directly or indirectly, 10% or more of any class of voting or equity interests.

As used in this definition, "Control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. Unless the context otherwise clearly requires, any reference to an "Affiliate" is a reference to an Affiliate of the Company.

Agreement, this -- is defined in Section 18.3.

Bankruptcy Code -- means the Bankruptcy Reform Act of 1978, as heretofore and hereafter amended, and codified as 11 U.S.C. Sec. 101 et seq.

Basket Transfer -- is defined in Section 11.7.

Board of Directors -- means, the board of directors of the Company or any committee thereof which, in the instance, shall have the lawful power to exercise the power and authority of such board of directors.

Business Day -- means any day other than a Saturday, Sunday or other day on which commercial banks in New York, New York or Cleveland, Ohio are authorized or required to close under the laws of the State of New York or the State of Ohio (other than a general banking moratorium or holiday for a period exceeding 4 consecutive days).

Capital Lease -- means, with respect to the Company or any of its Subsidiaries, a lease with respect to which such Person is required concurrently to recognize the acquisition of an asset and the incurrence of a liability in accordance with GAAP (whether pursuant to an entry or entries on the balance sheet of such Person or in a footnote to its financial statements).

Capital Lease Obligation -- means, with respect to the Company or any of its Subsidiaries and a Capital Lease, the amount of the obligation of such Person as the lessee under such Capital Lease which would, in accordance with GAAP, appear as a liability on a balance sheet of such Person.

Schedule B-1


Change in Control -- means, at any time, either

(a) the acquisition by any person (as such term is used in section 13(d) and section 14(d)(2) of the Exchange Act) or related persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act), directly or indirectly, of the beneficial ownership and control of more than 50% of the total voting power of all of the then issued and outstanding Voting Stock of the Company or any Successor Company, provided, however, if the Management Team or persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act) of which the Management Team is a part shall acquire, directly or indirectly, the beneficial ownership and control of more than 50% of the total voting power of the then issued and outstanding Voting Stock of the Company or any Successor Company, no "Change in Control" shall be deemed to have occurred or

(b) with respect to any period of 12 consecutive months, the failing by individuals who, at the beginning of such period, constitute the Board of Directors (such individuals being referred to herein as the "original members") (including among such original members (i) any new director who was elected by the Board of Directors during such period to replace any other director that may have died, may have become disabled, was involuntarily dismissed for breach of his or her fiduciary duties or otherwise voluntarily resigned for personal reasons during such period, (ii) any new director that is a member of the Management Team or (iii) any new director whose election to the Board of Directors or whose nomination for election by the Company's shareholders was approved by a vote of not less than 50% of the directors then still in office who either were original members, whose election or nomination was previously approved as provided in this clause (iii) by more than 50% of the original members or who qualify under either subclause (i) or (ii) above) to constitute for any reason a majority of the Board of Directors then in office, provided that if an original member should die, become disabled, be involuntarily dismissed for breach of his or her fiduciary duties or shall otherwise voluntarily resign for personal reasons during such period and shall not be replaced by the Board of Directors, then such original member shall be deemed, for purposes of this clause (b), to continue to be a director and an original member of the Company.

Closing -- is defined in Section 3.

Code -- means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder from time to time.

Company -- is defined in the introductory sentence of this Agreement.

Schedule B-2


Competitor -- means

(a) each Person which is (i) engaged in the design, manufacture or distribution of medical equipment for the home, healthcare, retail or extended care markets and (ii) identified as a "Competitor" on Schedule B-C and the successors and assigns thereof;

(b) each Person which is (i) engaged in the design, manufacture or distribution of medical equipment for the home, healthcare, retail or extended care markets and (ii) identified by the Company as a "Competitor" in a certification delivered to the holders of the Notes from time to time, which Person so identified is consented to by the Required Holders (which consent shall not be unreasonably withheld);

(c) any Person legally or beneficially owning, directly or indirectly, more than 25% of the issued and outstanding Voting Stock of any Person which would qualify as a "Competitor" under clause (a) or clause (b) of this definition; and

(d) any Person more than 25% of the issued and outstanding Voting Stock of which is legally or beneficially owned by any Person which would qualify as a "Competitor" under clause (a) or clause (b) of this definition,

provided that

(i) none of the Purchasers or their affiliates, and

(ii) no Person that is primarily a bank, trust company, savings and loan association or other financial institution, a pension plan (other than a pension plan for a Competitor), an investment company, an insurance company, a broker or dealer, or any other similar financial institution or entity (regardless of legal form),

shall be considered or deemed to be a "Competitor."

Confidential Information -- is defined in Section 21.

Consolidated Debt -- means, as of any date of determination, the total of all Debt of the Company and its Subsidiaries outstanding on such date, determined on a consolidated basis at such time in accordance with GAAP.

Consolidated Net Earnings -- means, with respect to any period, the net income (or loss) of the Company and its Subsidiaries for such period, as determined on a consolidated basis in accordance with GAAP.

Consolidated Net Worth -- means, at any time, the total shareholders' equity of the Company and its Subsidiaries as would be shown on a consolidated balance sheet of the Company and its Subsidiaries as of such time prepared in accordance with GAAP.

Consolidated Subsidiary Debt -- means, as of any date of determination, the total of all Debt of all Subsidiaries outstanding, in each case, on such date, after eliminating any such Debt owing by any Subsidiary to the Company or any other Subsidiary.

Schedule B-3


Consolidated Total Assets -- means, at any time, the total assets of the Company and its Subsidiaries determined on a consolidated basis at such time in accordance with GAAP.

Consolidated Total Capitalization -- means, at any time, the sum of Consolidated Debt at such time plus Consolidated Net Worth at such time.

Control Event means:

(a) the execution by the Company, a Subsidiary or an Affiliate of the Company of any agreement or letter of intent with respect to any proposed transaction or event or series of transactions or events which, individually or in the aggregate, may reasonably be expected to result in a Change in Control,

(b) the execution of any written agreement which, when fully performed by the parties thereto, would result in a Change in Control, or

(c) the making of any written offer by any person (as such term is used in section 13(d) and section 14(d)(2) of the Exchange Act) or related persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act) to the holders of the Voting Stock of the Company, which offer, if accepted by the requisite number of holders, would result in a Change in Control.

Control Prepayment Date -- is defined in Section 8.6.

Debt -- means, with respect to the Company or any of its Subsidiaries, without duplication,

(a) its liabilities for borrowed money and its redemption obligations in respect of mandatorily redeemable preferred stock;

(b) its liabilities for the deferred purchase price of property acquired by such Person (excluding accounts payable arising in the ordinary course of business, but including, without limitation, all liabilities created or arising under any conditional sale or other title retention agreement with respect to any such property);

(c) its Capital Lease Obligations;

(d) all liabilities for borrowed money secured by any Lien with respect to any property owned by such Person (whether or not it has assumed or otherwise become liable for such liabilities);

(e) all reimbursement obligations in respect of any letter of credit issued for the account of such Person other than (i) commercial letters of credit issued in the ordinary course of such Person's business (and not as a substitute for direct borrowing or Guaranties thereof) and (ii) letters of credit issued in the ordinary course of such Person's business that act as the functional equivalent of a surety bond or performance bond for such Person;

Schedule B-4


(f) Swaps of such Person; and

(g) any Guaranty of such Person with respect to liabilities of a type described in any of clauses (a) through (f) hereof.

For the purposes of the avoidance of doubt, "Debt" shall not include any benefit liability or funding obligation of the Company or any of its Subsidiaries in respect of any Plan. For purposes of determining "Debt," no amount listed above shall be included more than once in such determination.

Debt Offered Prepayment Application -- means, with respect to any Transfer of property, the offering, in writing, by the Company of cash in an amount not exceeding the Net Proceeds Amount with respect to such Transfer to pay any Senior Debt (other than Senior Debt owing to any Affiliate and other than Senior Debt in respect of any revolving credit or similar credit facility providing the Company or any Subsidiary with the right to obtain loans or other extensions of credit from time to time, except to the extent that in connection with such payment of Senior Debt the availability of credit under such credit facility is permanently reduced by an amount not less than the amount of such proceeds applied to the payment of such Senior Debt) and any interest and premium in respect thereof, provided that in connection with any such Transfer and payment of such Senior Debt, the Company shall have offered to prepay the Ratable Portion in respect of each outstanding Note in accordance with Section 8.4 and shall have prepaid each holder of each such Note that shall have accepted such offer of prepayment in accordance with said Section in a principal amount which, when added to the Make-Whole Amount applicable thereto, if any, and any accrued and unpaid interest thereon, equals the Ratable Portion for such Note. For purposes of Section 11.7, a Net Proceeds Amount shall be deemed applied to a Debt Offered Prepayment Application upon the extension of the offer in respect of such Debt Offered Prepayment Application, provided that if the actual prepayments in respect thereof, if any, are not made in accordance with the requirements of such offer or, in any case, are not made within 365 days after the applicable Transfer, such application of such Net Proceeds Amount will be deemed not to have been made.

Default -- means an event or condition the occurrence or existence of which would, with the lapse of time or the giving of notice or both, become an Event of Default.

Default Rate -- means the Series A Default Rate or the Series B Default Rate, as the case may be.

Environmental Laws -- means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including but not limited to those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.

ERISA -- means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder from time to time in effect.

Schedule B-5


ERISA Affiliate -- means any trade or business (whether or not incorporated) that is treated as a single employer together with the Company under section 414 of the Code.

Event of Default -- is defined in Section 12.

Exchange Act -- means the Securities Exchange Act of 1934, as amended from time to time.

Fair Market Value -- means, at any time and with respect to any property, the sale value of such property that would be realized in an arm's-length sale at such time between an informed and willing buyer and an informed and willing seller (neither being under a compulsion to buy or sell).

Fiscal Quarter -- means the fiscal period in respect of which the Company's consolidated quarterly financial statements are prepared.

Fiscal Year -- means the fiscal period in respect of which the Company's consolidated annual financial statements are prepared.

GAAP -- means generally accepted accounting principles as in effect from time to time in the United States of America.

Governmental Authority -- means

(a) the government of

(i) the United States of America or any state or other political subdivision thereof, or

(ii) any jurisdiction in which the Company or any of its Subsidiaries conducts all or any part of its business, or that asserts jurisdiction over any properties of any such Person, or

(b) any entity exercising executive, legislative, judicial, regulatory or administrative functions of, or pertaining to, any such government.

Guaranty -- means, with respect to any Person (for the purposes of this definition, the "guarantor"), any obligation (except the endorsement in the ordinary course of business of negotiable instruments for deposit or collection) of such Person guaranteeing or in effect guaranteeing any indebtedness, dividend or other obligation of any other Person (the "primary obligor") in any manner, whether directly or indirectly, including, without limitation, obligations incurred through an agreement, contingent or otherwise, by the guarantor:

(a) to purchase such indebtedness or obligation or any property constituting security therefor;

(b) to advance or supply funds

Schedule B-6


(i) for the purchase or payment of such indebtedness, dividend or obligation, or

(ii) to maintain working capital or other balance sheet condition or any income statement condition of the primary obligor or otherwise to advance or make available funds for the purchase or payment of such indebtedness, dividend or obligation;

(c) to lease property or to purchase securities or other property or services primarily for the purpose of assuring the owner of such indebtedness or obligation of the ability of the primary obligor to make payment of the indebtedness or obligation; or

(d) otherwise to assure the owner of the indebtedness or obligation of the primary obligor against loss in respect thereof.

For purposes of computing the amount of any guaranty in connection with any computation of indebtedness or other liability, it shall be assumed that the indebtedness or other liabilities that are the subject of such Guaranty are direct obligations of the issuer of such Guaranty.

Hazardous Material -- means any and all pollutants, toxic or hazardous wastes or any other substances that might pose a hazard to health or safety, the removal of which may be required or the generation, manufacture, refining, production, processing, treatment, storage, handling, transportation, transfer, use, disposal, release, discharge, spillage, seepage, or filtration of which is or shall be restricted, prohibited or penalized by any applicable law (including, without limitation, asbestos, urea formaldehyde foam insulation and polychlorinated biphenyls).

holder -- means, with respect to any Note, the Person in whose name such Note is registered in the register maintained by the Company pursuant to
Section 14.1.

ICC -- means Invacare Credit Corporation, an Ohio corporation.

Institutional Investor -- means (a) any original purchaser of a Note,
(b) any holder of a Note (other than a Competitor) holding more than 10% of the aggregate principal amount of the Notes then outstanding, (c) any bank, trust company, savings and loan association or other financial institution, any pension plan (other than a pension plan for a Competitor), any investment company, any insurance company, any broker or dealer, or any other similar financial institution or entity, regardless of legal form.

Lien -- means, with respect to the Company or any Subsidiary, any mortgage, lien, pledge, charge, security interest or other encumbrance, or any interest or title of any vendor, lessor, lender or other secured party to or of such Person under any conditional sale or other title retention agreement or Capital Lease, upon or with respect to any property or asset of such Person. The term "Lien" shall not include any so-called "negative pledge" provisions in agreements covering the incurrence of Debt.

Make-Whole Amount -- is defined in Section 8.7.

Schedule B-7


Management Team -- means the group of individuals set forth on Schedule B-MT, provided that, if more than 50% of such individuals shall no longer be actively involved in the management of the Company, whether pursuant to death, disability, voluntary or involuntary disassociation with the Company, retirement or otherwise, the "Management Team" will be deemed to no longer exist.

Material -- means material in relation to the business, operations, affairs, financial condition, assets, properties, or prospects of the Company and its Subsidiaries, taken as a whole.

Material Adverse Effect -- means a material adverse effect on (a) the business, operations, affairs, financial condition, assets, prospects or properties of the Company and its Subsidiaries, taken as a whole, or (b) the ability of the Company to perform its obligations under this Agreement, the Other Agreements and the Notes, or (c) the validity or enforceability of this Agreement, the Other Agreements or the Notes.

Material Subsidiary -- means any Subsidiary if

(a) the assets of such Subsidiary (valued at the greater of book or fair market) as of the last day of the then most recently completed Fiscal Year exceed 10% of Consolidated Total Assets determined on the same day; or

(b) the portion of Consolidated Net Earnings which was contributed by such Subsidiary during the then most recently completed Fiscal Year exceeds 10% of Consolidated Net Earnings for such Fiscal Year.

Memorandum -- is defined in Section 5.3.

Multiemployer Plan -- means any Plan that is a "multiemployer plan" (as such term is defined in section 4001(a)(3) of ERISA).

Net Proceeds Amount -- means, with respect to any Transfer of any property by the Company or any Subsidiary, an amount equal to the difference of

(a) the aggregate amount of the consideration (valued at the Fair Market Value of such consideration at the time of the consummation of such Transfer as determined by the Board of Directors of the Company in good faith) paid by the transferee in respect of such Transfer, minus

(b) all ordinary and reasonable out-of-pocket costs and expenses actually incurred by the transferor in connection with such Transfer and all Debt secured by such property and required by its terms to be paid in connection with the consummation of such Transfer.

Non-US Pension Plan -- means any plan, fund or other similar program that (a) is established or maintained outside of the United States of America by any one or more of the Company or its Subsidiaries primarily for the benefit of

Schedule B-8


the employees of the Company or such Subsidiaries substantially all of whom are non-resident aliens, which plan, fund or other similar program provides for retirement income for such employees or results in a deferral of income for such employees in contemplation of retirement and (b) is not subject to control under ERISA or the Code.

Notes -- is defined in Section 1.

Officer's Certificate -- means a certificate of a Senior Financial Officer or of any other officer of the Company whose responsibilities extend to the subject matter of such certificate.

Other Agreements -- is defined in Section 2.

Other Purchasers -- is defined in Section 2.

PBGC -- means the Pension Benefit Guaranty Corporation referred to and defined in ERISA or any successor thereto.

Person -- means an individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof.

Placement Agents -- means SPP Hambro & Co. and any of its affiliates and Carleton, McCreary, Holmes & Co., LLC and any of its affiliates.

Plan -- means an "employee benefit plan" (as defined in section 3(3) of ERISA) that is or, within the preceding five years, has been established or maintained, or to which contributions are or, within the preceding five years, have been made or required to be made, by the Company or any ERISA Affiliate or with respect to which the Company or any ERISA Affiliate may have any liability.

Preferred Stock -- means any class of capital stock of a corporation that is preferred over any other class of capital shares of such corporation as to the payment of dividends or the payment of any amount upon liquidation or dissolution of such corporation.

property or properties -- means, unless otherwise specifically limited, real or personal property of any kind, tangible or intangible, choate or inchoate.

Property Reinvestment Application -- means, with respect to any Transfer of property, the application of an amount not exceeding the Net Proceeds Amount with respect to such Transfer to the acquisition by the Company or a Subsidiary of (a) property to be used in the business of the Company and the Subsidiaries or (b) a business reasonably related to the business of the Company and the Subsidiaries, taken as a whole, and, in either case, of at least an equivalent value in respect of the property that was so Transferred.

PTE -- is defined in Section 6.2.

QPAM Exemption -- means Prohibited Transaction Class Exemption 84-14 issued by the United States Department of Labor.

Schedule B-9


Ratable Portion -- means, with respect to any Note and any Debt Offered Prepayment Application with respect thereto, an amount equal to the product of
(a) the Net Proceeds Amount being offered to the payment of Senior Debt in connection with such Debt Offered Prepayment Application multiplied by (b) a fraction the numerator of which is the outstanding principal amount of such Note and the denominator of which is the aggregate principal amount of all Senior Debt with respect to which such offer of prepayment is made.

Required Holders -- means, at any time, the holders of more than 50% in principal amount of the Notes at the time outstanding (exclusive of Notes then owned by the Company or any of its Subsidiaries or any Affiliates thereof).

Responsible Officers -- means any Senior Financial Officer and any other officer of the Company with responsibility for the administration of the relevant portion of this Agreement.

Securities Act -- means the Securities Act of 1933, as amended from time to time.

Senior Debt -- means (a) any unsecured Debt of the Company that is not in any manner subordinated in right of payment to the Notes or to any other Debt of the Company or (b) unsecured Debt of any Subsidiary, if, but only if, the Transfer of property giving rise to a corresponding Debt Offered Prepayment Application is in respect of property owned by such Subsidiary.

Senior Financial Officer -- means the chief financial officer, principal accounting officer, treasurer or comptroller of the Company.

Series -- means any of the Series A Notes or the Series B Notes issued hereunder.

Series A Default Rate -- means the lesser of

(a) the maximum rate of interest allowed by applicable law, and

(b) the greater of (i) 8.71% per annum and (ii) 2% per annum over the rate of interest publicly announced from time to time by Morgan Guaranty Trust Company of New York (or its successors) in New York, New York as its "base" or "prime" rate.

Series A Notes -- is defined in Section 1.

Series B Default Rate -- means the lesser of

(a) the maximum rate of interest allowed by applicable law, and

(b) the greater of (i) 8.60% per annum and (ii) 2% per annum over the rate of interest publicly announced from time to time by Morgan Guaranty Trust Company of New York (or its successors) in New York, New York as its "base" or "prime" rate.

Series B Notes -- is defined in Section 1.

Source -- is defined in Section 6.2.

Schedule B-10


Subsidiary -- means, as to any Person, any corporation, association, limited liability company or other similar business entity in which such Person or one or more of its Subsidiaries or such Person and one or more of its Subsidiaries owns sufficient equity or voting interests to enable it or them (as a group) ordinarily, in the absence of contingencies, to elect a majority of the directors (or Persons performing similar functions) of such entity, and any partnership or joint venture if more than a 50% interest in the profits or capital thereof is owned by such Person or one or more of its Subsidiaries or such Person and one or more of its Subsidiaries (unless such partnership can and does ordinarily take major business actions without the prior approval of such Person or one or more of its Subsidiaries). Unless the context otherwise clearly requires, any reference to a "Subsidiary" is a reference to a Subsidiary of the Company, provided that "Subsidiary" shall not include a special purpose entity
(a) that is formed for the sole purpose of acquiring receivables from ICC (or any other Subsidiary primarily responsible for providing credit to the customers of the Company and its Subsidiaries), (b) that meets the requirements of GAAP with respect to special purpose entities and the off-balance sheet treatment of the transfer of financial assets thereto, (c) that is not required by GAAP to be consolidated with the Company and its other Subsidiaries, (d) with respect to which the Transfer of such receivables is treated under GAAP as a sale of the same and (e) with respect to which the Transfer of such receivables qualifies as a so-called "true sale" under applicable law and such qualification is confirmed by the delivery to the Company of a customary "true sale" opinion issued by a nationally recognized securitization law firm.

Successor Company -- Section 11.2.

Swaps -- means, with respect to any Person, payment obligations with respect to interest rate swaps, currency swaps and similar obligations obligating such Person to make payments, whether periodically or upon the happening of a contingency. For the purposes of this Agreement, the amount of the obligation under any Swap shall be the amount determined in respect thereof as of the end of the then most recently ended fiscal quarter of such Person, based on the assumption that such Swap had terminated at the end of such fiscal quarter, and in making such determination, if any agreement relating to such Swap provides for the netting of amounts payable by and to such Person thereunder or if any such agreement provides for the simultaneous payment of amounts by and to such Person, then in each such case, the amount of such obligation shall be the net amount so determined. For purposes of this Agreement, any such interest rate swap, currency swap or other similar obligation which is or will be entered into and is being or will be used by such Person in the ordinary course of its business to hedge an existing or future risk or exposure of such Person in respect of its liabilities or assets (and not for speculative purposes) shall not be deemed a "Swap" for purposes of this definition.

Transfer -- means, with respect to the Company or any Subsidiary, any transaction in which such Person sells, conveys, transfers or leases (as lessor) any of its property. The verb "Transfer" has the meaning correlative to the meaning of the noun.

Voting Stock -- means capital stock or other equity interests or capital of any class or classes of a corporation, partnership, association or other business entity, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the directors (or Persons performing similar functions) of such entity (including, without limitation, capital stock and other equity interests of a Subsidiary).

Schedule B-11


Wholly-Owned Subsidiary -- means, at any time, any Subsidiary 100% of all of the equity interests (except directors' qualifying shares and other equity holdings (not in excess of 1% of such equity interests) required to comply with foreign local ownership requirements and the like) and voting interests of which are owned by any one or more of the Company and other Wholly-Owned Subsidiaries at such time.

Schedule B-12


SCHEDULE C
Wiring Instructions at Closing

To: National City Bank
Cleveland, Ohio
ABA No.: 041000124
Credit: Invacare Corporation
Account No.: 3307008
Contact: Ms. Terri L. Cable
Phone: (216) 575-3354


SCHEDULE 4.9

Changes in Corporate Structure

The Company through its wholly owned Subsidiary, Inva Acquisition Corp. was a party to a merger with Suburban Ostomy Supply Co., Inc. in January 1998. The Articles of Merger were filed with the State of Massachusetts on January 28, 1998.

Schedule 4.9-1


SCHEDULE 5.3

Disclosure Materials

None

Schedule 5.3-1


SCHEDULE 5.4
Ownership of the Company; Affiliates

(i)      The Company's Subsidiaries:

                                                     Jurisdiction of                    % of Voting
Name of Subsidiary                                   Incorporation                      Stock Owned
- -------------------                                  -------------------               --------------
Action Benelux N.V.                                  Belgium                                     100%
Allied Medical Supply, Inc.                          Virginia                                    100%
Aplex Medical Supply, Inc.                           Texas                                       100%
Bencraft Limited                                     United Kingdom                              100%
Canyon Products Corporation                          Ohio                                        100%
Care Management Enterprises, Inc.                    Texas                                       100%
Controls Dynamic Limited                             United Kingdom                              100%
Dynamic Controls Limited                             New Zealand                                 100%
Fabriorto LDA                                        Portugal                                    100%
Frohock-Stewart Inc.                                 Massachusetts                               100%
Healthtech Products, Inc.                            Missouri                                    100%
I.H.H. Corp.                                         Delaware                                    100%
Inva Acquisition Corp.                               Massachusetts                               100%
Invacare AB                                          Sweden                                      100%
Invacare Australia Pty Ltd.                          Australia                                   100%
Invacare Canada Inc.                                 Ontario                                     100%
Invacare Credit Corporation                          Ohio                                        100%
Invacare (Deutschland) GmbH                          Germany                                     100%
Invacare Florida Corporation                         Delaware                                    100%
Invacare Holdings Corporation                        Ohio                                        100%
Invacare International Corporation                   Ohio                                        100%
Invacare New Zealand Limited                         New Zealand                                 100%
Invacare Respiratory Corp.                           Ohio                                        100%
Invacare Trading Company, Inc.                       Virgin Islands                              100%
Invacare (UK) Limited                                United Kingdom                              100%
Invamex, S.A. de C.V.                                Mexico                                      100%
Invatection Insurance Company, Inc.                  Vermont                                     100%
Kuschall Design AG                                   Switzerland                                 100%
Medical Equipment Repair Services Inc.               Florida                                     100%
Mobilife Corporation                                 Missouri                                    100%
Mobilite Building Corporation                        Florida                                     100%
Mobilite Corporation                                 Florida                                     100%
Option 5 Inc.                                        Quebec                                      100%
Patient-Care Medical Sales                           California                                  100%
Patient Solutions, Inc.                              Delaware                                    100%
Peiser's, Inc.                                       Illinois                                    100%
Poirier Groupe Invacare                              France                                      100%
POK - Rollstuhle GmbH                                Germany                                     100%
Production Research Corporation                      Maryland                                    100%

Schedule 5.4-1


                                  SCHEDULE 5.4
                                  (continued)

Quantrix Consultants Limited                         New Zealand                                 100%
Rehadap S.A.                                         Spain                                       100%
Rollerchair Pty Ltd.                                 Australia                                   100%
SCI Des Hautes Roches                                France                                      100%
SCI Des Roches                                       France                                      100%
Silcraft Corporation                                 Michigan                                    100%
St. Louis Ostomy Distributors, Inc.                  Missouri                                    100%
Suburban Ostomy Supply Co., Inc.                     Massachusetts                               100%

(ii) The Company's Affiliates, other than Subsidiaries: (The following persons beneficially own or hold, directly or indirectly, 10% or more of a class of voting or equity interests of the Company).

A. Malachi Mixon, III
One Invacare Way
Elyria, OH 44035

Joseph B. Richey, II
One Invacare Way
Elyria, OH 44035

Invacare Corporation Employees' Stock Bonus Trust and Plan
One Invacare Way
Elyria, OH 44035

(iii) The Company's directors and senior officers:

         Name                                        Title or Office
         ----                                        ---------------
A. Malachi Mixon, III                       Chairman of the Board, Chief Executive Officer
Frank B. Carr                               Director
Michael F. Delaney                          Director
Dr. Bernadine P. Healy                      Director
Francis J. Callahan, Jr.                    Director
Whitney Evans                               Director
Dan T. Moore, III                           Director
Joseph B. Richey, II                        Director,  President  of  Invacare  Technologies,  Senior Vice
                                            President of Total Quality Management
William M. Weber                            Director
Gerald B. Blouch                            Director, President, Chief Operating Officer
Thomas R. Miklich                           Chief Financial Officer, Treasurer, General Counsel, Secretary
Louis F. J. Slangen                         Senior Vice President, Sales and Marketing
Larry E. Steward                            Corporate Vice President of Human Resources

SCHEDULE 5.5
Financial Statements

Schedule 5.4-2


1. The consolidated balance sheet, statements of earnings, shareholders' equity and cash flows of the Company and its Subsidiaries as reported on Form 10-K and filed with the Securities and Exchange Commission for the fiscal years ended December 31, 1996, December 31, 1995, December 31, 1994, and December 31, 1993.

2. The interim consolidated balance sheet, statements of earnings and cash flows of the Company and its Subsidiaries as reported on Form 10-Q and filed with the Securities and Exchange Commission for the nine-month period ended September 30, 1997.


SCHEDULE 5.8
Certain Litigation

None

Schedule 5.8-1


Schedule 5.11 Licenses, Permits, etc.

None

Schedule 5.11-1


SCHEDULE 5.12(g)

Certain Pension Plans

The Company maintains an unfunded non-qualified defined benefit Supplemental Executive Retirement Plan (SERP) effective May 1, 1995, for certain key executives to recapture benefits lost due to governmental limitations on qualified plan contributions.

Schedule 5.12(g)-1


Schedule 5.14 Use of Proceeds; Margin Stock

The proceeds of the sale of the Notes will be used by the Company to repay certain Debt outstanding under that certain Loan Agreement dated as of November 18, 1997 among the Company, certain Borrowing Subsidiaries named therein, the Banks named therein, NBD Bank as Agent, and KeyBank National Association as Co-Agent on the date of Closing hereof; and for its general corporate purposes.

Schedule 5.14-1


                                  SCHEDULE 5.15
                              Existing Indebtedness



                        Description                                 Borrower                As of 12/31/97
                        -----------                                 --------                --------------
$25,000,000 senior notes at 7.45%, mature in  February 2003    Invacare Corporation          $21,429,000

Loan Agreement dated as of November 18, 1997 ($425,000,000     Invacare Corporation and      $147,231,000
multi-currency) expires October 31, 2002(1)                    Certain Borrowing             ($68,481,000 of which
                                                               Subsidiaries named therein    constitutes loans to
                                                                                             Borrowing Subsidiaries)

Notes Payable to banks and other third parties(2)              Poirier Groupe Invacare,      $3,346,000
                                                               Invacare Corporation

Notes and mortgages payable, secured by buildings and          Invacare Corporation,         $3,064,000
equipment(3)                                                   Mobilite Building
                                                               Corporation

Capitalized lease obligations(4)                               Invacare Corporation,         $2,466,000
                                                               Certain foreign and
                                                               domestic Subsidiaries

(1) In January 1998, the Company increased its Debt under the Loan Agreement by approximately $135,000,000 in conjunction with the Offer to Purchase for Cash All Outstanding Shares of Common Stock of Suburban Ostomy Supply Co., Inc.

(2) Remaining balance on certain term notes payable to various French banks which were created prior to and existed on the closing date of the Company's acquisition of Etablissements Poirier S.A., subsequently renamed, Poirier Groupe Invacare. Also includes the remaining balance on a Payment Plan Agreement between the Company and Oracle Corporation dated November 21, 1996.

(3) Remaining balance on certain Industrial Development Revenue Bonds dated December 28, 1983, which were purchased and are currently held by SunTrust Bank. Also includes remaining balance on a Mortgage Note between the Company and Penn Mutual Life Insurance Company dated March 1, 1989.

(4) The capital lease obligations are principally for certain manufacturing facilities and certain equipment with payments due through 2005.

Schedule 5.15-1


                                 Schedule 11.6
                                 Existing Liens



Debt                      Lender                 Property Subject to Lien                              As of 12/31/97
----                      ------                 ------------------------                              --------------
Industrial Development      SunTrust Bank            Mortgaged property located at 2101                    $866,000
Revenue Bonds                                        E. Lake Mary Blvd, Sanford, Florida
                                                     and     certain      assets
                                                     incorporated    into    the
                                                     Project  as defined in that
                                                     certain   Debt   and   Loan
                                                     Obligation  Agreement dated
                                                     as of December 28,
                                                     1983.

Mortgage Loan               Penn Mutual              Mortgaged property located at 39400                   $2,198,000
                                                     Taylor Parkway, North Ridgeville,
                                                     Ohio

Capital Lease Obligations   Hewlett Packard          Certain computer equipment located                    $439,000
                                                     at 1200 Taylor Street, Elyria, Ohio

Schedule 11.6-1


                                  SCHEDULE B-C
                                  Competitors



Company                               Location                         Ownership
- -------                               --------                         ---------
Sunrise Medical, Inc.                  Boulder, CO                        Public

Graham Field Health
Products Inc.                          Hauppage, NY                       Public

Nellcor Puritan Bennett
(Subsidiary of Mallinckrodt Inc.)      St. Louis, MO                      Public

Respironics, Inc.                      Pittsburgh, PA                     Public

Resmed, Inc.                           San Diego, CA                      Public

MEYRA                                  Germany                           Private

Schedule B-C-1


Schedule B-MT Management Team

A. Malachi Mixon, III - Chairman of the Board and Chief Executive Officer

Gerald B. Blouch - President and Chief Operating Officer

Thomas R. Miklich - Chief Financial Officer, Treasurer and General Counsel

Joseph B. Richey, II - President of Invacare Technologies and Senior Vice President of Total Quality Management

Louis F. J. Slangen - Senior Vice President, Sales and Marketing

Larry Steward - Corporate Vice President of Human Resources

Schedule B-MT-1


EXHIBIT 1A

[FORM OF SERIES A SENIOR NOTE]

INVACARE CORPORATION

6.71% SERIES A SENIOR NOTE DUE FEBRUARY 27, 2008

No. RA-___
PPN: 461203 A* 2
$
--------------- --------- ---,------

FOR VALUE RECEIVED, the undersigned, INVACARE CORPORATION, an Ohio corporation (herein called the "Company"), hereby promises to pay to ________ or registered assigns, the principal sum of ________ DOLLARS ($________) on February 27, 2008, with interest (computed on the basis of a 360-day year of twelve 30-day months) (a) on the unpaid balance thereof at a rate equal to 6.71% per annum from the date hereof, payable semiannually on August 27 and February 27 in each year, commencing with the later of August 27, 1998 and the payment date next succeeding the date hereof, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law on any overdue payment (including any overdue prepayment) of principal, any overdue payment of interest and any overdue payment of any Make-Whole Amount (as defined in the Note Purchase Agreements), payable semiannually as aforesaid (or, at the option of the registered holder hereof, on demand), at a rate per annum from time to time equal to the Series A Default Rate (as defined in the Note Purchase Agreements).

Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at Elyria, Ohio or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreements referred to below.

This Note is one of a series of Series A Senior Notes (herein called the "Notes") issued pursuant to separate Note Purchase Agreements, each dated as of February 27, 1998 (as from time to time amended, the "Note Purchase Agreements"), among the Company and the respective Purchasers named therein and is entitled to the benefits thereof. Each holder of this Note will be deemed, by its acceptance hereof, (i) to have agreed to the confidentiality provisions set forth in Section 21 of the Note Purchase Agreements and (ii) to have made the representation set forth in Section 6.2 of the Note Purchase Agreements.

This Note is a registered Note and, as provided in the Note Purchase Agreements, upon surrender of this Note for registration of transfer, duly endorsed, or accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder's attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in the name of, the transferee. Prior to due presentment for registration of transfer, the Company may treat the person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Company will not be affected by any notice to the contrary.

Exhibit 1A-1


This Note is subject to certain prepayments in the events, on the terms and in the manner and amounts as provided in the Note Purchase Agreements. This Note is also subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreements, but not otherwise.

If an Event of Default, as defined in the Note Purchase Agreements, occurs and is continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreements.

THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK, EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE.

INVACARE CORPORATION

By________________________________
Name:
Title:

Exhibit 1A-2


EXHIBIT 1B

[FORM OF SERIES B SENIOR NOTE]

INVACARE CORPORATION

6.60% SERIES B SENIOR NOTE DUE FEBRUARY 27, 2005

No. RB-___
PPN: 461203 A@ 0
$-------- -------- --, ----

FOR VALUE RECEIVED, the undersigned, INVACARE CORPORATION, an Ohio corporation (herein called the "Company"), hereby promises to pay to ________ or registered assigns, the principal sum of ________ DOLLARS ($________) on February 27, 2005, with interest (computed on the basis of a 360-day year of twelve 30-day months) (a) on the unpaid balance thereof at a rate equal to 6.60% per annum from the date hereof, payable semiannually on August 27 and February 27 in each year, commencing with the later of August 27, 1998 and the payment date next succeeding the date hereof, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law on any overdue payment (including any overdue prepayment) of principal, any overdue payment of interest and any overdue payment of any Make-Whole Amount (as defined in the Note Purchase Agreements), payable semiannually as aforesaid (or, at the option of the registered holder hereof, on demand), at a rate per annum from time to time equal to the Series B Default Rate (as defined in the Note Purchase Agreements).

Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at Elyria, Ohio or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreements referred to below.

This Note is one of a series of Series B Senior Notes (herein called the "Notes") issued pursuant to separate Note Purchase Agreements, each dated as of February 27, 1998 (as from time to time amended, the "Note Purchase Agreements"), among the Company and the respective Purchasers named therein and is entitled to the benefits thereof. Each holder of this Note will be deemed, by its acceptance hereof, (i) to have agreed to the confidentiality provisions set forth in Section 21 of the Note Purchase Agreements and (ii) to have made the representation set forth in Section 6.2 of the Note Purchase Agreements.

This Note is a registered Note and, as provided in the Note Purchase Agreements, upon surrender of this Note for registration of transfer, duly endorsed, or accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder's attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in the name of, the transferee. Prior to due presentment for registration of transfer, the Company may treat the person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Company will not be affected by any notice to the contrary.

Exhibit 1B-1


This Note is subject to certain prepayments in the events, on the terms and in the manner and amounts as provided in the Note Purchase Agreements. This Note is also subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreements, but not otherwise.

If an Event of Default, as defined in the Note Purchase Agreements, occurs and is continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreements.

THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK, EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE.

INVACARE CORPORATION

By________________________________
Name:
Title:

Exhibit 1B-2


EXHIBIT 4.4(a)

[Form of Closing Opinion of Counsel for the Company]

[Letterhead of Company's General Counsel]

Exhibit 4.4(a)-1


EXHIBIT 4.4(b)

[Form of Closing Opinion of Special Counsel for the Company]

[Letterhead of Company's Special Counsel]

Exhibit 4.4(b) - 1


Exhibit 10(g)

AMENDMENT NO. 1
to the
INVACARE CORPORATION 1994
PERFORMANCE PLAN

Invacare Corporation hereby adopts Amendment No. 1 to the Invacare Corporation 1994 Performance Plan (the "Plan") pursuant to the following terms and provisions:

1. Section 2(i) of the Plan is hereby deleted and restated in its entirety to read as follows:

"(i) "Committee" - means the Compensation Committee of the Board of Directors, or any other committee of the Board of Directors that the Board of Directors or the Compensation Committee authorizes to administer all or any aspect of this Plan."

2. Section 2 of the Plan is hereby amended by adding thereto the following additional paragraph as subsection (s) and by re-designating
Section 2(s) through Section 2(y) as Section 2(t) through Section 2(z) respectively:

"(s) "Performance Objectives" - means the achievement of performance objectives established pursuant to this Plan. Performance Objectives may be described in terms of Company-wide objectives or objectives that are related to the performance of the individual Participant or the subsidiary, division, department or function within the Company in respect of which the Participant performs services. Any Performance Objectives applicable to Awards intended to qualify as "performance-based compensation" under Section 162(m) of the Code (the "Performance-Based Exception") shall be limited to specified levels of or increases in the Company's, or subsidiary's, or division's, or department's, or function's return on equity, earnings per Common Share, total earnings, earnings growth, return on capital, operating measures (including, but not limited to, operating margin and operating costs) return on assets, or increase in the Fair Market Value of the Common Shares. Except in the case of such an Award intended to qualify under Section 162(m) of the Code, if the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company, or the manner in which it conducts its business, or other events or circumstances render the Performance Objectives unsuitable, the Committee may modify such Performance Objectives or the related minimum acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable.

The Committee shall have the discretion to adjust the determinations of the degree of attainment of the pre-established Performance Objectives; provided, however, that Awards which are designed to qualify for the Performance-Based Exception, may not be adjusted upward (the Committee shall retain the discretion to adjust such Awards downward).

In the event that applicable tax and/or securities laws change to permit Committee discretion to alter the governing performance measures without obtaining shareholder approval of such changes, the Committee shall have sole discretion to make such changes without obtaining shareholder approval. In addition, in the event that the Committee determines that it is advisable to grant Awards which shall not qualify for the Performance-Based Exception, the Committee may make such grants without satisfying the requirements of Code Section 162(m)."

3. Section 3 of the Plan is hereby deleted and restated in its entirety to read as follows: "All Directors and employees of the Company and its Affiliates are eligible for the grant of Awards. The selection of any such persons to receive Awards will be within the discretion of the Committee. More than one Award may be granted to the same person.

Notwithstanding the foregoing, any individual who renounces in writing any right that he or she may have to receive Awards under the Plan shall not be eligible to receive any Awards hereunder."

4. Section 4(a) of the Plan is hereby deleted and restated in its entirety to read as follows, subject to shareholder approval at the 1998 Annual Meeting of Shareholders:

1

"(a) Number of Common Shares. The aggregate number of Common Shares that may be subject to Awards, including Stock Options, granted under this Plan during the term of this Plan will be equal to Three Million, Five Hundred Thousand (3,500,000) Common Shares, subject to any adjustments made in accordance with the terms of this Section 4.

The assumption of obligations in respect of awards granted by an organization acquired by the Company, or the grant of Awards under this Plan in substitution for any such awards, will not reduce the number of Common Shares available in any fiscal year for the grant of Awards under this Plan.

Common Shares subject to an Award that is forfeited, terminated, or canceled without having been exercised (other than Common Shares subject to a Stock Option that is canceled upon the exercise of a related Stock Appreciation Right) will again be available for grant under this Plan, without reducing the number of Common Shares available in any fiscal year for grant of Awards under this Plan, except to the extent that the availability of those Common Shares would cause this Plan or any Awards granted under this Plan to fail to qualify for the exemption provided by Rule 16b-3. In addition, any Common Shares which are retained to satisfy a Participant's withholding tax obligations or which are transferred to the Company by a Participant to satisfy such obligations or to pay all or any portion of the exercise price of the Award in accordance with the terms of the Plan, the Award Agreement or the Notice of Award, may be made available for reoffering under the Plan to any Participant, except to the extent that the availability of those Common Shares would cause this Plan or any Awards granted under this Plan to fail to qualify for the exemption provided by Rule 16b-3."

5. Section 5(b) of the Plan is hereby deleted and restated in its entirety to read as follows:

"(b) Delegation. The Committee may delegate any of its authority to any other person or persons that it deems appropriate."

6. Section 6(b)(iii) of the Plan is hereby deleted and restated in its entirety to read as follows:

"(iii) Stock Option - means a right to purchase a specified number of Common Shares, during a specified period, and at a specified exercise price, all as determined by the Committee. A Stock Option may be an Incentive Stock Option or a Stock Option that does not qualify as an Incentive Stock Option. In addition to the terms, conditions, vesting periods, and restrictions established by the Committee, Incentive Stock Options must comply with the requirements of Section 422 of the Code and regulations promulgated thereunder, including the requirement that the aggregate Fair Market Value of the Common Shares with respect to which the Incentive Stock Option first becomes exercisable in any calendar year shall not exceed $100,000 (measured as of the effective date of the award of an Incentive Stock Option). The exercise price of a Stock Option that does not qualify as an Incentive Stock Option may be more or less than the Fair Market Value of the Common Shares on the date the Stock Option is granted."

7. Section 6(b)(iv) of the Plan is hereby deleted and restated in its entirety to read as follows:

"(iv) Cash Award - An award denominated in cash. All or part of any Cash Award may be subject to conditions established by the Committee, including but not limited to future service with the Company or the achievement of the Performance Objectives."

8. Section 6(c) of the Plan is hereby deleted and restated in its entirety to read as follows:

"(c) Limits on Awards. The maximum aggregate number of Common Shares (i) for which Stock Options may be granted, and (ii) with respect to which Stock Appreciation Rights may be granted, to any particular employee during any calendar year during the term of this Plan is 200,000 Common Shares, subject to adjustment in accordance with Section 4(c) hereof. The maximum aggregate amount of cash which may be granted or awarded to any particular employee during any calendar year during the term of this Plan is $500,000."

2

9. Section 12 of the Plan is hereby deleted and restated in its entirety to read as follows:

"In the event of a Change in Control of the Company, unless and to the extent otherwise determined by the Board of Directors, (i) all Stock Appreciation Rights and Stock Options then outstanding will become fully exercisable as of the date of the Change in Control; (ii) all restrictions and conditions applicable to Restricted Stock and other Stock Awards will be deemed to have been satisfied as of the date of the Change in Control, and (iii) all Cash Awards shall be released and/or deemed to have been fully earned as of the date of the Change in Control. Any such determination by the Board of Directors that is made after the occurrence of a Change in Control will not be effective unless a majority of the Directors then in office are Continuing Directors and the determination is approved by a majority of the Continuing Directors."

10. Section 15 of the Plan is hereby deleted and restated in its entirety to read as follows:

"Unless otherwise determined by the Committee, (i) no Award granted under the Plan may be transferred or assigned by the Participant to whom it is granted other than by will, pursuant to the laws of descent and distribution, and (ii) an Award granted under this Plan may be exercised, during the Participant's lifetime, only by the Participant."

IN WITNESS WHEREOF, Invacare Corporation, by its appropriate officers duly authorized, has executed this instrument as of the 30th day of January, 1998.

INVACARE CORPORATION

By:   /S/ A. Malachi Mixon, III
     -----------------------------------------------------
A. Malachi Mixon, III, Chairman of the Board,  President and
Chief Executive Officer




By:  /S/ Thomas R. Miklich
    ------------------------------------------------------
Thomas R. Miklich, Chief Financial Officer, General Counsel,
Treasurer and Corporate Secretary

3

Exhibit 10(t)

INVACARE CORPORATION

DEFERRED COMPENSATION PLUS PLAN

(Effective January 1, 2005)


INVACARE CORPORATION
DEFERRED COMPENSATION PLUS PLAN
(Effective January 1, 2005)

                                Table of Contents



                                                                            Page


ARTICLE I. INTRODUCTION........................................................1
-----------------------
   1.2.     Name of Plan.......................................................1
   ----     -------------
   1.3.     Purposes of Plan...................................................1
   ----     -----------------
   1.4.     "Top Hat" Pension Benefit Plan.....................................1
   ----     -------------------------------
   1.5.     Plan Unfunded......................................................1
   ----     --------------
   1.6.     Effective Date and Restatement Date................................1
   ----     ------------------------------------
   1.7.     Administration.....................................................1
   ----     ---------------

ARTICLE II. DEFINITIONS AND CONSTRUCTION.......................................2
----------------------------------------
   2.1.     Definitions........................................................2
   ----     ------------
   2.2.     Number and Gender..................................................5
   ----     ------------------
   2.3.     Headings...........................................................6
   ----     ---------

ARTICLE III. PARTICIPATION AND ELIGIBILITY.....................................7
------------------------------------------
   3.1.     Participation......................................................7
   ----     --------------
   3.2.     Commencement of Participation......................................7
   ----     ------------------------------
   3.3.     Cessation of Active Participation..................................7
   ----     ----------------------------------

ARTICLE IV. CONTRIBUTIONS AND VESTING..........................................8
-------------------------------------
   4.1.     Deferrals by Participants..........................................8
   ----     --------------------------
   4.2.     Effective Date of Participation and Deferral Election Form.........8
   ----     -----------------------------------------------------------
   4.3.     Modification or Revocation of Election by Participant..............9
   ----     ------------------------------------------------------
   4.4.     Matching Contributions.............................................9
   ----     -----------------------
   4.5.     Make Whole Contributions...........................................9
   ----     -------------------------
   4.6.     Discretionary Contributions........................................9
   ----     ----------------------------
   4.7.     Suspension of Contributions........................................9
   ----     ----------------------------
   4.8.     Transfer of Contributions to 401(k) Plan...........................9
   ----     -----------------------------------------
   4.9.     Vesting...........................................................10
   ----     --------

ARTICLE V. ACCOUNTS...........................................................11
-------------------
   5.1.     Establishment of Bookkeeping Accounts.............................11
   ----     --------------------------------------
   5.2.     Subaccounts.......................................................11
   ----     ------------
   5.3.     Earnings Elections................................................11
   ----     -------------------
   5.4.     Hypothetical Accounts and Creditor Status of Participants.........12
   ----     ----------------------------------------------------------
   5.5.     Investments.......................................................12
   ----     ------------

                                       ii

ARTICLE VI. PAYMENT OF ACCOUNT................................................13
------------------------------
   6.1.     Timing of Distribution of Accounts................................13
   ----     -----------------------------------
   6.2.     Adjustment for Investment Gains and Losses Upon a Distribution....13
   ----     ---------------------------------------------------------------
   6.3.     Form of Payment...................................................13
   ----     ----------------
   6.4.     Change in Date or Form of Distribution............................14
   ----     ---------------------------------------
   6.5.     Protective Distributions..........................................14
   ----     -------------------------
   6.6.     Designation of Beneficiaries......................................14
   ----     -----------------------------
   6.7.     Change of Beneficiary Designation.................................15
   ----     ----------------------------------
   6.8.     Change in Marital Status..........................................15
   ----     -------------------------
   6.9.     No Beneficiary Designation........................................15
   ----     ---------------------------
   6.10.    Unclaimed Benefits................................................16
   -----    -------------------
   6.11.    Withdrawals for Unforeseeable Emergency...........................16
   -----    ----------------------------------------
   6.12.    Withholding.......................................................16
   -----    ------------

ARTICLE VII. ADMINISTRATION...................................................17
---------------------------
   7.1.     Committee.........................................................17
   ----     ----------
   7.2.     General Powers of Administration..................................17
   ----     ---------------------------------
   7.3.     Indemnification of Committee......................................18
   ----     -----------------------------

ARTICLE VIII. DETERMINATION OF BENEFITS, CLAIMS PROCEDURE AND ADMINISTRATION..19
----------------------------------------------------------------------------
   8.1.     Claims............................................................19
   ----     -------
   8.2.     Claim Decision....................................................19
   ----     ---------------
   8.3.     Request for Review of a Denied Claim..............................20
   ----     -------------------------------------
   8.4.     Review of Decision................................................20
   ----     -------------------
   8.5.     Discretionary Authority...........................................21
   ----     ------------------------

ARTICLE IX. AMENDMENT AND TERMINATION.........................................22
-------------------------------------
   9.1.     Power to Amend or Terminate.......................................22
   ----     ----------------------------
   9.2.     Distribution Upon Plan Termination................................22
   ----     -----------------------------------
   9.3.     Protective Amendments Due to Change in Law........................22
   ----     -------------------------------------------

ARTICLE X. MISCELLANEOUS......................................................24
------------------------
   10.1.    Plan Not a Contract of Employment.................................24
   -----    ----------------------------------
   10.2.    Non-Assignability of Benefits.....................................24
   -----    ------------------------------
   10.3.    Severability......................................................24
   -----    -------------
   10.4.    Governing Laws....................................................24
   -----    ---------------
   10.5.    Binding Effect....................................................24
   -----    ---------------
   10.6.    Entire Agreement..................................................24
   -----    -----------------
   10.7.    No Guaranty of Tax Consequences...................................25
   -----    --------------------------------

                                      iii

                              INVACARE CORPORATION
                         DEFERRED COMPENSATION PLUS PLAN
                           (Effective January 1, 2005)

ARTICLE I.
INTRODUCTION

1.2. Name of Plan.

Invacare Corporation (the "Company") hereby adopts the Invacare Corporation Deferred Compensation Plus Plan (the "Plan").

1.3. Purposes of Plan.

The purposes of the Plan are to provide deferred compensation for a select group of management or highly compensated Employees of the Company and to provide eligible Employees the opportunity to maximize their elective contributions to the Invacare Retirement Savings Plan (the "401(k) Plan") notwithstanding certain limitations in the Code.

1.4. "Top Hat" Pension Benefit Plan.

The Plan is an "employee pension benefit plan" within the meaning of ERISA
Section 3(2). The Plan is maintained, however, for a select group of management or highly compensated employees and, therefore, is exempt from Parts 2, 3 and 4 of Title 1 of ERISA. The Plan is not intended to qualify under Code Section 401(a).

1.5. Plan Unfunded.

The Plan is unfunded. All benefits will be paid from the general assets of the Company, which will continue to be subject to the claims of the Company's creditors. No amounts will be set aside for the benefit of Plan Participants or their Beneficiaries.

1.6. Effective Date and Restatement Date.

The Plan is effective as of the Effective Date.

1.7. Administration.

The Plan shall be administered by the Committee or its delegates, as set forth in Section 7.1.

1

ARTICLE II.
DEFINITIONS AND CONSTRUCTION

2.1. Definitions.

For purposes of the Plan, the following words and phrases shall have the respective meanings set forth below, unless their context clearly requires a different meaning:

(a) "Account" means the bookkeeping account or accounts maintained by the Company to reflect the Participant's Base Salary Deferrals, Bonus Deferrals, Matching Contributions, Discretionary Contributions, Profit Sharing Contributions and IQC Contributions, together with all earnings, gains and losses thereon. Accounts shall be further denominated as Retirement Accounts or In-Service Distribution Accounts.

(b) "Base Salary" means the base rate of cash compensation, including commissions, paid by the Company to or for the benefit of a Participant for services rendered or labor performed while a Participant, including base pay a Participant could have received in cash in lieu of (A) deferrals pursuant to Section 4.1 and (B) contributions made on his behalf to any qualified plan maintained by the Company or to any cafeteria plan under Section 125 of the Code maintained by the Company.

(c) "Base Salary Deferral" means the amount of a Participant's Base Salary which the Participant elects to have withheld on a pre-tax basis and credited to his Account pursuant to Section 4.1.

(d) "Beneficiary" means the person or persons designated by the Participant in accordance with Section 6.6 or, in the absence of an effective designation, the person or entity described in Section 6.9.

(e) "Board" means the Board of Directors of the Company.

(f) "Bonus Compensation" means the amount awarded to a Participant for a Plan Year under any bonus arrangement maintained by the Company.

(g) "Bonus Deferral" means the amount of a Participant's Bonus Compensation which the Participant elects to have withheld on a pre-tax basis and credited to his Account pursuant to Section 4.1.

(h) "Change In Control" means the happening of any of the following events:

(i) Any person or entity (other than any employee benefit plan or employee stock ownership plan of Invacare Corporation, or any person or entity organized, appointed, or established by Invacare

2

Corporation, for or pursuant to the terms of any such plan), alone or together with any of its Affiliates or Associates, becomes the Beneficial Owner of thirty percent (30%) or more of the total outstanding voting power of Invacare Corporation, as reflected by the power to vote in connection with the election of directors, or commences or publicly announces an intent to commence a tender offer or exchange offer the consummation of which would result in the Person becoming the Beneficial Owner of thirty percent (30%) or more of the total outstanding voting power of Invacare Corporation as reflected by the power to vote in connection with the election of directors. For purposes of this Section 2.1(h)(i), the terms "Affiliates," "Associates," and "Beneficial Owner" will have the meanings given them in the Rights Agreement, dated as of April 2, 1991, between Invacare Corporation and National City Bank, as Rights Agent, as amended from time to time.

(ii) At any time during a period of twenty-four (24) consecutive months, individuals who were directors at the beginning of the period no longer constitute a majority of the members of the Board, unless the election, or the nomination for election by the Invacare Corporation's shareholders, of each director who was not a director at the beginning of the period is approved by at least a majority of the directors who are in office at the time of the election or nomination and were either directors at the beginning of the period or are continuing directors.

(iii)A record date is established for determining shareholders entitled to vote upon:

(A) A merger or consolidation of the Invacare Corporation with another corporation (which is not an affiliate of Invacare Corporation) in which Invacare Corporation is not the surviving or continuing company or in which all or part of the outstanding common shares are to be converted into or exchanged for cash, securities, or other property;

(B) a sale or other disposition of all or substantially all of the assets of Invacare Corporation; or

(C) the dissolution or liquidation (but not partial liquidation) of Invacare Corporation.

(i) "Code" means the Internal Revenue Code of 1986, as amended.

(j) "Committee" means the administrative committee named to administer the Plan pursuant to Section 7.1.

3

(k) "Company" means Invacare Corporation and any successor thereto.

(l) "Deferral Period" means the period of time for which a Participant elects to defer receipt of the Base Salary Deferrals and Bonus Deferrals credited to such Participant's Account.

(m) "Directors" means the Board of Directors of the Company.

(n) "Disability" means that a Participant (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than 3 months under an accident and health plan covering employees of the Company.

(o) "Discretionary Contribution" means the Company's contribution, if any, made pursuant to Section 4.6.

(p) "Effective Date" means January 1, 2005, except where a different date is specifically set forth.

(q) "Employee" means any common-law employee of the Company.

(r) "ERISA" means the Employee Retirement Income Security Act of 1974, as amended.

(s) "401(k) Plan" means the Invacare Retirement Savings Plan, as in effect on January 1, 2005, and as amended from time to time thereafter.

(t) "In-Service Distribution Accounts" means an Account(s) to which a Participant's Base Salary Deferrals and Bonus Deferrals are credited pursuant to the terms of the Plan and the election of a Participant. Each of a Participant's In-Service Distribution Accounts is distributable in a future calendar year which is not less than two (2) years following the deferral of compensation into the Plan and which is selected by the Participant pursuant to Section 4.2 hereof. A Participant may have up to two (2) In-Service Distribution Accounts under the Plan at any one time.

(u) "Contribution" or "IQC" means the amount, if any, of non-elective non-matching contribution made by the Company under the 401(k) Plan for a Plan Year.

(v) "Make Whole IQC Contribution" means a contribution equal to the Invacare Quarterly Contribution that would have been made to the
401(k) Plan for a Participant but for the limitation on compensation contained in Code Section 401(a)(17).

(w) "Matching Contribution" means the amount, as determined by the Company on an annual basis, that would be credited to the Participant's Base

4

Salary Deferrals and Bonus Deferrals if such deferrals had been deferred by the Participant into the 401(k) Plan, and which is credited by the Company to the Retirement Account of each Participant based on such Participant's Base Salary and Bonus Deferrals.

(x) "Participant" means each Employee who has been selected for participation in the Plan and who has become a Participant pursuant to Article III.

(y) "Participation and Deferral Election Form" means the written agreement pursuant to which the Participant elects the amount of his Base Salary and/or his Bonus Compensation to be deferred pursuant to the Plan, the Account to which such deferrals are to be credited, the Deferral Period, if applicable, the deemed investment of amounts deferred and the time and form of payment of such amounts and such other matters as the Committee shall determine from time to time.

(z) "Plan" means the Invacare Corporation Deferred Compensation Plus Plan, as in effect on the Effective Date, and as amended from time to time hereafter.

(aa) "Plan Year" means the twelve-consecutive month period commencing January 1 of each year ending on the following December 31.

(bb) "Profit Sharing Contribution" means the amount credited to a Participant's Account under the Invacare Corporation 401(k) Benefit Equalization Plus Plan prior to December 31, 2004 and which is transferred to the Participant's Retirement Account under this Plan on or after the Effective Date.

(cc) "Retirement" means a Participant's termination of employment after either (I) the attainment of age fifty-five (55) and completion of ten
(10) or more Years of Service, or (II) the attainment of age sixty-five (65).

(dd) "Retirement Account" means an Account to which Base Salary Deferrals and Bonus Deferrals are credited pursuant to the terms of the Plan and the election of a Participant. A Participant's Retirement Account shall also be credited with any Matching Contributions, Make Whole IQC Contributions, Profit Sharing Contributions and Discretionary Contributions creditable to a Participant under the terms of the Plan. A Participant's Retirement Account is generally payable upon his Retirement.

(ee) "Valuation Date" means each business day and each special valuation date designated by the Committee.

(ff) "Years of Service" shall have the same meaning as in the 401(k) Plan.

2.2. Number and Gender.

Wherever appropriate herein, words used in the singular shall be considered to include the plural and words used in the plural shall be considered to include the singular. The masculine gender, where appearing in the Plan, shall be deemed to include the feminine gender.

5

2.3. Headings.

The headings of Articles and Sections herein are included solely for convenience, and if there is any conflict between such headings and the rest of the Plan, the text shall control.

6

ARTICLE III.
PARTICIPATION AND ELIGIBILITY

3.1. Participation.

Participants in the Plan are those Employees who are (a) subject to the income tax laws of the United States, (b) members of a select group of highly compensated or management Employees of the Company, and (c) selected by the Committee or its delegates, in its sole discretion, as Participants. The Committee shall notify each Participant of his selection as a Participant. An Employee who satisfies the eligibility requirements set forth in subsections (a) and (b) shall remain eligible to continue participation in the Plan for each Plan Year following his selection by the Committee as a Participant.

3.2. Commencement of Participation.

Except as provided in the following sentence, an Employee shall become a Participant effective as of the first day of the Plan Year following the date on which his Participation and Deferral Election Form becomes effective. A newly hired Employee who completes a Participation and Deferral Election Form within 30 days of the date on which he is selected by the Committee to be eligible to participate shall become a Participant as of the date on which his Participation and Deferral Election Form becomes effective under Section 4.2.

3.3. Cessation of Active Participation.

Notwithstanding any provision herein to the contrary, an individual who has become a Participant in the Plan shall cease to be a Participant hereunder effective as of any date designated by the Committee. Any such Committee action shall be communicated to such Participant prior to the effective date of such action.

7

ARTICLE IV.
CONTRIBUTIONS AND VESTING

4.1. Deferrals by Participants.

Before the first day of each calendar year, a Participant may file with the Committee a Participation and Deferral Election Form pursuant to which such Participant elects to make Base Salary Deferrals. A Participant must file a Participation and Deferral Election form to make Bonus Deferrals at a time prescribed by the Committee which time shall be not later than six (6) months before the end of the 12 month period over which the services upon which the Bonus Compensation is based are performed. A Participant shall be entitled to defer a whole percent of his Base Salary or Bonus Compensation, subject to a maximum deferral of fifty percent (50%) of Base Salary and one hundred percent (100%) of Bonus Compensation. Deferral elections shall be subject to any other rules prescribed by the Committee in its sole discretion.

At the time a Participant completes a Participation and Deferral Election Form, he shall elect to have his Base Salary Deferrals and Bonus Deferrals credited to a Retirement Account or a In-Service Distribution Account. An election to have amounts credited to a In-Service Distribution Account shall specify the calendar year in which payment of such amount shall be made or shall commence to be made. In the event a Participant does not elect a Deferral Period for any Base Salary Deferrals or Bonus Deferrals for a Plan Year, such Participant shall be deemed to have elected to have such amounts credited to a In-Service Distribution Account with a Deferral Period of five (5) years.

Base Salary Deferrals will be credited to the Account of each Participant as soon as practicable following each pay date, if and to the extent that the Participant earned such Base Salary as an Employee for such pay date. Bonus Deferrals will be credited to the Account of each Participant not later than the last day of the month in which such Bonus Compensation otherwise would have been paid to the Participant in cash, provided that the Participant is an Employee at the time such Bonus Compensation would have been paid. A Participant whose employment terminates prior to or during the calendar month in which his Bonus Compensation would have been paid to him in cash will be paid his Bonus Deferral in cash. Such termination of employment shall not affect Base Salary Deferrals and Bonus Deferrals previously credited to the Account of the affected Participant.

4.2. Effective Date of Participation and Deferral Election Form.

Except as provided below with respect to a new Participant, a Participant's Participation and Deferral Election Form shall become effective on the first day of the Plan Year to which it relates. The Participation and Deferral Election Form of an Employee who first becomes eligible to participate in the Plan during a Plan Year shall become effective with respect to services to be performed subsequent to the election which shall be made within thirty (30) days after the date the Employee first becomes eligible to participate in the Plan. If an Employee fails to timely complete a Participation and Deferral Election Form,

8

the Employee shall be deemed to have elected not to make Base Salary Deferrals and/or Bonus Deferrals for such Plan Year.

4.3. Modification or Revocation of Election by Participant.

A Participant may not prospectively change the amount of his Base Salary Deferrals or Bonus Deferrals during a Plan Year unless the Committee determines that he has suffered an unforeseeable emergency as is more fully described in
Section 6.11. Unless required or permitted by law, under no circumstances may a Participant's Participation and Deferral Election Form be made, modified or revoked retroactively.

4.4. Matching Contributions.

Each Participant who elects to make Base Salary Deferrals and/or Bonus Deferrals to the Plan and who has completed at least six (6) months of service will receive a Matching Contribution equal to a certain percentage of the sum of Participant's Base Salary Deferrals and Bonus Deferrals. The Matching Contribution percentage to be contributed to the Plan shall be equal to the matching contribution percentage provided under the 401(k) Plan. Matching Contributions will be credited to the Participant's Retirement Account as of the day on which the Base Salary Deferrals and/or Bonus Deferrals to which the Matching Contributions relate are credited to the Participant's Account.

4.5. Make Whole IQC Contributions.

For each calendar quarter, the Retirement Account of each eligible Participant shall be credited with the Make Whole IQC Contribution, if any, to which he is entitled under Section 2.1(v).

4.6. Discretionary Contributions.

For each Plan Year, the Retirement Account of each eligible Participant shall be credited with such Discretionary Contribution, if any, as is determined by the Company for such Plan Year.

4.7. Suspension of Contributions.

Anything contained herein to the contrary notwithstanding, a Participant who receives a distribution from the Plan due to an unforeseeable emergency shall not be eligible to make deferrals hereunder for a six (6) month period after receipt of such distribution. If required by the terms of the 401(k) Plan, a Participant who receives a hardship distribution under the 401(k) Plan shall not be eligible to make deferrals under this Plan for a six (6) month period after receipt of the hardship distribution.

4.8. Transfer of Contributions to 401(k) Plan.

As soon as practicable following the end of each Plan Year, but in no event later than March 15 of the Plan Year following the Plan Year for which the Participant executed the relevant Participation and Deferral Election Form, the lesser of:

9

(i) the allowable pre-tax contribution which may be made on behalf of the Participant to the 401(k) Plan for the Plan Year for which the Participant executed the Participation and Deferral Election Form, and

(ii) the sum of the Base Salary Deferral and the Bonus Deferral for the Plan Year for which the Participant executed the Participation and Deferral Election Form,

shall be paid directly to the Participant as compensation earned in the Plan Year for which the Participant executed the Participation and Deferral Election Form, unless the Participant previously elected (in both the Participation and Deferral Election Form and his 401(k) Plan elections) to have such amount contributed to the 401(k) Plan as an elective pre-tax contribution.

If the Participant elected to have such amount contributed to the 401(k) Plan as an elective pre-tax contribution, such amount together with an amount equal to the applicable Matching Contributions shall be transferred directly to the Participant's account(s) in the 401(k) Plan and the appropriate Accounts and subaccounts of the Participant under the Plan shall be charged accordingly. Notwithstanding the preceding, the Plan shall not make distributions to the Participant or the 401(k) Plan in excess of the Participant's Account balance. Distributions pursuant to this Section 4.8 may be made in one or more installments in the sole discretion of the Committee.

4.9. Vesting.

A Participant shall be 100% vested at all times in that portion of his Account which is attributable to Base Salary Deferrals and Bonus Deferrals. Matching Contributions, Make Whole IQC Contributions, Profit Sharing Contributions and Discretionary Contributions shall vest in accordance with the vesting schedule contained in the 401(k) Plan. Notwithstanding the foregoing, if permitted by the Secretary of the Treasury in regulations or rulings, all Matching Contributions, Make Whole IQC Contributions, Profit Sharing Contributions and Discretionary Contributions shall be 100% vested immediately upon a Change in Control. Any provisions of the Plan relating to the distribution of a Participant's Account shall mean only the vested portion of such Account. Since the Plan is unfunded, the portion of a Participant's Account which is not vested and therefore not distributed with the vested portion of his Account shall remain property of the Company and shall not be allocated to the Accounts of other Participants or otherwise inure to their benefit.

10

ARTICLE V.
ACCOUNTS

5.1. Establishment of Bookkeeping Accounts.

A separate bookkeeping Account or Accounts shall be maintained for each Participant. Such Account(s) shall be credited with the Base Salary Deferrals and Bonus Deferrals made by the Participant pursuant to Section 4.1, Matching Contributions made by the Company pursuant to Section 4.4, Make Whole IQC Contributions made pursuant to Section 4.5, Discretionary Contributions made pursuant to Section 4.6 and any unvested amounts held under the Invacare Corporation 401(k) Plus Benefit Equalization Plan prior to January 1, 2005 and transferred to this Plan, credited (or charged, as the case may be) with the hypothetical investment results determined pursuant to Section 5.3, and charged with distributions made to or with respect to a Participant.

5.2. Subaccounts.

Within each Participant's bookkeeping Account, separate subaccounts shall be maintained to the extent necessary or desirable for the administration of the Plan. In particular, separate bookkeeping accounts shall be maintained for distributions to be made upon a Participant's Retirement and for distributions to be made upon attainment of the future calendar year distribution dates selected by the Participant.

5.3. Earnings Elections.

Amounts credited to a Participant's Account shall be credited or charged with earnings and losses based on hypothetical investments elected by the Participant. A Participant may elect different investment allocations for new contributions and existing Account balances. Only whole percentages may be elected, the minimum percentage for any allocation is 1%, and the total elections must allocate 100% of all new contributions and 100% of all existing Account balances. Investment elections may be changed daily, by written direction. The hypothetical investment alternatives and the procedures relating to the election of such investments, other than those set forth in this Section 5.3, shall be determined by the Committee from time to time. A Participant's Account shall be adjusted as of each Valuation Date to reflect investment gains and losses.

Notwithstanding the foregoing provisions of this Section 5.3, if investment in Invacare Stock is permitted hereunder, the Company in its sole discretion, shall have the authority to place such restrictions upon the investment directions of any person who is subject to Section 16(b) of the Securities Exchange Act of 1934 as amended ("Insider") as shall be appropriate to comply with such section. Such restrictions shall include, but shall not be limited to the following: Insiders shall be permitted to submit investment directions relating to Invacare Stock only on a "semi-annual date" which is no less than six (6) months after the date of the most recent investment direction received from such Insider relating to Invacare Stock. For purposes of this Section 5.3, the term "semi-annual date" shall mean a date which is within the period that begins the third business day following the date on which the Company's first

11

fiscal quarter and third fiscal quarter summary statements of sales and earnings shall be released and which ends on the twelfth business day following such release date.

5.4. Hypothetical Accounts and Creditor Status of Participants.

The Accounts established under this Article V shall be hypothetical in nature and shall be maintained for bookkeeping purposes only, so that Base Salary Deferrals, Bonus Deferrals, Matching Contributions, Discretionary Contributions, Make Whole IQC Contributions and Profit Sharing Contributions can be credited to the Participant and so that earnings and losses on such amounts so credited can be credited (or charged, as the case may be). Neither the Plan nor any of the Accounts (or subaccounts) shall hold any actual funds or assets. The right of any person to receive one or more payments under the Plan shall be an unsecured claim against the general assets of the Company. Any liability of the Company to any Participant, former Participant, or Beneficiary with respect to a right to payment shall be based solely upon contractual obligations created by the Plan. Neither the Company, the Board, nor any other person shall be deemed to be a trustee of any amounts to be paid under the Plan. Nothing contained in the Plan, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship, between the Company and a Participant, former Participant, Beneficiary, or any other person.

5.5. Investments.

The Company may, in its sole discretion, acquire insurance policies, annuities or other financial vehicles for the purpose of providing future assets to the Company to meet its anticipated liabilities under the Plan. Such policies, annuities, or other investments, shall at all times be and remain unrestricted general property and assets of the Company or property of a trust established pursuant to this Plan. Participants and Beneficiaries shall have no rights, other than as general creditors, with respect to any such policies, annuities or other acquired assets.

12

ARTICLE VI.
PAYMENT OF ACCOUNT

6.1. Timing of Distribution of Accounts.

Distribution of a Participant's Retirement Account shall be made or shall commence to be made as soon as practicable following the Participant's Retirement. Distribution of a Participant's In-Service Distribution Accounts shall be made or shall commence to be made as soon as practicable following the expiration of the Deferral Period selected by the Participant for such Accounts. Notwithstanding the foregoing, the Participant's entire Account shall be distributed to him (or his Beneficiary in the event of his death) as soon as practicable following the earliest to occur of the following:

(i) the Participant's death;

(ii) the Participant's disability; or

(iii) the Participant's separation from service.

In the event of distribution upon separation from service (for reasons other than disability, death or Change in Control), actual payment of the Participant's Accounts shall not occur until six (6) months after the date of separation from service, if the Participant is a "key employee" (as defined under Internal Revenue Code Section 416(i) without regard to paragraph (5) thereof), and the Company's stock is publicly traded on an established securities market or otherwise.

6.2. Adjustment for Investment Gains and Losses Upon a Distribution.

Upon a distributable event described in Section 6.1, the balance of a Participant's Account shall be determined as of the Valuation Date immediately following such event.

6.3. Form of Payment.

Except as provided below, a Participant's Retirement Account shall be paid in one of the following forms as elected by the Participant:

(a) A lump sum amount which is equal to the applicable Account balance; or

(b) Substantially equal annual installments amortized over a period of years not to exceed fifteen (15) years. Gains and losses on the unpaid balance shall continue to be credited or charged to the Account in accordance with the provisions of Section 5.3. The amount of the

13

installments payable may be changed annually to reflect investment results.

Except as provided below, a Participant's In-Service Distribution Accounts shall be paid in one of the following forms as elected by the Participant:

(a) A lump sum amount which is equal to the applicable Account balance; or

(b) Substantially equal annual installments amortized over a period of years not to exceed five (5) years. Gains and losses on the unpaid balance shall continue to be credited or charged to the Account in accordance with the provisions of Section 5.3. The amount of the installments payable may be changed annually to reflect investment results.

The form elected by a Participant with respect to his Retirement Account and/or his In-Service Distribution Account(s) shall apply to each such entire Account.

Notwithstanding the form elected, if a Participant incurs a separation from service prior to his Retirement, disability, or death or if the Participant's total Account value is not more than Ten Thousand Dollars ($10,000) on the last Valuation Date prior to the commencement of distribution, the benefit shall be paid in a single lump sum as soon as practicable following his separation from service.

6.4. Change in Date or Form of Distribution.

A Participant's election with respect to the date or form of distribution may be revised at the Committee's sole discretion, provided that the revised election does not accelerate the distribution of his Account. Any revision to the date or form of payment shall be made at least 12 months prior to the original distribution date and any new payment commencement date must be at least five (5) years after the original commencement date.

6.5. Protective Distributions.

If the Administrator determines, in its sole discretion, that a Participant is not, or may not be, a member of a "select group of management or highly compensated employees" within the meaning of Section 201(2), 301(a)(3), 401(a)(1) or 4021(b)(6) of ERISA, then the Administrator may, in its sole discretion, terminate the Participant's participation in the Plan. In such event, if permitted by law and regulations, the Administrator may distribute all amounts credited to the Participant's Accounts in a single lump sum payment at such time as the Administrator shall determine in its sole discretion.

6.6. Designation of Beneficiaries.

Each Participant shall have the right, at any time, to designate one (1) or more persons or an entity as Beneficiary (both primary as well as secondary) to whom benefits under this Plan shall be paid in the event of a Participant's death prior to complete distribution of the Participant's Account. Each

14

Beneficiary designation shall be in a written form prescribed by the Committee and will be effective only when filed with the Committee during the Participant's lifetime. Designation by a married Participant of a Beneficiary other than the Participant's spouse shall not be effective unless the spouse executes a written consent that acknowledges the effect of the designation and is witnessed by a notary public, or the consent cannot be obtained because the spouse cannot be located.

6.7. Change of Beneficiary Designation.

Except as provided below, any nonspousal designation of Beneficiary may be changed by a Participant without the consent of such Beneficiary by the filing of a new designation with the Committee. The filing of a new designation shall cancel all designations previously filed.

6.8. Change in Marital Status.

If the Participant's marital status changes after the Participant has designated a Beneficiary, the following shall apply:

(a) If the Participant is married at death but was unmarried when the designation was made, the designation shall be void unless the spouse has consented to it in the manner prescribed above.

(b) If the Participant is unmarried at death but was married when the designation was made:

(i) The designation shall be void if the spouse was named as Beneficiary. The designation shall remain valid if a nonspouse Beneficiary was named.

(ii) If the Participant was married when the designation was made and is married to a different spouse at death, the designation shall be void unless the new spouse has consented to it in the manner prescribed above.

6.9. No Beneficiary Designation.

If any Participant fails to designate a Beneficiary in the manner provided above, or if the Beneficiary designated by a deceased Participant dies before the Participant or before complete distribution of the Participant's benefits, the Participant's Beneficiary shall be the person in the first of the following classes in which there is a survivor:

(a) The Participant's surviving spouse;

(b) The Participant's children in equal shares, except that if any of the children predeceases the Participant but leaves issue surviving, then such issue shall take by right of representation the share the parent would have taken if living;

15

(c) The Participant's parents;

(d) The Participant's estate.

6.10. Unclaimed Benefits.

In the case of a benefit payable on behalf of a Participant, if the Committee is unable to locate the Participant or Beneficiary to whom such benefit is payable, such benefit may be forfeited to the Company, upon the Committee's determination. Notwithstanding the foregoing, if subsequent to any such forfeiture the Participant or Beneficiary to whom such benefit is payable makes a valid claim for such benefit, such forfeited benefit shall be paid by the Company or restored to the Plan by the Company.

6.11. Withdrawals for Unforeseeable Emergency.

A Participant may apply in writing to the Committee for, and the Committee may permit, a withdrawal of all or any part of a Participant's Account derived from Base Salary and Bonus Deferrals if the Committee, in its sole discretion, determines that the Participant has incurred an unforeseeable emergency resulting from a sudden and unexpected illness or accident of the Participant or of a dependent (as defined in section 152(a) of the Code) of the Participant, loss of the Participant's property due to casualty, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. The amount that may be withdrawn shall be limited to the amount reasonably necessary to relieve the emergency upon which the request is based, plus the federal and state taxes due on the withdrawal, as determined by the Committee. The Committee may require a Participant who requests a withdrawal on account of an unforeseeable emergency to submit such evidence as the Committee, in its sole discretion, deems necessary or appropriate to substantiate the circumstances upon which the request is based.

6.12. Withholding.

All deferrals and distributions shall be subject to legally required income and employment tax withholding.

16

ARTICLE VII.
ADMINISTRATION

7.1. Committee.

The Plan shall be administered by a Committee, which shall include the Senior Vice President of Human Resources and the Chief Financial Officer. The Committee shall be responsible for the general operation and administration of the Plan and for carrying out the provisions thereof. The Committee may delegate to others certain aspects of the management and operational responsibilities of the Plan including the employment of advisors and the delegation of ministerial duties to qualified individuals, provided that such delegation is in writing. No member of the Committee who is a Participant shall participate in any matter relating to his status as a Participant or his rights or entitlement to benefits as a Participant.

7.2. General Powers of Administration.

The Committee shall be the Plan Administrator under ERISA. The Administrator will be responsible for the general administration of the Plan and will have all powers as may be necessary to carry out the provisions of the Plan and may, from time to time, establish rules for the administration of the Plan and the transaction of the Plan's business. In addition to any powers, rights and duties set forth elsewhere in this Plan, it will have the following powers and duties:

(a) To enact rules, regulations, and procedures and to prescribe the use of such forms as it deems advisable;

(b) To appoint or employ agents, attorneys, actuaries, accountants, assistants or other persons (who may also be Participants in this Plan or be employed by or represent the Company) at the expense of the Company, as it deems necessary to keep its records or to assist it in taking any other action authorized or required under the Plan;

(c) To interpret the Plan, and to resolve ambiguities, inconsistencies and omissions, to determine any question of fact, to determine the right to benefits of, and the amount of benefits, if any, payable to, any person in accordance with the provisions of the Plan and resolve all questions arising under the Plan;

(d) To administer the Plan in accordance with its terms and any rules and regulations it establishes; and

(e) To maintain records concerning the Plan as it deems sufficient to prepare reports, returns and other information required by the Plan or by law; and

17

(f) To direct the Company to pay benefits under the Plan, and to give other directions and instructions as may be necessary for the proper administration of the Plan.

Any decision, interpretation or other action made or taken by the Administrator arising out of or in connection with the Plan, will be within the absolute discretion of the Administrator, and will be final, binding and conclusive on the Company, and all Participants and Beneficiaries and their respective heirs, executors, administrators, successors and assigns. The Administrator's determinations under the Plan need not be uniform, and may be made selectively among Participants, whether or not they are similarly situated.

7.3. Indemnification of Committee.

The Company shall indemnify the members of the Committee against any and all claims, losses, damages, expenses, including attorney's fees, incurred by them, and any liability, including any amounts paid in settlement with their approval, arising from their action or failure to act, except when the same is judicially determined to be attributable to their gross negligence or willful misconduct.

18

ARTICLE VIII.
DETERMINATION OF BENEFITS, CLAIMS PROCEDURE AND ADMINISTRATION

8.1. Claims.

A Participant, Beneficiary or other person who believes that he or she is being denied a benefit to which he or she is entitled (hereinafter referred to as "Claimant"), or his or her duly authorized representative, may file a written request for such benefit with the Committee setting forth his or her claim. The request must be addressed to the Committee at the Company at its then principal place of business.

8.2. Claim Decision.

Upon receipt of a claim, the Committee shall advise the Claimant that a reply will be forthcoming within a reasonable period of time, but ordinarily not later than ninety days, and shall, in fact, deliver such reply within such period. However, the Committee may extend the reply period for an additional ninety days for reasonable cause. If the reply period will be extended, the Committee shall advise the Claimant in writing during the initial 90-day period indicating the special circumstances requiring an extension and the date by which the Committee expects to render the benefit determination.

If the claim is denied in whole or in part, the Committee will render a written opinion, using language calculated to be understood by the Claimant, setting forth:

(a) the specific reason or reasons for the denial;

(b) the specific references to pertinent Plan provisions on which the denial is based;

(c) a description of any additional material or information necessary for the Claimant to perfect the claim and an explanation as to why such material or such information is necessary;

(d) appropriate information as to the steps to be taken if the Claimant wishes to submit the claim for review, including a statement of the Claimant's right to bring a civil action under
Section 502(a) of ERISA following an adverse benefit determination on review; and

(e) the time limits for requesting a review of the denial under
Section 8.3 and for the actual review of the denial under Section 8.4.

If no notice is provided, the claim will be deemed denied. The interpretations, determinations and decisions of the Administrator will be final and binding upon all persons with respect to any right, benefit and privilege hereunder, subject to the review procedures set forth in this Article.

19

8.3. Request for Review of a Denied Claim.

Within sixty days after the receipt by the Claimant of the written opinion described above, the Claimant may request in writing that the Senior Vice President of Human Resources of the Company ("Executive Officer") review the Committee's prior determination. Such request must be addressed to the Executive Officer at the Company at its then principal place of business. The Claimant or his or her duly authorized representative may submit written comments, documents, records or other information relating to the denied claim, which information shall be considered in the review under this Section without regard to whether such information was submitted or considered in the initial benefit determination.

The Claimant or his or her duly authorized representative shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information which (i) was relied upon by the Committee in making its initial claims decision, (ii) was submitted, considered or generated in the course of the Committee making its initial claims decision, without regard to whether such instrument was actually relied upon by the Committee in making its decision or (iii) demonstrates compliance by the Committee with its administrative processes and safeguards designed to ensure and to verify that benefit claims determinations are made in accordance with governing Plan documents and that, where appropriate, the Plan provisions have been applied consistently with respect to similarly situated claimants. If the Claimant does not request a review of the Committee's determination within such 60-day period, he or she shall be barred and estopped from challenging such determination.

8.4. Review of Decision.

Within a reasonable period of time, ordinarily not later than sixty days, after the Executive Officer's receipt of a request for review, it will review the Committee's prior determination. If special circumstances require that the sixty-day time period be extended, the Executive Officer will so notify the Claimant within the initial 60-day period indicating the special circumstances requiring an extension and the date by which the Executive Officer expects to render its decision on review, which shall be as soon as possible but not later than 120 days after receipt of the request for review. In the event that the Executive Officer extends the determination period on review due to a Claimant's failure to submit information necessary to decide a claim, the period for making the benefit determination on review shall not take into account the period beginning on the date on which notification of extension is sent to the Claimant and ending on the date on which the Claimant responds to the request for additional information.

Benefits under the Plan will be paid only if the Executive Officer decides in its discretion that the Claimant is entitled to such benefits. The decision of the Executive Officer shall be final and non-reviewable, unless found to be arbitrary and capricious by a court of competent review. Such decision will be binding upon the Company and the Claimant.

If the Executive Officer makes an adverse benefit determination on review, the Executive Officer will render a written opinion, using language calculated to be understood by the Claimant, setting forth:

20

(a) the specific reason or reasons for the denial;

(b) the specific references to pertinent Plan provisions on which the denial is based;

(c) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information which (i) was relied upon by the Executive Officer in making its decision, (ii) was submitted, considered or generated in the course of the Executive Officer making its decision, without regard to whether such instrument was actually relied upon by the Executive Officer in making its decision or (iii) demonstrates compliance by the Executive Officer with its administrative processes and safeguards designed to ensure and to verify that benefit claims determinations are made in accordance with governing Plan documents, and that, where appropriate, the Plan provisions have been applied consistently with respect to similarly situated claimants; and

(d) a statement of the Claimant's right to bring a civil action under
Section 502(a) of ERISA following the adverse benefit determination on such review.

8.5. Discretionary Authority.

The Committee and Executive Officer shall both have discretionary authority to determine a Claimant's entitlement to benefits upon his claim or his request for review of a denied claim, respectively.

21

ARTICLE IX.
AMENDMENT AND TERMINATION

9.1. Power to Amend or Terminate.

The Company reserves the right, by action of its Board in its sole discretion, to retroactively or prospectively amend, modify or terminate this Plan at any time.

9.2. Distribution Upon Plan Termination.

In the event that the Plan is terminated and distribution is permitted by law or regulation, the balance in a Participant's Account shall be paid to such Participant or his Beneficiary in a lump sum or in equal monthly installments over the following period, unless the Committee determines otherwise:

Account Balance                                  Payout Period

$50,000 or less                                  Lump Sum

More than $50,000 but less than $250,000         3 Years

$250,000 or more                                 5 Years

Gains and losses shall continue to be credited or charged to the Account in accordance with the provisions of Section 5.3. The Company reserves the right to pay each Account in a lump sum, notwithstanding the above schedule.

9.3. Protective Amendments Due to Change in Law.

(a) Change in Tax Laws. Without limiting the generality of the amendment and termination provisions in Section 9.1, the Company may, by action of its Board in its sole discretion, unilaterally amend, modify or terminate the Plan, retroactively or prospectively, to address or reflect changes in the actual or anticipated federal, state or local income or payroll tax consequences (or any other tax consequences) affecting either the Company, or any Participant or Beneficiary, including without limitation, those due to any of the following:

(i) the enactment or amendment of any federal, state or local tax or revenue law;

(ii) the promulgation or publication of any regulation, ruling or similar announcement by the Secretary of the Treasury Department, the Internal Revenue Service or any other relevant federal, state or local tax authority;

22

(iii)a decision by a court of competent jurisdiction involving a Participant or Beneficiary;

(iv) a closing agreement made under Code Section 7121 that is approved by the Internal Revenue Service and involves a Participant, or any similar agreement involving any state or local tax authority; or

(v) any similar type of change or any alteration in the expectations of the Company regarding the income or payroll tax impacts of the Plan.

Any such amendment or modification should be consistent, as determined by the Company in its sole discretion, with the changes in tax consequences and may include the transfer of unanticipated tax burdens to Participants and Beneficiaries.

(b) Change in Securities Laws. Without limiting the generality of the amendment and termination provisions in Section 9.3, the -------------------------- Company may, by action of its Board in its sole discretion, unilaterally amend, modify or terminate the Plan, retroactively or prospectively, to address or reflect changes in the securities laws or changes in the expectations of the Company regarding the application of securities laws to the Plan or the Company with regard to the Plan. Any such amendment, modification or termination should be consistent, as determined by the Company in its sole discretion, with the changes in the actual or anticipated securities law impacts of the Plan and may include limiting the rights of individuals to make deferrals, refunding deferred amounts, distributing Accounts or allowing Participants to rescind deferral elections.

23

ARTICLE X.
MISCELLANEOUS

10.1. Plan Not a Contract of Employment.

The adoption and maintenance of the Plan shall not be or be deemed to be a contract between the Company and any person or to be consideration for the employment of any person. Nothing herein contained shall give or be deemed to give any person the right to be retained in the employ of the Company or to restrict the right of the Company to discharge any person at any time; nor shall the Plan give or be deemed to give the Company the right to require any person to remain in the employ of the Company or to restrict any person's right to terminate his employment at any time.

10.2. Non-Assignability of Benefits.

No Participant, Beneficiary or distributee of benefits under the Plan shall have any power or right to transfer, assign, anticipate, hypothecate or otherwise encumber any part or all of the amounts payable hereunder, which are expressly declared to be unassignable and non-transferable. Any such attempted assignment or transfer shall be void. No amount payable hereunder shall, prior to actual payment thereof, be subject to seizure by any creditor of any such Participant, Beneficiary or other distributee for the payment of any debt, judgment, or other obligation, by a proceeding at law or in equity, nor transferable by operation of law in the event of the bankruptcy, insolvency or death of such Participant, Beneficiary or other distributee hereunder.

10.3. Severability.

If any provision of this Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining provisions hereof; instead, each provision shall be fully severable and the Plan shall be construed and enforced as if said illegal or invalid provision had never been included herein.

10.4. Governing Laws.

All provisions of the Plan shall be construed in accordance with the internal laws (but not the choice of laws) of Ohio, except to the extent preempted by federal law.

10.5. Binding Effect.

This Plan shall be binding on each Participant and his heirs and legal representatives and on the Company and its successors and assigns.

10.6. Entire Agreement.

This document and any amendments contain all the terms and provisions of the Plan and shall constitute the entire Plan, any other alleged terms or provisions being of no effect.

24

10.7. No Guaranty of Tax Consequences.

While the Company has established, and will maintain, the Plan, the Company makes no representation, warranty, commitment, or guaranty concerning the income, employment, or other tax consequences of participation in the Plan under federal, state, or local law.

25

IN WITNESS WHEREOF, the Company has caused this Plan to be executed on this 28th day of December, 2004.

INVACARE CORPORATION

By /s/ Gregory C. Thompson
   _____________________________

And /s/ Joseph Usaj
   _____________________________

26

Exhibit 10(u)

INVACARE CORPORATION

DEATH BENEFIT ONLY PLAN

Effective: January 1, 2005


DEATH BENEFIT ONLY PLAN

                  THIS PLAN is adopted by INVACARE  CORPORATION,  an Ohio
corporation  (hereinafter  referred to as the "Company");

                                               W I T N E S S E T H:
                                               - - - - - - - - - -

                  WHEREAS, certain of the Company's key executives previously

have participated in Company-sponsored life insurance programs which is being terminated by the Company; and

WHEREAS, the Company desires to provide all or certain of such key executives with a plan providing only death benefits effective as of January 1, 2005, provided that such key executives satisfy the conditions for participation as determined by the Company in its sole and absolute discretion; and

WHEREAS, the Board of Directors of the Company has approved the establishment of this Plan.

NOW, THEREFORE, effective as of January 1, 2005, the Company hereby adopts the Invacare Corporation Death Benefit Only Plan, as follows:

ARTICLE I

DEFINITIONS

1.1 Affiliate. The word "affiliate" shall mean any corporation or business organization during any period during which it is a member of a controlled group of corporations or trades or businesses which includes the Company within the meaning of Sections 414(b) and 414(c) of the Internal Revenue Code.

1.2 Beneficiary. The word "beneficiary" shall mean any person who receives or is designated to receive payment of a benefit under the terms of this Plan on the death of a participant.

1.3 Bonus Plan. The words "Bonus Plan" shall mean the Management Incentive Plan of Invacare Corporation, as in effect on the date hereof and as it may be amended from time to time hereafter.

1.4 Committee. The word "Committee" shall mean chief financial officer, and the Company's Human Resources officer or director.

2

1.5 Company. The word "Company" shall mean Invacare Corporation, an Ohio corporation, or any successor corporation or other business organization which shall assume the obligations of the Company under this Plan as provided herein with respect to the participants and their beneficiaries.

1.6 Director. The word "Director" shall mean a member of the Company's Board of Directors.

1.7 Earnings. The word "Earnings" shall mean the Participant's annual base salary in effect on the immediately preceding April 1st or on the date of the Termination of Service of a Participant, if the Termination of Service occurs on April 1st, plus the Participant's Target Bonus.

1.8 Effective Date. The words "Effective Date" of this Plan shall mean January 1, 2005.

                  1.9      Employee.  The  word  "Employee"  shall  mean an
                           --------
individual  who  receives  salary  for personal services rendered to the
Company.

                  1.10     Final  Earnings.  The  words  "Final  Earnings"
                           ---------------

shall mean the Participant's highest annual Earnings in effect for each of the three years ending on his Termination of Service.

1.11 Normal Retirement Date. The words "Normal Retirement Date" shall mean the date the Participant attains age 65.

1.12 Participant. The word "Participant" shall mean any person who becomes a participant in this Plan and remains a participant in this Plan in accordance with Article II hereof. A participant shall cease to be a participant upon the occurrence of an event described in Section 2.4 hereof.

1.13 Plan. The word "Plan" shall mean Invacare Corporation Death Benefit Only Plan as set forth herein and as amended from time to time hereafter.

1.14 Plan Administrator. The words "Plan Administrator" shall mean the Committee.

1.15 Target Bonus. The words "Target Bonus" shall mean the annual base salary in effect on the immediately preceding April 1st or on the date of the Termination of Service of a Participant, if Termination of Service occurs on April 1st, times the Target Bonus percentage in effect on that same date under the Company's Bonus Plan.

1.16 Termination of Service. The words "Termination of Service" shall mean the Participant ceasing employment with the Company for any reason whatsoever whether voluntarily or involuntarily, including by reasons of retirement, death, or disability.

3

ARTICLE II

ELIGIBILITY AND PARTICIPATION

2.1 Eligibility to Participate. An Employee shall be qualified to become a participant under this Plan at such time as he is designated eligible to participate in the Plan by the Committee. The Committee shall notify an eligible Employee in writing of his eligibility and of the actions necessary to become a participant hereunder, and shall provide him with the opportunity to become a participant. Such Employee shall, within such time as the Committee shall determine:

(a)                                furnish to the Committee all information
                                   requested by it;

(b)                                execute such documents and such instruments
                                   as the Committee may require to facilitate
                                   the administration of this Plan;

(c)                                agree in such form and manner as the
                                   Committee may require to be bound by the
                                   terms of this Plan and by the terms of such
                                   Amendments as may be made hereto; and

(d)                                truthfully and fully answer any questions and
                                   supply any information which the Committee
                                   deems necessary or desirable for the proper
                                   administration of this Plan, without any
                                   reservations whatsoever.

                  2.2 Date of Participation. An eligible Employee who shall have

timely done all acts required of him to become a participant shall become a participant on or as of such date as shall be specified by the Committee.

2.3 Cessation of Participation. A participant shall cease his participation under this Plan in the event of the termination of this Plan pursuant to Section 6.1.

2.4 Participation in Other Death Benefit Plans. By becoming a Participant in this Plan, the Participant agrees to limit his coverage under the Group Life Insurance Plan, and all other group life insurance plans provided by the Company whether currently or in the future to $50,000. Any Participant in this Plan may still participate in any accidental death and dismemberment plan offered by the Company.

ARTICLE III

DEATH BENEFITS

4

3.1 Death During Employment. If a Participant's death occurs while he/she is in the employ of the Company and prior to his Normal Retirement Date, his beneficiary shall receive a death benefit equal to three (3) times the Participant's Earnings.

3.2 Post-Termination Death Benefit. A death benefit equal to one (1) times Final Earnings shall be payable on behalf of a Participant whose death occurs subsequent to either his Normal Retirement Date or his Termination of Employment.

3.3 Beneficiary Designation. A participant shall designate a beneficiary or beneficiaries to receive any amount due under this Article III by executing a written notice thereof to the Committee at any time prior to his death and may revoke or change the beneficiary designated therein without the consent of any person previously designated as beneficiary by written notice delivered to the Committee at any time and from time to time prior to his death. If a participant shall have failed to designate a beneficiary, or if no designated beneficiary shall survive him, then such amount shall be paid to his spouse, if his spouse survives him, or, if his spouse doesn't survive him, to the executor or administrator of his estate for distribution as part of his estate.

3.4 Restriction on Payment. Notwithstanding anything contained in this Plan to the contrary, no payment shall be made to the beneficiaries of a Participant under this Plan in the event that, within one year of the date of the Participant's participation in the Plan, the Participant dies by suicide, whether sane or insane.

ARTICLE IV

FINANCING OF BENEFITS

4.1 Funding. The undertakings of the Company herein constitute merely the unsecured promise of the Company to provide the benefits set forth herein. No property of the Company is or shall, by reason of this Plan, be held in trust for a participant, any designated beneficiary or any other person, and neither the participant nor any designated beneficiary nor any other person shall have, by reason of this Plan, any rights, title or interest of any kind in or to any property of the Company.

5

ARTICLE V

ADMINISTRATION

5.1 Rights and Duties of Committee. The Committee shall be responsible for the general administration of this Plan and shall have all such powers as may be necessary to carry out the provisions of this Plan and may, from time to time, establish rules for the administration of this Plan and the transaction of this Plan's business. The Committee shall have the following powers and duties:

(a)                                 To enact such rules, regulations, and
                                    procedures and to prescribe the use of such
                                    forms as it shall deem advisable.

(b)                                 To appoint or employ such agents, attorneys,
                                    actuaries, and assistants at the expense of
                                    the Company, as it may deem necessary to
                                    keep its records or to assist it in taking
                                    any other action.

(c)                                 To interpret this Plan, and to resolve
                                    ambiguities, inconsistencies, and omissions,
                                    to determine any question of fact, to
                                    determine the right to benefits of, and
                                    amount of benefits, if any, payable to, any
                                    person in accordance with the provisions of
                                    this Plan.

                   5.2 Claims Denial. If any beneficiary or the authorized

representative of a beneficiary shall file an application for benefits hereunder and such application is denied by the Committee, in whole or in part, he shall be notified in writing of the specific reason or reasons for such denial. The notice shall also set forth the specific Plan provisions upon which the denial is based, an explanation of the provisions of Section 6.3 hereof, and any other information deemed necessary or advisable by the Committee.

5.3 Review of Benefit Denial. Any beneficiary or any authorized representative of a beneficiary whose application for benefits hereunder has been denied, in whole or in part, by the Committee may, upon written notice to the Committee, request a review by the Board of Directors of the Company of such denial of his application. Such review may be made by written briefs submitted by the applicant and the Committee or at a hearing, or by both, as shall be deemed necessary by the Committee. If the applicant requests a hearing, the Board of Directors shall appoint from its members an Appeal Examiner to conduct such hearing. Any hearing conducted by an Appeal Examiner shall be held in such location as shall be reasonably convenient to the applicant. The date and time of any such hearing shall be designated by the Appeal Examiner upon not less than seven (7) days' notice to the applicant and the Committee unless both of them accept shorter notice. The Appeal Examiner shall make every effort to schedule the hearing on a day and at a time which is convenient to both the applicant and the Committee. If the applicant does not

6

request a hearing, the Board of Directors may review the denial of such benefits or may appoint an Appeal Examiner to review the denial. After the review has been completed, the Board of Directors or the Appeal Examiner shall render a decision in writing, a copy of which shall be sent to both the applicant and the Committee. In rendering its decision, the Board of Directors and the Appeal Examiner shall have full power and discretion to interpret this Plan, to resolve ambiguities, inconsistencies and omissions, to determine any question of fact, to determine the right to benefits of the applicant in accordance with the provisions of this Plan. Such decision shall set forth the specific reason or reasons for the decision and the specific Plan provisions upon which the decision is based and, if the decision is made by an Appeal Examiner, the rights of the applicant or the Committee to request a review by the entire Board of Directors of the decision of the Appeal Examiner. Either the applicant or the Committee may request a review of an adverse decision of the Appeal Examiner by filing a written request with the Board of Directors within thirty (30) days after they receive a copy of the Appeal Examiner's decision. The review of a decision of an Appeal Examiner shall be based solely on the written record and shall be conducted in accordance with the procedures of this Section 6.3. Except as provided in Section 6.4 hereof, there shall be no further appeal from a decision rendered by a quorum of the Board of Directors.

5.4 Exclusive Remedy. The interpretations, determinations and decisions of the Committee, Appeal Examiner and Board of Directors shall, except to the extent provided in Section 6.3 hereof and in this Section 6.4, be final and binding upon all persons with respect to any right, benefit and privilege hereunder. The review procedures of said Section 6.3 shall be the sole and exclusive remedy and shall be in lieu of all actions at law, in equity, pursuant to arbitration or otherwise.

5.5 Limitation of Duties. The Company, Committee, Appeal Examiner, Board of Directors, and their respective officers, members, employees and agents shall have no duty or responsibility under this Plan other than the duties and responsibilities expressly assigned to them herein or delegated to them pursuant hereto. None of them shall have any duty or responsibility with respect to the duties or responsibilities assigned or delegated to another of them.

5.6 No Personal Liability. The Committee, Board of Directors, Appeal Examiner, and their respective officers, employees, members and agents shall incur no personal liability of any nature whatsoever in connection with any act done or omitted to be done in the administration of this Plan. The Company shall indemnify, defend, and hold harmless the Committee, Board of Directors, Appeal Examiner, and their respective officers, employees, members and agents, for all acts taken or omitted in carrying out their responsibilities under the terms of this Plan. The Company shall indemnify such persons for expenses of defending an action by a participant, beneficiary, government entity, or other persons, including all legal fees and other costs of such defense. The Company will also reimburse such a person for any monetary recovery in a successful action against such person in any federal or state court or arbitration. In addition, if the claim is settled out of court with the concurrence of the Company, the Company shall indemnify such person for any monetary liability under said settlement.

7

ARTICLE VI

AMENDMENT AND TERMINATION

6.1 Power to Amend and Terminate. Subject to the provisions of
Section 7.2 hereof, this Plan may be amended by the Company (by action of the Committee) at any time, or from time to time, and may be terminated by the Company (also by action of the Committee) at any time, but no such amendment or termination will:

(a)                                deprive any beneficiary of a totally and
                                   permanently disabled participant of his right
                                   to receive death benefits as provided in
                                   Article III hereof, or reduce the amount of
                                   such death benefits, without his consent; or

(b)                                deprive any beneficiary of a participant who
                                   is a retired Employee of his right to receive
                                   death benefits as provided by Article III
                                   hereof, or reduce the amount of such death
                                   benefits, without his consent.

Any such amendment or termination may, however, reduce or eliminate the death benefits provided by Article III hereof with respect to any participant (and the designated beneficiary of such participant) who is an Employee at the date of such amendment or termination of this Plan.

ARTICLE VII

MISCELLANEOUS

7.1 No Guarantee of Employment. Neither anything contained herein, nor any acts done in pursuance of this Plan, shall be construed as entitling any participant to be retained as an Employee for any period of time nor as obliging the Company to retain any participant as an Employee for any period of time, nor shall any participant nor anyone else have any rights whatsoever, legal or equitable, against the Company as a result of this Plan except those expressly granted to him hereunder.

7.2 Taxes. The Company shall deduct from each Participant's compensation all applicable Federal or State taxes that may be required by law to be withheld resulting from the Company's funding of the benefits payable under the Plan.

7.3 Gross-Up Due to Taxable Income. The Company may, in its sole discretion, increase the Participant's compensation in an amount as

8

determined by the Company to provide additional compensation to the Participant to pay some or all of the income taxes on the taxable income referred to in
Section 7.2 above.

7.4 Construction Rules. Whenever any pronoun is used herein, it shall be construed to include the masculine pronoun, the feminine pronoun or the neuter pronoun as shall be appropriate.

7.5 Governing Law. This Plan shall be construed under and in accordance with and governed by the laws of the State of Ohio and the United States of America.

7.6 Savings Clause. In the event that any provisions or terms of this Plan, or any agreement or instrument required by the Committee hereunder, is determined by any judicial, quasi-judicial or administrative body to be void or not enforceable for any reason, all other provisions or terms of this Plan or such agreement or instrument shall remain in full force and effect and shall be enforceable as if such void or nonenforceable provision or term had never been a part of this Plan, or such agreement or instrument.

7.7 Non-Alienation. No benefits under this Plan shall be subject in any manner to be anticipated, alienated, sold, transferred, assigned, pledged, encumbered or charged, and any attempt to so anticipate, alienate, sell, transfer, assign, pledge, encumber or charge the same shall be void; nor shall any such benefits in any manner be liable for or subject to the debts, contracts, liabilities, engagements or torts of the person entitled to such benefits as are herein provided for him.

7.8 Satisfaction of Claims. Any payment to or for the benefit of any beneficiary, in accordance with the provisions of this Plan, shall to the extent thereof be in full satisfaction of all claims hereunder against this Plan, the Committee and the Company, any of whom may require such beneficiary, as a condition precedent to such payment, to execute a receipt and release therefor in such form as shall be determined by the Committee or the Company, as the case may be.

7.9 Payment to Third Party. If the Committee shall find that any person to whom any amount is payable under this Plan is unable to care for his affairs because of illness or accident, or is a minor, any payment due (unless a prior claim therefor shall have been made by a duly appointed guardian, committee or other legal representative) may be paid to the spouse, a child, a parent, or a brother or sister, or to any person deemed by the Committee to have incurred expense for such person otherwise entitled to payment, in such manner and proportions as the Committee may determine.

7.10 Successors and Assigns. The Company's obligations under this Plan shall be binding on the Company's successors and assigns.

9

IN WITNESS WHEREOF, INVACARE CORPORATION, by its duly authorized officers, has caused this Plan to be executed as of this 28th day of December, 2004.

INVACARE CORPORATION

("Company")

By /s/ Gregory C. Thompson
  ______________________________


Exhibit 10(v)

Rule 10b5-1 Sales Plan

I, A. Malachi Mixon, III, have, as of the date set forth below, established this Sales Plan (the "Plan") in order to sell Invacare Corporation (the "Issuer") common shares, no par value per share (the "Stock"), pursuant to the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

1. I elect to surrender Stock to the Issuer in order to satisfy the minimum tax withholding obligation required by federal, state and local governmental authorities (including such amount, if any, as may be required under the American Jobs Creation Act of 2004) with respect to the shares of stock I will receive on the respective maturity dates of the restricted stock grants and/or deferred option exercises as indicated on the Attachment A to the Plan.

2. On each respective maturity date set forth on Attachment A hereto the Issuer agrees to withhold such portion of the shares maturing on such date as is necessary to satisfy such minimum tax withholding obligation required by federal, state and local governmental authorities based on the rates in effect on the applicable maturity date at a price per share equal to the closing price of the Issuer Stock on the New York Stock Exchange on the applicable maturity date.

3. The Plan will terminate on the earliest of:

a. January 1, 2009;

b. the completion of the maturity of the Stock referenced in Section 1 of the Plan;

c. the Issuer's receipt of notice of my death or mental incapacity;

d. the Issuer's reasonable determination that: (i) the Plan does not comply with Rule 10b5-1 or other applicable securities laws; or (ii) I have not complied with the Plan, Rule 10b5-1 or other applicable securities laws;

e. the Issuer's receipt of written notice of termination from me by overnight service and facsimile certifying that I desire to terminate the Plan and have consulted with my legal advisors about the termination of the Plan;

f. the Issuer's receipt of notice from me by telephone or facsimile specifying that a legal, contractual or regulatory restriction applicable to me or my affiliates would prohibit any sale pursuant to the Plan or result in material adverse consequences to me as a result of any such sale, or

g. the public announcement of a public offering or other distribution of securities by the Issuer or of a merger, acquisition, tender or exchange offer, or other business combination resulting in the exchange or conversion of the Stock of the Issuer into shares of a company other than the Issuer.

4. In the event of a stock split, reverse stock split or stock dividend relating to the Stock, the dollar amount at which shares of Stock are to be surrendered to the Issuer and the number of shares to be surrendered will be automatically adjusted proportionately.

5. In the event of a reincorporation or other corporate reorganization resulting in an automatic share-for-share exchange of new shares for the type of shares of


Stock subject to the Plan, then the new shares will automatically replace the type of shares of Stock originally specified in the Plan.

6. The Plan may be modified or amended only upon the written agreement of myself and the Issuer.

7. The Plan may be signed in counterparts, each of which will be an original. I will not assign my rights or obligations under the Plan without the Issuer's consent.

8. The Plan, and the attached Representation Letter , dated the date hereof, constitutes the entire agreement and Plan between me and the Issuer and supersede any prior agreements or understandings regarding the Plan. The invalidity or unenforceability of any provision of the Plan will not affect the validity or enforceablity of any other provision.

9. All notices given by the parties under this Plan will be made in the manner specified in this Plan by telephone, facsimile or recognized overnight service as follows:

a. If to the Issuer:

Invacare Corporation Attn: Gregory C. Thompson One Invacare Way
Elyria, OH 44036
Tel: 440-329-6000 Fax: ( )

b. If to me:

A. Malachi Mixon, III
(One Invacare Way)

(Elyria, OH 44036)

(Tel: 440-329-6000)

(Fax: ( ))

10. This Plan will be governed by and construed in accordance with the laws of the State of Ohio, without giving effect to the conflict of law principles of that State.

The undersigned have signed this Sales Plan as of February 14, 2005.

/s/ A. Malachi Mixon, III
__________________________                     Invacare Corporation (the Issuer)

                                               By: /s/ Gregory C. Thompson
                                                   _______________________
                                                   Chief Financial Officer


Rule 10b5-1 Plan of: A. Malachi Mixon, III Executed on February 14, 2005

ATTACHMENT A

                                            Number of
Type of Grant             Maturity Date     Shares     Issuer   Type of Shares
-------------             -------------     ---------  -------  --------------

Deferred Option           March 22, 2005    66,374     Invacare    Common

Restricted Stock-R01001   May 1, 2005       2,917      Invacare    Common

Restricted Stock-R02001   May 1, 2005       3,176      Invacare    Common
Restricted Stock-R02001   May 1, 2006       3,175      Invacare    Common

Restricted Stock-R03001   May 1, 2005       3,671      Invacare    Common
Restricted Stock-R03001   May 1, 2006       3,671      Invacare    Common
Restricted Stock-R03001   May 1, 2007       3,670      Invacare    Common

Restricted Stock-R04001   May 1, 2005       2,628      Invacare    Common
Restricted Stock-R04001   May 1, 2006       2,628      Invacare    Common
Restricted Stock-R04001   May 1, 2007       2,627      Invacare    Common
Restricted Stock-R04001   May 1, 2008       2,627      Invacare    Common


Rule 10b5-1 Representation Letter

Invacare Corporation
Attn: Gregory C. Thompson
One Invacare Way
Elyria, OH 44036

Ladies and Gentlemen:

In consideration of Invacare Corporation ("Invacare") agreeing to accept the surrender of Invacare shares from the restricted stock or deferred options maturing in order to satisfy my minimum tax withholding obligation for federal, state and local taxes under a written plan (the "Plan") that I, A. Malachi Mixon, III, have established to meet the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and other good and valuable consideration I make the following representations, warranties and covenants:

1. A true and accurate copy of the Plan is attached.

2. I am entering into the Plan in good faith, in compliance with the requirements of Rule 10b5-1, and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or other federal securities laws. As of the date hereof, I am not aware of any material nonpublic information about Invacare (the "Issuer") or its securities.

3. I have consulted with my own advisors as to the legal, tax, business, and financial aspects of, and have not relied on Invacare in connection with, my adoption and implementation of the Plan and I have confirmed that the Plan meets the criteria set forth in Rule 10b5-1. I acknowledge that Invacare Corporation is not acting as a fiduciary or an advisor for me.

4. I have been granted all restricted shares and all deferred options that are subject to the Plan free and clear of liens, encumbrances, options or other limitation on disposition of any kind.

5. While the Plan is in effect, I agree that:

a. I will not enter into or alter any corresponding or hedging transaction or position with respect to the securities covered by the Plan (including, without limitation, with respect to any securities convertible or exchangeable into those securities) and I will not alter or deviate from the terms of the Plan; and

b. I will notify Invacare in advance of any sales or purchases of, or derivative transactions on, any of the Issuer's securities that I propose to make.

6. Except as provided under the terms of the Plan, I further agree that I will not exercise any subsequent influence over how, when or whether transactions are effected under the plan.

7. I agree to make or cause to be made in a timely manner all necessary filings applicable to me, including Rule 144 filings, filings pursuant to Sections 13 and 16 of the Exchange Act, and any other filings necessary pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the Exchange Act.


8. The execution and delivery of the Plan by me and the transactions contemplated by the Plan will not contravene any provision of applicable law or any agreement or other instrument binding on me or any of my affiliates or any judgment, order or decree of any governmental body having jurisdiction over me or my affiliates.

9. I agree to give Invacare notice as soon as possible of (a) any subsequent legal, contractual or regulatory restrictions imposed on me due to changes in the securities (or other) laws, contractual restrictions, or anticipated or changed events, that would prevent Invacare or me from complying with the Plan and (b) the occurrence of any event that could cause the Plan to terminate or be suspended under
Section 2 or Section 3 of the Plan.

Very truly yours,

/s/ A. Malachi Mixon, III
__________________________
Name:  A. Malachi Mixon, III
Date:  2/21/05


Exhibit 10(w)

Rule 10b5-1 Sales Plan

I, Gerald B. Blouch, have, as of the date set forth below, established this Sales Plan (the "Plan") in order to sell Invacare Corporation (the "Issuer") common shares, no par value per share (the "Stock"), pursuant to the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

1. I elect to surrender Stock to the Issuer in order to satisfy the minimum tax withholding obligation required by federal, state and local governmental authorities (including such amount, if any, as may be required under the American Jobs Creation Act of 2004) with respect to the shares of stock I will receive on the respective maturity dates of the restricted stock grants and/or deferred option exercises as indicated on the Attachment A to the Plan.

2. On each respective maturity date set forth on Attachment A hereto the Issuer agrees to withhold such portion of the shares maturing on such date as is necessary to satisfy such minimum tax withholding obligation required by federal, state and local governmental authorities based on the rates in effect on the applicable maturity date at a price per share equal to the closing price of the Issuer Stock on the New York Stock Exchange on the applicable maturity date.

3. The Plan will terminate on the earliest of:

a. January 1, 2009;

b. the completion of the maturity of the Stock referenced in Section 1 of the Plan;

c. the Issuer's receipt of notice of my death or mental incapacity;

d. the Issuer's reasonable determination that: (i) the Plan does not comply with Rule 10b5-1 or other applicable securities laws; or (ii) I have not complied with the Plan, Rule 10b5-1 or other applicable securities laws;

e. the Issuer's receipt of written notice of termination from me by overnight service and facsimile certifying that I desire to terminate the Plan and have consulted with my legal advisors about the termination of the Plan;

f. the Issuer's receipt of notice from me by telephone or facsimile specifying that a legal, contractual or regulatory restriction applicable to me or my affiliates would prohibit any sale pursuant to the Plan or result in material adverse consequences to me as a result of any such sale, or

g. the public announcement of a public offering or other distribution of securities by the Issuer or of a merger, acquisition, tender or exchange offer, or other business combination resulting in the exchange or conversion of the Stock of the Issuer into shares of a company other than the Issuer.

4. In the event of a stock split, reverse stock split or stock dividend relating to the Stock, the dollar amount at which shares of Stock are to be surrendered to the Issuer and the number of shares to be surrendered will be automatically adjusted proportionately.

5. In the event of a reincorporation or other corporate reorganization resulting in an automatic share-for-share exchange of new shares for the type of shares of


Stock subject to the Plan, then the new shares will automatically replace the type of shares of Stock originally specified in the Plan.

6. The Plan may be modified or amended only upon the written agreement of myself and the Issuer.

7. The Plan may be signed in counterparts, each of which will be an original. I will not assign my rights or obligations under the Plan without the Issuer's consent.

8. The Plan, and the attached Representation Letter , dated the date hereof, constitutes the entire agreement and Plan between me and the Issuer and supersede any prior agreements or understandings regarding the Plan. The invalidity or unenforceability of any provision of the Plan will not affect the validity or enforceablity of any other provision.

9. All notices given by the parties under this Plan will be made in the manner specified in this Plan by telephone, facsimile or recognized overnight service as follows:

a. If to the Issuer:

Invacare Corporation Attn: Gregory C. Thompson One Invacare Way
Elyria, OH 44036
Tel: 440-329-6000 Fax: ( )

b. If to me:

Gerald B. Blouch
One Invacare Way
Elyria, Ohio 44036


(Tel: 440-329-6000)

(Fax: ( ))

10. This Plan will be governed by and construed in accordance with the laws of the State of Ohio, without giving effect to the conflict of law principles of that State.

The undersigned have signed this Sales Plan as of February 22, 2005.

/s/ Gerald B. Blouch                       Invacare Corporation (the Issuer)
______________________
Name: Gerald B. Blouch

                                          By:    /s/ Gregory C. Thompson
                                                 _______________________
                                          Name:  Gregory C. Thompson
                                          Title: Senior Vice President and Chief
                                                 Financial Officer


Rule 10b5-1 Plan of Gerald B. Blouch Executed on February 22, 2005
ATTACHMENT A

                                               Number
Type of Grant                   Maturity Date  of Shares  Issuer  Type of Shares
-------------                   -------------  ---------  ------  --------------

Deferred Option Maturity        May 15, 2005   34,903     Invacare     Common

Restricted Stock Grant R01002   May 1, 2005     1,800     Invacare     Common

Restricted Stock Grant R02002   May 1, 2005     1,964     Invacare     Common
Restricted Stock Grant R02002   May 1, 2006     1,964     Invacare     Common

Restricted Stock Grant R03002   May 1, 2005     2,272     Invacare     Common
Restricted Stock Grant R03002   May 1, 2006     2,272     Invacare     Common
Restricted Stock Grant R03002   May 1, 2007     2,272     Invacare     Common

Restricted Stock Grant R04002   May 1, 2005     1,627     Invacare     Common
Restricted Stock Grant R04002   May 1, 2006     1,627     Invacare     Common
Restricted Stock Grant R04002   May 1, 2007     1,627     Invacare     Common
Restricted Stock Grant R04002   May 1, 2008     1,627     Invacare     Common


Rule 10b5-1 Representation Letter

Invacare Corporation
Attn: Gregory C. Thompson
One Invacare Way
Elyria, OH 44036

Ladies and Gentlemen:

In consideration of Invacare Corporation ("Invacare") agreeing to accept the surrender of Invacare shares from the restricted stock or deferred options maturing in order to satisfy my minimum tax withholding obligation for federal, state and local taxes under a written plan (the "Plan") that I, Gerald B. Blouch, have established to meet the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and other good and valuable consideration I make the following representations, warranties and covenants:

1. A true and accurate copy of the Plan is attached.

2. I am entering into the Plan in good faith, in compliance with the requirements of Rule 10b5-1, and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or other federal securities laws. As of the date hereof, I am not aware of any material nonpublic information about Invacare (the "Issuer") or its securities.

3. I have consulted with my own advisors as to the legal, tax, business, and financial aspects of, and have not relied on Invacare in connection with, my adoption and implementation of the Plan and I have confirmed that the Plan meets the criteria set forth in Rule 10b5-1. I acknowledge that Invacare Corporation is not acting as a fiduciary or an advisor for me.

4. I have been granted all restricted shares and all deferred options that are subject to the Plan free and clear of liens, encumbrances, options or other limitation on disposition of any kind.

5. While the Plan is in effect, I agree that:

a. I will not enter into or alter any corresponding or hedging transaction or position with respect to the securities covered by the Plan (including, without limitation, with respect to any securities convertible or exchangeable into those securities) and I will not alter or deviate from the terms of the Plan; and

b. I will notify Invacare in advance of any sales or purchases of, or derivative transactions on, any of the Issuer's securities that I propose to make.

6. Except as provided under the terms of the Plan, I further agree that I will not exercise any subsequent influence over how, when or whether transactions are effected under the plan.

7. I agree to make or cause to be made in a timely manner all necessary filings applicable to me, including Rule 144 filings, filings pursuant


to Sections 13 and 16 of the Exchange Act, and any other filings necessary pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the Exchange Act.

8. The execution and delivery of the Plan by me and the transactions contemplated by the Plan will not contravene any provision of applicable law or any agreement or other instrument binding on me or any of my affiliates or any judgment, order or decree of any governmental body having jurisdiction over me or my affiliates.

9. I agree to give Invacare notice as soon as possible of (a) any subsequent legal, contractual or regulatory restrictions imposed on me due to changes in the securities (or other) laws, contractual restrictions, or anticipated or changed events, that would prevent Invacare or me from complying with the Plan and (b) the occurrence of any event that could cause the Plan to terminate or be suspended under
Section 2 or Section 3 of the Plan.

Very truly yours,

        /s/Gerald B. Blouch
        ___________________
Name:    Gerald B. Blouch
Date:    February 22, 2005


Exhibit 10(x)

Rule 10b5-1 Sales Plan

I, Gregory C. Thompson, have, as of the date set forth below, established this Sales Plan (the "Plan") in order to sell Invacare Corporation (the "Issuer") common shares, no par value per share (the "Stock"), pursuant to the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

1. I elect to surrender Stock to the Issuer in order to satisfy the minimum tax withholding obligation required by federal, state and local governmental authorities (including such amount, if any, as may be required under the American Jobs Creation Act of 2004) with respect to the shares of stock I will receive on the respective maturity dates of the restricted stock grants and/or deferred option exercises as indicated on the Attachment A to the Plan.

2. On each respective maturity date set forth on Attachment A hereto the Issuer agrees to withhold such portion of the shares maturing on such date as is necessary to satisfy such minimum tax withholding obligation required by federal, state and local governmental authorities based on the rates in effect on the applicable maturity date at a price per share equal to the closing price of the Issuer Stock on the New York Stock Exchange on the applicable maturity date.

3. The Plan will terminate on the earliest of:

a. January 1, 2009;

b. the completion of the maturity of the Stock referenced in Section 1 of the Plan;

c. the Issuer's receipt of notice of my death or mental incapacity;

d. the Issuer's reasonable determination that: (i) the Plan does not comply with Rule 10b5-1 or other applicable securities laws; or (ii) I have not complied with the Plan, Rule 10b5-1 or other applicable securities laws;

e. the Issuer's receipt of written notice of termination from me by overnight service and facsimile certifying that I desire to terminate the Plan and have consulted with my legal advisors about the termination of the Plan;

f. the Issuer's receipt of notice from me by telephone or facsimile specifying that a legal, contractual or regulatory restriction applicable to me or my affiliates would prohibit any sale pursuant to the Plan or result in material adverse consequences to me as a result of any such sale, or

g. the public announcement of a public offering or other distribution of securities by the Issuer or of a merger, acquisition, tender or exchange offer, or other business combination resulting in the exchange or conversion of the Stock of the Issuer into shares of a company other than the Issuer.

4. In the event of a stock split, reverse stock split or stock dividend relating to the Stock, the dollar amount at which shares of Stock are to be surrendered to the Issuer and the number of shares to be surrendered will be automatically adjusted proportionately.

5. In the event of a reincorporation or other corporate reorganization resulting in an automatic share-for-share exchange of new shares for the type of shares of


Stock subject to the Plan, then the new shares will automatically replace the type of shares of Stock originally specified in the Plan.

6. The Plan may be modified or amended only upon the written agreement of myself and the Issuer.

7. The Plan may be signed in counterparts, each of which will be an original. I will not assign my rights or obligations under the Plan without the Issuer's consent.

8. The Plan, and the attached Representation Letter , dated the date hereof, constitutes the entire agreement and Plan between me and the Issuer and supersede any prior agreements or understandings regarding the Plan. The invalidity or unenforceability of any provision of the Plan will not affect the validity or enforceablity of any other provision.

9. All notices given by the parties under this Plan will be made in the manner specified in this Plan by telephone, facsimile or recognized overnight service as follows:

a. If to the Issuer:

Invacare Corporation Attn: Joseph Usaj One Invacare Way
Elyria, OH 44036
Tel: 440-329-6000 Fax: ( )

b. If to me:

Gregory C. Thomspon One Invacare Way
Elyria, OH 44036

(Tel: 440-329-6000)

Fax: ( )

10. This Plan will be governed by and construed in accordance with the laws of the State of Ohio, without giving effect to the conflict of law principles of that State.

The undersigned have signed this Sales Plan as of February 21, 2005.

/s/ Gregory C. Thompson                        Invacare Corporation (the Issuer)
_______________________
Name: Gregory C. Thompson

                                               By:      /s/ Joseph S. Usaj
                                                        __________________
                                               Name:    Joseph S. Usaj
                                               Title:   Sr VP Human Resources


Rule 10b5-1 Plan of: Gregory C. Thompson Executed on February 21, 2005

ATTACHMENT A

                                          Number
Type of Grant             Maturity Date   of Shares  Issuer    Type of Shares
-------------             -------------   ---------  ------    --------------

Restricted Stock R02007   Nov. 4, 2005      1,150    Invacare  Common Stock
Restricted Stock R02007   Nov. 4, 2006      1,150    Invacare  Common Stock
Restricted Stock R03003   May 1, 2005       1,281    Invacare  Common Stock
Restricted Stock R03003   May 1, 2006       1,280    Invacare  Common Stock
Restricted Stock R03003   May 1, 2007       1,280    Invacare  Common Stock
Restricted Stock R04003   May 1, 2005         873    Invacare  Common Stock
Restricted Stock R04003   May 1, 2006         873    Invacare  Common Stock
Restricted Stock R04003   May 1, 2007         873    Invacare  Common Stock
Restricted Stock R04003   May 1, 2008         873    Invacare  Common Stock


Rule 10b5-1 Representation Letter

Invacare Corporation
Attn: Joseph Usaj
One Invacare Way
Elyria, OH 44036

Ladies and Gentlemen:

In consideration of Invacare Corporation ("Invacare") agreeing to accept the surrender of Invacare shares from the restricted stock or deferred options maturing in order to satisfy my minimum tax withholding obligation for federal, state and local taxes under a written plan (the "Plan") that I, Gregory C. Thompson, have established to meet the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and other good and valuable consideration I make the following representations, warranties and covenants:

1. A true and accurate copy of the Plan is attached.

2. I am entering into the Plan in good faith, in compliance with the requirements of Rule 10b5-1, and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or other federal securities laws. As of the date hereof, I am not aware of any material nonpublic information about Invacare (the "Issuer") or its securities.

3. I have consulted with my own advisors as to the legal, tax, business, and financial aspects of, and have not relied on Invacare in connection with, my adoption and implementation of the Plan and I have confirmed that the Plan meets the criteria set forth in Rule 10b5-1. I acknowledge that Invacare Corporation is not acting as a fiduciary or an advisor for me.

4. I have been granted all restricted shares and all deferred options that are subject to the Plan free and clear of liens, encumbrances, options or other limitation on disposition of any kind.

5. While the Plan is in effect, I agree that:

a. I will not enter into or alter any corresponding or hedging transaction or position with respect to the securities covered by the Plan (including, without limitation, with respect to any securities convertible or exchangeable into those securities) and I will not alter or deviate from the terms of the Plan; and

b. I will notify Invacare in advance of any sales or purchases of, or derivative transactions on, any of the Issuer's securities that I propose to make.

6. Except as provided under the terms of the Plan, I further agree that I will not exercise any subsequent influence over how, when or whether transactions are effected under the plan.

7. I agree to make or cause to be made in a timely manner all necessary filings applicable to me, including Rule 144 filings, filings pursuant to Sections 13 and 16 of the Exchange Act, and any other filings necessary pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the Exchange Act.


8. The execution and delivery of the Plan by me and the transactions contemplated by the Plan will not contravene any provision of applicable law or any agreement or other instrument binding on me or any of my affiliates or any judgment, order or decree of any governmental body having jurisdiction over me or my affiliates.

9. I agree to give Invacare notice as soon as possible of (a) any subsequent legal, contractual or regulatory restrictions imposed on me due to changes in the securities (or other) laws, contractual restrictions, or anticipated or changed events, that would prevent Invacare or me from complying with the Plan and (b) the occurrence of any event that could cause the Plan to terminate or be suspended under
Section 2 or Section 3 of the Plan.

Very truly yours,

   /s/ Gregory C. Thompson
       ___________________
Name:  Gregory C. Thompson
Date:  2/21/05


Exhibit 10(y)

Supplemental Executive Retirement Plan
(As amended and restated effective February 1, 2000)


INVACARE CORPORATION
SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN
(As amended and restated effective February 1, 2000)

Table of Contents

Page

1. Introduction................................................................1
         1.1 Adoption and Name of Plan.........................................1
         1.2 Purpose of Plan...................................................1
         1.3 "Top Hat" Pension Benefit Plan....................................1
         1.4 Plan Unfunded.....................................................1
         1.5 Effective Date....................................................1
         1.6 Administration....................................................1

2. Definitions and Construction................................................2
         2.1 Definitions.......................................................2
                  2.1.1 Actuarial Equivalent...................................2
                  2.1.2 Beneficiary............................................2
                  2.1.3 Board..................................................2
                  2.1.4 Bonus Plan.............................................2
                  2.1.5 Change of Control......................................2
                  2.1.6 Change of Control Benefit..............................2
                  2.1.7 Code...................................................2
                  2.1.8 Committee..............................................2
                  2.1.9 Company................................................3
                  2.1.10 Company Contribution Offset...........................3
                  2.1.11 Death Benefit.........................................3
                  2.1.12 Disability............................................3
                  2.1.13 Disability Benefit....................................3
                  2.1.14 Early Retirement Benefit..............................3
                  2.1.15 Early Retirement Date.................................4
                  2.1.16 Earnings..............................................4
                  2.1.17 Effective Date........................................4
                  2.1.18 Employee..............................................4
                  2.1.19 ERISA.................................................4
                  2.1.20 Final Earnings........................................4
                  2.1.21 Normal Retirement Benefit.............................4
                  2.1.22 Normal Retirement Date................................5
                  2.1.23 Offset................................................5
                  2.1.24 Participant...........................................5
                  2.1.25 Participation Agreement...............................5
                  2.1.26 Plan..................................................5
                  2.1.27 Prior Distribution Offset.............................5
                  2.1.28 Service...............................................5
                  2.1.29 Service Ratio.........................................6
                  2.1.30 Social Security Offset................................6
                  2.1.31 Target Bonus..........................................6
                  2.1.32 Target Replacement Ratio..............................6
                  2.1.33 Termination Benefit...................................6
                  2.1.34 Vesting Percentage....................................7

                  2.1.35 Vesting Service.......................................7
         2.2 Number and Gender.................................................7
         2.3 Heading...........................................................7
         2.4 Other Definitions.................................................7

3. Participation and Eligibility...............................................8
         3.1 Participation.....................................................8
         3.2 Commencement of Participation.....................................8
         3.3 Cessation of Active Participation.................................8

4. Benefits....................................................................9
         4.1 Normal Retirement Benefit.........................................9
         4.2 Early Retirement Benefit..........................................9
         4.3 Disability Benefit................................................9
         4.4 Termination Benefit...............................................9
         4.5 Death Benefit.....................................................9
         4.6 Change of Control Benefit.........................................9
         4.7 Form of Benefits..................................................9
         4.8 Vesting..........................................................10
         4.9 Designation of Beneficiaries.....................................10
         4.10 Amendments......................................................10
         4.11 Change in Marital Status........................................10
         4.12 No Beneficiary Designation......................................11
         4.13 Unclaimed Benefits..............................................11
         4.14 Eligibility for More Than One Benefit...........................11
         4.15 Reemployment....................................................12

5. Administration.............................................................13
         5.1 Committee........................................................13
         5.2 General Powers of Administration.................................13
         5.3 Indemnification of Committee.....................................13

6. Claims Procedure...........................................................14
         6.1 Claims...........................................................14
         6.2 Claim Decision...................................................14
         6.3 Request for Review...............................................14
         6.4 Review of Decision...............................................15
         6.5 Discretionary Authority..........................................15

7. Miscellaneous..............................................................16
         7.1 Plan Not a Contract of Employment................................16
         7.2 Non-Assignability of Benefits....................................16
         7.3 Amendment and Termination........................................16
         7.4 Unsecured General Creditor Status Of Employee....................16
         7.5 Severability.....................................................17
         7.6 Governing Laws...................................................17
         7.7 Binding Effect...................................................17
         7.8 Entire Agreement.................................................17
         7.9 No Guarantee of Tax Consequences.................................17
         7.10 Withholding.....................................................17
         7.11 Set Off.........................................................17
         7.12 Plan Year.......................................................18


INVACARE CORPORATION
SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN
(As amended and restated effective February 1, 2000)

1. Introduction

1.1 Adoption and Name of Plan.

The Company adopts the amended and restated Invacare Corporation Supplemental Executive Retirement Plan.

1.2 Purpose of Plan.

The purpose of the Plan is to provide deferred compensation for a select group of management or highly compensated Employees of the Company and to supplement the benefits under other retirement and savings plans offered by the Company for such Employees.

1.3 . "Top Hat" Pension Benefit Plan.

The Plan is an "employee pension benefit plan" within the meaning of ERISA
Section 3(2). The Plan is maintained, however, for a select group of management or highly compensated employees and, therefore, is exempt from Parts 2, 3 and 4 of Title 1 of ERISA. The Plan is not intended to qualify under Code Section 401(a).

1.4 Plan Unfunded.

The Plan is unfunded. All benefits will be paid from the general assets of the Company, which will continue to be subject to the claims of the Company's creditors. No amounts will be set aside for the benefit of Plan Participants or their Beneficiaries.

1.5 Effective Date.

The Plan was originally adopted effective May 1, 1995. The amended and restated Plan is effective as of the Effective Date.

1.6 Administration.

The Plan shall be administered by the Committee.

1

2. Definitions and Construction.

2.1 Definitions.

For purposes of the Plan, the following words and phrases shall have the respective meanings set forth below, unless their context clearly requires a different meaning:

2.1.1 Actuarial Equivalent.

"Actuarial Equivalent" means an amount having equal value when computed on the basis of (a) the greater of an eight percent (8%) annual interest rate or Moody's Corporate Bond Yield Average for the prior calendar year and (b) the 1983 Group Annuity Mortality Table.

2.1.2 Beneficiary.

"Beneficiary" means a person or entity entitled to receive any benefits payable with respect to a deceased Participant.

2.1.3 Board.

"Board" means the board of directors of the Company.

2.1.4 Bonus Plan.

"Bonus Plan" means the Management Incentive Plan of the Company, as amended from time to time.

2.1.5 Change of Control.

"Change of Control" has the same meaning ascribed to it under the Company's
401(k) Plus Benefit Equalization Plan.

2.1.6 Change of Control Benefit.

"Change of Control Benefit" means a lump sum benefit which is the Actuarial Equivalent of the Normal Retirement Benefit (even if the Participant is not then eligible for such benefit) assuming the Vesting Percentage is one hundred percent (100%) and the Service Ratio is one (1).

2.1.7 Code.

"Code" means the Internal Revenue Code of 1986, as amended.

2.1.8 Committee.

"Committee" means the administrative committee described in Section 5.1.

2

2.1.9 Company.

"Company" means Invacare Corporation

2.1.10 Company Contribution Offset.

"Company Contribution Offset" means the Actuarial Equivalent of the benefit to be derived from contributions made by the Company on behalf of the Participant to the Company's 401(k) Plan, 401(k) Plus Benefit Equalization Plan, and Profit Sharing Plan.

2.1.11 Death Benefit.

"Death Benefit" means an Actuarial Equivalent of the Normal Retirement Benefit (even if the Participant is not then eligible for such benefit) assuming the Vesting Percentage and the Service Ratio at the time of Participant's death. The Participant may elect the form of payment with Committee approval. If no election is made, the Committee will determine the form of payment. In no event, shall the total benefits payable be less than the Participant's Final Earnings.

2.1.12 Disability.

"Disability" shall have the same meaning as defined in the Company's Long Term Disability Plan.

2.1.13 Disability Benefit.

"Disability Benefit" means an annual benefit equal to the difference between

(a) the product of Final Earnings x Target Replacement Ratio x Service Ratio and

(b) all Offsets but in no event less than zero.

Except as otherwise provided in Section 4.7, such benefit shall be paid monthly.

2.1.14 Early Retirement Benefit.

"Early Retirement Benefit" means an annual benefit equal to the difference between

(a) Final Earnings x Target Replacement Ratio x Service Ratio x Vesting Percentage (expressed in decimal form) x (1.00 minus the product of the number of years prior to what would have been the Participant's Normal Retirement Date had he remained employed until such date x .06) and

(b) all Offsets but in no event less than zero.

3

Except as otherwise provided in Section 4.7, such benefit shall be paid monthly:

2.1.15 Early Retirement Date.

"Early Retirement Date" means the date a Participant's employment with the Company terminates for a reason other than death or Disability and prior to his Normal Retirement Date on or after he has attained at least fifty five (55) years of age and completed at least ten (10) years of Service.

2.1.16 Earnings.

"Earnings" means the sum of (a) the Participant's annual base salary in effect on the April 1st immediately preceding or coincident with the date of the Participant's termination of employment, plus (b) the Participant's Target Bonus on such date.

2.1.17 Effective Date.

"Effective Date" means February 1, 2000.

2.1.18 Employee.

"Employee" means any common-law employee of the Company.

2.1.19 ERISA.

"ERISA" means the Employee Retirement Income Security Act of 1974, as amended.

2.1.20 Final Earnings.

"Final Earnings" means the Participant's Earnings in effect on the date of his termination of employment, except in the case of Disability, where the Final Earnings are the Earnings in effect on the last day preceding the Disability.

2.1.21 Normal Retirement Benefit.

"Normal Retirement Benefit" means an annual benefit equal to the difference between

(a) the product of Final Earnings x Target Replacement Ratio x Service Ratio x Vesting Percentage (expressed in decimal form) and

(b) all Offsets but in no event less than zero.

Except as otherwise provided in Section 4.7, such benefit shall be paid monthly.

4

2.1.22 Normal Retirement Date.

"Normal Retirement Date" means the date a Participant's employment terminates for a reason other than death or Disability:

(a) on or after he has attained at least sixty five (65) years of age, or

(b) on or after he has attained at least sixty two (62) years of age and completed at least fifteen (15) years of Service, or

(c) with the Committee's consent.

2.1.23 Offset.

"Offset" means the Company Contribution Offset, the Prior Distribution Offset and/or the Social Security Offset.

2.1.24 Participant.

"Participant" means each Employee who has been selected for participation in the Plan and who has become a Participant pursuant to Section 3.2.

2.1.25 Participation Agreement.

"Participation Agreement" means the written agreement between an Employee and the Company which evidences and confirms his participation in the Plan and his agreement to be bound by all of its terms and conditions and which contains such other matters as the Committee shall determine from time to time.

2.1.26 Plan.

"Plan" means the Invacare Corporation Supplemental Executive Retirement Plan, as amended from time to time.

2.1.27 Prior Distribution Offset.

"Prior Distribution Offset" means the Actuarial Equivalent of the sum of benefit payments previously distributed to a Participant under the Plan.

2.1.28 Service.

"Service" means the greater of

(a) a Participant's continuous employment by the Company, including periods of Disability, rounded to the nearest whole number of years,

(b) the number of years set forth in Appendix A as amended from time to time.

5

2.1.29 Service Ratio.

"Service Ratio" means the lesser of one (1) or the quotient of Service divided by fifteen (15) or such greater ratio set forth in Appendix A as amended from time to time.

2.1.30 Social Security Offset.

"Social Security Offset" means if payment of benefits commences prior to the date a Participant attains sixty two (62) years of age, fifty percent (50%) of the estimated monthly old age benefit for a Participant, exclusive of benefits for relatives or dependents, that would be or would have been available from time to time from and after his attainment of sixty two (62) years of age under the then current provisions of the Social Security Act (including increases or decreases in such benefits caused by changes in the law or otherwise) determined without regard as to whether such benefit would be delayed, suspended, reduced or forfeited because of failure to apply, continued employment, the Participant's death or any other reason. However, the Social Security Offset shall not be applicable until the date a Participant attains or would have attained sixty two (62) years of age. If payment of benefits commences on or after the date a Participant attains sixty two (62) years of age, the Social Security Offset shall be computed in the same manner as described in the first sentence of this Section 2.1.30 except the age to be used shall be the actual age when payment of benefits commences. In determining the Social Security Offset for a Participant who dies prior to the time payment of benefits commences, it will be assumed that his earnings for the calendar year of his death and all future years equal the then current Social Security Taxable Wage Base.

2.1.31 Target Bonus.

"Target Bonus" means the annual base salary in effect on the April 1st immediately preceding or coincident with the date of a Participant's termination of employment, multiplied by the target bonus percentage in effect on that same date under the Bonus Plan.

2.1.32 Target Replacement Ratio.

"Target Replacement Ratio" means fifty percent (50%) expressed in decimal form.

2.1.33 Termination Benefit.

"Termination Benefit" means an annual benefit equal to the difference between

(a) Final Earnings x Target Replacement Ratio x Service Ratio x Vesting Percentage (expressed in decimal form) x (1.00 minus the product of the number of years prior to what would have been the Participant's Normal Retirement Date had he remained employed until such date x .06) and

(b) all Offsets but in no event less than zero.

6

Except as otherwise provided in Section 4.7, such benefit shall be paid monthly.

2.1.34 Vesting Percentage.

"Vesting Percentage" means the percentage of a Participant's benefit which is nonforfeitable as set forth in Section 4.8.

2.1.35 Vesting Service.

"Vesting Service" means, except as hereinafter provided, a Participant's Service while a Participant. Notwithstanding the foregoing, if a Participant's Vesting Service would be at least two (2) years under the preceding sentence, his Service shall be his Vesting Service.

2.2 Number and Gender.

Wherever appropriate herein, words used in the singular shall be considered to include the plural and words used in the plural shall be considered to include the singular. The masculine gender, where appearing in the Plan, shall be deemed to include the feminine gender.

2.3 Headings.

The heading of Sections herein is included solely for convenience, and if there is any conflict between such headings and the rest of the Plan, the text shall control.

2.4 Other Definitions.

In addition to the definitions in Section 2.1, certain other words and phrases are defined in other portions of the Plan.

7

3. Participation and Eligibility.

3.1 Participation.

Participants in the Plan are those Employees who are (a) subject to the income tax laws of the United States, (b) members of a select group of highly compensated or management Employees of the Company, and (c) selected by the Committee, in its sole discretion, as Participants. The Committee shall notify each Participant of his selection as a Participant. Subject to the provisions of
Section 3.3 a Participant shall remain eligible to continue participation in the Plan for each Plan Year following his initial year of participation in the Plan.

3.2 Commencement of Participation.

An Employee shall become a Participant effective as of the first day of the month following the date on which he executes his Participation Agreement and any other documents required by the Committee.

3.3 Cessation of Active Participation.

Notwithstanding any provision herein to the contrary, an individual who has become a Participant shall cease to be an active Participant effective as of any date designated by the Committee. In the event of such cessation, for purposes of determining the Participant's Earnings and Final Earnings, the Participant shall be deemed to have terminated employment as of the date of such cessation but he shall continue to be credited with Service. Such cessation shall not preclude the individual from subsequently being selected to once again be a Participant.

8

4. Benefits.

4.1 Normal Retirement Benefit.

Upon the termination of the Participant's employment on or after his Normal Retirement Date for a reason other than Disability or death, the Participant shall thereupon be entitled to receive his Normal Retirement Benefit.

4.2 Early Retirement Benefit.

Upon the termination of the Participant's employment on or after his Early Retirement Date for a reason other than Disability or death, the Participant shall thereupon be entitled to receive his Early Retirement Benefit.

4.3 Disability Benefit.

Upon a Participant's Disability, whether or not his employment terminates due to Disability, the Participant shall thereupon be entitled to receive his Disability Benefit.

4.4 Termination Benefit.

If a Participant's employment terminates for a reason other than death, and other than as described in Sections 4.1, 4.2, or 4.3 above, the Participant shall be entitled to receive his Termination Benefit commencing on the first date that could have been the Participant's Early Retirement Date or Normal Retirement Date had he remained employed if he is still alive on such date.

4.5 Death Benefit.

Upon the death of the Participant while employed, his Beneficiary shall be entitled, to receive an amount equal to his Death Benefit.

4.6 Change of Control Benefit.

Upon termination of a Participant's employment for a reason other than death within two (2) years of a Change of Control, he shall be entitled to receive his Change of Control Benefit.

4.7 Form of Benefits.

The normal form of all benefits payable monthly shall be a life annuity commencing with the month following the month which triggers payment. Each monthly payment shall be one twelfth (1/12) of the annual payment. Notwithstanding the foregoing, in lieu of such normal form, the Actuarial Equivalent of any such annuity benefit may be paid in a lump sum, a seventy five percent (75%) or fifty percent (50%) joint and survivor annuity, or such other forms as the Committee may permit from time to time if such optional form of benefit is elected prior to the occurrence of the event which triggers distribution. All benefits payable as a lump sum shall be paid as soon as practicable after the event which triggers payment of such benefit.

9

4.8 Vesting.

A Participant's Vested Percentage shall be based upon his years of Vesting Service as follows:

Years of Vesting Service                Percentage Vested

      Less than 1                              0
          1                                   20
          2                                   40
          3                                   60
          4                                   80
      5 or more                              100

Notwithstanding the foregoing, a Participant's benefits shall become fully vested upon his attainment of age sixty five (65) while employed, Disability while employed, death while employed, and termination of employment pursuant to
Section 4.6.

4.9 Designation of Beneficiaries.

Each Participant shall have the right, at any time, to designate one (1) or more persons or an entity as Beneficiary (both primary as well as secondary) to whom benefits under this Plan shall be paid in the event of a Participant's death if any such benefits are payable after his death. Each Beneficiary designation shall be in a written form prescribed by the Committee and will be effective only when filed with the Committee during the Participant's lifetime. In case of a Participant who is a resident of a community property state, designation by a married Participant of a Beneficiary other than the Participant's spouse shall not be effective unless the spouse executes a written consent that acknowledges the effect of the designation and is witnessed by a notary public, or the consent cannot be obtained because the spouse cannot be located.

4.10 Amendments.

Except as provided below, any nonspousal designation of Beneficiary may be changed by a Participant without the consent of such Beneficiary by the filing of a new designation with the Committee. The filing of a new designation shall cancel all designations previously filed.

4.11 Change in Marital Status.

If the marital status of a Participant residing in a community property state changes after the Participant has designated a Beneficiary, the following shall apply:

(a) If the Participant is married at death but was unmarried when the designation was made, the designation shall be void unless the spouse has consented to it in the manner prescribed above.

(b) If the Participant is unmarried at death but was married when the designation was made:

10

(i) The designation shall be void if the spouse was named as Beneficiary.

(ii) The designation shall remain valid if a nonspouse Beneficiary was named.

(c) If the Participant was married when the designation was made and is married to a different spouse at death, the designation shall be void unless the new spouse has consented to it in the manner prescribed above.

4.12 No Beneficiary Designation.

If any Participant fails to designate a Beneficiary in the manner provided above, or if the Beneficiary designated by a deceased Participant dies before the Participant or before complete distribution of the Participant's benefits, the Participant's Beneficiary shall be the person in the first of the following classes in which there is a survivor:

(a) The Participant's surviving spouse;

(b) The Participant's children in equal shares, except that if any of the children predeceases the Participant but leaves issue surviving, then such issue shall take by right of representation the share the parent would have taken if living;

(c) The Participant's estate.

4.13 Unclaimed Benefits.

In the case of a benefit payable on behalf of such Participant, if the Committee is unable to locate the Participant or Beneficiary to whom such benefit is payable, such benefit may be forfeited to the Company, upon the Committee's determination. Notwithstanding the foregoing, if subsequent to any such forfeiture the Participant or Beneficiary to whom such benefit is payable makes a valid claim for such benefit, such forfeited benefit shall be paid by the Company or restored to the Plan by the Company.

4.14 Eligibility for More Than One Benefit.

If a Participant is eligible for more than one form of benefit (such as a Change of Control Benefit and an Early Retirement Benefit), he shall be entitled to receive the benefit which is the greatest, on the basis of a vested Actuarial Equivalent, or, if the benefits are equal on such basis, the one determined by the Committee.

4.15 Reemployment.

In the event that a Participant receiving an annuity benefit is reemployed or returns to active employment after recovering from Disability, such benefit shall cease during reemployment or return to active employment. Upon subsequent

11

termination of employment or Disability, the Participant and/or his Beneficiary shall be eligible to receive the benefits, if any, to which he is then entitled under the Plan.

12

5. Administration.

5.1 Committee.

The Plan shall be administered by a Committee which shall consist of the Company's Chief Executive Officer and Chief Financial Officer. The Committee shall be responsible for the general operation and administration of the Plan and for carrying out the provisions thereof. The Committee may delegate to others certain aspects of the management and operational responsibilities of the Plan including the employment of advisors and the delegation of ministerial duties to qualified individuals, provided that such delegation is in writing. No member of the Committee who is a Participant shall participate in any matter relating to his status as a Participant or his rights or entitlement to benefits as a Participant.

5.2 General Powers of Administration.

The Committee shall have all powers necessary or appropriate to enable it to carry out its administrative duties. Not in limitation, but in application of the foregoing, the Committee shall have discretionary authority to construe and interpret the Plan and determine all questions that may arise hereunder as to the status and rights of Employees, Participants, and Beneficiaries. The Committee may exercise the powers hereby granted in its sole and absolute discretion. The Committee may promulgate such regulations as it deems appropriate for the operation and administration of the Plan. No member of the Committee shall be personally liable for any actions taken by the Committee unless the member's action involves willful misconduct.

5.3 Indemnification of Committee.

The Company shall indemnify the members of the Committee against any and all claims, losses, damages, expenses, including attorney's fees, incurred by them, and any liability, including any amounts paid in settlement with their approval, arising from their action or failure to act, except when the same is judicially determined to be attributable to their gross negligence or willful misconduct.

13

6. Claims Procedure.

6.1 Claims.

A person who believes that he is being denied a benefit to which he is entitled under the Plan (the "Claimant") may file a written request for such benefit with the Committee, setting forth his claim. The request must be addressed to the Committee at the Company at its then principal place of business.

6.2 Claim Decision.

Upon receipt of a claim, the Committee shall advise the Claimant that a reply will be forthcoming within ninety (90) days and shall, in fact, deliver such reply within such period. The Committee may, however, extend the reply period for an additional ninety (90) days for reasonable cause.

If the claim is denied in whole or in part, the Committee shall adopt a written opinion, using language calculated to be understood by the Claimant, setting forth:

(a) The specific reason or reasons for such denial;

(b) The specific reference to pertinent provisions of the Plan on which such denial is based;

(c) A description of any additional material or information necessary for the Claimant to perfect his claim and an explanation why such material or such information is necessary;

(d) Appropriate information as to the steps to be taken if the Claimant wishes to submit the claim for review; and

(e) The time limits for requesting a review under Section 6.3 and for review under Section 6.4 hereof.

6.3 Request for Review.

Within sixty (60) days after the receipt by the Claimant of the written opinion described above, the Claimant may request in writing that the Secretary of the Company (the "Secretary") review the determination of the Committee. Such request must be addressed to the Secretary of the Company, at its then principal place of business. The Claimant or his duly authorized representative may, but need not, review the pertinent documents and submit issues and comments in writing for consideration by the Secretary. If the Claimant does not request a review of the Committee's determination by the Secretary of the Company within such sixty (60) day period, he shall be barred and estopped from challenging the Committee's determination.

14

6.4 Review of Decision.

Within sixty (60) days after the Secretary's receipt of a request for review, he will review the Committee's determination. After considering all materials presented by the Claimant, the Secretary will render a written opinion, written in a manner calculated to be understood by the Claimant, setting forth the specific reasons for the decision and containing specific references to the pertinent provisions of the Plan on which the decision is based. If special circumstances require that the sixty (60) day time period be extended, the Secretary will so notify the Claimant and will render the decision as soon as possible, but no later than one hundred twenty (120) days after receipt of the request for review.

6.5 Discretionary Authority.

The Committee and Secretary shall both have discretionary authority to determine a Claimant's entitlement to benefits upon his claim or his request for review of a denied claim, respectively.

15

7. Miscellaneous.

7.1 Plan Not a Contract of Employment.

The adoption and maintenance of the Plan shall not be or be deemed to be a contract between the Company and any person or to be consideration for the employment of any person. Nothing herein contained shall give or be deemed to give any person the right to be retained in the employ of the Company or to restrict the right of the Company to discharge any person at any time; nor shall the Plan give or be deemed to give the Company the right to require any person to remain in the employ of the Company or to restrict any person's right to terminate his employment at any time.

7.2 Non-Assignability of Benefits.

No Participant, Beneficiary or distributee of benefits under the Plan shall have any power or right to transfer, assign, anticipate, hypothecate or otherwise encumber any part or all of the amounts payable hereunder, which are expressly declared to be unassignable and non-transferable. Any such attempted assignment or transfer shall be void. No amount payable hereunder shall, prior to actual payment thereof, be subject to seizure by any creditor of any such Participant, Beneficiary or other distributee for the payment of any debt, judgment, or other obligation, by a proceeding at law or in equity, nor transferable by operation of law in the event of the bankruptcy, insolvency or death of such Participant, Beneficiary or other distributee hereunder.

7.3 Amendment and Termination.

The Board may from time to time, in its discretion, amend, in whole or in part, any or all of the provisions of the Plan; provided, however, that no amendment may be made which would impair the rights of a Participant with respect to benefits then earned. The Board may terminate the Plan at any time. In the event that the Plan is terminated, the benefits earned shall be paid to such Participant or his Beneficiary in a lump sum or in equal monthly installments as the Committee determines.

7.4 Unsecured General Creditor Status Of Employee.

The payments to Participant, his Beneficiary or any other distributee hereunder shall be made from assets which shall continue, for all purposes, to be a part of the general, unrestricted assets of the Company; no person shall have nor acquire any interest in any such assets by virtue of the provisions of this Agreement. The Company's obligation hereunder shall be an unfunded and unsecured promise to pay money in the future. To the extent that the Participant, a Beneficiary, or other distributee acquires a right to receive payments from the Company under the provisions hereof, such right shall be no greater than the right of any unsecured general creditor of the Company; no such person shall have nor require any legal or equitable right, interest or claim in or to any property or assets of the Company. In the event that, in its discretion, the Company purchases an insurance policy or policies insuring the life of the Participant (or any other property) to allow the Company to recover the cost of providing the benefits, in whole, or in part, hereunder, neither the Participant, his Beneficiary or other distributee shall have nor acquire any

16

rights whatsoever therein or in the proceeds therefrom. The Company shall be the sole owner and beneficiary of any such policy or policies and, as such, shall possess and may exercise all incidents of ownership therein. No such policy, policies or other property shall be held in any trust for a Participant, Beneficiary or other distributee or held as collateral security for any obligation of the Company hereunder.

7.5 Severability.

If any provision of this Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining provisions hereof; instead, each provision shall be fully severable and the Plan shall be construed and enforced as if said illegal or invalid provision had never been included herein.

7.6 Governing Laws.

All provisions of the Plan shall be construed in accordance with the laws of Ohio except to the extent preempted by federal law.

7.7 Binding Effect.

This Plan shall be binding on each Participant and his heirs and legal representatives and on the Company and its successors and assigns.

7.8 Entire Agreement.

This document and any amendments contain all the terms and provisions of the Plan and shall constitute the entire Plan, any other alleged terms or provisions being of no effect.

7.9 No Guarantee of Tax Consequences.

While the Company has established, and will maintain and administer, the Plan, the Company makes no representation, warranty, commitment, or guaranty concerning the income, employment, or other tax consequences of participation in the Plan under federal, state, or local law.

7.10 Withholding.

The Company may, at the time any payment is made under the Plan, withhold from such payment any amount necessary to satisfy federal, state and local income, employment, and/or other tax withholding requirements, with respect to such payment, or any benefit under the Plan. In addition, the Company may (a) require a Participant or other payee to tender to the Company cash in the amount necessary to comply with any such withholding requirements and/or (b) withhold any such amount from any other compensation, remuneration or other amounts payable by the Company to or with respect to a Participant.

7.11 Set Off.

If, at the time any benefits become payable to or with respect to a Participant, such Participant has any debt, obligation, or other liability owing

17

to the Company of any nature whatsoever, whether liquidated or contingent, the Company may offset the amount the Participant owes to it against the amount of benefits payable to or with respect to the Participant under the Plan.

7.12 Plan Year.

The records of the Plan shall be kept on a calendar year basis.

IN WITNESS WHEREOF, the Company has caused this Plan to be executed on the 1st day of February, 2000.

INVACARE CORPORATION

By: /s/ Thomas R. Miklich
    _____________________


 Title: CFO


Exhibit 10(z)

[GRAPHIC OMITTED][GRAPHIC OMITTED]

AWARD AGREEMENT
(For Non-Qualified Stock Option)

To: Number:


(Name of Optionee)

Date of Grant:
(Social Security Number)

There hereby is granted to you, as an outside Director of Invacare Corporation ( "Invacare" ), an option to purchase _____ Invacare Common Shares, no par value, at an option price of $____ per Share. This option is granted to you pursuant to the Invacare Corporation 1994 Performance Plan (the "Plan") and is subject to the terms and conditions set forth below. This option is not an incentive stock option as defined in Section 422 of the Internal Revenue Code (the "Code"). Please acknowledge your acceptance of the terms of this option by signing on the reverse side.

/s/ A. Malachi Mixon, III
____________________________________
A. Malachi Mixon, III
Chairman and Chief Executive Officer


I. PURCHASE RIGHTS & EXERCISE DATES
You shall be entitled to exercise this option with respect to the percentage of shares indicated on or after the date shown opposite such percentage, rounded to the nearest whole share:

 Cumulative Maximum
 Percentage of Optioned
 Shares which may be
 purchased by exercise              Date beginning on which
 of the Option                      Option may be exercised
___________________________________________________________

To the extent that the option becomes exercisable with respect to any shares, as shown above, the option may thereafter be exercised by you either with respect to all or any number of such shares at any time or from time to time prior to the expiration of the option. However, no fractional shares may be purchased. Except as provided herein, the option may not be exercised unless you are an employee at the time of exercise.

II. TERM OF OPTION The term of the option shall be for a period of ten (10) years commencing on the Date of Grant as set forth above. The option shall expire at the close of regular business hours at Invacare's principal office on the last day of the term of the option, or, if earlier, on the applicable expiration date provided in this Agreement.

If you cease to be a Director for any reason other than death, you may exercise your option only to the extent of such purchase rights as may exist pursuant to Paragraph I as of the date you cease to be a Director and which have not been exercised. Upon your ceasing to be a Director such purchase rights shall in any event terminate upon the earlier of (a) three (3) months [one (1) year if you ceased to be a Director, because of a disability (as such term is defined in
Section 72(m) (7) of the Code)] after the date you ceased to be a Director, or
(b) the last day of the term of the option.

(b) If you die while you are a Director, or within three (3) months of your having ceased to be a Director, a personal representative may exercise the option to the extent of your purchase rights as may exist pursuant to Paragraph I at the date of your death and which have not been exercised; provided, however, that such purchase rights shall in any event terminate upon the earlier of: (i) one (1) year after you cease to be a Director, or (ii) the last day of the term of the option.

(c) If the Committee finds that you intentionally committed an act materially inimical to the interests of Invacare or a subsidiary, your unexercised purchase rights will terminate as of the time you committed such act, as determined by the Committee.

III. TERMINATION OF OPTION UNDER CERTAIN CIRCUMSTANCES

The Committee may cancel your option at any time if you are not in compliance with all applicable provisions of this Agreement or the Plan or if you, without the prior written consent of the Committee, engage in any of the following activities: (i) you render services for an organization, or engage in a business, that is, in the judgment of the Committee, in competition with Invacare; or (ii) you disclose to anyone outside of Invacare, or use for any purpose other than Invacare's business, any confidential information or material relating to Invacare, whether acquired by you during or after employment with Invacare, in a fashion or with a result that is or may be injurious to the best interests of Invacare, as determined by the Committee.

The Committee may, in its discretion and as a condition to the exercise of your option, require you to represent in writing that you are in compliance with all applicable provisions of this Agreement and the Plan and have not engaged in any activities referred to in clauses (i) and (ii) above.

IV. EXERCISE OF OPTION The option may be exercised by delivering to the Invacare Finance Department, at Invacare's principal office, a completed Notice of Exercise of Option (obtainable from the Finance Department) setting forth the number of shares with respect to which your option is being exercised. Such Notice shall be accompanied by either payment in full for the shares, or the execution of a cashless exercise in accordance with the procedures established by the Committee.

V. CHANGE IN CONTROL
Upon a change in control (as such term is defined in the Plan), unless and to the extent otherwise determined by Invacare's Board of Directors, you may exercise your option with respect to all shares covered therein.

VI. TRANSFERABILITY This Agreement shall be binding upon and inure to the benefit of any successor of Invacare and your heirs, estate and personal representative. Your option shall not be transferable other than by Will or the laws of descent and distribution, and your option may be exercised during your lifetime only by you provided that a guardian or other legal representative, who has been duly appointed may, except as otherwise provided in the Plan, exercise the option on your behalf. Your personal representative shall act in your place with respect to exercising the option or taking any other action pursuant to the Agreement.

VII. ADJUSTMENTS OR AMENDMENTS In the event that, subsequent to the date of this Agreement, the outstanding common shares of Invacare are, as a result of a stock split, stock dividend, combination or exchange of shares, exchange of other securities, reclassification, reorganization, redesignation, merger, consolidation, recapitalization, liquidation, dissolution, sale of assets or other such change, including, without limitation, any transaction described in Section 424(a) of the Code, increased, decreased, changed into or exchanged for a different number or kind of shares of stock or other securities of Invacare or another entity or converted into cash, then, except as otherwise provided below, (i) there shall automatically be substituted for each Invacare common share subject to an unexercised option, the amount of cash or other securities into which each outstanding Invacare common share shall be converted or exchanged and (ii) the option price per common share or unit of securities shall be increased or decreased proportionally so that the aggregate purchase price for any securities subject to the option shall remain the same as immediately prior to such event. Notwithstanding the preceding provisions of this Article VII, the Committee may, in its sole discretion, make other adjustments or amendments to the securities subject to options and/or amend the provisions of the Plan and/or this Agreement (including, without limitation, accelerating the date on which unexercised options shall expire or terminate), to the extent appropriate, equitable and in compliance with the provisions of Section 424(a) of the Code to the extent applicable and any such adjustment or amendment shall be final, binding and conclusive. Any such adjustment or amendment shall provide for the elimination of fractional shares.

VIII. PROVISIONS OF PLAN CONTROL This Agreement is subject to all of the terms, conditions and provisions of the Plan (all of which are incorporated herein by reference) and to such rules, regulations, and interpretations related to the Plan as may be adopted by the Committee and as may be in effect from time to time. In the event and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions, and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Committee has authority to interpret and construe any provision of this Agreement and its interpretation and construction shall be binding and conclusive.

IX. LIABILITY The liability of Invacare under this Agreement and any distribution of shares made hereunder is limited to the obligations set forth herein with respect to such distribution and no term or provision of this Agreement shall be construed to impose any liability on Invacare, its officers, employees or any subsidiary with respect to any loss, cost or expense which you may incur in connection with or arising out of any transaction in connection with this Agreement.

X. WITHHOLDING
You agree that, as a condition to your exercise of this Option, Invacare may make appropriate provision for tax withholding with respect to the transactions contemplated by this Agreement.

ACCEPTANCE

The undersigned hereby accepts the terms of the stock option granted herein and acknowledges receipt of a copy of the Invacare Corporation 1994 Performance Plan.


(Signature of Optionee) (Date)


Exhibit (aa)

[GRAPHIC OMITTED][GRAPHIC OMITTED]

AWARD AGREEMENT
(For Non-Qualified Stock Option)

To: Number:


(Name of Optionee)

Date of Grant:
(Social Security Number)

There hereby is granted to you, as a Director of Invacare Corporation ( "Invacare" ) or of a subsidiary, an option to purchase ____Invacare Common Shares, no par value, at an option price of $____ per Share. This option is granted to you pursuant to the Invacare Corporation 2003 Performance Plan (the "Plan") and is subject to the terms and conditions set forth below. This option is not an incentive stock option as defined in Section 422 of the Internal Revenue Code (the "Code"). Please acknowledge your acceptance of the terms of this option by signing on the reverse side.

/s/ A. Malachi Mixon, III
____________________________________
A. Malachi Mixon, III
Chairman and Chief Executive Officer


I. PURCHASE RIGHTS & EXERCISE DATES
You shall be entitled to exercise this option with respect to the percentage of shares indicated on or after the date shown opposite such percentage, rounded to the nearest whole share:

   Cumulative Maximum
Percentage of Optioned
  Shares which may be
 purchased by exercise              Date beginning on which
       of the Option                 Option may be exercised
____________________________________________________________

To the extent that the option becomes exercisable with respect to any shares, as shown above, the option may thereafter be exercised by you either with respect to all or any number of such shares at any time or from time to time prior to the expiration of the option. However, no fractional shares may be purchased. Except as provided herein, the option may not be exercised unless you are a Director at the time of exercise.

II. TERM OF OPTION The term of the option shall be for a period of ten (10) years commencing on the Date of Grant as set forth above. The option shall expire at the close of regular business hours at Invacare's principal office on the last day of the term of the option, or, if earlier, on the applicable expiration date provided in this Agreement.

(a) Your option shall not be affected by any temporary leave of absence approved in writing by Invacare and described in Section 1.421- 7(h) of the Federal Income Tax Regulations. If you cease to be a Director for any reason other than death or retirement as defined by Invacare's Compensation Committee (the "Committee"), (in which case you shall become a Retired Director), you may exercise your option only to the extent of such purchase rights as may exist pursuant to Paragraph I as of the date you cease to be a Director and which have not been exercised. Upon your ceasing to be a Director, other than by Retirement as defined by the Committee, such purchase rights shall in any event terminate upon the earlier of (a) three (3) months [one (1) year if you ceased to be a Director, because of a disability (as such term is defined in Section 72(m) (7) of the Code)] after the date you ceased to be a Director, or (b) the last day of the term of the option. If you become a Retired Director, as defined, you retain your purchase rights pursuant to Paragraph I, until the option terminates pursuant to Paragraph II.

(b) If you die while you are a Director, a Retired Director or within three
(3) months of your having ceased to be a Director, a personal representative may exercise the option to the extent of your purchase rights as may exist pursuant to Paragraph I at the date of your death and which have not been exercised; provided, however, that such purchase rights shall in any event terminate upon the earlier of: (i) one (1) year after you cease to be an employee, unless you are a Retired Director in which case you shall have one (1) year subsequent to your death; or (ii) the last day of the term of the option.

(c) If the Committee finds that you intentionally committed an act materially inimical to the interests of Invacare or a subsidiary, your unexercised purchase rights will terminate as of the time you committed such act, as determined by the Committee.


III. TERMINATION OF OPTION UNDER CERTAIN CIRCUMSTANCES

The Committee may cancel your option at any time if you are not in compliance with all applicable provisions of this Agreement or the Plan or if you, without the prior written consent of the Committee, engage in any of the following activities: (i) you render services for an organization, or engage in a business, that is, in the judgment of the Committee, in competition with Invacare; or (ii) you disclose to anyone outside of Invacare, or use for any purpose other than Invacare's business, any confidential information or material relating to Invacare, whether acquired by you during or after employment with Invacare, in a fashion or with a result that is or may be injurious to the best interests of Invacare, as determined by the Committee.

The Committee may, in its discretion and as a condition to the exercise of your option, require you to represent in writing that you are in compliance with all applicable provisions of this Agreement and the Plan and have not engaged in any activities referred to in clauses (i) and (ii) above.

IV. EXERCISE OF OPTION The option may be exercised by delivering to the Invacare Finance Department, at Invacare's principal office, a completed Notice of Exercise of Option (obtainable from the Finance Department) setting forth the number of shares with respect to which your option is being exercised. Such Notice shall be accompanied by either payment in full for the shares, or the execution of a cashless exercise in accordance with the procedures established by the Committee.

V. CHANGE IN CONTROL
Upon a change in control (as such term is defined in the Plan), unless and to the extent otherwise determined by Invacare's Board of Directors, you may exercise your option with respect to all shares covered therein.

VI. TRANSFERABILITY This Agreement shall be binding upon and inure to the benefit of any successor of Invacare and your heirs, estate and personal representative. Your option shall not be transferable other than by Will or the laws of descent and distribution, and your option may be exercised during your lifetime only by you provided that a guardian or other legal representative, who has been duly appointed may, except as otherwise provided in the Plan, exercise the option on your behalf. Your personal representative shall act in your place with respect to exercising the option or taking any other action pursuant to the Agreement.

VII. ADJUSTMENTS OR AMENDMENTS In the event that, subsequent to the date of this Agreement, the outstanding common shares of Invacare are, as a result of a stock split, stock dividend, combination or exchange of shares, exchange of other securities, reclassification, reorganization, redesignation, merger, consolidation, recapitalization, liquidation, dissolution, sale of assets or other such change, including, without limitation, any transaction described in Section 424(a) of the Code, increased, decreased, changed into or exchanged for a different number or kind of shares of stock or other securities of Invacare or another entity or converted into cash, then, except as otherwise provided below, (i) there shall automatically be substituted for each Invacare common share subject to an unexercised option, the amount of cash or other securities into which each outstanding Invacare common share shall be converted or exchanged and (ii) the option price per common share or unit of securities shall be increased or decreased proportionally so that the aggregate purchase price for any securities subject to the option shall remain the same as immediately prior to such event. Notwithstanding the preceding provisions of this Article VII, the Committee may, in its sole discretion, make other adjustments or amendments to the securities subject to options and/or amend the provisions of the Plan and/or this Agreement (including, without limitation, accelerating the date on which unexercised options shall expire or terminate), to the extent appropriate, equitable and in compliance with the provisions of Section 424(a) of the Code to the extent applicable and any such adjustment or amendment shall be final, binding and conclusive. Any such adjustment or amendment shall provide for the elimination of fractional shares.

VIII. PROVISIONS OF PLAN CONTROL This Agreement is subject to all of the terms, conditions and provisions of the Plan (all of which are incorporated herein by reference) and to such rules, regulations, and interpretations related to the Plan as may be adopted by the Committee and as may be in effect from time to time. In the event and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions, and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Committee has authority to interpret and construe any provision of this Agreement and its interpretation and construction shall be binding and conclusive.

IX. LIABILITY The liability of Invacare under this Agreement and any distribution of shares made hereunder is limited to the obligations set forth herein with respect to such distribution and no term or provision of this Agreement shall be construed to impose any liability on Invacare, its officers, employees or any subsidiary with respect to any loss, cost or expense which you may incur in connection with or arising out of any transaction in connection with this Agreement.

X. WITHHOLDING
You agree that, as a condition to your exercise of this Option, Invacare may, if so required by tax regulations, make appropriate provision for tax withholding with respect to the transactions contemplated by this Agreement.

ACCEPTANCE

The undersigned hereby accepts the terms of the stock option granted herein and acknowledges receipt of a copy of the Invacare Corporation 2003 Performance Plan.


(Signature of Optionee) (Date)

Exhibit 10(ab)

[GRAPHIC OMITTED][GRAPHIC OMITTED]

AWARD AGREEMENT
(For Non-Qualified Stock Option)

To: Number:


(Name of Optionee)

Date of Grant:
(Social Security Number)

There hereby is granted to you, as a Director of Invacare Corporation ( "Invacare" ) or of a subsidiary, an option to purchase ____ Invacare Common Shares, no par value, at an option price of $___ per Share. This option is granted to you pursuant to the Invacare Corporation 2003 Performance Plan (the "Plan") and is subject to the terms and conditions set forth below. This option is not an incentive stock option as defined in Section 422 of the Internal Revenue Code (the "Code"). Please acknowledge your acceptance of the terms of this option by signing on the reverse side.

/s/ A. Malachi Mixon, III
____________________________________
A. Malachi Mixon, III
Chairman and Chief Executive Officer


I. PURCHASE RIGHTS & EXERCISE DATES
You shall be entitled to exercise this option with respect to the percentage of shares indicated on or after the date shown opposite such percentage, rounded to the nearest whole share:

   Cumulative Maximum
Percentage of Optioned          Date beginning on which
  Shares which may be           of the Option Option
 purchased by exercise          may be exercised
_______________________________________________________

To the extent that the option becomes exercisable with respect to any shares, as shown above, the option may thereafter be exercised by you either with respect to all or any number of such shares based upon the exercise date(s) you have elected as of the date of this grant and are attached to this option agreement, or at such other dates as provided in Section II (b) or Section V. However, no fractional shares may be purchased. Except as provided herein, the option may not be exercised unless you are a Director at the time of exercise.

II. TERM OF OPTION The term of the option shall be for a period of ten (10) years commencing on the Date of Grant as set forth above. The option shall expire at the close of regular business hours at Invacare's principal office on the last day of the term of the option, or, if earlier, on the applicable expiration date provided in this Agreement.

(a) Your option shall not be affected by any temporary leave of absence approved in writing by Invacare and described in Section 1.421-7(h) of the Federal Income Tax Regulations. If you cease to be a Director for any reason other than death or retirement as defined by Invacare's Compensation Committee (the "Committee"), (in which case you shall become a Retired Director), you may exercise your option only to the extent of such purchase rights as may exist pursuant to Paragraph I as of the date you cease to be a Director and which have not been exercised. Upon your ceasing to be a Director, other than by Retirement as defined by the Committee, such purchase rights shall in any event terminate upon the earlier of (a) three (3) months [one (1) year if you ceased to be a Director, because of a disability (as such term is defined in Section 72(m) (7) of the Code)] after the date you ceased to be a Director, or (b) the exercise date you have elected as of the date of this grant. If you become a Retired Director, as defined, you retain your purchase rights pursuant to Paragraph I, until the option terminates pursuant to Paragraph II.

(b) If you die while you are a Director, a Retired Director or within nine
(9) months of your having ceased to be a Director, a personal representative may exercise the option to the extent of your purchase rights as may exist pursuant to Paragraph I at the date of your death and which have not been exercised; provided, however, that such purchase rights shall in any event terminate upon the earlier of: (i) one (1) year after you cease to be an employee, unless you are a Retired Director in which case you shall have one (1) year subsequent to your death; or (ii) the exercise date you have elected as of the date of this grant.

(c) In the event you cease to serve on the Board during the applicable period your option shall be pro-rated for the percent of time served. If you do not attend a meeting of the Board and would not have received a cash payment for such meeting, then your option grant shall be proportionately reduced.

(d) If permitted by law, in the event the Committee finds that you intentionally committed an act materially inimical to the interests of Invacare or a subsidiary, your unexercised purchase rights will terminate as of the time you committed such act, as determined by the Committee.

III. TERMINATION OF OPTION UNDER CERTAIN CIRCUMSTANCES If permitted by law, the Committee may cancel your option at any time if you are not in compliance with all applicable provisions of this Agreement or the Plan or if you, without the prior written consent of the Committee, engage in any of the following activities: (i) you render services for an organization, or engage in a business, that is, in the judgment of the Committee, in competition with Invacare; or (ii) you disclose to anyone outside of Invacare, or use for any purpose other than Invacare's business, any confidential information or material relating to Invacare, whether acquired by you during or after employment with Invacare, in a fashion or with a result that is or may be injurious to the best interests of Invacare, as determined by the Committee.

The Committee may, in its discretion and as a condition to the exercise of your option, require you to represent in writing that you are in compliance with all applicable provisions of this Agreement and the Plan and have not engaged in any activities referred to in clauses (i) and (ii) above.

IV. EXERCISE OF OPTION The option may be exercised by delivering to the Invacare Finance Department, at Invacare's principal office, a completed Notice of Exercise of Option (obtainable from the Finance Department) setting forth the number of shares with respect to which your option is being exercised. Such Notice shall be accompanied by either payment in full for the shares, or the execution of a cashless exercise in accordance with the procedures established by the Committee.

V. CHANGE IN CONTROL
Upon a change in control (as such term is defined in the Plan as in effect at the time of such event), unless and to the extent otherwise determined by Invacare's Board of Directors, you may exercise your option with respect to all shares covered therein.

VI. TRANSFERABILITY This Agreement shall be binding upon and inure to the benefit of any successor of Invacare and your heirs, estate and personal representative. Your option shall not be transferable other than by Will or the laws of descent and distribution, and your option may be exercised during your lifetime only by you provided that a guardian or other legal representative, who has been duly appointed may, except as otherwise provided in the Plan, exercise the option on your behalf. Your personal representative shall act in your place with respect to exercising the option or taking any other action pursuant to the Agreement.

VII. ADJUSTMENTS OR AMENDMENTS In the event that, subsequent to the date of this Agreement, the outstanding common shares of Invacare are, as a result of a stock split, stock dividend, combination or exchange of shares, exchange of other securities, reclassification, reorganization, redesignation, merger, consolidation, recapitalization, liquidation, dissolution, sale of assets or other such change, including, without limitation, any transaction described in Section 424(a) of the Code, increased, decreased, changed into or exchanged for a different number or kind of shares of stock or other securities of Invacare or another entity or converted into cash, then, except as otherwise provided below, (i) there shall automatically be substituted for each Invacare common share subject to an unexercised option, the amount of cash or other securities into which each outstanding Invacare common share shall be converted or exchanged and (ii) the option price per common share or unit of securities shall be increased or decreased proportionally so that the aggregate purchase price for any securities subject to the option shall remain the same as immediately prior to such event. Notwithstanding the preceding provisions of this Article VII, the Committee may, in its sole discretion, make other adjustments or amendments to the securities subject to options and/or amend the provisions of the Plan and/or this Agreement (including, without limitation, accelerating the date on which unexercised options shall expire or terminate), to the extent appropriate, equitable and in compliance with the provisions of Section 424(a) of the Code to the extent applicable and any such adjustment or amendment shall be final, binding and conclusive. Any such adjustment or amendment shall provide for the elimination of fractional shares.

VIII. PROVISIONS OF PLAN CONTROL This Agreement is subject to all of the terms, conditions and provisions of the Plan (all of which are incorporated herein by reference) and to such rules, regulations, and interpretations related to the Plan as may be adopted by the Committee and as may be in effect from time to time. In the event and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions, and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Committee has authority to interpret and construe any provision of this Agreement and its interpretation and construction shall be binding and conclusive.

IX. LIABILITY The liability of Invacare under this Agreement and any distribution of shares made hereunder is limited to the obligations set forth herein with respect to such distribution and no term or provision of this Agreement shall be construed to impose any liability on Invacare, its officers, employees or any subsidiary with respect to any loss, cost or expense which you may incur in connection with or arising out of any transaction in connection with this Agreement.

X. WITHHOLDING
You agree that, as a condition to your exercise of this Option, Invacare may, if so required by tax regulations, make appropriate provision for tax withholding with respect to the transactions contemplated by this Agreement.

ACCEPTANCE

The undersigned hereby accepts the terms of the stock option granted herein and acknowledges receipt of a copy of the Invacare Corporation 2003 Performance Plan.


(Signature of Optionee) (Date)


Exhibit 10(ac)

[GRAPHIC OMITTED][GRAPHIC OMITTED]

AWARD AGREEMENT
(For Restricted Stock Award)

To: Number:


(Name of Award Recipient)

Date of Grant:
(Social Security Number)

There hereby is granted to you, as a key employee of Invacare Corporation ( "Invacare" ) or of a subsidiary, a restricted award for _____ Invacare Common Shares, no par value, at an award price of $0.0 per Share. This award is granted to you pursuant to the Invacare Corporation 2003 Performance Plan (the "Plan") and is subject to the terms and conditions set forth below. This award is granted for valuable future services to be rendered by you to Invacare Corporation. Please acknowledge your acceptance of the terms of this award by signing on the reverse side.

/s/ A. Malachi Mixon, III
____________________________________
A. Malachi Mixon, III
Chairman and Chief Executive Officer


I. VESTING AND DELIVERY OF SHARES
You shall vest and will receive a certificate for the percentage of shares indicated on the date shown opposite such percentage, rounded to the nearest whole share:

Percentage of Award
Shares to be delivered
On the corresponding
Date indicated Date of Delivery of Shares

Except as provided herein, the award will not vest, and you shall not receive a certificate on each vesting date indicated above unless you are a current employee of Invacare or a subsidiary on a continuous basis from the date hereof through such vesting date.

II. TERM OF AWARD

Your award shall not be affected by any temporary leave of absence approved in writing by Invacare and described in Section 1.421-7(h) of the Federal Income Tax Regulations. If you cease to be an employee for any reason other than death or retirement as defined by Invacare's Compensation Committee, in its sole discretion (the "Committee"), (in which case you shall become a Retired employee), you will forfeit any unvested shares you have not received as of the date you terminate your employment. If you become a Retired employee, as defined, you retain your rights pursuant to Paragraph I, until the award has fully vested and you have received all of the shares pursuant to this award.

If you die while you are an employee or a Retired employee, your estate or personal representative shall receive the award and be entitled to all remaining award rights pursuant to Paragraph I, until the award has fully vested and your estate or personal representative has received all of the remaining shares not delivered to you as of the date of your death.

If the Committee finds that you intentionally committed an act materially inimical to the interests of Invacare or a subsidiary, your unexercised purchase rights will terminate as of the time you committed such act, as determined by the Committee.

III. TERMINATION OF AWARD UNDER CERTAIN CIRCUMSTANCES The Committee may cancel your award at any time, in which case you shall forfeit any unvested shares as of the date of such cancellation, if you are not in compliance with all applicable provisions of this Agreement or the Plan or if you, without the prior written consent of the Committee, engage in any of the following activities: (i) you render services for an organization, or engage in a business, that is, in the judgment of the Committee, in competition with Invacare; or (ii) you disclose to anyone outside of Invacare, or use for any purpose other than Invacare's business, any confidential information or material relating to Invacare, whether acquired by you during or after employment with Invacare, in a fashion or with a result that is or may be injurious to the best interests of Invacare, as determined by the Committee.

The Committee may, in its discretion and as a condition to the continuance of this award, require you to represent in writing that you are in compliance with all applicable provisions of this Agreement and the Plan and have not engaged in any activities referred to in clauses (i) and (ii) above.


IV. DIVIDENDS You shall be entitled to all dividends with respect to all of the shares comprising this award as of the date of the grant of this award, irrespective of whether the shares have become vested. Such amount shall be paid to you and treated appropriately for tax purposes.

V. CHANGE IN CONTROL
Upon a change in control (as such term is defined in the Plan), unless and to the extent otherwise determined by Invacare's Board of Directors, the vesting of this award will accelerate and you shall receive all shares not previously vested and delivered to you.

VI. TRANSFERABILITY This Agreement shall be binding upon and inure to the benefit of any successor of Invacare and your heirs, estate and personal representative. Your award shall not be transferable other than by Will or the laws of descent and distribution.

VII. ADJUSTMENTS OR AMENDMENTS In the event that, subsequent to the date of this Agreement, the outstanding common shares of Invacare are, as a result of a stock split, stock dividend, combination or exchange of shares, exchange of other securities, reclassification, reorganization, redesignation, merger, consolidation, recapitalization, liquidation, dissolution, sale of assets or other such change, including, without limitation, any transaction described in Section 424(a) of the Code, increased, decreased, changed into or exchanged for a different number or kind of shares of stock or other securities of Invacare or another entity or converted into cash, then, except as otherwise provided below, there shall automatically be substituted for each Invacare common share subject to the unvested portion of the award, the amount of cash or other securities or property into which each outstanding Invacare Common Share shall be converted or exchanged. Notwithstanding the preceding provisions of this Article VII, the Committee may, in its sole discretion, make other adjustments or amendments to the securities subject to the award and/or amend the provisions of the Plan and/or this Agreement (including, without limitation, accelerating the date on which shares shall vest), to the extent appropriate, equitable and in compliance with the provisions of Section 424(a) of the Code to the extent applicable and any such adjustment or amendment shall be final, binding and conclusive. Any such adjustment or amendment shall provide for the elimination of fractional shares.

VIII. PROVISIONS OF PLAN CONTROL This Agreement is subject to all of the terms, conditions and provisions of the Plan (all of which are incorporated herein by reference) and to such rules, regulations, and interpretations related to the Plan as may be adopted by the Committee and as may be in effect from time to time. In the event and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions, and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Committee has authority to interpret and construe any provision of this Agreement and its interpretation and construction shall be binding and conclusive.

IX. LIABILITY The liability of Invacare under this Agreement and any distribution of shares made hereunder is limited to the obligations set forth herein with respect to such distribution and no term or provision of this Agreement shall be construed to impose any liability on Invacare, its officers, employees or any subsidiary with respect to any loss, cost or expense which you may incur in connection with or arising out of any transaction in connection with this Agreement.

X. WITHHOLDING
You agree that, as a condition to your receipt of the shares awarded hereunder, Invacare may make appropriate provision for tax withholding with respect to the transactions contemplated by this Agreement.

XI. EXECUTION OF STOCK POWERS Four stock certificates, each prepared in your name, shall be produced as of the date of this award. Each certificate shall correspond to the number of shares you shall receive on a specific vesting date pursuant to paragraph I, and will be retained by Invacare until such vesting date. You agree that, as a condition to your receipt of this award, that you will execute a blank stock power to be referenced to and attached to each certificate, and you further agree and understand that in the event you forfeit any unvested shares for any reason as further described in this award, Invacare will use such stock power you have exercised to transfer title of the certificate to Invacare Corporation. Upon delivery of any certificate on the appropriate vesting date, the related executed stock power shall also be delivered to you, or in the event of your death, to your estate or personal representative.

ACCEPTANCE

The undersigned hereby accepts the terms of the restricted stock award granted herein and acknowledges receipt of a copy of the Invacare Corporation 2003 Performance Plan.


(Signature of Award Recipient) (Date)

Exhibit 10(ad)
[GRAPHIC OMITTED][GRAPHIC OMITTED]
AWARD AGREEMENT
(For Non-Qualified Stock Option)

To: Number:


(Name of Optionee)

Date of Grant:
(Social Security Number)

There hereby is granted to you, as a key employee of Invacare Corporation ( "Invacare" ) or of a subsidiary, an option to purchase _____ Invacare Common Shares, no par value, at an option price of $_____ per share. This option is granted to you pursuant to the Invacare Corporation 2003 Performance Plan (the "Plan") and is subject to the terms and conditions set forth below. This option is not an incentive stock option as defined in Section 422 of the Internal Revenue Code (the "Code"). Please acknowledge your acceptance of the terms of this option by signing on the reverse side.

/s/ A. Malachi Mixon, III
____________________________________
A. Malachi Mixon, III
Chairman and Chief Executive Officer


I. PURCHASE RIGHTS & EXERCISE DATES
You shall be entitled to exercise this option with respect to the percentage of shares indicated on or after the date shown opposite such percentage, rounded to the nearest whole share:

   Cumulative Maximum
Percentage of Optioned
  Shares which may be
 purchased by exercise              Date beginning on which
       of the Option                 Option may be exercised
____________________________________________________________

To the extent that the option becomes exercisable with respect to any shares, as shown above, the option may thereafter be exercised by you either with respect to all or any number of such shares at any time or from time to time prior to the expiration of the option. However, no fractional shares may be purchased. Except as provided herein, the option may not be exercised unless you are an employee at the time of exercise.

II. TERM OF OPTION The term of the option shall be for a period of ten (10) years commencing on the Date of Grant as set forth above. The option shall expire at the close of regular business hours at Invacare's principal office on the last day of the term of the option, or, if earlier, on the applicable expiration date provided in this Agreement.

(a) Your option shall not be affected by any temporary leave of absence approved in writing by Invacare and described in Section 1.421- 7(h) of the Federal Income Tax Regulations. If you cease to be an employee for any reason other than death or retirement as defined by Invacare's Compensation Committee (the "Committee"), (in which case you shall become a Retired employee), you may exercise your option only to the extent of such purchase rights as may exist pursuant to Paragraph I as of the date you cease to be an employee and which have not been exercised. Upon your ceasing to be an employee, other than by Retirement as defined by the Committee, such purchase rights shall in any event terminate upon the earlier of (a) three (3) months [one (1) year if you ceased to be an employee, because of a disability (as such term is defined in Section
72(m) (7) of the Code)] after the date you ceased to be an employee, or (b) the last day of the term of the option. If you become a Retired employee, as defined, you retain your purchase rights pursuant to Paragraph I, until the option terminates pursuant to Paragraph II.

(b) If you die while you are an employee, a Retired employee or within three (3) months of your having ceased to be an employee, a personal representative may exercise the option to the extent of your purchase rights as may exist pursuant to Paragraph I at the date of your death and which have not been exercised; provided, however, that such purchase rights shall in any event terminate upon the earlier of: (i) one (1) year after you cease to be an employee, unless you are a Retired employee in which case you shall have one (1) year subsequent to your death; or (ii) the last day of the term of the option.

(c) If the Committee finds that you intentionally committed an act materially inimical to the interests of Invacare or a subsidiary, your unexercised purchase rights will terminate as of the time you committed such act, as determined by the Committee.


III. TERMINATION OF OPTION UNDER CERTAIN CIRCUMSTANCES The Committee may cancel your option at any time if you are not in compliance with all applicable provisions of this Agreement or the Plan or if you, without the prior written consent of the Committee, engage in any of the following activities: (i) you render services for an organization, or engage in a business, that is, in the judgment of the Committee, in competition with Invacare; or (ii) you disclose to anyone outside of Invacare, or use for any purpose other than Invacare's business, any confidential information or material relating to Invacare, whether acquired by you during or after employment with Invacare, in a fashion or with a result that is or may be injurious to the best interests of Invacare, as determined by the Committee.

The Committee may, in its discretion and as a condition to the exercise of your option, require you to represent in writing that you are in compliance with all applicable provisions of this Agreement and the Plan and have not engaged in any activities referred to in clauses (i) and (ii) above.

IV. EXERCISE OF OPTION The option may be exercised by delivering to the Invacare Finance Department, at Invacare's principal office, a completed Notice of Exercise of Option (obtainable from the Finance Department) setting forth the number of shares with respect to which your option is being exercised. Such Notice shall be accompanied by either payment in full for the shares, or the execution of a cashless exercise in accordance with the procedures established by the Committee.

V. CHANGE IN CONTROL
Upon a change in control (as such term is defined in the Plan), unless and to the extent otherwise determined by Invacare's Board of Directors, you may exercise your option with respect to all shares covered therein.

VI. TRANSFERABILITY This Agreement shall be binding upon and inure to the benefit of any successor of Invacare and your heirs, estate and personal representative. Your option shall be transferable to (1) certain people or entities that you designate, in accordance with and pursuant to procedures established by the Committee, or by (2) Will or the laws of descent and distribution, and your option may be exercised during your lifetime only by you, or such permitted transferee under clause (1) of the preceding sentence, provided that a guardian or other legal representative, who has been duly appointed may, except as otherwise provided in the Plan, exercise the option on your behalf. Your personal representative shall act in your place with respect to exercising the option or taking any other action pursuant to the Agreement.

VII. ADJUSTMENTS OR AMENDMENTS In the event that, subsequent to the date of this Agreement, the outstanding common shares of Invacare are, as a result of a stock split, stock dividend, combination or exchange of shares, exchange of other securities, reclassification, reorganization, redesignation, merger, consolidation, recapitalization, liquidation, dissolution, sale of assets or other such change, including, without limitation, any transaction described in Section 424(a) of the Code, increased, decreased, changed into or exchanged for a different number or kind of shares of stock or other securities of Invacare or another entity or converted into cash, then, except as otherwise provided below, (i) there shall automatically be substituted for each Invacare common share subject to an unexercised option, the amount of cash or other securities into which each outstanding Invacare common share shall be converted or exchanged and (ii) the option price per common share or unit of securities shall be increased or decreased proportionally so that the aggregate purchase price for any securities subject to the option shall remain the same as immediately prior to such event. Notwithstanding the preceding provisions of this Article VII, the Committee may, in its sole discretion, make other adjustments or amendments to the securities subject to options and/or amend the provisions of the Plan and/or this Agreement (including, without limitation, accelerating the date on which unexercised options shall expire or terminate), to the extent appropriate, equitable and in compliance with the provisions of Section 424(a) of the Code to the extent applicable and any such adjustment or amendment shall be final, binding and conclusive. Any such adjustment or amendment shall provide for the elimination of fractional shares.

VIII. PROVISIONS OF PLAN CONTROL This Agreement is subject to all of the terms, conditions and provisions of the Plan (all of which are incorporated herein by reference) and to such rules, regulations, and interpretations related to the Plan as may be adopted by the Committee and as may be in effect from time to time. In the event and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions, and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Committee has authority to interpret and construe any provision of this Agreement and its interpretation and construction shall be binding and conclusive.

IX. LIABILITY The liability of Invacare under this Agreement and any distribution of shares made hereunder is limited to the obligations set forth herein with respect to such distribution and no term or provision of this Agreement shall be construed to impose any liability on Invacare, its officers, employees or any subsidiary with respect to any loss, cost or expense which you may incur in connection with or arising out of any transaction in connection with this Agreement.

X. WITHHOLDING
You agree that, as a condition to your exercise of this Option, Invacare may make appropriate provision for tax withholding with respect to the transactions contemplated by this Agreement.

ACCEPTANCE

The undersigned hereby accepts the terms of the stock option granted herein and acknowledges receipt of a copy of the Invacare Corporation 2003 Performance Plan.


(Signature of Optionee) (Date)


Exhibit 10(ae)

INVACARE CORPORATION

BOARD OF DIRECTORS COMPENSATION

Retainer Fee                 $30,000

Regular Meeting Fees         $2,000

Committee Meeting Fees       Member - $1,500

                             Chair - $2,000

Telephonic Meetings          50% for interim conference calls that are conducted
                             between scheduled meetings

Stock Components             Option grant of 2,000 shares

Non-Employee Director        Non-employee directors may elect to defer all or a
Elective Stock Option        portion of their director fees into discounted


Program                      stock options.


Exhibit 31.1

CERTIFICATIONS

I, A. Malachi Mixon, III, certify that:

1. I have reviewed this annual report on Form 10-K of Invacare Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

INVACARE CORPORATION

                                             By:/s/ A. Malachi Mixon, III
                                                    -------------------------
                                                    A. Malachi Mixon, III
                                                    Chief Executive Officer
                                                   (Principal Executive Officer)

Date:  March 11, 2005


Exhibit 31.2

CERTIFICATIONS

I, Gregory C. Thompson, certify that:

1. I have reviewed this annual report on Form 10-K of Invacare Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

INVACARE CORPORATION

                                            By:/s/ Gregory C. Thompson
                                                   -----------------------------
                                                   Gregory C. Thompson
                                                   Chief Financial Officer
                                                  (Principal Financial Officer)

Date:  March 11, 2005


Exhibit 32.1

Certification Pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Invacare Corporation (the "Company") on Form 10-K for the period ending December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, A. Malachi Mixon, III, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  March 11, 2005
                                                     /s/ A. Malachi Mixon, III
                                                         ______________________
                                                         A. Malachi Mixon, III
                                                         Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to Invacare Corporation and will be retained by Invacare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.


Exhibit 32.2

Certification Pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Invacare Corporation (the "Company") on Form 10-K for the period ending December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gregory C. Thompson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  March 11, 2005
                                                     /s/ Gregory C. Thompson
                                                         ___________________
                                                         Gregory C. Thompson
                                                         Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Invacare Corporation and will be retained by Invacare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.